[{"text": "At 4 hours, losartan blocked 43% of the  Ang II  induced systolic blood pressure increase;  valsartan   51%; and irbesartan, 88% (P<0.01 between drugs)", "triple_list": [["valsartan", "DOWNREGULATOR", "Ang II"]]}, {"text": "At 4 hours, losartan blocked 43% of the  Ang II  induced systolic blood pressure increase; valsartan, 51%; and  irbesartan   88% (P<0.01 between drugs)", "triple_list": [["irbesartan", "DOWNREGULATOR", "Ang II"]]}, {"text": "This study thus demonstrates that the first administration of the recommended starting dose of  irbesartan  induces a greater and longer lasting  Ang II receptor  blockade than that of valsartan and losartan in normotensive subjects.", "triple_list": [["irbesartan", "DOWNREGULATOR", "Ang II receptor"]]}, {"text": "This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting  Ang II receptor  blockade than that of  valsartan  and losartan in normotensive subjects.", "triple_list": [["valsartan", "DOWNREGULATOR", "Ang II receptor"]]}, {"text": "This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting  Ang II receptor  blockade than that of valsartan and  losartan  in normotensive subjects.", "triple_list": [["losartan", "DOWNREGULATOR", "Ang II receptor"]]}, {"text": "In humans, prolonged administration of the  beta 2-adrenoceptor  agonist  terbutaline  leads to a desensitization of  beta 2-adrenoceptor -mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen", "triple_list": [["terbutaline", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective  beta-adrenoceptor  agonist  isoprenaline   beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia", "triple_list": [["isoprenaline", "AGONIST", "beta-adrenoceptor"]]}, {"text": "OBJECTIVES: This study examined the effect of a small-molecule, direct  thrombin  inhibitor,  argatroban   on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)", "triple_list": [["argatroban", "DOWNREGULATOR", "thrombin"]]}, {"text": "In vitro and in vivo studies have shown that  argatroban  has advantages over heparin for the inhibition of clot-bound  thrombin  and for the enhancement of thrombolysis with TPA", "triple_list": [["argatroban", "DOWNREGULATOR", "thrombin"]]}, {"text": "At clinically relevant concentrations,  candesartan  is an insurmountable and long-lasting antagonist of the vascular contractile responses to  Ang II  ", "triple_list": [["candesartan", "DOWNREGULATOR", "Ang II"]]}, {"text": "In both vascular preparations,  candesartan  caused a marked decrease in the maximal contractile response of the  angiotensin II  (Ang II) concentration-response curve", "triple_list": [["candesartan", "DOWNREGULATOR", "angiotensin II"]]}, {"text": "In both vascular preparations,  candesartan  caused a marked decrease in the maximal contractile response of the angiotensin II ( Ang II   concentration-response curve", "triple_list": [["candesartan", "DOWNREGULATOR", "Ang II"]]}, {"text": "The functional inhibitory characteristics of the  angiotensin II type 1 receptor  blockers (ARB) candesartan;  irbesartan   and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro", "triple_list": [["irbesartan", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "The functional inhibitory characteristics of the  angiotensin II type 1 receptor  blockers (ARB)  candesartan   irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro", "triple_list": [["candesartan", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "The functional inhibitory characteristics of the  angiotensin II type 1 receptor  blockers (ARB) candesartan; irbesartan; and  losartan  and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro", "triple_list": [["losartan", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "In addition, when  candesartan  was given to conscious rats, the inhibitory effect on  Ang II  induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of  candesartan  at 24 hours", "triple_list": [["candesartan", "DOWNREGULATOR", "Ang II"]]}, {"text": "The functional inhibitory characteristics of the  angiotensin II type 1 receptor  blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite  EXP 3174  (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro", "triple_list": [["EXP 3174", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "The functional inhibitory characteristics of the  angiotensin II type 1 receptor  blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite  EXP  3174 ( EXP   were studied in rabbit aortic strips and rat portal vein preparations in vitro", "triple_list": [["EXP", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "Dose-dependent inhibition of platelet  cyclooxygenase-1  and monocyte cyclooxygenase-2 by  meloxicam  in healthy subjects", "triple_list": [["meloxicam", "DOWNREGULATOR", "cyclooxygenase-1"]]}, {"text": "Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte  cyclooxygenase-2  by  meloxicam  in healthy subjects", "triple_list": [["meloxicam", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "In contrast, the administration of 7.5 and 15 mg of  meloxicam  caused dose-dependent reductions in monocyte  COX-2  activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "In contrast, the administration of 7.5 and 15 mg of  meloxicam  caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet  COX-1  activity by 25% and 35%, respectively", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-1"]]}, {"text": "Although the IC50 value of  meloxicam  for inhibition of  COX-1  was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of  meloxicam  on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-1"]]}, {"text": "Although the IC50 value of  meloxicam  for inhibition of COX-1 was 10-fold higher than the IC50 value of  COX-2  in vitro, this biochemical selectivity was inadequate to clearly separate the effects of  meloxicam  on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "Concentration-response curves for the inhibition of monocyte  COX-2  and platelet COX-1 were obtained in vitro after the incubation of  meloxicam  with whole blood samples", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "Concentration-response curves for the inhibition of monocyte COX-2 and platelet  COX-1  were obtained in vitro after the incubation of  meloxicam  with whole blood samples", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-1"]]}, {"text": "Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and  prostaglandin E2  was measured in plasma as an index of monocyte  COX-2  activity", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-2"]]}, {"text": "The production of  thromboxane B2  in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet  COX-1  activity", "triple_list": [["thromboxane B2", "PRODUCT-OF", "COX-1"]]}, {"text": "In distinction, the preferential  beta 1-AR  antagonist,  betaxolol   and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT", "triple_list": [["betaxolol", "ANTAGONIST", "beta 1-AR"]]}, {"text": "In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential  beta 2-AR  antagonist,  ICI118,551   did not increase basal levels of DA, NAD, or 5-HT", "triple_list": [["ICI118,551", "ANTAGONIST", "beta 2-AR"]]}, {"text": "The selective  5-HT1A  receptor antagonist,  WAY100,635   slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective", "triple_list": [["WAY100,635", "ANTAGONIST", "5-HT1A"]]}, {"text": "The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective  5-HT1B  antagonist,  SB224,289   was ineffective", "triple_list": [["SB224,289", "ANTAGONIST", "5-HT1B"]]}, {"text": "UNLABELLED:  Entacapone  is a potent and specific peripheral  catechol-O-methyltransferase  (COMT) inhibitor", "triple_list": [["Entacapone", "DOWNREGULATOR", "catechol-O-methyltransferase"]]}, {"text": "UNLABELLED:  Entacapone  is a potent and specific peripheral catechol-O-methyltransferase ( COMT   inhibitor", "triple_list": [["Entacapone", "DOWNREGULATOR", "COMT"]]}, {"text": "We found that  5-HT  stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating  eNOS  activation", "triple_list": [["5-HT", "ACTIVATOR", "eNOS"]]}, {"text": " 5-hydroxytryptamine  evokes  endothelial nitric oxide synthase  activation in bovine aortic endothelial cell cultures", "triple_list": [["5-hydroxytryptamine", "ACTIVATOR", "endothelial nitric oxide synthase"]]}, {"text": "These findings lend evidence of a  5-HT 1B receptor/ eNOS  pathway, accounting in part for the activation of  eNOS  by  5-HT   Further investigation is needed to determine the role of other vascular  5-HT  receptors in the stimulation of  eNOS  activity.", "triple_list": [["5-HT", "ACTIVATOR", "eNOS"]]}, {"text": "The high affinity  5-HT1B  receptor agonist,  5-nonyloxytryptamine  (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent", "triple_list": [["5-nonyloxytryptamine", "AGONIST", "5-HT1B"]]}, {"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the  eNOS  selective antagonists (0.01-10 microM):  L-Nomega -monomethyl-L-arginine  (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)", "triple_list": [["L-Nomega -monomethyl-L-arginine", "ANTAGONIST", "eNOS"]]}, {"text": "These responses were effectively blocked by the  5-HT1B  receptor antagonist, isamoltane, the  5-HT1B  5-HT2 receptor antagonist,  methiothepin   and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)", "triple_list": [["methiothepin", "ANTAGONIST", "5-HT1B"]]}, {"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/ 5-HT2 receptor  antagonist,  methiothepin   and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)", "triple_list": [["methiothepin", "ANTAGONIST", "5-HT2 receptor"]]}, {"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the  eNOS  selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine ( L-NMMA   and L-N omega-iminoethyl-L-ornithine (L-NIO)", "triple_list": [["L-NMMA", "ANTAGONIST", "eNOS"]]}, {"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the  eNOS  selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and  L-N omega-iminoethyl-L-ornithine  (L-NIO)", "triple_list": [["L-N omega-iminoethyl-L-ornithine", "ANTAGONIST", "eNOS"]]}, {"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the  eNOS  selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine ( L-NIO  ", "triple_list": [["L-NIO", "ANTAGONIST", "eNOS"]]}, {"text": "Here, we tested the hypothesis that 5-HT receptors mediate  eNOS  activation by measuring agonist-stimulated  [3H]L-citrulline  ([3H]L-Cit) formation in BAEC cultures", "triple_list": [["[3H]L-citrulline", "PRODUCT-OF", "eNOS"]]}, {"text": "Here, we tested the hypothesis that 5-HT receptors mediate  eNOS  activation by measuring agonist-stimulated [3H]L-citrulline ( [3H]L-Cit   formation in BAEC cultures", "triple_list": [["[3H]L-Cit", "PRODUCT-OF", "eNOS"]]}, {"text": "We found that 5-HT stimulated the conversion of  [3H]L-arginine  ([3H]L-Arg) to [3H]L-Cit, indicating  eNOS  activation", "triple_list": [["[3H]L-arginine", "PRODUCT-OF", "eNOS"]]}, {"text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ( [3H]L-Arg   to [3H]L-Cit, indicating  eNOS  activation", "triple_list": [["[3H]L-Arg", "PRODUCT-OF", "eNOS"]]}, {"text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to  [3H]L-Cit   indicating  eNOS  activation", "triple_list": [["[3H]L-Cit", "PRODUCT-OF", "eNOS"]]}, {"text": "Activation of endothelial  nitric oxide  synthase (eNOS) results in the production of  nitric oxide  (NO) that mediates the vasorelaxing properties of endothelial cells", "triple_list": [["nitric oxide", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Activation of endothelial  nitric oxide  synthase ( eNOS   results in the production of  nitric oxide  (NO) that mediates the vasorelaxing properties of endothelial cells", "triple_list": [["nitric oxide", "PRODUCT-OF", "eNOS"]]}, {"text": "Activation of  endothelial nitric oxide synthase  (e NO S) results in the production of nitric oxide ( NO   that mediates the vasorelaxing properties of endothelial cells", "triple_list": [["NO", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Activation of endothelial nitric oxide synthase (e NO S  results in the production of nitric oxide ( NO   that mediates the vasorelaxing properties of endothelial cells", "triple_list": [["NO", "PRODUCT-OF", "eNOS"]]}, {"text": "We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by  caffeine  in vivo and that  ATM  kinase activity is directly inhibited by  caffeine  in vitro", "triple_list": [["caffeine", "DOWNREGULATOR", "ATM"]]}, {"text": "We report that the radiation-induced activation of the  kinase  Cds1 [4] (also known as Chk2 [5]) is inhibited by  caffeine  in vivo and that ATM  kinase  activity is directly inhibited by  caffeine  in vitro", "triple_list": [["caffeine", "DOWNREGULATOR", "kinase"]]}, {"text": "Inhibition of  ATM  provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of  caffeine  treated cells [6] [7] [8].", "triple_list": [["caffeine", "DOWNREGULATOR", "ATM"]]}, {"text": "We report that the radiation-induced activation of the  kinase  Cds1 [4] (also known as Chk2 [5]) is inhibited by  caffeine  in vivo and that ATM  kinase  activity is directly inhibited by  caffeine  in vitro", "triple_list": [["caffeine", "DOWNREGULATOR", "kinase"]]}, {"text": "We report that the radiation-induced activation of the kinase  Cds1  [4] (also known as Chk2 [5]) is inhibited by  caffeine  in vivo and that ATM kinase activity is directly inhibited by  caffeine  in vitro", "triple_list": [["caffeine", "DOWNREGULATOR", "Cds1"]]}, {"text": "We report that the radiation-induced activation of the kinase Cds1 [4] (also known as  Chk2  [5]) is inhibited by  caffeine  in vivo and that ATM kinase activity is directly inhibited by  caffeine  in vitro", "triple_list": [["caffeine", "DOWNREGULATOR", "Chk2"]]}, {"text": " Caffeine  inhibits the checkpoint  kinase  ATM", "triple_list": [["Caffeine", "DOWNREGULATOR", "kinase"]]}, {"text": " Caffeine  inhibits the checkpoint kinase  ATM   The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells", "triple_list": [["Caffeine", "DOWNREGULATOR", "ATM"]]}, {"text": "The turnover of  SERT  was determined from the rate of recovery of binding after administration of  RTI-76   an irreversible inhibitor of ligand binding", "triple_list": [["RTI-76", "DOWNREGULATOR", "SERT"]]}, {"text": "In preliminary studies, in vitro incubation of rat cerebral cortex with  RTI-76  produced a wash and temperature resistant inhibition of  SERT  binding densities (Bmax)", "triple_list": [["RTI-76", "DOWNREGULATOR", "SERT"]]}, {"text": "Citalopram protected against the  RTI-76  induced inhibition of  SERT  binding", "triple_list": [["RTI-76", "DOWNREGULATOR", "SERT"]]}, {"text": "The decrease and recovery of  [3H]-5-HT  uptake correlated highly (r = 0.93) with the recovery of  SERT  binding.", "triple_list": [["[3H]-5-HT", "PRODUCT-OF", "SERT"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan,  saprisartan   zolasartan, irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["saprisartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan,  zolasartan   irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["zolasartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan,  irbesartan   valsartan, telmisartan, E3174)", "triple_list": [["irbesartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan,  valsartan   telmisartan, E3174)", "triple_list": [["valsartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan,  telmisartan   E3174)", "triple_list": [["telmisartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan,  E3174  ", "triple_list": [["E3174", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of  losartan   10, tasosartan 20,  losartan  50, eprosartan 100 and the prodrug candesartan cilexetil 280", "triple_list": [["losartan", "ANTAGONIST", "AT1"]]}, {"text": " Losartan  was the first, but by no means remained the only,  AT1  receptor antagonist", "triple_list": [["Losartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10,  tasosartan  20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280", "triple_list": [["tasosartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is:  candesartan  1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug  candesartan  cilexetil 280", "triple_list": [["candesartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1,  telmisartan  10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280", "triple_list": [["telmisartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10,  E3174  (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280", "triple_list": [["E3174", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of  losartan ) 10, tasosartan 20,  losartan  50, eprosartan 100 and the prodrug candesartan cilexetil 280", "triple_list": [["losartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50,  eprosartan  100 and the prodrug candesartan cilexetil 280", "triple_list": [["eprosartan", "ANTAGONIST", "AT1"]]}, {"text": "Among the current  AT1  receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug  candesartan cilexetil  280", "triple_list": [["candesartan cilexetil", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive ( losartan   tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["losartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan,  tasosartan   eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["tasosartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan,  eprosartan   or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["eprosartan", "ANTAGONIST", "AT1"]]}, {"text": "The mode of (functional)  AT1  receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive ( candesartan   saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)", "triple_list": [["candesartan", "ANTAGONIST", "AT1"]]}, {"text": "The mNQO activity was insensitive to  dicoumarol   a potent inhibitor of cytosolic  NQO1   Western analysis of microsomal proteins revealed 29- and 18-kDa bands that cross-reacted with polyclonal antibodies raised against cytosolic  NQO1 ", "triple_list": [["dicoumarol", "DOWNREGULATOR", "NQO1"]]}, {"text": "A role of cytosolic  NQO1  in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of  quinones  was established", "triple_list": [["quinones", "PRODUCT-OF", "NQO1"]]}, {"text": "The  mNQO  activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of  2,6-dichlorophenolindophenol  and menadione", "triple_list": [["2,6-dichlorophenolindophenol", "PRODUCT-OF", "mNQO"]]}, {"text": "The  mNQO  activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and  menadione   The  mNQO  activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1", "triple_list": [["menadione", "PRODUCT-OF", "mNQO"]]}, {"text": " Quinone oxidoreductases  are flavoproteins that catalyze two-electron reduction and detoxification of  quinones   This leads to the protection of cells against toxicity, mutagenicity, and cancer due to exposure to environmental and synthetic  quinones  and its precursors", "triple_list": [["quinones", "PRODUCT-OF", "Quinone oxidoreductases"]]}, {"text": "The related piperidines ohmefentanyl and  sufentanil  and the nonselective opioid receptor agonist etorphine were less potent  nociceptin receptor  agonists", "triple_list": [["sufentanil", "AGONIST", "nociceptin receptor"]]}, {"text": "The related piperidines ohmefentanyl and sufentanil and the nonselective  opioid receptor  agonist  etorphine  were less potent nociceptin receptor agonists", "triple_list": [["etorphine", "AGONIST", "opioid receptor"]]}, {"text": "The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist  etorphine  were less potent  nociceptin receptor  agonists", "triple_list": [["etorphine", "AGONIST", "nociceptin receptor"]]}, {"text": "The nonselective  opioid receptor  partial agonist  buprenorphine  and the nonselective  opioid receptor  antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors", "triple_list": [["buprenorphine", "AGONIST", "opioid receptor"]]}, {"text": "The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist  (-)-quadazocine  exhibited pure antagonism at rat brain receptors, but displayed partial agonism at  human ORL1  receptors", "triple_list": [["(-)-quadazocine", "AGONIST", "human ORL1"]]}, {"text": "The  mu-opioid receptor  selective agonist  lofentanil  potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM)", "triple_list": [["lofentanil", "AGONIST", "mu-opioid receptor"]]}, {"text": " Lofentanil  exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant  ORL1  receptors (EC(50) 50 nM)", "triple_list": [["Lofentanil", "AGONIST", "ORL1"]]}, {"text": "The related  piperidines  ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent  nociceptin receptor  agonists", "triple_list": [["piperidines", "AGONIST", "nociceptin receptor"]]}, {"text": "The related piperidines  ohmefentanyl  and sufentanil and the nonselective opioid receptor agonist etorphine were less potent  nociceptin receptor  agonists", "triple_list": [["ohmefentanyl", "AGONIST", "nociceptin receptor"]]}, {"text": "The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist  naloxone benzoylhydrazone  was a pure antagonist at both rat brain and human  ORL1  receptors", "triple_list": [["naloxone benzoylhydrazone", "ANTAGONIST", "ORL1"]]}, {"text": "The kappa(1)+kappa(3)-opioid receptor agonist/ mu-opioid receptor  antagonist  naloxone benzoylhydrazone  was a pure antagonist at both rat brain and human ORL1 receptors", "triple_list": [["naloxone benzoylhydrazone", "ANTAGONIST", "mu-opioid receptor"]]}, {"text": "The nonselective  opioid receptor  partial agonist buprenorphine and the nonselective  opioid receptor  antagonist  (-)-quadazocine  exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors", "triple_list": [["(-)-quadazocine", "ANTAGONIST", "opioid receptor"]]}, {"text": "Thirty-week administration of  UFT  with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of  thymidylate synthase  inhibition and the decrease of thymidine kinase activity in the tumor cells", "triple_list": [["UFT", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Thirty-week administration of  UFT  with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of  thymidine kinase  activity in the tumor cells", "triple_list": [["UFT", "DOWNREGULATOR", "thymidine kinase"]]}, {"text": "Thirty-week administration of UFT with or without  leucovorin  markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of  thymidylate synthase  inhibition and the decrease of thymidine kinase activity in the tumor cells", "triple_list": [["leucovorin", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Thirty-week administration of UFT with or without  leucovorin  markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of  thymidine kinase  activity in the tumor cells", "triple_list": [["leucovorin", "DOWNREGULATOR", "thymidine kinase"]]}, {"text": " Thymidylate synthase  is inhibited by  5-fluorodeoxyuridine monophosphate   forming an inactive ternary complex with intracellular folate", "triple_list": [["5-fluorodeoxyuridine monophosphate", "DOWNREGULATOR", "Thymidylate synthase"]]}, {"text": " Thymidylate synthase  and thymidine kinase are key enzymes involved in the de novo and salvage pathways for  pyrimidine nucleotide  synthesis, respectively", "triple_list": [["pyrimidine nucleotide", "PRODUCT-OF", "Thymidylate synthase"]]}, {"text": "Thymidylate synthase and  thymidine kinase  are key enzymes involved in the de novo and salvage pathways for  pyrimidine nucleotide  synthesis, respectively", "triple_list": [["pyrimidine nucleotide", "PRODUCT-OF", "thymidine kinase"]]}, {"text": "Ornithine decarboxylase ( ODC   catalyses the first step in the synthesis of the polyamines putrescine,  spermidine  and spermine", "triple_list": [["spermidine", "PRODUCT-OF", "ODC"]]}, {"text": " Ornithine decarboxylase  (ODC) catalyses the first step in the synthesis of the polyamines putrescine,  spermidine  and spermine", "triple_list": [["spermidine", "PRODUCT-OF", "Ornithine decarboxylase"]]}, {"text": "Ornithine decarboxylase ( ODC   catalyses the first step in the synthesis of the polyamines putrescine, spermidine and  spermine   The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis", "triple_list": [["spermine", "PRODUCT-OF", "ODC"]]}, {"text": " Ornithine decarboxylase  (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and  spermine   The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis", "triple_list": [["spermine", "PRODUCT-OF", "Ornithine decarboxylase"]]}, {"text": "Ornithine decarboxylase ( ODC   catalyses the first step in the synthesis of the polyamines  putrescine   spermidine and spermine", "triple_list": [["putrescine", "PRODUCT-OF", "ODC"]]}, {"text": " Ornithine decarboxylase  (ODC) catalyses the first step in the synthesis of the polyamines  putrescine   spermidine and spermine", "triple_list": [["putrescine", "PRODUCT-OF", "Ornithine decarboxylase"]]}, {"text": "In  alpha(2A)-adrenoceptor  transfected cells the rank order of agonist potency was  A-54741  (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)", "triple_list": [["A-54741", "AGONIST", "alpha(2A)-adrenoceptor"]]}, {"text": "In  alpha(2A)-adrenoceptor  transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)> dexmedetomidine  (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)", "triple_list": [["dexmedetomidine", "AGONIST", "alpha(2A)-adrenoceptor"]]}, {"text": "In  alpha(2A)-adrenoceptor  transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)> UK-14304  (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)", "triple_list": [["UK-14304", "AGONIST", "alpha(2A)-adrenoceptor"]]}, {"text": "In  alpha(2A)-adrenoceptor  transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)> B-HT 920  (7.05)>noradrenaline (6.92)", "triple_list": [["B-HT 920", "AGONIST", "alpha(2A)-adrenoceptor"]]}, {"text": "In  alpha(2A)-adrenoceptor  transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)> noradrenaline  (6.92)", "triple_list": [["noradrenaline", "AGONIST", "alpha(2A)-adrenoceptor"]]}, {"text": " Glucocorticoid receptors  were activated by  dexamethasone  as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT", "triple_list": [["dexamethasone", "ACTIVATOR", "Glucocorticoid receptors"]]}, {"text": "The  glucocorticoid receptor  antagonist  RU-486  (mifepristone) significantly counteracted the effect of dexamethasone on  glucocorticoid receptor  activation, indicating that the dexamethasone effect is specific and is mediated through the  glucocorticoid receptor ", "triple_list": [["RU-486", "ANTAGONIST", "glucocorticoid receptor"]]}, {"text": "The  glucocorticoid receptor  antagonist RU-486 ( mifepristone   significantly counteracted the effect of dexamethasone on  glucocorticoid receptor  activation, indicating that the dexamethasone effect is specific and is mediated through the  glucocorticoid receptor ", "triple_list": [["mifepristone", "ANTAGONIST", "glucocorticoid receptor"]]}, {"text": "RESULTS:  Quetiapine  was an effective antipsychotic and improved the extrapyramidal symptoms and  prolactin  level elevation noted at baseline", "triple_list": [["Quetiapine", "ACTIVATOR", "prolactin"]]}, {"text": "In a physiological K(+) gradient,  TWIK-2  is half inhibited by 0.1 mm  Ba(2+)   quinine, and quinidine", "triple_list": [["Ba(2+)", "DOWNREGULATOR", "TWIK-2"]]}, {"text": "In a physiological K(+) gradient,  TWIK-2  is half inhibited by 0.1 mm Ba(2+),  quinine   and quinidine", "triple_list": [["quinine", "DOWNREGULATOR", "TWIK-2"]]}, {"text": "In a physiological K(+) gradient,  TWIK-2  is half inhibited by 0.1 mm Ba(2+), quinine, and  quinidine   Finally, cysteine 53 in the M1P1 external loop is required for functional expression of  TWIK-2  but is not critical for subunit self-assembly", "triple_list": [["quinidine", "DOWNREGULATOR", "TWIK-2"]]}, {"text": "Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of  eicosapentaenoic acid  (EPA) blocked  Delta-5-desaturase  activity, the terminal enzymatic step in AA synthesis", "triple_list": [["eicosapentaenoic acid", "DOWNREGULATOR", "Delta-5-desaturase"]]}, {"text": "Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid ( EPA   blocked  Delta-5-desaturase  activity, the terminal enzymatic step in AA synthesis", "triple_list": [["EPA", "DOWNREGULATOR", "Delta-5-desaturase"]]}, {"text": "BACKGROUND: This study examines the effects of  nicorandil   a  K(+) channel  opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)", "triple_list": [["nicorandil", "ACTIVATOR", "K(+) channel"]]}, {"text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone,  d-sotalol  (100 micromol/L) to block  I(Kr)  (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model)", "triple_list": [["d-sotalol", "DOWNREGULATOR", "I(Kr)"]]}, {"text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone,  d-sotalol  (100 micromol/L) to block I(Kr) (LQT2 model), and  ATX-II  (20 nmol/L) to augment late I(Na) (LQT3 model)", "triple_list": [["d-sotalol", "DOWNREGULATOR", "ATX-II"]]}, {"text": " Isoproterenol  (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block  I(Kr)  (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model)", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "I(Kr)"]]}, {"text": " Isoproterenol  (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and  ATX-II  (20 nmol/L) to augment late I(Na) (LQT3 model)", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "ATX-II"]]}, {"text": " Peroxisome proliferator-activated receptor alpha  (PPARalpha) activators,  bezafibrate  and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["bezafibrate", "ACTIVATOR", "Peroxisome proliferator-activated receptor alpha"]]}, {"text": "Peroxisome proliferator-activated receptor alpha (PPARalpha) activators,  bezafibrate  and Wy-14,643, increase  uncoupling protein-3  mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["bezafibrate", "ACTIVATOR", "uncoupling protein-3"]]}, {"text": "Peroxisome proliferator-activated receptor alpha ( PPARalpha   activators,  bezafibrate  and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["bezafibrate", "ACTIVATOR", "PPARalpha"]]}, {"text": " Peroxisome proliferator-activated receptor alpha  (PPARalpha) activators, bezafibrate and  Wy-14,643   increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["Wy-14,643", "ACTIVATOR", "Peroxisome proliferator-activated receptor alpha"]]}, {"text": "Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and  Wy-14,643   increase  uncoupling protein-3  mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["Wy-14,643", "ACTIVATOR", "uncoupling protein-3"]]}, {"text": "Peroxisome proliferator-activated receptor alpha ( PPARalpha   activators, bezafibrate and  Wy-14,643   increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", "triple_list": [["Wy-14,643", "ACTIVATOR", "PPARalpha"]]}, {"text": "The induction in  UCP-3  expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after  bezafibrate  or Wy-14,643 treatment", "triple_list": [["bezafibrate", "ACTIVATOR", "UCP-3"]]}, {"text": "The induction in  UCP-3  expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or  Wy-14,643  treatment", "triple_list": [["Wy-14,643", "ACTIVATOR", "UCP-3"]]}, {"text": "Since it has been proposed that  UCP-3  could be involved in the regulation of the use of fatty acids as fuel substrates, the  UCP-3  induction achieved after  bezafibrate  and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides", "triple_list": [["bezafibrate", "ACTIVATOR", "UCP-3"]]}, {"text": "Since it has been proposed that  UCP-3  could be involved in the regulation of the use of fatty acids as fuel substrates, the  UCP-3  induction achieved after bezafibrate and  Wy-14, 643  treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides", "triple_list": [["Wy-14, 643", "ACTIVATOR", "UCP-3"]]}, {"text": "Thus,  bezafibrate  treatment resulted in an 8-fold induction in  UCP-3  mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes", "triple_list": [["bezafibrate", "ACTIVATOR", "UCP-3"]]}, {"text": " Uncoupling proteins  (UCPs) are inner mitochondrial membrane transporters which act as pores for  H(+)  ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis", "triple_list": [["H(+)", "PRODUCT-OF", "Uncoupling proteins"]]}, {"text": "Uncoupling proteins ( UCPs   are inner mitochondrial membrane transporters which act as pores for  H(+)  ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis", "triple_list": [["H(+)", "PRODUCT-OF", "UCPs"]]}, {"text": "The ensemble of results suggests that the ability of  Sch B  pretreatment to enhance hepatocellular  DTD  activity may at least in part be attributed to the protection against menadione hepatotoxicity.", "triple_list": [["Sch B", "ACTIVATOR", "DTD"]]}, {"text": " Schisandrin B  protects against menadione-induced hepatotoxicity by enhancing  DT-diaphorase  activity", "triple_list": [["Schisandrin B", "ACTIVATOR", "DT-diaphorase"]]}, {"text": "Hepatocytes isolated from  Sch B  pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in  DTD  activity", "triple_list": [["Sch B", "ACTIVATOR", "DTD"]]}, {"text": "Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against  menadione  induced hepatic oxidative damage in mice, as evidenced by decreases in plasma  alanine aminotransferase  activity (78%) and hepatic malondialdehyde level (70%), when compared with the  menadione  intoxicated control", "triple_list": [["menadione", "DOWNREGULATOR", "alanine aminotransferase"]]}, {"text": " Creatine phosphokinase  activity in plasma increased slightly (compared to control,  pyridostigmine  or exercise group) in mice treated with  pyridostigmine  plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination", "triple_list": [["pyridostigmine", "ACTIVATOR", "Creatine phosphokinase"]]}, {"text": " Creatine phosphokinase  activity in plasma increased slightly (compared to control,  pyridostigmine  or exercise group) in mice treated with  pyridostigmine  plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination", "triple_list": [["pyridostigmine", "ACTIVATOR", "Creatine phosphokinase"]]}, {"text": "The group treated with  pyridostigmine  alone showed decreased plasma  butyrylcholinesterase  (BChE) activity (87% of control), whereas  pyridostigmine  plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination", "triple_list": [["pyridostigmine", "DOWNREGULATOR", "butyrylcholinesterase"]]}, {"text": "The group treated with  pyridostigmine  alone showed decreased plasma butyrylcholinesterase ( BChE   activity (87% of control), whereas  pyridostigmine  plus exercise significantly decreased the  BChE  activity (79% of control), indicating an interactive effect of the combination", "triple_list": [["pyridostigmine", "DOWNREGULATOR", "BChE"]]}, {"text": "The group treated with  pyridostigmine  alone showed decreased plasma butyrylcholinesterase ( BChE ) activity (87% of control), whereas  pyridostigmine  plus exercise significantly decreased the  BChE  activity (79% of control), indicating an interactive effect of the combination", "triple_list": [["pyridostigmine", "DOWNREGULATOR", "BChE"]]}, {"text": "However,  AChE  activity in triceps muscle decreased significantly (78% of control) in the group treated with  pyridostigmine  plus exercise", "triple_list": [["pyridostigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on  MCP-1  expression, whereas  danazol  (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on  MCP-1  expression", "triple_list": [["danazol", "DOWNREGULATOR", "MCP-1"]]}, {"text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on  MCP-1  expression, whereas danazol (10(-7)-10(-5) M), a  testosterone  analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on  MCP-1  expression", "triple_list": [["testosterone", "DOWNREGULATOR", "MCP-1"]]}, {"text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on  MCP-1  expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and  dexamethasone   an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on  MCP-1  expression", "triple_list": [["dexamethasone", "DOWNREGULATOR", "MCP-1"]]}, {"text": "RESULT(S):  Buserelin acetate   a  GnRH  agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression", "triple_list": [["Buserelin acetate", "AGONIST", "GnRH"]]}, {"text": "Mobility shift assays on whole cell extracts showed that  clenbuterol  increased AP1 binding in 3T3 cells prior to increasing  NGF  synthesis", "triple_list": [["clenbuterol", "ACTIVATOR", "NGF"]]}, {"text": "Clenbuterol was without effect on  NGF  mRNA levels in L929 cells, whereas  CB1093  caused significant increases in both  NGF  mRNA and protein levels in both 3T3 and L929 cells", "triple_list": [["CB1093", "ACTIVATOR", "NGF"]]}, {"text": "This study demonstrates that  CB1093  and clenbuterol stimulate  NGF  levels in vitro and that AP-1 binding could be a commonality between the mechanism of  NGF  induction of these two compounds.", "triple_list": [["CB1093", "ACTIVATOR", "NGF"]]}, {"text": "This study demonstrates that  CB1093  and clenbuterol stimulate  NGF  levels in vitro and that AP-1 binding could be a commonality between the mechanism of  NGF  induction of these two compounds.", "triple_list": [["CB1093", "ACTIVATOR", "NGF"]]}, {"text": "This study demonstrates that CB1093 and  clenbuterol  stimulate  NGF  levels in vitro and that AP-1 binding could be a commonality between the mechanism of  NGF  induction of these two compounds.", "triple_list": [["clenbuterol", "ACTIVATOR", "NGF"]]}, {"text": "This study demonstrates that CB1093 and  clenbuterol  stimulate  NGF  levels in vitro and that AP-1 binding could be a commonality between the mechanism of  NGF  induction of these two compounds.", "triple_list": [["clenbuterol", "ACTIVATOR", "NGF"]]}, {"text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue ( CB1093   with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce  NGF  synthesis in vivo", "triple_list": [["CB1093", "ACTIVATOR", "NGF"]]}, {"text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and  clenbuterol   a long-acting beta(2)-adrenoceptor agonist, both of which induce  NGF  synthesis in vivo", "triple_list": [["clenbuterol", "ACTIVATOR", "NGF"]]}, {"text": " Clenbuterol  caused significant increases in both  NGF  mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure", "triple_list": [["Clenbuterol", "ACTIVATOR", "NGF"]]}, {"text": "The present studies were undertaken to compare two compounds, a  vitamin D(3)  analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce  NGF  synthesis in vivo", "triple_list": [["vitamin D(3)", "DOWNREGULATOR", "NGF"]]}, {"text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and  clenbuterol   a long-acting  beta(2)-adrenoceptor  agonist, both of which induce NGF synthesis in vivo", "triple_list": [["clenbuterol", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": "CONCLUSIONS: After the initial bleach,  halothane  impeded photon absorption by  rhodopsin  by inhibiting metabolic  rhodopsin  regeneration", "triple_list": [["halothane", "DOWNREGULATOR", "rhodopsin"]]}, {"text": "RESULTS:  Halothane  anesthesia reversibly inhibited metabolic  rhodopsin  regeneration and thus prevented  rhodopsin  from absorbing high numbers of photons during light exposure", "triple_list": [["Halothane", "DOWNREGULATOR", "rhodopsin"]]}, {"text": "RESULTS:  Halothane  anesthesia reversibly inhibited metabolic  rhodopsin  regeneration and thus prevented  rhodopsin  from absorbing high numbers of photons during light exposure", "triple_list": [["Halothane", "DOWNREGULATOR", "rhodopsin"]]}, {"text": "Protective effect of  halothane  anesthesia on retinal light damage: inhibition of metabolic  rhodopsin  regeneration", "triple_list": [["halothane", "DOWNREGULATOR", "rhodopsin"]]}, {"text": "METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with  5-HT1A  and 5-HT1B receptor agonists [ buspirone  (partial  5-HT1A  agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test", "triple_list": [["buspirone", "AGONIST", "5-HT1A"]]}, {"text": "METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and  5-HT1B  receptor agonists [buspirone (partial 5-HT1A agonist),  anpirtoline  ( 5-HT1B  agonist)] in the mouse forced swimming test", "triple_list": [["anpirtoline", "AGONIST", "5-HT1B"]]}, {"text": " Pemetrexed disodium  (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase,  dihydrofolate reductase   and glycinamide ribonucleotide formyl transferase", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": " Pemetrexed disodium  (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and  glycinamide ribonucleotide formyl transferase   This agent is broadly active in a wide variety of solid tumors, including breast cancer", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "glycinamide ribonucleotide formyl transferase"]]}, {"text": " Pemetrexed disodium  (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits  thymidylate synthase   dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Pemetrexed disodium ( Alimta   LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase,  dihydrofolate reductase   and glycinamide ribonucleotide formyl transferase", "triple_list": [["Alimta", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": "Pemetrexed disodium ( Alimta   LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and  glycinamide ribonucleotide formyl transferase   This agent is broadly active in a wide variety of solid tumors, including breast cancer", "triple_list": [["Alimta", "DOWNREGULATOR", "glycinamide ribonucleotide formyl transferase"]]}, {"text": "Pemetrexed disodium ( Alimta   LY231514) is a novel, multitargeted antifolate that inhibits  thymidylate synthase   dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase", "triple_list": [["Alimta", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Pemetrexed disodium (Alimta,  LY231514   is a novel, multitargeted antifolate that inhibits thymidylate synthase,  dihydrofolate reductase   and glycinamide ribonucleotide formyl transferase", "triple_list": [["LY231514", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": "Pemetrexed disodium (Alimta,  LY231514   is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and  glycinamide ribonucleotide formyl transferase   This agent is broadly active in a wide variety of solid tumors, including breast cancer", "triple_list": [["LY231514", "DOWNREGULATOR", "glycinamide ribonucleotide formyl transferase"]]}, {"text": "Pemetrexed disodium (Alimta,  LY231514   is a novel, multitargeted antifolate that inhibits  thymidylate synthase   dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase", "triple_list": [["LY231514", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "To mechanistically evaluate this regional selectivity, we assessed  cyclo-oxygenase-2  (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and  AOM  treated rats", "triple_list": [["AOM", "ACTIVATOR", "cyclo-oxygenase-2"]]}, {"text": "To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 ( COX-2   expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and  AOM  treated rats", "triple_list": [["AOM", "ACTIVATOR", "COX-2"]]}, {"text": "We took advantage of the previous observations that  phosphatidylserine  inhibits  DGK-delta  (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H", "triple_list": [["phosphatidylserine", "DOWNREGULATOR", "DGK-delta"]]}, {"text": " Diacylglycerol kinase  (DGK) catalyzes the conversion of  diacylglycerol  to phosphatidic acid, making it an attractive candidate for a signal transduction component", "triple_list": [["diacylglycerol", "PRODUCT-OF", "Diacylglycerol kinase"]]}, {"text": "Diacylglycerol kinase ( DGK   catalyzes the conversion of  diacylglycerol  to phosphatidic acid, making it an attractive candidate for a signal transduction component", "triple_list": [["diacylglycerol", "PRODUCT-OF", "DGK"]]}, {"text": " Diacylglycerol kinase  (DGK) catalyzes the conversion of diacylglycerol to  phosphatidic acid   making it an attractive candidate for a signal transduction component", "triple_list": [["phosphatidic acid", "PRODUCT-OF", "Diacylglycerol kinase"]]}, {"text": "Diacylglycerol kinase ( DGK   catalyzes the conversion of diacylglycerol to  phosphatidic acid   making it an attractive candidate for a signal transduction component", "triple_list": [["phosphatidic acid", "PRODUCT-OF", "DGK"]]}, {"text": " Nordihydroguaiaretic acid  (NDGA) has been shown to inhibit both 5-lipoxygenase and  ornithine decarboxylase  and is active against several cancer cell lines and at least one mouse tumor model", "triple_list": [["Nordihydroguaiaretic acid", "DOWNREGULATOR", "ornithine decarboxylase"]]}, {"text": " Nordihydroguaiaretic acid  (NDGA) has been shown to inhibit both  5-lipoxygenase  and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model", "triple_list": [["Nordihydroguaiaretic acid", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": "Nordihydroguaiaretic acid ( NDGA   has been shown to inhibit both 5-lipoxygenase and  ornithine decarboxylase  and is active against several cancer cell lines and at least one mouse tumor model", "triple_list": [["NDGA", "DOWNREGULATOR", "ornithine decarboxylase"]]}, {"text": "Nordihydroguaiaretic acid ( NDGA   has been shown to inhibit both  5-lipoxygenase  and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model", "triple_list": [["NDGA", "DOWNREGULATOR", "5-lipoxygenase"]]}, {"text": " Carbonic anhydrase  (CA) is a zinc enzyme that catalyses the reversible hydration reaction of  CO2  and plays a major role in the acid-base balance", "triple_list": [["CO2", "PRODUCT-OF", "Carbonic anhydrase"]]}, {"text": "Carbonic anhydrase ( CA   is a zinc enzyme that catalyses the reversible hydration reaction of  CO2  and plays a major role in the acid-base balance", "triple_list": [["CO2", "PRODUCT-OF", "CA"]]}, {"text": "The temporal profile of butyrylcholinesterase ( BuChE ) and in vitro  pralidoxime  reactivated  BuChE  was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment", "triple_list": [["pralidoxime", "ACTIVATOR", "BuChE"]]}, {"text": "Reactivation potentials of  BuChE  (the difference between  oxime  reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion", "triple_list": [["oxime", "ACTIVATOR", "BuChE"]]}, {"text": "Patients who received  oxime  prior to hospitalization had a higher rate of intermediate syndrome and lower levels of  BuChE  at admission than those who had not", "triple_list": [["oxime", "DOWNREGULATOR", "BuChE"]]}, {"text": "Reactivation potentials of  BuChE  (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after  organophosphate  ingestion", "triple_list": [["organophosphate", "DOWNREGULATOR", "BuChE"]]}, {"text": "CONCLUSIONS: The  alpha(2)-adrenoceptor  agonists  brimonidine   apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery", "triple_list": [["brimonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "CONCLUSIONS: The  alpha(2)-adrenoceptor  agonists brimonidine,  apraclonidine   and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery", "triple_list": [["apraclonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "CONCLUSIONS: The  alpha(2)-adrenoceptor  agonists brimonidine, apraclonidine, and  oxymetazoline  are potent vasoconstrictors in the porcine ciliary artery", "triple_list": [["oxymetazoline", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "The segments were contracted with the  alpha(2)-adrenoceptor  agonists  brimonidine   apraclonidine, and oxymetazoline", "triple_list": [["brimonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "The segments were contracted with the  alpha(2)-adrenoceptor  agonists brimonidine,  apraclonidine   and oxymetazoline", "triple_list": [["apraclonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "The segments were contracted with the  alpha(2)-adrenoceptor  agonists brimonidine, apraclonidine, and  oxymetazoline   To determine which subtypes of the  alpha(2)-adrenoceptor  mediate this contraction, antagonists subselective for the different  alpha(2)-adrenoceptor s were added to the vessel bath before concentration-response curves for brimonidine were obtained", "triple_list": [["oxymetazoline", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "RESULTS: The  alpha(2)-adrenoceptor  agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar:  brimonidine  2.11, oxymetazoline 5.26, and apraclonidine 13.0", "triple_list": [["brimonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "RESULTS: The  alpha(2)-adrenoceptor  agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11,  oxymetazoline  5.26, and apraclonidine 13.0", "triple_list": [["oxymetazoline", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "RESULTS: The  alpha(2)-adrenoceptor  agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and  apraclonidine  13.0", "triple_list": [["apraclonidine", "AGONIST", "alpha(2)-adrenoceptor"]]}, {"text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for  BRL44408  (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional  alpha(2A)-adrenoceptors   Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue", "triple_list": [["BRL44408", "ANTAGONIST", "alpha(2A)-adrenoceptors"]]}, {"text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8),  ARC 239  (5.8) and for prazosin (6.0) suggesting the presence of functional  alpha(2A)-adrenoceptors   Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue", "triple_list": [["ARC 239", "ANTAGONIST", "alpha(2A)-adrenoceptors"]]}, {"text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for  prazosin  (6.0) suggesting the presence of functional  alpha(2A)-adrenoceptors   Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue", "triple_list": [["prazosin", "ANTAGONIST", "alpha(2A)-adrenoceptors"]]}, {"text": "The following alpha(2)-adrenoceptor antagonists were applied:  BRL44408  ( alpha(2A)  selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)", "triple_list": [["BRL44408", "ANTAGONIST", "alpha(2A)"]]}, {"text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective),  ARC239  ( alpha(2B)   and alpha(2C)-selective), and prazosin ( alpha(2B) - and alpha(2C)-selective)", "triple_list": [["ARC239", "ANTAGONIST", "alpha(2B)"]]}, {"text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective),  ARC239  (alpha(2B)- and  alpha(2C)  selective), and prazosin (alpha(2B)- and  alpha(2C) -selective)", "triple_list": [["ARC239", "ANTAGONIST", "alpha(2C)"]]}, {"text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 ( alpha(2B) - and alpha(2C)-selective), and  prazosin  ( alpha(2B)   and alpha(2C)-selective)", "triple_list": [["prazosin", "ANTAGONIST", "alpha(2B)"]]}, {"text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and  alpha(2C) -selective), and  prazosin  (alpha(2B)- and  alpha(2C)  selective)", "triple_list": [["prazosin", "ANTAGONIST", "alpha(2C)"]]}, {"text": " Pemetrexed disodium  (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes,  thymidylate synthase   dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": " Pemetrexed disodium  (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase,  dihydrofolate reductase   and glycinamide ribonucleotide formyltransferase", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": " Pemetrexed disodium  (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and  glycinamide ribonucleotide formyltransferase    Pemetrexed disodium  is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers", "triple_list": [["Pemetrexed disodium", "DOWNREGULATOR", "glycinamide ribonucleotide formyltransferase"]]}, {"text": "Pemetrexed disodium ( ALIMTA   is a novel antimetabolite that inhibits at least three folate-dependent enzymes,  thymidylate synthase   dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase", "triple_list": [["ALIMTA", "DOWNREGULATOR", "thymidylate synthase"]]}, {"text": "Pemetrexed disodium ( ALIMTA   is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase,  dihydrofolate reductase   and glycinamide ribonucleotide formyltransferase", "triple_list": [["ALIMTA", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": "Pemetrexed disodium ( ALIMTA   is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and  glycinamide ribonucleotide formyltransferase   Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers", "triple_list": [["ALIMTA", "DOWNREGULATOR", "glycinamide ribonucleotide formyltransferase"]]}, {"text": " DHFS  is present exclusively in the mitochondria, making this compartment the sole site of synthesis of  dihydrofolate  in the plant cell", "triple_list": [["dihydrofolate", "PRODUCT-OF", "DHFS"]]}, {"text": "CONCLUSION:  Rabeprazole  is a well tolerated  proton pump  inhibitor", "triple_list": [["Rabeprazole", "DOWNREGULATOR", "proton pump"]]}, {"text": "UNLABELLED:  Rabeprazole  is an inhibitor of the  gastric proton pump   It causes dose-dependent inhibition of acid secretion", "triple_list": [["Rabeprazole", "DOWNREGULATOR", "gastric proton pump"]]}, {"text": "At the same time, mean plasma active  renin  was increased 16- and 34-fold at the highest dose of  Aliskiren   Plasma drug levels of  Aliskiren  were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing", "triple_list": [["Aliskiren", "ACTIVATOR", "renin"]]}, {"text": "In conclusion, the  renin  inhibitor  Aliskiren  dose-dependently decreases Ang II levels in humans following oral administration", "triple_list": [["Aliskiren", "DOWNREGULATOR", "renin"]]}, {"text": "In conclusion, the renin inhibitor  Aliskiren  dose-dependently decreases  Ang II  levels in humans following oral administration", "triple_list": [["Aliskiren", "DOWNREGULATOR", "Ang II"]]}, {"text": " Aliskiren  has the potential to become the first orally active  renin  inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.", "triple_list": [["Aliskiren", "DOWNREGULATOR", "renin"]]}, {"text": " Aliskiren  has the potential to become the first orally active renin inhibitor that provides a true alternative to  ACE  inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.", "triple_list": [["Aliskiren", "DOWNREGULATOR", "ACE"]]}, {"text": "We tested the new orally active nonpeptidic  renin  inhibitor  SPP100  (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol", "triple_list": [["SPP100", "DOWNREGULATOR", "renin"]]}, {"text": "We tested the new orally active nonpeptidic  renin  inhibitor SPP100 ( Aliskiren   an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol", "triple_list": [["Aliskiren", "DOWNREGULATOR", "renin"]]}, {"text": "We tested the new orally active nonpeptidic  renin  inhibitor SPP100 (Aliskiren, an  octanamide  with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol", "triple_list": [["octanamide", "DOWNREGULATOR", "renin"]]}, {"text": "There was a dose-dependent decrease in plasma  renin  activity, Ang I, and Ang II following single doses of  Aliskiren  starting with 40 mg", "triple_list": [["Aliskiren", "DOWNREGULATOR", "renin"]]}, {"text": "There was a dose-dependent decrease in plasma renin activity,  Ang I   and  Ang I I following single doses of  Aliskiren  starting with 40 mg", "triple_list": [["Aliskiren", "DOWNREGULATOR", "Ang I"]]}, {"text": "There was a dose-dependent decrease in plasma renin activity, Ang I, and  Ang II  following single doses of  Aliskiren  starting with 40 mg", "triple_list": [["Aliskiren", "DOWNREGULATOR", "Ang II"]]}, {"text": " Angiotensin II  suppression in humans by the orally active renin inhibitor  Aliskiren  (SPP100): comparison with enalapril", "triple_list": [["Aliskiren", "DOWNREGULATOR", "Angiotensin II"]]}, {"text": "Angiotensin II suppression in humans by the orally active  renin  inhibitor  Aliskiren  (SPP100): comparison with enalapril", "triple_list": [["Aliskiren", "DOWNREGULATOR", "renin"]]}, {"text": " Angiotensin II  suppression in humans by the orally active renin inhibitor Aliskiren ( SPP100  : comparison with enalapril", "triple_list": [["SPP100", "DOWNREGULATOR", "Angiotensin II"]]}, {"text": "Angiotensin II suppression in humans by the orally active  renin  inhibitor Aliskiren ( SPP100  : comparison with enalapril", "triple_list": [["SPP100", "DOWNREGULATOR", "renin"]]}, {"text": "Inhibition was still marked and significant after repeated dosing with maximal decreases in  Ang II  levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of  Aliskiren  was compared with placebo", "triple_list": [["Aliskiren", "DOWNREGULATOR", "Ang II"]]}, {"text": " Aliskiren  has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and  Ang II receptor  antagonists in therapy for hypertension and other cardiovascular and renal diseases.", "triple_list": [["Aliskiren", "ANTAGONIST", "Ang II receptor"]]}, {"text": "The earliest known  AChE  inhibitors, namely,  physostigmine  and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)", "triple_list": [["physostigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "The earliest known  AChE  inhibitors, namely, physostigmine and  tacrine   performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)", "triple_list": [["tacrine", "DOWNREGULATOR", "AChE"]]}, {"text": " Donepezil hydrochloride  inaugurates a new class of  AChE  inhibitors with longer and more selective action and with manageable adverse effects.", "triple_list": [["Donepezil hydrochloride", "DOWNREGULATOR", "AChE"]]}, {"text": " Thalidomide  -removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of  TNF alpha   It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma", "triple_list": [["Thalidomide", "DOWNREGULATOR", "TNF alpha"]]}, {"text": "As a prodrug  leflunomide  is completely converted to its active metabolite A 77 1726 (M1) which blocks the  dihydroorotate dehydrogenase   a key enzyme of the pyrimidine de novo synthesis", "triple_list": [["leflunomide", "DOWNREGULATOR", "dihydroorotate dehydrogenase"]]}, {"text": "As a prodrug leflunomide is completely converted to its active metabolite  A 77 1726  (M1) which blocks the  dihydroorotate dehydrogenase   a key enzyme of the pyrimidine de novo synthesis", "triple_list": [["A 77 1726", "DOWNREGULATOR", "dihydroorotate dehydrogenase"]]}, {"text": "A recent study showed that  anastrozole   an  aromatase  inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy", "triple_list": [["anastrozole", "DOWNREGULATOR", "aromatase"]]}, {"text": " Fulvestrant   the first agent in this new class, not only induces the degradation of the  estrogen receptor  but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile", "triple_list": [["Fulvestrant", "DOWNREGULATOR", "estrogen receptor"]]}, {"text": " Lovastatin   a specific inhibitor of  HMG-CoA reductase   induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC", "triple_list": [["Lovastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": "Chronic treatment with the  NET  inhibitor,  desipramine  (DMI), reduced  NET  levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of  NET  by antidepressant drugs", "triple_list": [["desipramine", "DOWNREGULATOR", "NET"]]}, {"text": "Chronic treatment with the  NET  inhibitor,  desipramine  (DMI), reduced  NET  levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of  NET  by antidepressant drugs", "triple_list": [["desipramine", "DOWNREGULATOR", "NET"]]}, {"text": "Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific  alpha(4)beta(2*) nAChR  agonist  metanicotine   or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates", "triple_list": [["metanicotine", "AGONIST", "alpha(4)beta(2*) nAChR"]]}, {"text": "Probes were perfused with artificial cerebrospinal fluid containing  nicotine , the specific  alpha(4)beta(2*) nAChR  agonist meta nicotine , or  nicotine  plus nAChR antagonists and norepinephrine measured in the microdialysates", "triple_list": [["nicotine", "AGONIST", "alpha(4)beta(2*) nAChR"]]}, {"text": " Cilostazol  decreases levels of serum triglycerides and causes some increase in  HDL  cholesterol levels", "triple_list": [["Cilostazol", "ACTIVATOR", "HDL"]]}, {"text": " Cilostazol  undergoes intensive and finally complete hepatic metabolism via the  cytochrome P450  systems", "triple_list": [["Cilostazol", "PRODUCT-OF", "cytochrome P450"]]}, {"text": "In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for  cilostazol  but no difference for milrinone from the recombinant  PDE3A   Molecular models show that the PDE3 inhibitors  cilostazol  and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE3A"]]}, {"text": "In contrast, the mutants  T844A   F972A and Q975A showed increased K(i) for  cilostazol  but no difference for milrinone from the recombinant PDE3A", "triple_list": [["cilostazol", "DOWNREGULATOR", "T844A"]]}, {"text": "In contrast, the mutants T844A,  F972A  and Q975A showed increased K(i) for  cilostazol  but no difference for milrinone from the recombinant PDE3A", "triple_list": [["cilostazol", "DOWNREGULATOR", "F972A"]]}, {"text": "In contrast, the mutants T844A, F972A and  Q975A  showed increased K(i) for  cilostazol  but no difference for milrinone from the recombinant PDE3A", "triple_list": [["cilostazol", "DOWNREGULATOR", "Q975A"]]}, {"text": "In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for  milrinone  from the recombinant  PDE3A   Molecular models show that the PDE3 inhibitors cilostazol and  milrinone  share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site", "triple_list": [["milrinone", "DOWNREGULATOR", "PDE3A"]]}, {"text": "In contrast, the mutants  T844A   F972A and Q975A showed increased K(i) for cilostazol but no difference for  milrinone  from the recombinant PDE3A", "triple_list": [["milrinone", "DOWNREGULATOR", "T844A"]]}, {"text": "In contrast, the mutants T844A,  F972A  and Q975A showed increased K(i) for cilostazol but no difference for  milrinone  from the recombinant PDE3A", "triple_list": [["milrinone", "DOWNREGULATOR", "F972A"]]}, {"text": "In contrast, the mutants T844A, F972A and  Q975A  showed increased K(i) for cilostazol but no difference for  milrinone  from the recombinant PDE3A", "triple_list": [["milrinone", "DOWNREGULATOR", "Q975A"]]}, {"text": "Molecular models show that the  PDE3  inhibitors  cilostazol  and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against  PDE3  active site", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE3"]]}, {"text": "Molecular models show that the  PDE3  inhibitors cilostazol and  milrinone  share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against  PDE3  active site", "triple_list": [["milrinone", "DOWNREGULATOR", "PDE3"]]}, {"text": "Our study implies that highly conserved residuals Y751, D950 and F1004 in the  PDE  families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the  cilostazol  selectivity of  PDE 3A", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE"]]}, {"text": "Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the  cilostazol  selectivity of  PDE3A   Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE3A"]]}, {"text": "We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by  milrinone  and cilostazol, specific inhibitors of  PDE3   The mutants displayed differential sensitivity to the inhibitors", "triple_list": [["milrinone", "DOWNREGULATOR", "PDE3"]]}, {"text": "We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and  cilostazol   specific inhibitors of  PDE3   The mutants displayed differential sensitivity to the inhibitors", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE3"]]}, {"text": "Mutants  Y751A   D950A, and F1004A had reduced sensitivity to  milrinone  (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)", "triple_list": [["milrinone", "DOWNREGULATOR", "Y751A"]]}, {"text": "Mutants Y751A,  D950A   and F1004A had reduced sensitivity to  milrinone  (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)", "triple_list": [["milrinone", "DOWNREGULATOR", "D950A"]]}, {"text": "Mutants Y751A, D950A, and  F1004A  had reduced sensitivity to  milrinone  (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)", "triple_list": [["milrinone", "DOWNREGULATOR", "F1004A"]]}, {"text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to  milrinone  (K(i) changed from 0.66 microM for the recombinant  PDE3A  to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant  PDE3A )", "triple_list": [["milrinone", "DOWNREGULATOR", "PDE3A"]]}, {"text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant  PDE3A  to 7.5 to 156 microM for the mutants), and diminished sensitivity to  cilostazol  (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant  PDE3A  ", "triple_list": [["cilostazol", "DOWNREGULATOR", "PDE3A"]]}, {"text": "The bacterial enzyme  maltodextrin phosphorylase  (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as  glucose-1-phosphate  (Glc1P)", "triple_list": [["glucose-1-phosphate", "PRODUCT-OF", "maltodextrin phosphorylase"]]}, {"text": "The bacterial enzyme maltodextrin phosphorylase ( MalP   catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as  glucose-1-phosphate  (Glc1P)", "triple_list": [["glucose-1-phosphate", "PRODUCT-OF", "MalP"]]}, {"text": "The bacterial enzyme  maltodextrin phosphorylase  (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ( Glc1P  ", "triple_list": [["Glc1P", "PRODUCT-OF", "maltodextrin phosphorylase"]]}, {"text": "The bacterial enzyme maltodextrin phosphorylase ( MalP   catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ( Glc1P  ", "triple_list": [["Glc1P", "PRODUCT-OF", "MalP"]]}, {"text": "OBJECTIVE:  Fondaparinux sodium  is the first in a new class of synthetic  factor Xa  inhibitors that binds reversibly with high affinity to antithrombin III", "triple_list": [["Fondaparinux sodium", "DOWNREGULATOR", "factor Xa"]]}, {"text": "It is caused by a deficiency of  propionyl-CoA  carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of  propionyl-CoA  to D-methylmalonyl-CoA", "triple_list": [["propionyl-CoA", "PRODUCT-OF", "propionyl-CoA carboxylase"]]}, {"text": "It is caused by a deficiency of  propionyl-CoA  carboxylase ( PCC   EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of  propionyl-CoA  to D-methylmalonyl-CoA", "triple_list": [["propionyl-CoA", "PRODUCT-OF", "PCC"]]}, {"text": "It is caused by a deficiency of  propionyl-CoA  carboxylase (PCC,  EC 6.4.1.3  , a biotin-dependent enzyme that catalyzes the carboxylation of  propionyl-CoA  to D-methylmalonyl-CoA", "triple_list": [["propionyl-CoA", "PRODUCT-OF", "EC 6.4.1.3"]]}, {"text": "It is caused by a deficiency of  propionyl-CoA carboxylase  (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to  D-methylmalonyl-CoA   PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits", "triple_list": [["D-methylmalonyl-CoA", "PRODUCT-OF", "propionyl-CoA carboxylase"]]}, {"text": "It is caused by a deficiency of propionyl-CoA carboxylase ( PCC   EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to  D-methylmalonyl-CoA    PCC  is a heteropolymeric enzyme composed of alpha- and beta-subunits", "triple_list": [["D-methylmalonyl-CoA", "PRODUCT-OF", "PCC"]]}, {"text": "It is caused by a deficiency of propionyl-CoA carboxylase (PCC,  EC 6.4.1.3  , a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to  D-methylmalonyl-CoA   PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits", "triple_list": [["D-methylmalonyl-CoA", "PRODUCT-OF", "EC 6.4.1.3"]]}, {"text": "Although only  clozapine  and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined  5-HT(2A)  and D(2) blockade", "triple_list": [["clozapine", "DOWNREGULATOR", "5-HT(2A)"]]}, {"text": "Although only  clozapine  and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and  D(2)  blockade", "triple_list": [["clozapine", "DOWNREGULATOR", "D(2)"]]}, {"text": "Although only clozapine and  ziprasidone  are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined  5-HT(2A)  and D(2) blockade", "triple_list": [["ziprasidone", "DOWNREGULATOR", "5-HT(2A)"]]}, {"text": "Although only clozapine and  ziprasidone  are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and  D(2)  blockade", "triple_list": [["ziprasidone", "DOWNREGULATOR", "D(2)"]]}, {"text": "Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists,  WAY100635   a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined  5-HT(2A)  and D(2) blockade", "triple_list": [["WAY100635", "DOWNREGULATOR", "5-HT(2A)"]]}, {"text": "Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists,  WAY100635   a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and  D(2)  blockade", "triple_list": [["WAY100635", "DOWNREGULATOR", "D(2)"]]}, {"text": "However,  5-HT(1A)  agonism may be important only for  quetiapine  induced ACh release.", "triple_list": [["quetiapine", "AGONIST", "5-HT(1A)"]]}, {"text": "Although only  clozapine  and ziprasidone are directly acting  5-HT(1A)  agonists, WAY100635, a selective  5-HT(1A)  antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade", "triple_list": [["clozapine", "AGONIST", "5-HT(1A)"]]}, {"text": "Although only clozapine and  ziprasidone  are directly acting  5-HT(1A)  agonists, WAY100635, a selective  5-HT(1A)  antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade", "triple_list": [["ziprasidone", "AGONIST", "5-HT(1A)"]]}, {"text": "Although only clozapine and ziprasidone are directly acting  5-HT(1A)  agonists,  WAY100635   a selective  5-HT(1A)  antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade", "triple_list": [["WAY100635", "ANTAGONIST", "5-HT(1A)"]]}, {"text": "BACKGROUND: The novel antiepileptic drug  retigabine  is the first selective M-current potassium channel opener for  KCNQ2/3  and KCNQ3/5 channels", "triple_list": [["retigabine", "ACTIVATOR", "KCNQ2/3"]]}, {"text": "BACKGROUND: The novel antiepileptic drug  retigabine  is the first selective M-current potassium channel opener for KCNQ2/3 and  KCNQ3/5  channels", "triple_list": [["retigabine", "ACTIVATOR", "KCNQ3/5"]]}, {"text": "BACKGROUND: The novel antiepileptic drug  retigabine  is the first selective  M-current potassium channel  opener for KCNQ2/3 and KCNQ3/5 channels", "triple_list": [["retigabine", "ACTIVATOR", "M-current potassium channel"]]}, {"text": "OBJECTIVE: Because of these physiological effects and the widespread use of the selective  COX-2  inhibitor,  celecoxib   we wanted to determine if inhibition of  COX-2  would affect incisional skin wound healing", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of  COX -2 in the wound healing process by comparing the effects of a nonselective  COX  inhibitor,  diclofenac   with a selective  COX -2 inhibitor, SC-791", "triple_list": [["diclofenac", "DOWNREGULATOR", "COX"]]}, {"text": "The effects of histamine H1-receptor antagonists,  promethazine  and homochlorcyclizine, both of which are inhibitors of  CYP2D6   on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks", "triple_list": [["promethazine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "The effects of histamine H1-receptor antagonists, promethazine and  homochlorcyclizine   both of which are inhibitors of  CYP2D6   on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks", "triple_list": [["homochlorcyclizine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "Thus, the current study suggests that coadministration of clinical doses of  promethazine  and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the  CYP2D6  catalyzed metabolism of haloperidol and reduced haloperidol.", "triple_list": [["promethazine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and  homochlorcyclizine  increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the  CYP2D6  catalyzed metabolism of haloperidol and reduced haloperidol.", "triple_list": [["homochlorcyclizine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "The effects of  histamine H1-receptor  antagonists,  promethazine  and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks", "triple_list": [["promethazine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": "The effects of  histamine H1-receptor  antagonists, promethazine and  homochlorcyclizine   both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks", "triple_list": [["homochlorcyclizine", "ANTAGONIST", "histamine H1-receptor"]]}, {"text": " Histamine H1-receptor  antagonists,  promethazine  and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol", "triple_list": [["promethazine", "ANTAGONIST", "Histamine H1-receptor"]]}, {"text": " Histamine H1-receptor  antagonists, promethazine and  homochlorcyclizine   increase the steady-state plasma concentrations of haloperidol and reduced haloperidol", "triple_list": [["homochlorcyclizine", "ANTAGONIST", "Histamine H1-receptor"]]}, {"text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of  haloperidol  and reduced  haloperidol  via the inhibitory effects on the  CYP2D6  catalyzed metabolism of  haloperidol  and reduced  haloperidol  ", "triple_list": [["haloperidol", "PRODUCT-OF", "CYP2D6"]]}, {"text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of  haloperidol  and reduced  haloperidol  via the inhibitory effects on the  CYP2D6  catalyzed metabolism of  haloperidol  and reduced  haloperidol .", "triple_list": [["haloperidol", "PRODUCT-OF", "CYP2D6"]]}, {"text": "The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of  OTCase  to  ornithine  and to arginase and appear to be involved in transducing and enhancing the signal given by  ornithine  for the closure of the catalytic domain.", "triple_list": [["ornithine", "DOWNREGULATOR", "OTCase"]]}, {"text": "Inhibition of binding of both  plasminogen  and plasmin to gp330 by  benzamidine  was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of  plasminogen  to gp330", "triple_list": [["benzamidine", "DOWNREGULATOR", "plasminogen"]]}, {"text": "Inhibition of binding of both  plasmin ogen and  plasmin  to gp330 by  benzamidine  was similar, although EACA inhibited the binding of  plasmin  to gp330 slightly more than the binding of  plasmin ogen to gp330", "triple_list": [["benzamidine", "DOWNREGULATOR", "plasmin"]]}, {"text": "Inhibition of binding of both  plasmin ogen and  plasmin  to gp330 by benzamidine was similar, although  EACA  inhibited the binding of  plasmin  to gp330 slightly more than the binding of  plasmin ogen to gp330", "triple_list": [["EACA", "DOWNREGULATOR", "plasmin"]]}, {"text": "Inhibition of binding of both  plasminogen  and plasmin to gp330 by benzamidine was similar, although  EACA  inhibited the binding of plasmin to gp330 slightly more than the binding of  plasminogen  to gp330", "triple_list": [["EACA", "DOWNREGULATOR", "plasminogen"]]}, {"text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective  alpha-adrenoceptor  antagonists,  phentolamine  (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg)", "triple_list": [["phentolamine", "ANTAGONIST", "alpha-adrenoceptor"]]}, {"text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective  alpha-adrenoceptor  antagonists, phentolamine (0.3-3 mg/kg) and  phenoxybenzamine  (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg)", "triple_list": [["phenoxybenzamine", "ANTAGONIST", "alpha-adrenoceptor"]]}, {"text": "Involvement of  alpha(1)-adrenoceptor s was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective  alpha(1)-adrenoceptor  antagonist,  prazosin  (0.3 mg/kg)", "triple_list": [["prazosin", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "The  alpha(2)-adrenoceptor  antagonist,  rauwolscine  (0.5 mg/kg), was without antagonistic effects", "triple_list": [["rauwolscine", "ANTAGONIST", "alpha(2)-adrenoceptor"]]}, {"text": " alpha(1A)-Adrenoceptor  selective antagonists,  2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane  (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane", "ANTAGONIST", "alpha(1A)-Adrenoceptor"]]}, {"text": " alpha(1A)-Adrenoceptor  selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane ( WB-4101   0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["WB-4101", "ANTAGONIST", "alpha(1A)-Adrenoceptor"]]}, {"text": " alpha(1A)-Adrenoceptor  selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and  5-methylurapidil  (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["5-methylurapidil", "ANTAGONIST", "alpha(1A)-Adrenoceptor"]]}, {"text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the  alpha(1B)-adrenoceptor  selective antagonist,  4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline  (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline", "ANTAGONIST", "alpha(1B)-adrenoceptor"]]}, {"text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the  alpha(1B)-adrenoceptor  selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline ( L-765314   0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["L-765314", "ANTAGONIST", "alpha(1B)-adrenoceptor"]]}, {"text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the  alpha(1D)-adrenoceptor  selective antagonist,  8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione  (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione", "ANTAGONIST", "alpha(1D)-adrenoceptor"]]}, {"text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the  alpha(1D)-adrenoceptor  selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione ( BMY-7378   1 mg/kg), were used to delineate the adrenoceptor subtypes involved", "triple_list": [["BMY-7378", "ANTAGONIST", "alpha(1D)-adrenoceptor"]]}, {"text": "To further investigate this positive correlation and its possible therapeutic implications, a selective  COX-2  inhibitor,  etodolac   was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and  COX-2  expression levels", "triple_list": [["etodolac", "DOWNREGULATOR", "COX-2"]]}, {"text": "However, other  alpha(1)-adrenoceptor  antagonists ( tamsulosin   WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit  alpha(1)-adrenoceptor  antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding", "triple_list": [["tamsulosin", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "However, other  alpha(1)-adrenoceptor  antagonists (tamsulosin,  WB4101  and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit  alpha(1)-adrenoceptor  antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding", "triple_list": [["WB4101", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "However, other  alpha(1)-adrenoceptor  antagonists (tamsulosin, WB4101 and  corynanthine   did not inhibit the binding at a range of concentrations that generally exhibit  alpha(1)-adrenoceptor  antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding", "triple_list": [["corynanthine", "ANTAGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "A comparison of the results with previous data for desipramine and cocaine inhibition of  norepinephrine  uptake by the mutant  hNETs  reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.", "triple_list": [["norepinephrine", "PRODUCT-OF", "hNETs"]]}, {"text": "The potency of MrIA was greater for inhibition of uptake by  hNET  of  [3H]norepinephrine  (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)", "triple_list": [["[3H]norepinephrine", "PRODUCT-OF", "hNET"]]}, {"text": "The potency of MrIA was greater for inhibition of uptake by  hNET  of [3H]norepinephrine (Ki 1.89 microM) than  [3H]dopamine  (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)", "triple_list": [["[3H]dopamine", "PRODUCT-OF", "hNET"]]}, {"text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase,  ACY-1   [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of  N-acylated L-amino acids  except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced", "triple_list": [["N-acylated L-amino acids", "PRODUCT-OF", "ACY-1"]]}, {"text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [ EC 3.5.1.14  , a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of  N-acylated L-amino acids  except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced", "triple_list": [["N-acylated L-amino acids", "PRODUCT-OF", "EC 3.5.1.14"]]}, {"text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric  metalloprotein  having two Zn2+ in the molecule, which catalyzes the deacylation of  N-acylated L-amino acids  except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced", "triple_list": [["N-acylated L-amino acids", "PRODUCT-OF", "metalloprotein"]]}, {"text": "A cDNA encoding the complete amino acid sequence of  aminoacylase 1  (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of  N-acylated L-amino acids  except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced", "triple_list": [["N-acylated L-amino acids", "PRODUCT-OF", "aminoacylase 1"]]}, {"text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 ( N-acylamino acid aminohydrolase   ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of  N-acylated L-amino acids  except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced", "triple_list": [["N-acylated L-amino acids", "PRODUCT-OF", "N-acylamino acid aminohydrolase"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a  cyclooxygenase-2  (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications,  salsalate   or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["salsalate", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ( COX-2   inhibitor comparator (traditional nonsteroidal antiinflammatory medications,  salsalate   or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["salsalate", "DOWNREGULATOR", "COX-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a  cyclooxygenase-2  (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or  acetaminophen   randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["acetaminophen", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ( COX-2   inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or  acetaminophen   randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["acetaminophen", "DOWNREGULATOR", "COX-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a  cyclooxygenase-2  (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received  celecoxib  200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["celecoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ( COX-2   inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received  celecoxib  200 mg/day or rofecoxib 25 mg/day for three weeks", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a  cyclooxygenase-2  (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or  rofecoxib  25 mg/day for three weeks", "triple_list": [["rofecoxib", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ( COX-2   inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or  rofecoxib  25 mg/day for three weeks", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS:  Eprosartan  tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating  Ang-II  levels (p<0.01)", "triple_list": [["Eprosartan", "ACTIVATOR", "Ang-II"]]}, {"text": "We sought to assess the effects of the  angiotensin type 1 (AT1) receptor  blocker  eprosartan  on HRV and BRG", "triple_list": [["eprosartan", "DOWNREGULATOR", "angiotensin type 1 (AT1) receptor"]]}, {"text": " AT1  antagonism by  eprosartan  lowers heart rate variability and baroreflex gain", "triple_list": [["eprosartan", "ANTAGONIST", "AT1"]]}, {"text": "CONCLUSIONS:  AT1  antagonism by  eprosartan  lowers heart rate variability and baroreflex gain", "triple_list": [["eprosartan", "ANTAGONIST", "AT1"]]}, {"text": "The antinociceptive activity of the  alpha 2-adrenoceptor  agonist  clonidine  was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31)", "triple_list": [["clonidine", "AGONIST", "alpha 2-adrenoceptor"]]}, {"text": "In seven normal subjects, basal  ACTH  plasma levels were significantly suppressed 3 h after  loperamide  administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001)", "triple_list": [["loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms  human CRH   100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "human CRH"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms  GnRH   100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "GnRH"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms  GH-releasing hormone   and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "GH-releasing hormone"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms  TRH  , the ACTH peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "TRH"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the  ACTH  peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of  ACTH  from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the  ACTH  peak (maximum increase at 30 min) was significantly blunted by  loperamide  from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of  ACTH  from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05)", "triple_list": [["loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": " Loperamide   an opiate agonist of high specificity for mu-receptors, was recently reported to suppress  ACTH  and cortisol levels in normal subjects, but not in patients with proven  ACTH -dependent Cushing's disease", "triple_list": [["Loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": "In summary,  loperamide  is able to reduce basal and  CRH  induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin", "triple_list": [["loperamide", "DOWNREGULATOR", "CRH"]]}, {"text": "In summary,  loperamide  is able to reduce basal and CRH-induced  ACTH  and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin", "triple_list": [["loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": "We also examined the effects of  WEB 2086   a  platelet-activating factor (PAF) receptor  antagonist, in parallel", "triple_list": [["WEB 2086", "ANTAGONIST", "platelet-activating factor (PAF) receptor"]]}, {"text": "The compounds identified as  5-LO  inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where  hydroxamic acids  are potent and more selective inhibitors of  5-LO   The benzothiophene hydroxyurea, zileuton, is the first selective  5-LO  inhibitor evaluated for the treatment of patients with IBD", "triple_list": [["hydroxamic acids", "DOWNREGULATOR", "5-LO"]]}, {"text": "The  benzothiophene hydroxyurea   zileuton, is the first selective  5-LO  inhibitor evaluated for the treatment of patients with IBD", "triple_list": [["benzothiophene hydroxyurea", "DOWNREGULATOR", "5-LO"]]}, {"text": "The benzothiophene hydroxyurea,  zileuton   is the first selective  5-LO  inhibitor evaluated for the treatment of patients with IBD", "triple_list": [["zileuton", "DOWNREGULATOR", "5-LO"]]}, {"text": "The unique role of the enzyme  5-lipoxygenase  (5-LO) in the production of  leukotrienes  (LTs) makes it a likely target for biochemical manipulation", "triple_list": [["leukotrienes", "PRODUCT-OF", "5-lipoxygenase"]]}, {"text": "The unique role of the enzyme 5-lipoxygenase ( 5-LO   in the production of  leukotrienes  (LTs) makes it a likely target for biochemical manipulation", "triple_list": [["leukotrienes", "PRODUCT-OF", "5-LO"]]}, {"text": "The unique role of the enzyme  5-lipoxygenase  (5-LO) in the production of leukotrienes ( LTs   makes it a likely target for biochemical manipulation", "triple_list": [["LTs", "PRODUCT-OF", "5-lipoxygenase"]]}, {"text": "The unique role of the enzyme 5-lipoxygenase ( 5-LO   in the production of leukotrienes ( LTs   makes it a likely target for biochemical manipulation", "triple_list": [["LTs", "PRODUCT-OF", "5-LO"]]}, {"text": "In PC3 cells,  hydroxyurea  inhibited  hRRM2  and resulted in increased sensitivity to UV irradiation", "triple_list": [["hydroxyurea", "DOWNREGULATOR", "hRRM2"]]}, {"text": "Ribonucleotide reductase ( RR   is responsible for the de novo conversion of the ribonucleoside diphosphates to  deoxyribonucleoside diphosphates   which are essential for DNA synthesis and repair", "triple_list": [["deoxyribonucleoside diphosphates", "PRODUCT-OF", "RR"]]}, {"text": " Ribonucleotide reductase  (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to  deoxyribonucleoside diphosphates   which are essential for DNA synthesis and repair", "triple_list": [["deoxyribonucleoside diphosphates", "PRODUCT-OF", "Ribonucleotide reductase"]]}, {"text": "Ribonucleotide reductase ( RR   is responsible for the de novo conversion of the  ribonucleoside diphosphates  to deoxy ribonucleoside diphosphates , which are essential for DNA synthesis and repair", "triple_list": [["ribonucleoside diphosphates", "PRODUCT-OF", "RR"]]}, {"text": " Ribonucleotide reductase  (RR) is responsible for the de novo conversion of the  ribonucleoside diphosphates  to deoxy ribonucleoside diphosphates , which are essential for DNA synthesis and repair", "triple_list": [["ribonucleoside diphosphates", "PRODUCT-OF", "Ribonucleotide reductase"]]}, {"text": "Furthermore, RT-PCR analyses revealed that  minocycline  treatment increased expression of  interleukin-10  mRNA but decreased tumor necrosis factor-alpha expression", "triple_list": [["minocycline", "ACTIVATOR", "interleukin-10"]]}, {"text": "In addition,  minocycline  treatment significantly reduced the specific  caspase-3  activity after SCI as compared to that of vehicle control", "triple_list": [["minocycline", "DOWNREGULATOR", "caspase-3"]]}, {"text": "Furthermore, RT-PCR analyses revealed that  minocycline  treatment increased expression of interleukin-10 mRNA but decreased  tumor necrosis factor-alpha  expression", "triple_list": [["minocycline", "DOWNREGULATOR", "tumor necrosis factor-alpha"]]}, {"text": "CONCLUSION:  Nandrolone phenylpropionate  up-regulated the density of  AR  in liver tissue, whereas it had no significant effects on the density of  AR  in testis and ovary tissues", "triple_list": [["Nandrolone phenylpropionate", "ACTIVATOR", "AR"]]}, {"text": "RESULTS: The density of  AR  in liver tissue in  NP  group was higher than that in control group (P < 0.05)", "triple_list": [["NP", "ACTIVATOR", "AR"]]}, {"text": "The pretreatment with  salbutamol  induced a 59% down-regulation of left ventricular  beta(2)-adrenoceptors  compared to control", "triple_list": [["salbutamol", "DOWNREGULATOR", "beta(2)-adrenoceptors"]]}, {"text": "Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective  beta(2)-adrenoceptor  agonist  salbutamol  (40 microg/kg/h) for 1 week to induce  beta(2)-adrenoceptor  desensitization", "triple_list": [["salbutamol", "AGONIST", "beta(2)-adrenoceptor"]]}, {"text": "Rats received a concomitant treatment with the selective  beta(1)-adrenoceptor  antagonist,  bisoprolol  (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization", "triple_list": [["bisoprolol", "ANTAGONIST", "beta(1)-adrenoceptor"]]}, {"text": "Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of  TRPM8  to  menthol  (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["menthol", "ACTIVATOR", "TRPM8"]]}, {"text": "The Ca(2+) response of  hVR1  transfected HEK293 cells to the endogenous VR1 agonist  N-arachidonoyl-dopamine  was potentiated by low pH", "triple_list": [["N-arachidonoyl-dopamine", "ACTIVATOR", "hVR1"]]}, {"text": "In contrast,  menthol   and icilin-activated  TRPM8  currents were suppressed by low pH", "triple_list": [["menthol", "ACTIVATOR", "TRPM8"]]}, {"text": "In contrast, menthol- and  icilin  activated  TRPM8  currents were suppressed by low pH", "triple_list": [["icilin", "ACTIVATOR", "TRPM8"]]}, {"text": "TRPM8 ( CMR1   is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol,  eucalyptol  and icilin", "triple_list": [["eucalyptol", "ACTIVATOR", "CMR1"]]}, {"text": "TRPM8 (CMR1) is a  Ca(2+)-permeable channel   which can be activated by low temperatures, menthol,  eucalyptol  and icilin", "triple_list": [["eucalyptol", "ACTIVATOR", "Ca(2+)-permeable channel"]]}, {"text": " TRPM8  (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol,  eucalyptol  and icilin", "triple_list": [["eucalyptol", "ACTIVATOR", "TRPM8"]]}, {"text": "TRPM8 ( CMR1   is a Ca(2+)-permeable channel, which can be activated by low temperatures,  menthol   eucalyptol and icilin", "triple_list": [["menthol", "ACTIVATOR", "CMR1"]]}, {"text": "TRPM8 (CMR1) is a  Ca(2+)-permeable channel   which can be activated by low temperatures,  menthol   eucalyptol and icilin", "triple_list": [["menthol", "ACTIVATOR", "Ca(2+)-permeable channel"]]}, {"text": " TRPM8  (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures,  menthol   eucalyptol and icilin", "triple_list": [["menthol", "ACTIVATOR", "TRPM8"]]}, {"text": "TRPM8 ( CMR1   is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and  icilin   It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)", "triple_list": [["icilin", "ACTIVATOR", "CMR1"]]}, {"text": "TRPM8 (CMR1) is a  Ca(2+)-permeable channel   which can be activated by low temperatures, menthol, eucalyptol and  icilin   It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)", "triple_list": [["icilin", "ACTIVATOR", "Ca(2+)-permeable channel"]]}, {"text": " TRPM8  (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and  icilin   It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)", "triple_list": [["icilin", "ACTIVATOR", "TRPM8"]]}, {"text": "Known VR1 antagonists ( BCTC   thio- BCTC  and capsazepine) were also able to block the response of  TRPM8  to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["BCTC", "DOWNREGULATOR", "TRPM8"]]}, {"text": "Known VR1 antagonists (BCTC,  thio-BCTC  and capsazepine) were also able to block the response of  TRPM8  to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["thio-BCTC", "DOWNREGULATOR", "TRPM8"]]}, {"text": "Known VR1 antagonists (BCTC, thio-BCTC and  capsazepine   were also able to block the response of  TRPM8  to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["capsazepine", "DOWNREGULATOR", "TRPM8"]]}, {"text": "The Ca(2+) response of h VR1 -transfected HEK293 cells to the endogenous  VR1  agonist  N-arachidonoyl-dopamine  was potentiated by low pH", "triple_list": [["N-arachidonoyl-dopamine", "AGONIST", "VR1"]]}, {"text": "Known  VR1  antagonists ( BCTC   thio- BCTC  and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["BCTC", "ANTAGONIST", "VR1"]]}, {"text": "Known  VR1  antagonists (BCTC,  thio-BCTC  and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["thio-BCTC", "ANTAGONIST", "VR1"]]}, {"text": "Known  VR1  antagonists (BCTC, thio-BCTC and  capsazepine   were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)", "triple_list": [["capsazepine", "ANTAGONIST", "VR1"]]}, {"text": "The inhibitory effects of  tranylcypromine   a nonselective irreversible inhibitor of  monoamine oxidase  (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "The inhibitory effects of  tranylcypromine   a nonselective irreversible inhibitor of monoamine oxidase ( MAO  , on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "MAO"]]}, {"text": "The results demonstrated that  tranylcypromine  is a competitive inhibitor of  CYP2C19  (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "CYP2C19"]]}, {"text": "The results demonstrated that  tranylcypromine  is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and  CYP2D6  (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "CYP2D6"]]}, {"text": "The results demonstrated that  tranylcypromine  is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of  CYP2C9  (Ki = 56 microM)", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "CYP2C9"]]}, {"text": "Inhibitory effects of the  monoamine oxidase  inhibitor  tranylcypromine  on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than  atorvastatin   a compound that blocks  HMG-CoA reductase   GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat", "triple_list": [["atorvastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": "Compounds of several other structural families, including the  quinoxaline  AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["quinoxaline", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the  quinoxaline  AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["quinoxaline", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline  AG1296   the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["AG1296", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline  AG1296   the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["AG1296", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the  bis(1H-2-indolyl)-1-methanone  D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["bis(1H-2-indolyl)-1-methanone", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the  bis(1H-2-indolyl)-1-methanone  D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["bis(1H-2-indolyl)-1-methanone", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone  D-65476   the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["D-65476", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone  D-65476   the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["D-65476", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the  indolinones  SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["indolinones", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the  indolinones  SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["indolinones", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones  SU5416  and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["SU5416", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones  SU5416  and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["SU5416", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and  SU11248   the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["SU11248", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and  SU11248   the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["SU11248", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the  indolocarbazoles  PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["indolocarbazoles", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the  indolocarbazoles  PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["indolocarbazoles", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles  PKC412  and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["PKC412", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles  PKC412  and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["PKC412", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and  CEP-701   and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["CEP-701", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and  CEP-701   and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["CEP-701", "DOWNREGULATOR", "kinase"]]}, {"text": "Although highly homologous to other class III  RTKs , Flt3 is resistant to the  phenylaminopyrimidine  STI571 (Gleevec, Imatinib), a potent inhibitor of other  RTKs  in the family, such as the PDGFbeta-receptor or c-Kit", "triple_list": [["phenylaminopyrimidine", "DOWNREGULATOR", "RTKs"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the  phenylaminopyrimidine  STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the  PDGFbeta-receptor  or c-Kit", "triple_list": [["phenylaminopyrimidine", "DOWNREGULATOR", "PDGFbeta-receptor"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the  phenylaminopyrimidine  STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or  c-Kit   STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571", "triple_list": [["phenylaminopyrimidine", "DOWNREGULATOR", "c-Kit"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the  piperazonyl quinazoline  CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["piperazonyl quinazoline", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the  piperazonyl quinazoline  CT53518, are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["piperazonyl quinazoline", "DOWNREGULATOR", "kinase"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline  CT53518   are potent inhibitors of  Flt3  kinase", "triple_list": [["CT53518", "DOWNREGULATOR", "Flt3"]]}, {"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline  CT53518   are potent inhibitors of Flt3  kinase   They exhibit different selectivity profiles, both with respect to other  kinase s and among wildtype Flt3 and its activated versions", "triple_list": [["CT53518", "DOWNREGULATOR", "kinase"]]}, {"text": "Although highly homologous to other class III  RTKs , Flt3 is resistant to the phenylaminopyrimidine  STI571  (Gleevec, Imatinib), a potent inhibitor of other  RTKs  in the family, such as the PDGFbeta-receptor or c-Kit", "triple_list": [["STI571", "DOWNREGULATOR", "RTKs"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine  STI571  (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the  PDGFbeta-receptor  or c-Kit", "triple_list": [["STI571", "DOWNREGULATOR", "PDGFbeta-receptor"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine  STI571  (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or  c-Kit    STI571  binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to  STI571 ", "triple_list": [["STI571", "DOWNREGULATOR", "c-Kit"]]}, {"text": "Although highly homologous to other class III  RTKs , Flt3 is resistant to the phenylaminopyrimidine STI571 ( Gleevec   Imatinib), a potent inhibitor of other  RTKs  in the family, such as the PDGFbeta-receptor or c-Kit", "triple_list": [["Gleevec", "DOWNREGULATOR", "RTKs"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 ( Gleevec   Imatinib), a potent inhibitor of other RTKs in the family, such as the  PDGFbeta-receptor  or c-Kit", "triple_list": [["Gleevec", "DOWNREGULATOR", "PDGFbeta-receptor"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 ( Gleevec   Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or  c-Kit   STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571", "triple_list": [["Gleevec", "DOWNREGULATOR", "c-Kit"]]}, {"text": "Although highly homologous to other class III  RTKs , Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec,  Imatinib  , a potent inhibitor of other  RTKs  in the family, such as the PDGFbeta-receptor or c-Kit", "triple_list": [["Imatinib", "DOWNREGULATOR", "RTKs"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec,  Imatinib  , a potent inhibitor of other RTKs in the family, such as the  PDGFbeta-receptor  or c-Kit", "triple_list": [["Imatinib", "DOWNREGULATOR", "PDGFbeta-receptor"]]}, {"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec,  Imatinib  , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or  c-Kit   STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571", "triple_list": [["Imatinib", "DOWNREGULATOR", "c-Kit"]]}, {"text": " STI571  binding to  Flt3  is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding  Flt3  mutant sensitive to  STI571   Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of  Flt3  kinase", "triple_list": [["STI571", "DOWNREGULATOR", "Flt3"]]}, {"text": " Hydralazine  induced rapid and transient expression of  HIF-1alpha  and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "HIF-1alpha"]]}, {"text": " Hydralazine  induced rapid and transient expression of  HIF -1alpha and downstream targets of  HIF  (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "HIF"]]}, {"text": " Hydralazine  induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ( endothelin-1   adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "endothelin-1"]]}, {"text": " Hydralazine  induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1,  adrenomedullin   haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "adrenomedullin"]]}, {"text": " Hydralazine  induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin,  haem oxygenase 1   and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "haem oxygenase 1"]]}, {"text": " Hydralazine  induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and  vascular endothelial growth factor  [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "vascular endothelial growth factor"]]}, {"text": " Hydralazine  induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [ VEGF  ) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation", "triple_list": [["Hydralazine", "ACTIVATOR", "VEGF"]]}, {"text": " Hydralazine  dose-dependently inhibited PHD activity and induced nonhydroxylated  HIF-1alpha   evidence for HIF stabilization specifically by inhibition of PHD enzyme activity", "triple_list": [["Hydralazine", "ACTIVATOR", "HIF-1alpha"]]}, {"text": "In vivo,  hydralazine  induced HIF-1alpha and  VEGF  protein in tissue extracts and elevated plasma  VEGF  levels", "triple_list": [["hydralazine", "ACTIVATOR", "VEGF"]]}, {"text": "In vivo,  hydralazine  induced  HIF-1alpha  and VEGF protein in tissue extracts and elevated plasma VEGF levels", "triple_list": [["hydralazine", "ACTIVATOR", "HIF-1alpha"]]}, {"text": "In vivo,  hydralazine  induced HIF-1alpha and  VEGF  protein in tissue extracts and elevated plasma  VEGF  levels", "triple_list": [["hydralazine", "ACTIVATOR", "VEGF"]]}, {"text": "Novel mechanism of action for  hydralazine   induction of  hypoxia-inducible factor-1alpha   vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases", "triple_list": [["hydralazine", "ACTIVATOR", "hypoxia-inducible factor-1alpha"]]}, {"text": "Novel mechanism of action for  hydralazine   induction of hypoxia-inducible factor-1alpha,  vascular endothelial growth factor   and angiogenesis by inhibition of prolyl hydroxylases", "triple_list": [["hydralazine", "ACTIVATOR", "vascular endothelial growth factor"]]}, {"text": "Thus,  hydralazine  activates the  HIF  pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype", "triple_list": [["hydralazine", "ACTIVATOR", "HIF"]]}, {"text": " Hydralazine  dose-dependently inhibited  PHD  activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of  PHD  enzyme activity", "triple_list": [["Hydralazine", "DOWNREGULATOR", "PHD"]]}, {"text": " Hydralazine  dose-dependently inhibited  PHD  activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of  PHD  enzyme activity", "triple_list": [["Hydralazine", "DOWNREGULATOR", "PHD"]]}, {"text": "Novel mechanism of action for  hydralazine   induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of  prolyl hydroxylases   The vasodilator  hydralazine , used clinically in cardiovascular therapy, relaxes arterial smooth muscle by inhibiting accumulation of intracellular free Ca2+ via an unidentified primary target", "triple_list": [["hydralazine", "DOWNREGULATOR", "prolyl hydroxylases"]]}, {"text": "Thus,  hydralazine  activates the HIF pathway through inhibition of  PHD  activity and initiates a pro-angiogenic phenotype", "triple_list": [["hydralazine", "DOWNREGULATOR", "PHD"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas  NS398   carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting  COX-2  than COX-1", "triple_list": [["NS398", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas  NS398   carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than  COX-1   All canine tissues examined, including those from the gastrointestinal tract, coexpressed  COX-1  and -2 mRNA, although protein expression was observed only for  COX-1 ", "triple_list": [["NS398", "DOWNREGULATOR", "COX-1"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398,  carprofen   tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting  COX-2  than COX-1", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398,  carprofen   tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than  COX-1   All canine tissues examined, including those from the gastrointestinal tract, coexpressed  COX-1  and -2 mRNA, although protein expression was observed only for  COX-1 ", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-1"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen,  tolfenamic acid   nimesulide, and etodolac had more than 5 times greater preference for inhibiting  COX-2  than COX-1", "triple_list": [["tolfenamic acid", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen,  tolfenamic acid   nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than  COX-1   All canine tissues examined, including those from the gastrointestinal tract, coexpressed  COX-1  and -2 mRNA, although protein expression was observed only for  COX-1 ", "triple_list": [["tolfenamic acid", "DOWNREGULATOR", "COX-1"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid,  nimesulide   and etodolac had more than 5 times greater preference for inhibiting  COX-2  than COX-1", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid,  nimesulide   and etodolac had more than 5 times greater preference for inhibiting COX-2 than  COX-1   All canine tissues examined, including those from the gastrointestinal tract, coexpressed  COX-1  and -2 mRNA, although protein expression was observed only for  COX-1 ", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-1"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and  etodolac  had more than 5 times greater preference for inhibiting  COX-2  than COX-1", "triple_list": [["etodolac", "DOWNREGULATOR", "COX-2"]]}, {"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and  etodolac  had more than 5 times greater preference for inhibiting COX-2 than  COX-1   All canine tissues examined, including those from the gastrointestinal tract, coexpressed  COX-1  and -2 mRNA, although protein expression was observed only for  COX-1 ", "triple_list": [["etodolac", "DOWNREGULATOR", "COX-1"]]}, {"text": "CONCLUSIONS AND CLINICAL RELEVANCE:  Canine COX-2  was selectively inhibited by  etodolac   nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs", "triple_list": [["etodolac", "DOWNREGULATOR", "Canine COX-2"]]}, {"text": "CONCLUSIONS AND CLINICAL RELEVANCE:  Canine COX-2  was selectively inhibited by etodolac,  nimesulide   and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs", "triple_list": [["nimesulide", "DOWNREGULATOR", "Canine COX-2"]]}, {"text": "CONCLUSIONS AND CLINICAL RELEVANCE:  Canine COX-2  was selectively inhibited by etodolac, nimesulide, and  NS398   tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs", "triple_list": [["NS398", "DOWNREGULATOR", "Canine COX-2"]]}, {"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine  COX-2  was selectively inhibited by etodolac, nimesulide, and NS398;  tolfenamic acid  and carprofen also appeared to be preferential  COX-2  inhibitors in dogs", "triple_list": [["tolfenamic acid", "DOWNREGULATOR", "COX-2"]]}, {"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine  COX-2  was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and  carprofen  also appeared to be preferential  COX-2  inhibitors in dogs", "triple_list": [["carprofen", "DOWNREGULATOR", "COX-2"]]}, {"text": " Acarbose  served as inhibitor of an interfering  acid alpha-glucosidase  present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed", "triple_list": [["Acarbose", "DOWNREGULATOR", "acid alpha-glucosidase"]]}, {"text": "Univariate regression analyses showed that only the use of  carvedilol  was correlated with the decrease in  plasma BNP  concentration (p <0.03)", "triple_list": [["carvedilol", "DOWNREGULATOR", "plasma BNP"]]}, {"text": "After 12 months of treatment,  carvedilol  significantly improved all end points (plasma concentration of  B-type natriuretic peptide  [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)", "triple_list": [["carvedilol", "DOWNREGULATOR", "B-type natriuretic peptide"]]}, {"text": "After 12 months of treatment,  carvedilol  significantly improved all end points (plasma concentration of B-type natriuretic peptide [ BNP   from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma  BNP  concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)", "triple_list": [["carvedilol", "DOWNREGULATOR", "BNP"]]}, {"text": " Terbinafine  is a potent non-competitive inhibitor of  squalene epoxidase  from Candida (Ki = 30 nM)", "triple_list": [["Terbinafine", "DOWNREGULATOR", "squalene epoxidase"]]}, {"text": " Terbinafine   mode of action and properties of the  squalene epoxidase  inhibition", "triple_list": [["Terbinafine", "DOWNREGULATOR", "squalene epoxidase"]]}, {"text": " Terbinafine  (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of  squalene epoxidase  inhibition", "triple_list": [["Terbinafine", "DOWNREGULATOR", "squalene epoxidase"]]}, {"text": "In contrast, inhibition of rat liver  squalene  epoxidase only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with  squalene   Thus, terbinafine has no effect on cholesterol biosynthesis in vivo", "triple_list": [["squalene", "DOWNREGULATOR", "rat liver squalene epoxidase"]]}, {"text": "Terbinafine ( Lamisil   has primarily fungicidal action against many fungi as a result of its specific mechanism of  squalene epoxidase  inhibition", "triple_list": [["Lamisil", "DOWNREGULATOR", "squalene epoxidase"]]}, {"text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced  apoA-I  more efficiently than  simvastatin  and atorvastatin", "triple_list": [["simvastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced  apoA-I  more efficiently than simvastatin and  atorvastatin   Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased  apoA-I  production in the HepG2 cells", "triple_list": [["atorvastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Further study revealed that  pitavastatin  increased  ABCA1  mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells", "triple_list": [["pitavastatin", "ACTIVATOR", "ABCA1"]]}, {"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and  Y27632   increased  apoA-I  production in the HepG2 cells", "triple_list": [["Y27632", "ACTIVATOR", "apoA-I"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases  apoA-I  in the culture medium of HepG2 cells by promoting  apoA-I  production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting  apoA-I  from catabolism through ABCA1 induction and lipidation of  apoA-I .", "triple_list": [["pitavastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases  apoA-I  in the culture medium of HepG2 cells by promoting  apoA-I  production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting  apoA-I  from catabolism through ABCA1 induction and lipidation of  apoA-I .", "triple_list": [["pitavastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through  ABCA1  induction and lipidation of apoA-I.", "triple_list": [["pitavastatin", "ACTIVATOR", "ABCA1"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases  apoA-I  in the culture medium of HepG2 cells by promoting  apoA-I  production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting  apoA-I  from catabolism through ABCA1 induction and lipidation of  apoA-I  ", "triple_list": [["pitavastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Each statin induced  apoA-I  expression (mRNA and protein) dose-dependently: the rank order of the  apoA-I  induction  pitavastatin  (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)", "triple_list": [["pitavastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Each statin induced  apoA-I  expression (mRNA and protein) dose-dependently: the rank order of the  apoA-I  induction pitavastatin (3 microM)> simvastatin  (10 microM)>atorvastatin (30 microM)", "triple_list": [["simvastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Each statin induced  apoA-I  expression (mRNA and protein) dose-dependently: the rank order of the  apoA-I  induction pitavastatin (3 microM)>simvastatin (10 microM)> atorvastatin  (30 microM)", "triple_list": [["atorvastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Based on HMG-CoA reductase inhibition,  pitavastatin  induced  apoA-I  more efficiently than simvastatin and atorvastatin", "triple_list": [["pitavastatin", "ACTIVATOR", "apoA-I"]]}, {"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that  Rho  and  Rho  kinase inhibitor (C3T and  Y27632   increased apoA-I production in the HepG2 cells", "triple_list": [["Y27632", "DOWNREGULATOR", "Rho"]]}, {"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and  Rho kinase  inhibitor (C3T and  Y27632   increased apoA-I production in the HepG2 cells", "triple_list": [["Y27632", "DOWNREGULATOR", "Rho kinase"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of  HMG-CoA reductase  and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "triple_list": [["pitavastatin", "DOWNREGULATOR", "HMG-CoA reductase"]]}, {"text": "These results suggest that  pitavastatin  efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of  Rho  activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "triple_list": [["pitavastatin", "DOWNREGULATOR", "Rho"]]}, {"text": "The induction of  apoA-I  by statins disappeared with addition of  mevalonate   which indicates that the effect is HMG-CoA reductase inhibition-dependent", "triple_list": [["mevalonate", "DOWNREGULATOR", "apoA-I"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two  receptor tyrosine kinase  inhibitors,  imatinib  and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition", "triple_list": [["imatinib", "DOWNREGULATOR", "receptor tyrosine kinase"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors,  imatinib  and SU11248, were used to disrupt  PDGFR  mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition", "triple_list": [["imatinib", "DOWNREGULATOR", "PDGFR"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors,  imatinib  and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or  VEGFR  inhibition", "triple_list": [["imatinib", "DOWNREGULATOR", "VEGFR"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two  receptor tyrosine kinase  inhibitors, imatinib and  SU11248   were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition", "triple_list": [["SU11248", "DOWNREGULATOR", "receptor tyrosine kinase"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and  SU11248   were used to disrupt  PDGFR  mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition", "triple_list": [["SU11248", "DOWNREGULATOR", "PDGFR"]]}, {"text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and  SU11248   were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or  VEGFR  inhibition", "triple_list": [["SU11248", "DOWNREGULATOR", "VEGFR"]]}, {"text": "RESULTS:  Imatinib   despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or  VEGFR  inhibition", "triple_list": [["Imatinib", "DOWNREGULATOR", "VEGFR"]]}, {"text": "In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable  COX-1  prostanoid TXB2 was significantly reduced by  phenylbutazone  (P<0.05), but not etodolac", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX-1"]]}, {"text": "The objective of the present study was to compare the anti-inflammatory effects of the preferential  COX -2 inhibitor etodolac with the non-selective  COX  inhibitor  phenylbutazone  in horses with lipopolysaccharide (LPS)-induced synovitis", "triple_list": [["phenylbutazone", "DOWNREGULATOR", "COX"]]}, {"text": "Effect of  bosentan  ( ETA  ETB receptor antagonist) on metabolic changes during stress and diabetes", "triple_list": [["bosentan", "ANTAGONIST", "ETA"]]}, {"text": "Effect of  bosentan  (ETA/ ETB  receptor antagonist) on metabolic changes during stress and diabetes", "triple_list": [["bosentan", "ANTAGONIST", "ETB"]]}, {"text": "To test this, we studied the possible effect of the  endothelin receptor  antagonist,  bosentan  (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals", "triple_list": [["bosentan", "ANTAGONIST", "endothelin receptor"]]}, {"text": "Pre-irradiation administration of RP-1 enhanced levels of  GSH  induced increase in  complex I  (upto 16 h),  complex I /III (4 h)  complex I I/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)", "triple_list": [["GSH", "ACTIVATOR", "complex I"]]}, {"text": "Pre-irradiation administration of RP-1 enhanced levels of  GSH  induced increase in complex I (upto 16 h),  complex I/III  (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)", "triple_list": [["GSH", "ACTIVATOR", "complex I/III"]]}, {"text": "Pre-irradiation administration of RP-1 enhanced levels of  GSH  induced increase in complex I (upto 16 h), complex I/III (4 h)  complex II/III  activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)", "triple_list": [["GSH", "ACTIVATOR", "complex II/III"]]}, {"text": "Moreover,  minocycline  efficiently suppressed the release of  cytochrome c  from mitochondria of the liver tissues from Jo2-challenged mice", "triple_list": [["minocycline", "DOWNREGULATOR", "cytochrome c"]]}, {"text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by  minocycline  may involve a mitochondrial apoptotic pathway, probably through preventing  cytochrome c  release and thereby blocking downstream caspase activation.", "triple_list": [["minocycline", "DOWNREGULATOR", "cytochrome c"]]}, {"text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by  minocycline  may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream  caspase  activation.", "triple_list": [["minocycline", "DOWNREGULATOR", "caspase"]]}, {"text": "placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic  myeloperoxidase oxidase  (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63;  PAG   2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52;  PAG , 3.03+/-0.47; P<0.05  PAG  c.f", "triple_list": [["PAG", "ACTIVATOR", "myeloperoxidase oxidase"]]}, {"text": "placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase ( MPO   activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63;  PAG   2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52;  PAG , 3.03+/-0.47; P<0.05  PAG  c.f", "triple_list": [["PAG", "ACTIVATOR", "MPO"]]}, {"text": "Also, prophylactic, as well as therapeutic, treatment with the  CSE  inhibitor,  DL-propargylglycine  (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f", "triple_list": [["DL-propargylglycine", "DOWNREGULATOR", "CSE"]]}, {"text": "Also, prophylactic, as well as therapeutic, treatment with the  CSE  inhibitor, DL-propargylglycine ( PAG  , significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305;  PAG , 7904+/-495; therapeutic treatment: placebo, 10427+/-470;  PAG , 7811+/-428; P<0.05  PAG  c.f", "triple_list": [["PAG", "DOWNREGULATOR", "CSE"]]}, {"text": "Cystathionine-gamma-lyase ( CSE   and cystathionine-beta-synthase (CBS) utilize  L-cysteine  as substrate to form H2S", "triple_list": [["L-cysteine", "PRODUCT-OF", "CSE"]]}, {"text": "Cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS) utilize  L-cysteine  as substrate to form H2S", "triple_list": [["L-cysteine", "PRODUCT-OF", "cystathionine-beta-synthase"]]}, {"text": "Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS   utilize  L-cysteine  as substrate to form H2S", "triple_list": [["L-cysteine", "PRODUCT-OF", "CBS"]]}, {"text": " Cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS) utilize  L-cysteine  as substrate to form H2S", "triple_list": [["L-cysteine", "PRODUCT-OF", "Cystathionine-gamma-lyase"]]}, {"text": "Cystathionine-gamma-lyase ( CSE   and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form  H2S   Of these two enzymes, cystathionine-gamma-lyase ( CSE ) is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "CSE"]]}, {"text": "Cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS) utilize L-cysteine as substrate to form  H2S   Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "cystathionine-beta-synthase"]]}, {"text": "Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS   utilize L-cysteine as substrate to form  H2S   Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "CBS"]]}, {"text": " Cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form  H2S   Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "Cystathionine-gamma-lyase"]]}, {"text": "Of these two enzymes,  cystathionine-gamma-lyase  (CSE) is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "cystathionine-gamma-lyase"]]}, {"text": "Of these two enzymes, cystathionine-gamma-lyase ( CSE   is believed to be the key enzyme that forms  H2S  in the cardiovascular system", "triple_list": [["H2S", "PRODUCT-OF", "CSE"]]}, {"text": "ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors ( LXRs  , which are also activated by oxy sterols  and some derivatives of plant  sterols   NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant  sterols ", "triple_list": [["sterols", "ACTIVATOR", "LXRs"]]}, {"text": " NPC1L1  could recently be identified as a major sterol transporter for the intestinal uptake of  cholesterol  as well as plant sterols", "triple_list": [["cholesterol", "PRODUCT-OF", "NPC1L1"]]}, {"text": "NPC1L1 could recently be identified as a major  sterol transporter  for the intestinal uptake of  cholesterol  as well as plant sterols", "triple_list": [["cholesterol", "PRODUCT-OF", "sterol transporter"]]}, {"text": " NPC1L1  could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant  sterols   Studies in  NPC1L1  knockout mice indicate that this transporter is essential for the intestinal uptake of  sterols  and that  NPC1L1  might also be involved in the mechanism of action of ezetimibe", "triple_list": [["sterols", "PRODUCT-OF", "NPC1L1"]]}, {"text": "NPC1L1 could recently be identified as a major  sterol transporter  for the intestinal uptake of cholesterol as well as plant  sterols   Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of  sterols  and that NPC1L1 might also be involved in the mechanism of action of ezetimibe", "triple_list": [["sterols", "PRODUCT-OF", "sterol transporter"]]}, {"text": " Bupropion  has an antidepressant effect through blocking the  dopamine transporter   By 99mTc-TRODAT-SPECT, we measured the baseline DAT activity of depressed patients", "triple_list": [["Bupropion", "DOWNREGULATOR", "dopamine transporter"]]}, {"text": "Our results demonstrate that the combination of denileukin diftitox and  bexarotene  is well tolerated and that even low doses (150 mg/day) of  bexarotene  are capable of in vivo upregulation of  CD25  expression on circulating leukemia cells.", "triple_list": [["bexarotene", "ACTIVATOR", "CD25"]]}, {"text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid,  bexarotene   at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the  p55  and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox", "triple_list": [["bexarotene", "ACTIVATOR", "p55"]]}, {"text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid,  bexarotene   at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and  p75  subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox", "triple_list": [["bexarotene", "ACTIVATOR", "p75"]]}, {"text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid,  bexarotene   at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the  IL-2R  and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox", "triple_list": [["bexarotene", "ACTIVATOR", "IL-2R"]]}, {"text": " PSMA  acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including  folate   the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["folate", "PRODUCT-OF", "PSMA"]]}, {"text": "PSMA acts as a  glutamate carboxypeptidase  (GCPII) on small molecule substrates, including  folate   the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["folate", "PRODUCT-OF", "glutamate carboxypeptidase"]]}, {"text": "PSMA acts as a glutamate carboxypeptidase ( GCPII   on small molecule substrates, including  folate   the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["folate", "PRODUCT-OF", "GCPII"]]}, {"text": " PSMA  acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug  methotrexate   and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["methotrexate", "PRODUCT-OF", "PSMA"]]}, {"text": "PSMA acts as a  glutamate carboxypeptidase  (GCPII) on small molecule substrates, including folate, the anticancer drug  methotrexate   and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["methotrexate", "PRODUCT-OF", "glutamate carboxypeptidase"]]}, {"text": "PSMA acts as a glutamate carboxypeptidase ( GCPII   on small molecule substrates, including folate, the anticancer drug  methotrexate   and the neuropeptide N-acetyl-l-aspartyl-l-glutamate", "triple_list": [["methotrexate", "PRODUCT-OF", "GCPII"]]}, {"text": " PSMA  acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide  N-acetyl-l-aspartyl-l-glutamate   Here we present the 3.5-A crystal structure of the  PSMA  ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity", "triple_list": [["N-acetyl-l-aspartyl-l-glutamate", "PRODUCT-OF", "PSMA"]]}, {"text": "PSMA acts as a  glutamate carboxypeptidase  (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide  N-acetyl-l-aspartyl-l-glutamate   Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity", "triple_list": [["N-acetyl-l-aspartyl-l-glutamate", "PRODUCT-OF", "glutamate carboxypeptidase"]]}, {"text": "Elucidation of the  PSMA  structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate  N-acetyl-l-aspartyl-l-glutamate   The  PSMA  structure will facilitate development of chemotherapeutics, cancer-imaging agents, and agents for treatment of neurological disorders.", "triple_list": [["N-acetyl-l-aspartyl-l-glutamate", "PRODUCT-OF", "PSMA"]]}, {"text": "While the substituted  benzamide  prokinetics (for example, metoclopramide, cisapride) also block  5-HT3  receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor", "triple_list": [["benzamide", "DOWNREGULATOR", "5-HT3"]]}, {"text": "While the substituted benzamide prokinetics (for example,  metoclopramide   cisapride) also block  5-HT3  receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor", "triple_list": [["metoclopramide", "DOWNREGULATOR", "5-HT3"]]}, {"text": "While the substituted benzamide prokinetics (for example, metoclopramide,  cisapride   also block  5-HT3  receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor", "triple_list": [["cisapride", "DOWNREGULATOR", "5-HT3"]]}, {"text": "While the substituted  benzamide  prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative  5-HT4  receptor", "triple_list": [["benzamide", "AGONIST", "5-HT4"]]}, {"text": "While the substituted benzamide prokinetics (for example,  metoclopramide   cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative  5-HT4  receptor", "triple_list": [["metoclopramide", "AGONIST", "5-HT4"]]}, {"text": "While the substituted benzamide prokinetics (for example, metoclopramide,  cisapride   also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative  5-HT4  receptor", "triple_list": [["cisapride", "AGONIST", "5-HT4"]]}, {"text": "Some 5-HT3 antagonists have  5-HT4  agonist activity (for example,  renzapride   zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a  5-HT4  antagonist", "triple_list": [["renzapride", "AGONIST", "5-HT4"]]}, {"text": "Some 5-HT3 antagonists have  5-HT4  agonist activity (for example, renzapride,  zacopride   and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a  5-HT4  antagonist", "triple_list": [["zacopride", "AGONIST", "5-HT4"]]}, {"text": "A number of selective  5-HT3  antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and  zacopride   While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block  5-HT3  receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor", "triple_list": [["zacopride", "ANTAGONIST", "5-HT3"]]}, {"text": "Some  5-HT3  antagonists have 5-HT4 agonist activity (for example,  renzapride   zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist", "triple_list": [["renzapride", "ANTAGONIST", "5-HT3"]]}, {"text": "Some  5-HT3  antagonists have 5-HT4 agonist activity (for example, renzapride,  zacopride   and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist", "triple_list": [["zacopride", "ANTAGONIST", "5-HT3"]]}, {"text": "Some 5-HT3 antagonists have  5-HT4  agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while  tropisetron  in high concentrations is a  5-HT4  antagonist", "triple_list": [["tropisetron", "ANTAGONIST", "5-HT4"]]}, {"text": "A number of selective  5-HT3  antagonists have been developed including  ondansetron   granisetron, tropisetron renzapride and zacopride", "triple_list": [["ondansetron", "ANTAGONIST", "5-HT3"]]}, {"text": "A number of selective  5-HT3  antagonists have been developed including ondansetron,  granisetron   tropisetron renzapride and zacopride", "triple_list": [["granisetron", "ANTAGONIST", "5-HT3"]]}, {"text": "A number of selective  5-HT3  antagonists have been developed including ondansetron, granisetron,  tropisetron  renzapride and zacopride", "triple_list": [["tropisetron", "ANTAGONIST", "5-HT3"]]}, {"text": "A number of selective  5-HT3  antagonists have been developed including ondansetron, granisetron, tropisetron  renzapride  and zacopride", "triple_list": [["renzapride", "ANTAGONIST", "5-HT3"]]}, {"text": "We present our studies to demonstrate that HM74A, but not HM74, binds  niacin  at high affinities and effectively mediates  Gi  signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A", "triple_list": [["niacin", "ACTIVATOR", "Gi"]]}, {"text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the  KGD1  (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of  succinate  than the wild-type strain, while the SDH1 ( succinate  dehydrogenase) gene-disrupted mutant produced an increased level of  succinate ", "triple_list": [["succinate", "PRODUCT-OF", "KGD1"]]}, {"text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 ( alpha-ketoglutarate dehydrogenase   gene disrupted mutant produced a lower level of  succinate  than the wild-type strain, while the SDH1 ( succinate  dehydrogenase) gene-disrupted mutant produced an increased level of  succinate ", "triple_list": [["succinate", "PRODUCT-OF", "alpha-ketoglutarate dehydrogenase"]]}, {"text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of  succinate  than the wild-type strain, while the  SDH1  ( succinate  dehydrogenase) gene-disrupted mutant produced an increased level of  succinate   On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all", "triple_list": [["succinate", "PRODUCT-OF", "SDH1"]]}, {"text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of  succinate  than the wild-type strain, while the SDH1 ( succinate  dehydrogenase  gene-disrupted mutant produced an increased level of  succinate   On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all", "triple_list": [["succinate", "PRODUCT-OF", "succinate dehydrogenase"]]}, {"text": "On the other hand, the  FUM1  (fumarase) gene disrupted mutant produced significantly higher levels of  fumarate  but did not form malate at all", "triple_list": [["fumarate", "PRODUCT-OF", "FUM1"]]}, {"text": "On the other hand, the FUM1 ( fumarase   gene disrupted mutant produced significantly higher levels of  fumarate  but did not form malate at all", "triple_list": [["fumarate", "PRODUCT-OF", "fumarase"]]}, {"text": "When the growth condition was shifted from aerobic to anaerobic, the increased level of  succinate  in  SDH1  disruptants was no longer observed, whereas the decreased level of  succinate  in the KGD1 diruptant was still observed", "triple_list": [["succinate", "PRODUCT-OF", "SDH1"]]}, {"text": "When the growth condition was shifted from aerobic to anaerobic, the increased level of  succinate  in SDH1 disruptants was no longer observed, whereas the decreased level of  succinate  in the  KGD1  diruptant was still observed", "triple_list": [["succinate", "PRODUCT-OF", "KGD1"]]}, {"text": "A double mutant of the two  fumarate reductase  isozyme genes (OSM1 and FRDS) showed a  succinate  productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution", "triple_list": [["succinate", "PRODUCT-OF", "fumarate reductase"]]}, {"text": "A double mutant of the two fumarate reductase isozyme genes ( OSM1  and FRDS) showed a  succinate  productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution", "triple_list": [["succinate", "PRODUCT-OF", "OSM1"]]}, {"text": "A double mutant of the two fumarate reductase isozyme genes (OSM1 and  FRDS   showed a  succinate  productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution", "triple_list": [["succinate", "PRODUCT-OF", "FRDS"]]}, {"text": "However, plasma  high-density lipoprotein  cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in  vitamin E  group after 8 weeks", "triple_list": [["vitamin E", "ACTIVATOR", "high-density lipoprotein"]]}, {"text": "However, plasma high-density lipoprotein-cholesterol ( HDL  C) and  HDL -C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in  vitamin E  group after 8 weeks", "triple_list": [["vitamin E", "ACTIVATOR", "HDL"]]}, {"text": "However, plasma high-density lipoprotein-cholesterol ( HDL -C) and  HDL  C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in  vitamin E  group after 8 weeks", "triple_list": [["vitamin E", "ACTIVATOR", "HDL"]]}, {"text": "However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma  paraoxonase  activity were only significantly higher in  vitamin E  group after 8 weeks", "triple_list": [["vitamin E", "ACTIVATOR", "paraoxonase"]]}, {"text": "Hepatic ACAT activity was significantly lower in both vitamin E and  probucol  groups than in HC-control group, while  HMG-CoA reductase  activity was the highest only in the  probucol  group", "triple_list": [["probucol", "ACTIVATOR", "HMG-CoA reductase"]]}, {"text": " Vitamin E  and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and  low-density lipoprotein  cholesterol compared to HC-control group", "triple_list": [["Vitamin E", "DOWNREGULATOR", "low-density lipoprotein"]]}, {"text": "Vitamin E and  probucol  significantly suppressed an increase in plasma total-cholesterol (total-C) and  low-density lipoprotein  cholesterol compared to HC-control group", "triple_list": [["probucol", "DOWNREGULATOR", "low-density lipoprotein"]]}, {"text": "Hepatic  ACAT  activity was significantly lower in both  vitamin E  and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group", "triple_list": [["vitamin E", "DOWNREGULATOR", "ACAT"]]}, {"text": "Hepatic  ACAT  activity was significantly lower in both vitamin E and  probucol  groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the  probucol  group", "triple_list": [["probucol", "DOWNREGULATOR", "ACAT"]]}, {"text": "Hepatic mRNA expressions of  apo B-100  and apo C-III were significantly lower in  probucol  group than in other groups", "triple_list": [["probucol", "DOWNREGULATOR", "apo B-100"]]}, {"text": "Hepatic mRNA expressions of apo B-100 and  apo C-III  were significantly lower in  probucol  group than in other groups", "triple_list": [["probucol", "DOWNREGULATOR", "apo C-III"]]}, {"text": "Vitamin E supplementation was found to alter the plasma  HDL -C-related factors; meanwhile,  probucol  supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma  HDL  C concentration.", "triple_list": [["probucol", "DOWNREGULATOR", "HDL"]]}, {"text": "However, as with the human receptor,  maraviroc  was shown to be a high affinity, potent functional antagonist of  macaque CCR5  thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.", "triple_list": [["maraviroc", "ANTAGONIST", "macaque CCR5"]]}, {"text": "However, as with the human receptor,  maraviroc  was shown to be a high affinity, potent functional antagonist of macaque  CCR5  thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel  CCR5  antagonists.", "triple_list": [["maraviroc", "ANTAGONIST", "CCR5"]]}, {"text": "The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel  CCR5  antagonists, such as  maraviroc  (UK-427,857)", "triple_list": [["maraviroc", "ANTAGONIST", "CCR5"]]}, {"text": "The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel  CCR5  antagonists, such as maraviroc ( UK-427,857  ", "triple_list": [["UK-427,857", "ANTAGONIST", "CCR5"]]}, {"text": " Maraviroc  inhibited binding of [125I]-MIP-1beta to  CCR5  from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through  CCR5  from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively)", "triple_list": [["Maraviroc", "ANTAGONIST", "CCR5"]]}, {"text": "Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of  CRABPI  for localized sequestration of  retinoids  that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.", "triple_list": [["retinoids", "ACTIVATOR", "CRABPI"]]}, {"text": "Its special profile of actions, especially the rise in  HDL  cholesterol levels induced by  nicotinic acid   is unique among the currently available pharmacological tools to treat lipid disorders", "triple_list": [["nicotinic acid", "ACTIVATOR", "HDL"]]}, {"text": "RATIONALE: Several drugs used to treat bipolar disorder ( lithium  and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective  phospholipase A(2)   Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter  phospholipase A(2)  activity, suggesting that it targets a different enzyme in the turnover pathway", "triple_list": [["lithium", "DOWNREGULATOR", "phospholipase A(2)"]]}, {"text": "MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases ( Acsl ), we show in vitro that  valproic acid  is a non-competitive inhibitor of  Acsl   as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme", "triple_list": [["valproic acid", "DOWNREGULATOR", "Acsl"]]}, {"text": "RATIONALE: Several drugs used to treat bipolar disorder (lithium and  carbamazepine  , when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective  phospholipase A(2)   Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter  phospholipase A(2)  activity, suggesting that it targets a different enzyme in the turnover pathway", "triple_list": [["carbamazepine", "DOWNREGULATOR", "phospholipase A(2)"]]}, {"text": " Valproic acid  selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by  brain microsomal long-chain fatty acyl-CoA synthetases   relevance to bipolar disorder", "triple_list": [["Valproic acid", "DOWNREGULATOR", "brain microsomal long-chain fatty acyl-CoA synthetases"]]}, {"text": "CONCLUSIONS: This study shows that  valproic acid  acts as a non-competitive inhibitor of  brain microsomal Acsl   and that inhibition is substrate-selective", "triple_list": [["valproic acid", "DOWNREGULATOR", "brain microsomal Acsl"]]}, {"text": "Valproic acid selectively inhibits conversion of  arachidonic acid  to arachidonoyl-CoA by  brain microsomal long-chain fatty acyl-CoA synthetases   relevance to bipolar disorder", "triple_list": [["arachidonic acid", "PRODUCT-OF", "brain microsomal long-chain fatty acyl-CoA synthetases"]]}, {"text": "Valproic acid selectively inhibits conversion of arachidonic acid to  arachidonoyl-CoA  by  brain microsomal long-chain fatty acyl-CoA synthetases   relevance to bipolar disorder", "triple_list": [["arachidonoyl-CoA", "PRODUCT-OF", "brain microsomal long-chain fatty acyl-CoA synthetases"]]}, {"text": "On the other hand, holocarboxylase synthetase ( HCS   mRNA levels were markedly low in the deficient animals, and increased upon  biotin  injection", "triple_list": [["biotin", "ACTIVATOR", "HCS"]]}, {"text": "On the other hand,  holocarboxylase synthetase  (HCS) mRNA levels were markedly low in the deficient animals, and increased upon  biotin  injection", "triple_list": [["biotin", "ACTIVATOR", "holocarboxylase synthetase"]]}, {"text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by  indomethacin   a preferential  COX-1  inhibitor, but not by NS-398, a selective COX-2 inhibitor", "triple_list": [["indomethacin", "DOWNREGULATOR", "COX-1"]]}, {"text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by  NS-398   a selective  COX-2  inhibitor", "triple_list": [["NS-398", "DOWNREGULATOR", "COX-2"]]}, {"text": "Involvement of  COX-1  and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced  prostaglandin E2  production by microglia", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "COX-1"]]}, {"text": "Involvement of COX-1 and up-regulated  prostaglandin E synthases  in phosphatidylserine liposome-induced  prostaglandin E2  production by microglia", "triple_list": [["prostaglandin E2", "PRODUCT-OF", "prostaglandin E synthases"]]}, {"text": "These observations strongly suggest that the up-regulation of terminal  PGESs  that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced  PGE2  production by microglia", "triple_list": [["PGE2", "PRODUCT-OF", "PGESs"]]}, {"text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with  COX-1   especially mPGES-2, plays the pivotal role in PS liposome-induced  PGE2  production by microglia", "triple_list": [["PGE2", "PRODUCT-OF", "COX-1"]]}, {"text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially  mPGES-2   plays the pivotal role in PS liposome-induced  PGE2  production by microglia", "triple_list": [["PGE2", "PRODUCT-OF", "mPGES-2"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple- kinase  inhibitors (MKIs)  sorafenib   sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta", "triple_list": [["sorafenib", "DOWNREGULATOR", "kinase"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs)  sorafenib   sunitinib, and AG013736, which target multiple  VEGFRs  as well as PDGFR-beta", "triple_list": [["sorafenib", "DOWNREGULATOR", "VEGFRs"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs)  sorafenib   sunitinib, and AG013736, which target multiple VEGFRs as well as  PDGFR-beta   Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and  PDGFR-beta ", "triple_list": [["sorafenib", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple- kinase  inhibitors (MKIs) sorafenib,  sunitinib   and AG013736, which target multiple VEGFRs as well as PDGFR-beta", "triple_list": [["sunitinib", "DOWNREGULATOR", "kinase"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib,  sunitinib   and AG013736, which target multiple  VEGFRs  as well as PDGFR-beta", "triple_list": [["sunitinib", "DOWNREGULATOR", "VEGFRs"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib,  sunitinib   and AG013736, which target multiple VEGFRs as well as  PDGFR-beta   Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and  PDGFR-beta ", "triple_list": [["sunitinib", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple- kinase  inhibitors (MKIs) sorafenib, sunitinib, and  AG013736   which target multiple VEGFRs as well as PDGFR-beta", "triple_list": [["AG013736", "DOWNREGULATOR", "kinase"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and  AG013736   which target multiple  VEGFRs  as well as PDGFR-beta", "triple_list": [["AG013736", "DOWNREGULATOR", "VEGFRs"]]}, {"text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and  AG013736   which target multiple VEGFRs as well as  PDGFR-beta   Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and  PDGFR-beta ", "triple_list": [["AG013736", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": " Sorafenib  has the added advantage of inhibiting multiple different  Raf  isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta", "triple_list": [["Sorafenib", "DOWNREGULATOR", "Raf"]]}, {"text": " Sorafenib  has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target  TGF-alpha  EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta", "triple_list": [["Sorafenib", "DOWNREGULATOR", "TGF-alpha"]]}, {"text": " Sorafenib  has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/ EGFR  signaling and may also enhance its inhibition of V EGFR  and PDGFR-beta", "triple_list": [["Sorafenib", "DOWNREGULATOR", "EGFR"]]}, {"text": " Sorafenib  has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of  VEGFR  and PDGFR-beta", "triple_list": [["Sorafenib", "DOWNREGULATOR", "VEGFR"]]}, {"text": " Sorafenib  has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and  PDGFR-beta   This review will examine the recent advances in our understanding of the biology of clear-cell RCC and show how those advances have helped delineate new targets of opportunity for treatment", "triple_list": [["Sorafenib", "DOWNREGULATOR", "PDGFR-beta"]]}, {"text": "Low  TS  expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with  5FU   Accordingly, patients having at least two favourable or unfavourable variables were classified respectively as 'low risk' and 'high risk', the former showing significantly longer PFS (p=0.0299)", "triple_list": [["5FU", "DOWNREGULATOR", "TS"]]}, {"text": "Our conclusion is that chronic  DPDPE  treatment preferentially reduces  delta-opioid receptor  binding activity", "triple_list": [["DPDPE", "DOWNREGULATOR", "delta-opioid receptor"]]}, {"text": "Therefore, in the present studies, animals were rendered tolerant to the  delta-opioid receptor  selective agonist [D-Pen2,D-Pen5]enkephalin ( DPDPE  , and receptor binding activities were measured", "triple_list": [["DPDPE", "AGONIST", "delta-opioid receptor"]]}, {"text": "Therefore, in the present studies, animals were rendered tolerant to the  delta-opioid receptor  selective agonist  [D-Pen2,D-Pen5]enkephalin  (DPDPE), and receptor binding activities were measured", "triple_list": [["[D-Pen2,D-Pen5]enkephalin", "AGONIST", "delta-opioid receptor"]]}, {"text": "Complementary experiments using the  5-HT3 -dependent Bezold-Jarisch reflex confirmed that  amoxapine  really acts in vivo as a  5-HT3  antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on  5-HT3  receptors", "triple_list": [["amoxapine", "ANTAGONIST", "5-HT3"]]}, {"text": "Competitive radioligand binding assays were performed using cells expressing either the  human serotonin (5-HT) transporter  (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for  DVS  of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively", "triple_list": [["DVS", "DOWNREGULATOR", "human serotonin (5-HT) transporter"]]}, {"text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter ( hSERT   or norepinephrine (NE) transporter (hNET) with K(i) values for  DVS  of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively", "triple_list": [["DVS", "DOWNREGULATOR", "hSERT"]]}, {"text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or  norepinephrine (NE) transporter  (hNET) with K(i) values for  DVS  of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively", "triple_list": [["DVS", "DOWNREGULATOR", "norepinephrine (NE) transporter"]]}, {"text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter ( hNET   with K(i) values for  DVS  of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively", "triple_list": [["DVS", "DOWNREGULATOR", "hNET"]]}, {"text": "To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory  5-HT(1A)  autoreceptors, a  5-HT(1A)  antagonist,  N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt  (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally)", "triple_list": [["N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt", "ANTAGONIST", "5-HT(1A)"]]}, {"text": "To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory  5-HT(1A)  autoreceptors, a  5-HT(1A)  antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt ( WAY-100635   (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally)", "triple_list": [["WAY-100635", "ANTAGONIST", "5-HT(1A)"]]}, {"text": "Inhibition of  [3H]5-HT  or [3H]NE uptake by DVS for the  hSERT  or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively", "triple_list": [["[3H]5-HT", "PRODUCT-OF", "hSERT"]]}, {"text": "Inhibition of [3H]5-HT or  [3H]NE  uptake by DVS for the hSERT or  hNET  produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively", "triple_list": [["[3H]NE", "PRODUCT-OF", "hNET"]]}, {"text": "Further,  cholesterol  metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of  sterol regulatory element binding protein-1c  (SREBP-1c) that bound to the regulatory regions of these genes", "triple_list": [["cholesterol", "ACTIVATOR", "sterol regulatory element binding protein-1c"]]}, {"text": "Further,  cholesterol  metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c ( SREBP-1c   that bound to the regulatory regions of these genes", "triple_list": [["cholesterol", "ACTIVATOR", "SREBP-1c"]]}, {"text": "Further, cholesterol metabolites, predominantly the  oxysterols   the natural ligands for liver X receptor (LXR), induced these genes via upregulation of  sterol regulatory element binding protein-1c  (SREBP-1c) that bound to the regulatory regions of these genes", "triple_list": [["oxysterols", "ACTIVATOR", "sterol regulatory element binding protein-1c"]]}, {"text": "Further, cholesterol metabolites, predominantly the  oxysterols   the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c ( SREBP-1c   that bound to the regulatory regions of these genes", "triple_list": [["oxysterols", "ACTIVATOR", "SREBP-1c"]]}, {"text": "The tissue  RA  level is maintained through a cascade of metabolic reactions where  retinal dehydrogenases  ( RA LDHs) catalyze the terminal reaction of  RA  biosynthesis from retinal, a rate-limiting step", "triple_list": [["RA", "PRODUCT-OF", "retinal dehydrogenases"]]}, {"text": "The tissue  RA  level is maintained through a cascade of metabolic reactions where retinal dehydrogenases ( RA LDHs  catalyze the terminal reaction of  RA  biosynthesis from retinal, a rate-limiting step", "triple_list": [["RA", "PRODUCT-OF", "RALDHs"]]}, {"text": "The tissue RA level is maintained through a cascade of metabolic reactions where  retinal  dehydrogenases (RALDHs) catalyze the terminal reaction of RA biosynthesis from  retinal   a rate-limiting step", "triple_list": [["retinal", "PRODUCT-OF", "retinal dehydrogenases"]]}, {"text": "The tissue RA level is maintained through a cascade of metabolic reactions where  retinal  dehydrogenases ( RALDHs   catalyze the terminal reaction of RA biosynthesis from  retinal   a rate-limiting step", "triple_list": [["retinal", "PRODUCT-OF", "RALDHs"]]}, {"text": "Hypermethlyation of  RELN and GAD67 promoters  can be induced by treating mice with  methionine   and these mice display brain and behavioral abnormalities similar to +/rl", "triple_list": [["methionine", "ACTIVATOR", "RELN and GAD67 promoters"]]}, {"text": "Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the  AT1  antagonist  olmesartan medoxomil  ", "triple_list": [["olmesartan medoxomil", "ANTAGONIST", "AT1"]]}, {"text": "Functional and bioenergetic consequences of  AT1  antagonist  olmesartan medoxomil  in hearts with postinfarction LV remodeling", "triple_list": [["olmesartan medoxomil", "ANTAGONIST", "AT1"]]}, {"text": "RESULTS:  Imatinib  inhibited  RET  Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure", "triple_list": [["Imatinib", "DOWNREGULATOR", "RET"]]}, {"text": "RESULTS:  Imatinib  inhibited RET  Y1062  phosphorylation in a dose-dependent manner after 1.5 hours of exposure", "triple_list": [["Imatinib", "DOWNREGULATOR", "Y1062"]]}, {"text": "CONCLUSIONS:  Imatinib  inhibits  RET  mediated MTC cell growth affecting  RET  protein levels in vitro in a dose-dependent manner", "triple_list": [["Imatinib", "DOWNREGULATOR", "RET"]]}, {"text": "CONCLUSIONS:  Imatinib  inhibits  RET -mediated MTC cell growth affecting  RET  protein levels in vitro in a dose-dependent manner", "triple_list": [["Imatinib", "DOWNREGULATOR", "RET"]]}, {"text": "The concentration of  imatinib  necessary to inhibit  RET  in vitro, however, makes it impossible to conclude that  imatinib  monotherapy will be a good option for systemic therapy of MTC.", "triple_list": [["imatinib", "DOWNREGULATOR", "RET"]]}, {"text": "We evaluated  imatinib   a  tyrosine kinase  inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors", "triple_list": [["imatinib", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "In eukaryotes, the most prominent Mo-enzymes are (1)  sulfite oxidase   which catalyzes the final step in the degradation of  sulfur  containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation", "triple_list": [["sulfur", "PRODUCT-OF", "sulfite oxidase"]]}, {"text": " Retinoid  is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of  nuclear hormone receptor  superfamily", "triple_list": [["Retinoid", "ACTIVATOR", "nuclear hormone receptor"]]}, {"text": " Retinoid  is a collective term for compounds which bind to and activate  retinoic acid receptors  (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily", "triple_list": [["Retinoid", "ACTIVATOR", "retinoic acid receptors"]]}, {"text": " Simvastatin  abolished these anti- CD11a  mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity", "triple_list": [["Simvastatin", "DOWNREGULATOR", "CD11a"]]}, {"text": "The cholesterol-lowering drug  simvastatin  inhibits  LFA-1  signaling by binding to an allosteric site on CD11a ( LFA-1  alpha chain), which leads to immunomodulation", "triple_list": [["simvastatin", "DOWNREGULATOR", "LFA-1"]]}, {"text": " Menthol   popularly known for its cooling effect, activates  TRPM8  -a cold-activated thermoTRP ion channel", "triple_list": [["Menthol", "ACTIVATOR", "TRPM8"]]}, {"text": " Menthol   popularly known for its cooling effect, activates TRPM8--a cold-activated  thermoTRP ion channel   However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3", "triple_list": [["Menthol", "ACTIVATOR", "thermoTRP ion channel"]]}, {"text": "However, human physiological studies demonstrate a paradoxical role of  menthol  in modulation of warm sensation, and here, we show that  menthol  also activates heat-activated  TRPV3   We further show that  menthol  inhibits TRPA1, potentially explaining the use of  menthol  as an analgesic", "triple_list": [["menthol", "ACTIVATOR", "TRPV3"]]}, {"text": "Similar to  menthol   both camphor and cinnamaldehyde (initially reported to be specific activators of  TRPV3  and TRPA1, respectively) also modulate other thermoTRPs", "triple_list": [["menthol", "ACTIVATOR", "TRPV3"]]}, {"text": "Similar to  menthol   both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and  TRPA1   respectively) also modulate other thermoTRPs", "triple_list": [["menthol", "ACTIVATOR", "TRPA1"]]}, {"text": "Similar to menthol, both  camphor  and cinnamaldehyde (initially reported to be specific activators of  TRPV3  and TRPA1, respectively) also modulate other thermoTRPs", "triple_list": [["camphor", "ACTIVATOR", "TRPV3"]]}, {"text": "Similar to menthol, both  camphor  and cinnamaldehyde (initially reported to be specific activators of TRPV3 and  TRPA1   respectively) also modulate other thermoTRPs", "triple_list": [["camphor", "ACTIVATOR", "TRPA1"]]}, {"text": "Similar to menthol, both camphor and  cinnamaldehyde  (initially reported to be specific activators of  TRPV3  and TRPA1, respectively) also modulate other thermoTRPs", "triple_list": [["cinnamaldehyde", "ACTIVATOR", "TRPV3"]]}, {"text": "Similar to menthol, both camphor and  cinnamaldehyde  (initially reported to be specific activators of TRPV3 and  TRPA1   respectively) also modulate other thermoTRPs", "triple_list": [["cinnamaldehyde", "ACTIVATOR", "TRPA1"]]}, {"text": "We further show that  menthol  inhibits  TRPA1   potentially explaining the use of  menthol  as an analgesic", "triple_list": [["menthol", "DOWNREGULATOR", "TRPA1"]]}, {"text": "These currents were produced by  glutamate-aspartate transporters  (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by  dihydrokainate   an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas", "triple_list": [["dihydrokainate", "DOWNREGULATOR", "glutamate-aspartate transporters"]]}, {"text": "These currents were produced by glutamate-aspartate transporters ( GLAST   (excitatory amino acid transporter 1) because they were weakly inhibited by  dihydrokainate   an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in  GLAST -/- cochleas", "triple_list": [["dihydrokainate", "DOWNREGULATOR", "GLAST"]]}, {"text": "These currents were produced by glutamate-aspartate transporters (GLAST) ( excitatory amino acid transporter 1   because they were weakly inhibited by  dihydrokainate   an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas", "triple_list": [["dihydrokainate", "DOWNREGULATOR", "excitatory amino acid transporter 1"]]}, {"text": "These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by  dihydrokainate   an antagonist of  glutamate transporter-1  (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas", "triple_list": [["dihydrokainate", "ANTAGONIST", "glutamate transporter-1"]]}, {"text": "These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by  dihydrokainate   an antagonist of glutamate transporter-1 ( excitatory amino acid transporter 2   and were absent from IPCs in GLAST-/- cochleas", "triple_list": [["dihydrokainate", "ANTAGONIST", "excitatory amino acid transporter 2"]]}, {"text": "Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated  anion channel  and blocked by the transporter antagonist  D,L-threo-beta-benzyloxyaspartate   These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas", "triple_list": [["D,L-threo-beta-benzyloxyaspartate", "ANTAGONIST", "anion channel"]]}, {"text": "The  glutamate -aspartate transporter  GLAST  mediates  glutamate  uptake at inner hair cell afferent synapses in the mammalian cochlea", "triple_list": [["glutamate", "PRODUCT-OF", "GLAST"]]}, {"text": "The  glutamate -aspartate transporter GLAST mediates  glutamate  uptake at inner hair cell afferent synapses in the mammalian cochlea", "triple_list": [["glutamate", "PRODUCT-OF", "glutamate-aspartate transporter"]]}, {"text": "Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by  L-glutamate   a prominent feature of  GLAST   and examination of cochlea from  GLAST -Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs", "triple_list": [["L-glutamate", "PRODUCT-OF", "GLAST"]]}, {"text": "Overexpression of  proline  oxidase induces  proline  dependent and mitochondria-mediated apoptosis", "triple_list": [["proline", "PRODUCT-OF", "proline oxidase"]]}, {"text": "We conclude that in the presence of  proline   high  POX  activity is sufficient to induce mitochondria-mediated apoptosis.", "triple_list": [["proline", "PRODUCT-OF", "POX"]]}, {"text": " Proline oxidase  (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of  proline  to pyrroline- 5-carboxylate (P5C)", "triple_list": [["proline", "PRODUCT-OF", "Proline oxidase"]]}, {"text": "Proline oxidase ( POX  , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of  proline  to pyrroline- 5-carboxylate (P5C)", "triple_list": [["proline", "PRODUCT-OF", "POX"]]}, {"text": " Proline oxidase  (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to  pyrroline- 5-carboxylate  (P5C)", "triple_list": [["pyrroline- 5-carboxylate", "PRODUCT-OF", "Proline oxidase"]]}, {"text": "Proline oxidase ( POX  , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to  pyrroline- 5-carboxylate  (P5C)", "triple_list": [["pyrroline- 5-carboxylate", "PRODUCT-OF", "POX"]]}, {"text": " Proline oxidase  (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate ( P5C  ", "triple_list": [["P5C", "PRODUCT-OF", "Proline oxidase"]]}, {"text": "Proline oxidase ( POX  , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate ( P5C  ", "triple_list": [["P5C", "PRODUCT-OF", "POX"]]}, {"text": "To further investigate the molecular basis of  POX -induced apoptosis, we utilized the DLD-1. POX  cells to show that cells overproducing  POX  exhibit an  L-proline  dependent apoptotic response", "triple_list": [["L-proline", "PRODUCT-OF", "POX"]]}, {"text": "The apoptotic effect is specific for  L-proline , detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of  L-proline  to cells with maximally induced  POX   The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation/DNA fragmentation, and cell shrinkage", "triple_list": [["L-proline", "PRODUCT-OF", "POX"]]}, {"text": "The exception was  bupropion   a dual  norepinephrine transporter  dopamine transporter blocker, which tended to increase spontaneous locomotor activity", "triple_list": [["bupropion", "DOWNREGULATOR", "norepinephrine transporter"]]}, {"text": "The exception was  bupropion   a dual norepinephrine transporter/ dopamine transporter  blocker, which tended to increase spontaneous locomotor activity", "triple_list": [["bupropion", "DOWNREGULATOR", "dopamine transporter"]]}, {"text": "Coadministration of reboxetine and the  dopamine transporter  blocker  GBR 12909  also increased spontaneous locomotor activity", "triple_list": [["GBR 12909", "DOWNREGULATOR", "dopamine transporter"]]}, {"text": " Fulvestrant  is a novel  ER  antagonist that destroys the  ER  and its signaling pathway and is not associated with tamoxifen-like agonist effects", "triple_list": [["Fulvestrant", "DOWNREGULATOR", "ER"]]}, {"text": " Tamoxifen  blocks the action of estrogen by binding to the  ER , and possesses both  ER  agonist and antagonist properties", "triple_list": [["Tamoxifen", "AGONIST", "ER"]]}, {"text": " Tamoxifen  blocks the action of estrogen by binding to the  ER , and possesses both  ER  agonist and antagonist properties", "triple_list": [["Tamoxifen", "ANTAGONIST", "ER"]]}, {"text": " Fulvestrant  is a novel  ER  antagonist that destroys the  ER  and its signaling pathway and is not associated with tamoxifen-like agonist effects", "triple_list": [["Fulvestrant", "ANTAGONIST", "ER"]]}, {"text": "Binding of  cGMP  to GAF-A increases  cNPK  phosphorylation of PDE5 and improves catalytic site affinity for  cGMP  or inhibitors", "triple_list": [["cGMP", "ACTIVATOR", "cNPK"]]}, {"text": "Binding of  cGMP  to GAF-A increases cNPK phosphorylation of  PDE5  and improves catalytic site affinity for  cGMP  or inhibitors", "triple_list": [["cGMP", "ACTIVATOR", "PDE5"]]}, {"text": " Phosphodiesterase-5  (PDE5) contains a catalytic domain (C domain) that hydrolyzes  cGMP  and a regulatory domain (R domain) that contains two mammalian  cGMP -binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)", "triple_list": [["cGMP", "PRODUCT-OF", "Phosphodiesterase-5"]]}, {"text": "Phosphodiesterase-5 ( PDE5   contains a catalytic domain (C domain) that hydrolyzes  cGMP  and a regulatory domain (R domain) that contains two mammalian  cGMP -binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)", "triple_list": [["cGMP", "PRODUCT-OF", "PDE5"]]}, {"text": "K(m) values of the mutants for  cGMP  were similar to that of full-length  PDE5   All  PDE5  constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B", "triple_list": [["cGMP", "PRODUCT-OF", "PDE5"]]}, {"text": " Telmisartan  downregulates angiotensin II type 1 receptor through activation of  peroxisome proliferator-activated receptor gamma   OBJECTIVE:  Telmisartan , an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of  peroxisome proliferator-activated receptor gamma  (PPARgamma)", "triple_list": [["Telmisartan", "ACTIVATOR", "peroxisome proliferator-activated receptor gamma"]]}, {"text": "Since the suppression of  AT1R  expression was prevented by pretreatment with  GW9662   a PPARgamma antagonist, PPARgamma should have participated in the process", "triple_list": [["GW9662", "ACTIVATOR", "AT1R"]]}, {"text": "CONCLUSION: Our data provides a novel insight into an effect of  telmisartan :  telmisartan  inhibits AT1R gene expression through  PPARgamma  activation", "triple_list": [["telmisartan", "ACTIVATOR", "PPARgamma"]]}, {"text": "Decreased  AT1R  promoter activity with unchanged mRNA stability suggested that  telmisartan  suppressed  AT1R  gene expression at the transcriptional level", "triple_list": [["telmisartan", "DOWNREGULATOR", "AT1R"]]}, {"text": " Telmisartan  downregulates  angiotensin II type 1 receptor  through activation of peroxisome proliferator-activated receptor gamma", "triple_list": [["Telmisartan", "DOWNREGULATOR", "angiotensin II type 1 receptor"]]}, {"text": "The deletion and mutation analysis of the  AT1R  gene promoter indicated that a GC box located in the proximal promoter region is responsible for the  telmisartan  induced downregulation", "triple_list": [["telmisartan", "DOWNREGULATOR", "AT1R"]]}, {"text": "The deletion and mutation analysis of the AT1R gene promoter indicated that a  GC box  located in the proximal promoter region is responsible for the  telmisartan  induced downregulation", "triple_list": [["telmisartan", "DOWNREGULATOR", "GC box"]]}, {"text": "CONCLUSION: Our data provides a novel insight into an effect of  telmisartan :  telmisartan  inhibits  AT1R  gene expression through PPARgamma activation", "triple_list": [["telmisartan", "DOWNREGULATOR", "AT1R"]]}, {"text": "RESULTS:  Telmisartan  decreased the expression of  AT1R  at the mRNA and protein levels in a dose- and time-dependent manner", "triple_list": [["Telmisartan", "DOWNREGULATOR", "AT1R"]]}, {"text": "OBJECTIVE:  Telmisartan   an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of  peroxisome proliferator-activated receptor gamma  (PPARgamma)", "triple_list": [["Telmisartan", "AGONIST", "peroxisome proliferator-activated receptor gamma"]]}, {"text": "OBJECTIVE:  Telmisartan   an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma ( PPARgamma  ", "triple_list": [["Telmisartan", "AGONIST", "PPARgamma"]]}, {"text": "However, the expression of  AT1R  was not suppressed by other  AT1R  antagonists such as  candesartan  or olmesartan", "triple_list": [["candesartan", "ANTAGONIST", "AT1R"]]}, {"text": "However, the expression of  AT1R  was not suppressed by other  AT1R  antagonists such as candesartan or  olmesartan   Since the suppression of  AT1R  expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process", "triple_list": [["olmesartan", "ANTAGONIST", "AT1R"]]}, {"text": "OBJECTIVE:  Telmisartan   an  angiotensin II type 1 receptor  (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)", "triple_list": [["Telmisartan", "ANTAGONIST", "angiotensin II type 1 receptor"]]}, {"text": "OBJECTIVE:  Telmisartan   an angiotensin II type 1 receptor ( AT1R   antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)", "triple_list": [["Telmisartan", "ANTAGONIST", "AT1R"]]}, {"text": "Since the suppression of AT1R expression was prevented by pretreatment with  GW9662   a  PPARgamma  antagonist,  PPARgamma  should have participated in the process", "triple_list": [["GW9662", "ANTAGONIST", "PPARgamma"]]}, {"text": "Upon differentiation, osteoclasts express vesicular  glutamate  transporter 1 (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of  glutamate  in neurons", "triple_list": [["glutamate", "PRODUCT-OF", "vesicular glutamate transporter 1"]]}, {"text": "Upon differentiation, osteoclasts express vesicular  glutamate  transporter 1 ( VGLUT1  , which is essential for vesicular storage and subsequent exocytosis of  glutamate  in neurons", "triple_list": [["glutamate", "PRODUCT-OF", "VGLUT1"]]}, {"text": " VGLUT1  is localized in transcytotic vesicles and accumulates  L-glutamate   Osteoclasts secrete  L-glutamate  and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner", "triple_list": [["L-glutamate", "PRODUCT-OF", "VGLUT1"]]}, {"text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble  methotrexate  (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of  mammalian DHFR  activity", "triple_list": [["methotrexate", "DOWNREGULATOR", "mammalian DHFR"]]}, {"text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate ( MTX   1) structure features and fitted with functional groups believed to enhance inhibition of  mammalian DHFR  activity", "triple_list": [["MTX", "DOWNREGULATOR", "mammalian DHFR"]]}, {"text": "In order to produce potent new leads for anticancer drugs, a new series of  quinazoline  analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of  mammalian DHFR  activity", "triple_list": [["quinazoline", "DOWNREGULATOR", "mammalian DHFR"]]}, {"text": "Synthesis,  dihydrofolate reductase  inhibition, antitumor testing, and molecular modeling study of some new  4(3H)-quinazolinone  analogs", "triple_list": [["4(3H)-quinazolinone", "DOWNREGULATOR", "dihydrofolate reductase"]]}, {"text": "CONCLUSION: Intake of high  SFAs  and MUFAs appears to increase expression of PBMC  D6D  and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC  D6D  and D5D genes", "triple_list": [["SFAs", "ACTIVATOR", "D6D"]]}, {"text": "CONCLUSION: Intake of high  SFAs  and MUFAs appears to increase expression of PBMC D6D and  D5D  genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and  D5D  genes", "triple_list": [["SFAs", "ACTIVATOR", "D5D"]]}, {"text": "CONCLUSION: Intake of high SFAs and  MUFAs  appears to increase expression of PBMC  D6D  and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC  D6D  and D5D genes", "triple_list": [["MUFAs", "ACTIVATOR", "D6D"]]}, {"text": "CONCLUSION: Intake of high SFAs and  MUFAs  appears to increase expression of PBMC D6D and  D5D  genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and  D5D  genes", "triple_list": [["MUFAs", "ACTIVATOR", "D5D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC  D6D  and D5D genes, but a significant negative correlation between dietary intake of  linoleic acid  (LA) and alpha-linolenic acid (LNA) and the expression of PBMC  D6D  and D5D genes", "triple_list": [["linoleic acid", "DOWNREGULATOR", "D6D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and  D5D  genes, but a significant negative correlation between dietary intake of  linoleic acid  (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and  D5D  genes", "triple_list": [["linoleic acid", "DOWNREGULATOR", "D5D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC  D6D  and D5D genes, but a significant negative correlation between dietary intake of linoleic acid ( LA   and alpha-linolenic acid (LNA) and the expression of PBMC  D6D  and D5D genes", "triple_list": [["LA", "DOWNREGULATOR", "D6D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and  D5D  genes, but a significant negative correlation between dietary intake of linoleic acid ( LA   and alpha-linolenic acid (LNA) and the expression of PBMC D6D and  D5D  genes", "triple_list": [["LA", "DOWNREGULATOR", "D5D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC  D6D  and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and  alpha-linolenic acid  (LNA) and the expression of PBMC  D6D  and D5D genes", "triple_list": [["alpha-linolenic acid", "DOWNREGULATOR", "D6D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and  D5D  genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and  alpha-linolenic acid  (LNA) and the expression of PBMC D6D and  D5D  genes", "triple_list": [["alpha-linolenic acid", "DOWNREGULATOR", "D5D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC  D6D  and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid ( LNA   and the expression of PBMC  D6D  and D5D genes", "triple_list": [["LNA", "DOWNREGULATOR", "D6D"]]}, {"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and  D5D  genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid ( LNA   and the expression of PBMC D6D and  D5D  genes", "triple_list": [["LNA", "DOWNREGULATOR", "D5D"]]}, {"text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC  D6D  and D5D genes, whilst high  EFAs  intake appears to decrease expression of PBMC  D6D  and D5D genes", "triple_list": [["EFAs", "DOWNREGULATOR", "D6D"]]}, {"text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and  D5D  genes, whilst high  EFAs  intake appears to decrease expression of PBMC D6D and  D5D  genes", "triple_list": [["EFAs", "DOWNREGULATOR", "D5D"]]}, {"text": " Decitabine  inhibits  DNA methyltransferase  and has shown therapeutic effects in patients with hematologic malignancies", "triple_list": [["Decitabine", "DOWNREGULATOR", "DNA methyltransferase"]]}, {"text": "Our data suggest that  l-arginine  is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ( SLC3A2  SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution", "triple_list": [["l-arginine", "PRODUCT-OF", "SLC3A2"]]}, {"text": "KIEs were measured on the arsenolysis of  5'-methylthioadenosine  (MTA) catalyzed by  MTAP  and were corrected for the forward commitment to catalysis", "triple_list": [["5'-methylthioadenosine", "PRODUCT-OF", "MTAP"]]}, {"text": "KIEs were measured on the arsenolysis of 5'-methylthioadenosine ( MTA   catalyzed by  MTA P and were corrected for the forward commitment to catalysis", "triple_list": [["MTA", "PRODUCT-OF", "MTAP"]]}, {"text": "Blocking  retinyl ester  formation by a targeted knock down of  Lratb  results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects", "triple_list": [["retinyl ester", "PRODUCT-OF", "Lratb"]]}, {"text": "During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to  retinal dehydrogenase 2  (raldh2), the key enzyme for  retinoic acid  synthesis", "triple_list": [["retinoic acid", "PRODUCT-OF", "retinal dehydrogenase 2"]]}, {"text": "During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 ( raldh2  , the key enzyme for  retinoic acid  synthesis", "triple_list": [["retinoic acid", "PRODUCT-OF", "raldh2"]]}, {"text": " ADP  initiates platelet aggregation by 'simultaneous activation of two  G protein-coupled receptors   P2Y1 and P2Y12", "triple_list": [["ADP", "ACTIVATOR", "G protein-coupled receptors"]]}, {"text": " ADP  initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors,  P2Y1  and  P2Y1 2", "triple_list": [["ADP", "ACTIVATOR", "P2Y1"]]}, {"text": " ADP  initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and  P2Y12    P2Y12  has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel", "triple_list": [["ADP", "ACTIVATOR", "P2Y12"]]}, {"text": "Our results imply that  P2Y12  has the potential to be inhibited by  ADP  ATP analogs, and it suggests that  P2Y12  acts as a target of new drugs that inhibit platelet aggregation.", "triple_list": [["ADP", "DOWNREGULATOR", "P2Y12"]]}, {"text": "Our results imply that  P2Y12  has the potential to be inhibited by ADP/ ATP  analogs, and it suggests that  P2Y12  acts as a target of new drugs that inhibit platelet aggregation.", "triple_list": [["ATP", "DOWNREGULATOR", "P2Y12"]]}, {"text": " Cd  rapidly increased  c-jun   c-fos and PDGFA expression", "triple_list": [["Cd", "ACTIVATOR", "c-jun"]]}, {"text": " Cd  rapidly increased c-jun,  c-fos  and PDGFA expression", "triple_list": [["Cd", "ACTIVATOR", "c-fos"]]}, {"text": " Cd  rapidly increased c-jun, c-fos and  PDGFA  expression", "triple_list": [["Cd", "ACTIVATOR", "PDGFA"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating  Akt   ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "Akt"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and  PDGFRalpha  kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "PDGFRalpha"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha  kinases  activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "kinases"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating  c-fos   c-jun and PDGFA by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "c-fos"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos,  c-jun  and PDGFA by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "c-jun"]]}, {"text": "In conclusion, our results indicate that  Cd  increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and  PDGFA  by an ERalpha-dependent mechanism.", "triple_list": [["Cd", "ACTIVATOR", "PDGFA"]]}, {"text": " Cd  also increased ERK1/2,  Akt  and PDGFRalpha phosphorylation while ICI blocked it", "triple_list": [["Cd", "ACTIVATOR", "Akt"]]}, {"text": " Cd  also increased ERK1/2, Akt and  PDGFRalpha  phosphorylation while ICI blocked it", "triple_list": [["Cd", "ACTIVATOR", "PDGFRalpha"]]}, {"text": " Cd  decreased  ERalpha  expression, but not ERbeta", "triple_list": [["Cd", "DOWNREGULATOR", "ERalpha"]]}, {"text": "Gonadotropin-releasing hormone functionally antagonizes  testosterone  activation of the  human androgen receptor  in prostate cells through focal adhesion complexes involving Hic-5", "triple_list": [["testosterone", "ACTIVATOR", "human androgen receptor"]]}, {"text": " GnRH  induced  Pyk2  activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative  Pyk2  enhanced the  GnRH -induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor", "triple_list": [["GnRH", "ACTIVATOR", "Pyk2"]]}, {"text": " GnRH  induced  c-Src  activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor", "triple_list": [["GnRH", "ACTIVATOR", "c-Src"]]}, {"text": "In contrast to  testosterone   GnRH-induced nuclear translocation did not transcriptionally activate the  androgen receptor   We then demonstrated that GnRH can also stimulate  androgen receptor  mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism", "triple_list": [["testosterone", "ACTIVATOR", "androgen receptor"]]}, {"text": " GnRH  induced Pyk2 activation opposed the association of  Hic-5  with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the  GnRH -induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor", "triple_list": [["GnRH", "DOWNREGULATOR", "Hic-5"]]}, {"text": " GnRH  induced Pyk2 activation opposed the association of Hic-5 with  androgen receptor  as overexpression of a dominant negative Pyk2 enhanced the  GnRH -induced nuclear translocation of a green fluorescent protein-tagged human  androgen receptor ", "triple_list": [["GnRH", "DOWNREGULATOR", "androgen receptor"]]}, {"text": " Gonadotropin-releasing hormone  functionally antagonizes testosterone activation of the  human androgen receptor  in prostate cells through focal adhesion complexes involving Hic-5", "triple_list": [["Gonadotropin-releasing hormone", "ANTAGONIST", "human androgen receptor"]]}, {"text": "EC50 values for  S-(+)-METH  were 0.89, 0.92, and 4.44 microM for  rTAAR1   mTAAR1, and h-rChTAAR1, respectively", "triple_list": [["S-(+)-METH", "ACTIVATOR", "rTAAR1"]]}, {"text": "EC50 values for  S-(+)-METH  were 0.89, 0.92, and 4.44 microM for rTAAR1,  mTAAR1   and h-rChTAAR1, respectively", "triple_list": [["S-(+)-METH", "ACTIVATOR", "mTAAR1"]]}, {"text": "EC50 values for  S-(+)-METH  were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and  h-rChTAAR1   respectively", "triple_list": [["S-(+)-METH", "ACTIVATOR", "h-rChTAAR1"]]}, {"text": "The discovery that  METH  and AMPH activate the  rTAAR1  motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)", "triple_list": [["METH", "ACTIVATOR", "rTAAR1"]]}, {"text": "The discovery that METH and  AMPH  activate the  rTAAR1  motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)", "triple_list": [["AMPH", "ACTIVATOR", "rTAAR1"]]}, {"text": "Furthermore, because S-(+)-isomers of  METH  and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of  TAAR1   In response to  METH , AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of  TAAR1  was concentration- and isomer-dependent", "triple_list": [["METH", "ACTIVATOR", "TAAR1"]]}, {"text": "Furthermore, because S-(+)-isomers of METH and  AMPH  are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of  TAAR1   In response to METH,  AMPH , or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of  TAAR1  was concentration- and isomer-dependent", "triple_list": [["AMPH", "ACTIVATOR", "TAAR1"]]}, {"text": " PEA  was a potent and full agonist at each species of  TAAR1   whereas TYR was a full agonist for the rodent  TAAR1 s but was a partial agonist at h-rCh TAAR1 ", "triple_list": [["PEA", "AGONIST", "TAAR1"]]}, {"text": "PEA was a potent and full agonist at each species of TAAR1, whereas  TYR  was a full agonist for the  rodent TAAR1s  but was a partial agonist at h-rChTAAR1", "triple_list": [["TYR", "AGONIST", "rodent TAAR1s"]]}, {"text": "PEA was a potent and full agonist at each species of TAAR1, whereas  TYR  was a full agonist for the rodent TAAR1s but was a partial agonist at  h-rChTAAR1   Interestingly, both isomers of METH were full agonists at mTAAR1 and  h-rChTAAR1 , whereas both were partial agonists at rTAAR1", "triple_list": [["TYR", "AGONIST", "h-rChTAAR1"]]}, {"text": "Interestingly, both isomers of  METH  were full agonists at  mTAAR1  and h-rChTAAR1, whereas both were partial agonists at rTAAR1", "triple_list": [["METH", "AGONIST", "mTAAR1"]]}, {"text": "Interestingly, both isomers of  METH  were full agonists at mTAAR1 and  h-rChTAAR1   whereas both were partial agonists at rTAAR1", "triple_list": [["METH", "AGONIST", "h-rChTAAR1"]]}, {"text": "Interestingly, both isomers of  METH  were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at  rTAAR1   Taken together, these in vitro results suggest that, in vivo, TAAR1 could be a novel mediator of the effects of these drugs.", "triple_list": [["METH", "AGONIST", "rTAAR1"]]}, {"text": "Finally, we showed that  chlorate  activated endocrine cell development by inducing  neurogenin 3  (Neurog3) expression in early endocrine progenitor cells", "triple_list": [["chlorate", "ACTIVATOR", "neurogenin 3"]]}, {"text": "Finally, we showed that  chlorate  activated endocrine cell development by inducing neurogenin 3 ( Neurog3   expression in early endocrine progenitor cells", "triple_list": [["chlorate", "ACTIVATOR", "Neurog3"]]}, {"text": "The metallic taste reported as a side effect after the treatment with systemic  sulfonamides  may be due to the inhibition of the  salivary CA VI   Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.", "triple_list": [["sulfonamides", "DOWNREGULATOR", "salivary CA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide,  dichlorophenamide   dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["dichlorophenamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as  acetazolamide   methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["acetazolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide,  methazolamide   ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["methazolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide,  ethoxzolamide   dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["ethoxzolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "DNA cloning, characterization, and inhibition studies of the  human secretory isoform VI   a new target for  sulfonamide  and sulfamate inhibitors", "triple_list": [["sulfonamide", "DOWNREGULATOR", "human secretory isoform VI"]]}, {"text": "DNA cloning, characterization, and inhibition studies of the  human secretory isoform VI   a new target for sulfonamide and  sulfamate  inhibitors", "triple_list": [["sulfamate", "DOWNREGULATOR", "human secretory isoform VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide,  dorzolamide   brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["dorzolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide,  brinzolamide   topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["brinzolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide,  topiramate   sulpiride, and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["topiramate", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate,  sulpiride   and indisulam, or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["sulpiride", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and  indisulam   or the orphan drug benzolamide, showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["indisulam", "DOWNREGULATOR", "hCA VI"]]}, {"text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug  benzolamide   showed effective  hCA VI  inhibitory activity, with inhibition constants of 0.8-79 nM", "triple_list": [["benzolamide", "DOWNREGULATOR", "hCA VI"]]}, {"text": "The best inhibitors were  brinzolamide  and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a  CA VI  selective inhibitor", "triple_list": [["brinzolamide", "DOWNREGULATOR", "CA VI"]]}, {"text": "The best inhibitors were brinzolamide and  sulpiride  (KI values of 0.8-0.9 nM), the latter compound being also a  CA VI  selective inhibitor", "triple_list": [["sulpiride", "DOWNREGULATOR", "CA VI"]]}, {"text": "Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant  CO2  hydrase activity of enamel  CA VI   which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.", "triple_list": [["CO2", "PRODUCT-OF", "CA VI"]]}, {"text": "Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel  CA VI   which leads to the formation of protons and  bicarbonate  and may have a role in cariogenesis.", "triple_list": [["bicarbonate", "PRODUCT-OF", "CA VI"]]}, {"text": "The kinetic parameters for the  CO2  hydration reaction proved  hCA VI  to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C)", "triple_list": [["CO2", "PRODUCT-OF", "hCA VI"]]}, {"text": "Transmembrane isoforms of  adenylate cyclases  (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate  cAMP  production in response to calcium entry", "triple_list": [["cAMP", "PRODUCT-OF", "adenylate cyclases"]]}, {"text": "Transmembrane isoforms of adenylate cyclases ( AC   integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate  cAMP  production in response to calcium entry", "triple_list": [["cAMP", "PRODUCT-OF", "AC"]]}, {"text": "Here, we report that the antifibrotic drug  5-methyl-1-phenyl-2-(1H)-pyridone  (pirfenidone, PFD) elicits growth-inhibitory effects and reduces  TGF-beta2  protein levels in human glioma cell lines", "triple_list": [["5-methyl-1-phenyl-2-(1H)-pyridone", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone ( pirfenidone   PFD) elicits growth-inhibitory effects and reduces  TGF-beta2  protein levels in human glioma cell lines", "triple_list": [["pirfenidone", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone,  PFD   elicits growth-inhibitory effects and reduces  TGF-beta2  protein levels in human glioma cell lines", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": "This reduction in  TGF-beta2  is biologically relevant since  PFD  treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": "This reduction in  TGF-beta 2 is biologically relevant since  PFD  treatment reduces the growth inhibition of  TGF-beta  sensitive CCL-64 cells mediated by conditioned media of glioma cells", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta"]]}, {"text": " PFD  leads to a reduction of  TGF-beta2  mRNA levels and of the mature  TGF-beta2  protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": " PFD  leads to a reduction of  TGF-beta2  mRNA levels and of the mature  TGF-beta2  protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta2"]]}, {"text": " PFD  leads to a reduction of  TGF-beta 2 mRNA levels and of the mature  TGF-beta 2 protein due to decreased expression and direct inhibition of the  TGF-beta  pro-protein convertase furin", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta"]]}, {"text": " PFD  leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta  pro-protein convertase  furin", "triple_list": [["PFD", "DOWNREGULATOR", "pro-protein convertase"]]}, {"text": " PFD  leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase  furin   In addition,  PFD  reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and  furin  substrate involved in carcinogenesis", "triple_list": [["PFD", "DOWNREGULATOR", "furin"]]}, {"text": "In addition,  PFD  reduces the protein levels of the  matrix metalloproteinase (MMP)-11   a TGF-beta target gene and furin substrate involved in carcinogenesis", "triple_list": [["PFD", "DOWNREGULATOR", "matrix metalloproteinase (MMP)-11"]]}, {"text": "In addition,  PFD  reduces the protein levels of the matrix metalloproteinase (MMP)-11, a  TGF-beta  target gene and furin substrate involved in carcinogenesis", "triple_list": [["PFD", "DOWNREGULATOR", "TGF-beta"]]}, {"text": " Pirfenidone  inhibits  TGF-beta  expression in malignant glioma cells", "triple_list": [["Pirfenidone", "DOWNREGULATOR", "TGF-beta"]]}, {"text": "UNLABELLED:  Bile acid-coenzyme A:amino acid N-acyltransferase  (BAAT) is the sole enzyme responsible for conjugation of primary and secondary  bile acids  to taurine and glycine", "triple_list": [["bile acids", "PRODUCT-OF", "Bile acid-coenzyme A:amino acid N-acyltransferase"]]}, {"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ( BAAT   is the sole enzyme responsible for conjugation of primary and secondary  bile acids  to taurine and glycine", "triple_list": [["bile acids", "PRODUCT-OF", "BAAT"]]}, {"text": "UNLABELLED:  Bile acid-coenzyme A:amino acid N-acyltransferase  (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to  taurine  and glycine", "triple_list": [["taurine", "PRODUCT-OF", "Bile acid-coenzyme A:amino acid N-acyltransferase"]]}, {"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ( BAAT   is the sole enzyme responsible for conjugation of primary and secondary bile acids to  taurine  and glycine", "triple_list": [["taurine", "PRODUCT-OF", "BAAT"]]}, {"text": "UNLABELLED:  Bile acid-coenzyme A:amino acid N-acyltransferase  (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and  glycine   Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions", "triple_list": [["glycine", "PRODUCT-OF", "Bile acid-coenzyme A:amino acid N-acyltransferase"]]}, {"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ( BAAT   is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and  glycine   Previous studies indicate a peroxisomal location of  BAAT  in peroxisomes with variable amounts up to 95% detected in cytosolic fractions", "triple_list": [["glycine", "PRODUCT-OF", "BAAT"]]}, {"text": "The absence or presence of a cytosolic pool of  BAAT  has important implications for the intracellular transport of unconjugated/deconjugated  bile salts   We used immunofluorescence microscopy and digitonin permeabilization assays to determine the subcellular location of endogenous  BAAT  in primary human and rat hepatocytes", "triple_list": [["bile salts", "PRODUCT-OF", "BAAT"]]}, {"text": "The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the  riboflavin  kinase  enzyme that converts  riboflavin  to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated", "triple_list": [["riboflavin", "PRODUCT-OF", "riboflavin kinase"]]}, {"text": "The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the  riboflavin kinase   enzyme that converts riboflavin to  flavinmononucleotide   driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated", "triple_list": [["flavinmononucleotide", "PRODUCT-OF", "riboflavin kinase"]]}, {"text": " Mouse ornithine decarboxylase  (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor,  alpha-difluoromethylornithine  (DFMO)", "triple_list": [["alpha-difluoromethylornithine", "DOWNREGULATOR", "Mouse ornithine decarboxylase"]]}, {"text": "Mouse ornithine decarboxylase ( ODC   was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor,  alpha-difluoromethylornithine  (DFMO)", "triple_list": [["alpha-difluoromethylornithine", "DOWNREGULATOR", "ODC"]]}, {"text": " Mouse ornithine decarboxylase  (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ( DFMO  ", "triple_list": [["DFMO", "DOWNREGULATOR", "Mouse ornithine decarboxylase"]]}, {"text": "Mouse ornithine decarboxylase ( ODC   was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ( DFMO  ", "triple_list": [["DFMO", "DOWNREGULATOR", "ODC"]]}, {"text": "Mechanism of the irreversible inactivation of  mouse ornithine decarboxylase  by  alpha-difluoromethylornithine   Characterization of sequences at the inhibitor and coenzyme binding sites", "triple_list": [["alpha-difluoromethylornithine", "DOWNREGULATOR", "mouse ornithine decarboxylase"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by  ASCT2   SNAT1, and SNAT2", "triple_list": [["alanine", "PRODUCT-OF", "ASCT2"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by ASCT2,  SNAT1   and SNAT2", "triple_list": [["alanine", "PRODUCT-OF", "SNAT1"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by ASCT2, SNAT1, and  SNAT2   MNI- alanine  has favorable photochemical properties and is stable in aqueous solution", "triple_list": [["alanine", "PRODUCT-OF", "SNAT2"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by  ASCT2   SNAT1, and SNAT2", "triple_list": [["alanine", "PRODUCT-OF", "ASCT2"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by ASCT2,  SNAT1   and SNAT2", "triple_list": [["alanine", "PRODUCT-OF", "SNAT1"]]}, {"text": "Here, we describe a new photolabile  alanine  derivative based on protection of  alanine  with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of  alanine  transport by ASCT2, SNAT1, and  SNAT2   MNI- alanine  has favorable photochemical properties and is stable in aqueous solution", "triple_list": [["alanine", "PRODUCT-OF", "SNAT2"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the  4-methoxy-7-nitroindolinyl  (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by  ASCT2   SNAT1, and SNAT2", "triple_list": [["4-methoxy-7-nitroindolinyl", "PRODUCT-OF", "ASCT2"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the  4-methoxy-7-nitroindolinyl  (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2,  SNAT1   and SNAT2", "triple_list": [["4-methoxy-7-nitroindolinyl", "PRODUCT-OF", "SNAT1"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the  4-methoxy-7-nitroindolinyl  (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and  SNAT2   MNI-alanine has favorable photochemical properties and is stable in aqueous solution", "triple_list": [["4-methoxy-7-nitroindolinyl", "PRODUCT-OF", "SNAT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the  neutral amino acid transporters  of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "neutral amino acid transporters"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the  solute carrier 1  [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "solute carrier 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [ SLC1   alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "SLC1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine serine cysteine transporter 1  (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "alanine serine cysteine transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ( ASCT1  , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "ASCT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and  ASCT2   and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "ASCT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and  SLC38  families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "SLC38"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [ sodium-coupled neutral amino acid transporter 1  (SNAT1), SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "sodium-coupled neutral amino acid transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ( SNAT1  , SNAT2, and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "SNAT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1),  SNAT2   and SNAT4]", "triple_list": [["amino acids", "PRODUCT-OF", "SNAT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral  amino acids   such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and  SNAT4  ", "triple_list": [["amino acids", "PRODUCT-OF", "SNAT4"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ( MNI   caging group, which we use for pre-steady-state kinetic analysis of alanine transport by  ASCT2   SNAT1, and SNAT2", "triple_list": [["MNI", "PRODUCT-OF", "ASCT2"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ( MNI   caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2,  SNAT1   and SNAT2", "triple_list": [["MNI", "PRODUCT-OF", "SNAT1"]]}, {"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ( MNI   caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and  SNAT2    MNI -alanine has favorable photochemical properties and is stable in aqueous solution", "triple_list": [["MNI", "PRODUCT-OF", "SNAT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the  neutral amino acid transporters  of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "neutral amino acid transporters"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the  solute carrier 1  [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "solute carrier 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [ SLC1   alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "SLC1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine serine cysteine transporter 1  (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "alanine serine cysteine transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ( ASCT1  , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "ASCT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and  ASCT2   and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "ASCT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and  SLC38  families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "SLC38"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [ sodium-coupled neutral amino acid transporter 1  (SNAT1), SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "sodium-coupled neutral amino acid transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ( SNAT1  , SNAT2, and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "SNAT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1),  SNAT2   and SNAT4]", "triple_list": [["glutamine", "PRODUCT-OF", "SNAT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as  glutamine  and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and  SNAT4  ", "triple_list": [["glutamine", "PRODUCT-OF", "SNAT4"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the  neutral amino acid transporters  of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "neutral amino acid transporters"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the  solute carrier 1  [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "solute carrier 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [ SLC1    alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "SLC1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "alanine serine cysteine transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 ( ASCT1  , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "ASCT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and  ASCT2   and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "ASCT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [ sodium-coupled neutral amino acid transporter 1  (SNAT1), SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "sodium-coupled neutral amino acid transporter 1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ( SNAT1  , SNAT2, and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "SNAT1"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1),  SNAT2   and SNAT4]", "triple_list": [["alanine", "PRODUCT-OF", "SNAT2"]]}, {"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and  alanine   is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1,  alanine  serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and  SNAT4  ", "triple_list": [["alanine", "PRODUCT-OF", "SNAT4"]]}, {"text": "Stimulated  P-selectin  and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after  aspirin   Platelet COX-2 expression was detected in 12 +/- 7% (n = 10) of platelets in the upper tertile, and in 7 +/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)", "triple_list": [["aspirin", "ACTIVATOR", "P-selectin"]]}, {"text": "Stimulated P-selectin and  integrin alpha(IIb)beta(3)  expression were also higher in the upper tertile both before and after  aspirin   Platelet COX-2 expression was detected in 12 +/- 7% (n = 10) of platelets in the upper tertile, and in 7 +/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)", "triple_list": [["aspirin", "ACTIVATOR", "integrin alpha(IIb)beta(3)"]]}, {"text": "Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the  ERbeta  agonist,  DPN   protected against dopamine cell loss", "triple_list": [["DPN", "AGONIST", "ERbeta"]]}, {"text": "At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the  ER  antagonist,  ICI 182,780   Moreover,  ER alpha mediated the protection afforded by estrogen since only the  ER alpha agonist, HPTE, but not the  ER beta agonist, DPN, protected against dopamine cell loss", "triple_list": [["ICI 182,780", "ANTAGONIST", "ER"]]}, {"text": "Differential activation of  cAMP response element binding protein  in discrete nucleus accumbens subregions during early and late  cocaine  sensitization", "triple_list": [["cocaine", "ACTIVATOR", "cAMP response element binding protein"]]}, {"text": "The temporal and anatomical determinants of  cocaine  induced  CREB  activity may indicate functional differences among NAc shell subregions and suggest the involvement of  CREB  in early and late  cocaine  effects.", "triple_list": [["cocaine", "ACTIVATOR", "CREB"]]}, {"text": "The present study examined the differential  cocaine  induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein ( CREB   throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats", "triple_list": [["cocaine", "ACTIVATOR", "CREB"]]}, {"text": "The present study examined the differential  cocaine  induced activation of the  cyclic adenosine monophosphate (cAMP) response element binding protein  (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats", "triple_list": [["cocaine", "ACTIVATOR", "cyclic adenosine monophosphate (cAMP) response element binding protein"]]}, {"text": "Using immunohistochemistry, the authors analyzed changes in  CREB  phosphorylation in the NAc after 5 days of  cocaine   a short or long drug-free period, and a subsequent challenge injection", "triple_list": [["cocaine", "ACTIVATOR", "CREB"]]}, {"text": "Repeated  cocaine  resulted in  CREB  phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated  cocaine , but rats challenged after 2 drug-free days yielded a more localized activation of  CREB  in the 3 most dorsomedial zones of the shell", "triple_list": [["cocaine", "ACTIVATOR", "CREB"]]}, {"text": "Repeated  cocaine  resulted in  CREB  phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated  cocaine   but rats challenged after 2 drug-free days yielded a more localized activation of  CREB  in the 3 most dorsomedial zones of the shell", "triple_list": [["cocaine", "ACTIVATOR", "CREB"]]}, {"text": "The carboxylation of  glutamic acid  residues to gamma-carboxy glutamic acid  (Gla) by the  vitamin K-dependent gamma-glutamyl carboxylase  (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["glutamic acid", "PRODUCT-OF", "vitamin K-dependent gamma-glutamyl carboxylase"]]}, {"text": "The carboxylation of  glutamic acid  residues to gamma-carboxy glutamic acid  (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase ( gamma-carboxylase   is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["glutamic acid", "PRODUCT-OF", "gamma-carboxylase"]]}, {"text": "The carboxylation of glutamic acid residues to  gamma-carboxyglutamic acid  (Gla) by the  vitamin K-dependent gamma-glutamyl carboxylase  (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["gamma-carboxyglutamic acid", "PRODUCT-OF", "vitamin K-dependent gamma-glutamyl carboxylase"]]}, {"text": "The carboxylation of glutamic acid residues to  gamma-carboxyglutamic acid  (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase ( gamma-carboxylase   is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["gamma-carboxyglutamic acid", "PRODUCT-OF", "gamma-carboxylase"]]}, {"text": "The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( Gla   by the  vitamin K-dependent gamma-glutamyl carboxylase  (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["Gla", "PRODUCT-OF", "vitamin K-dependent gamma-glutamyl carboxylase"]]}, {"text": "The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( Gla   by the vitamin K-dependent gamma-glutamyl carboxylase ( gamma-carboxylase   is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation", "triple_list": [["Gla", "PRODUCT-OF", "gamma-carboxylase"]]}, {"text": " RAMH  inhibition of cholangiocyte growth was associated with decreased cAMP levels and  PKA  ERK1/2/Elk-1 phosphorylation", "triple_list": [["RAMH", "DOWNREGULATOR", "PKA"]]}, {"text": " RAMH  inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ ERK1/2  Elk-1 phosphorylation", "triple_list": [["RAMH", "DOWNREGULATOR", "ERK1/2"]]}, {"text": " RAMH  inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/ Elk-1  phosphorylation", "triple_list": [["RAMH", "DOWNREGULATOR", "Elk-1"]]}, {"text": "We posed the following questions: (1) Do cholangiocytes express  H3R ? (2) Does in vivo administration of  (R)-(alpha)-(-)-methylhistamine dihydrobromide  (RAMH) ( H3R  agonist), thioperamide maleate ( H3R  antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of  H3R  was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats", "triple_list": [["(R)-(alpha)-(-)-methylhistamine dihydrobromide", "AGONIST", "H3R"]]}, {"text": "We posed the following questions: (1) Do cholangiocytes express  H3R ? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide ( RAMH   ( H3R  agonist), thioperamide maleate ( H3R  antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does  RAMH  inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of  H3R  was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats", "triple_list": [["RAMH", "AGONIST", "H3R"]]}, {"text": "We posed the following questions: (1) Do cholangiocytes express  H3R ? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) ( H3R  agonist),  thioperamide maleate  ( H3R  antagonist) or histamine, in the absence/presence of  thioperamide maleate , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of  H3R  was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats", "triple_list": [["thioperamide maleate", "ANTAGONIST", "H3R"]]}, {"text": " Proline dehydrogenase  (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of  proline  to glutamate", "triple_list": [["proline", "PRODUCT-OF", "Proline dehydrogenase"]]}, {"text": "Proline dehydrogenase ( PRODH   and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of  proline  to glutamate", "triple_list": [["proline", "PRODUCT-OF", "PRODH"]]}, {"text": "Proline dehydrogenase (PRODH) and  Delta(1)-pyrroline-5-carboxylate dehydrogenase  (P5CDH) catalyze the two-step oxidation of  proline  to glutamate", "triple_list": [["proline", "PRODUCT-OF", "Delta(1)-pyrroline-5-carboxylate dehydrogenase"]]}, {"text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase ( P5CDH   catalyze the two-step oxidation of  proline  to glutamate", "triple_list": [["proline", "PRODUCT-OF", "P5CDH"]]}, {"text": " Proline dehydrogenase  (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to  glutamate   They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria", "triple_list": [["glutamate", "PRODUCT-OF", "Proline dehydrogenase"]]}, {"text": "Proline dehydrogenase ( PRODH   and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to  glutamate   They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria", "triple_list": [["glutamate", "PRODUCT-OF", "PRODH"]]}, {"text": "Proline dehydrogenase (PRODH) and  Delta(1)-pyrroline-5-carboxylate dehydrogenase  (P5CDH) catalyze the two-step oxidation of proline to  glutamate   They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria", "triple_list": [["glutamate", "PRODUCT-OF", "Delta(1)-pyrroline-5-carboxylate dehydrogenase"]]}, {"text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase ( P5CDH   catalyze the two-step oxidation of proline to  glutamate   They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria", "triple_list": [["glutamate", "PRODUCT-OF", "P5CDH"]]}, {"text": "This is significant because  superoxide  production underlies the role of  human PRODH  in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.", "triple_list": [["superoxide", "PRODUCT-OF", "human PRODH"]]}, {"text": "Results of early clinical trials with both topically ( cipamfylline   CP80,633) and systemically (CC-10004) active  PDE4  inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis", "triple_list": [["cipamfylline", "DOWNREGULATOR", "PDE4"]]}, {"text": "Results of early clinical trials with both topically (cipamfylline,  CP80,633   and systemically (CC-10004) active  PDE4  inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis", "triple_list": [["CP80,633", "DOWNREGULATOR", "PDE4"]]}, {"text": "Consequently,  PDE4  inhibitors including  cilomilast  and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation", "triple_list": [["cilomilast", "DOWNREGULATOR", "PDE4"]]}, {"text": "Consequently,  PDE4  inhibitors including cilomilast and  AWD 12-281  have been tested in several models of allergic and irritant skin inflammation", "triple_list": [["AWD 12-281", "DOWNREGULATOR", "PDE4"]]}, {"text": "The  phosphodiesterase (PDE) 4  is the predominant  cyclic AMP  degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes", "triple_list": [["cyclic AMP", "PRODUCT-OF", "phosphodiesterase (PDE) 4"]]}, {"text": "Although considerable functional diversity exists, most  C2 domains  are activated by  Ca2+  binding and then dock to a specific cellular membrane", "triple_list": [["Ca2+", "ACTIVATOR", "C2 domains"]]}, {"text": " Bile acid coenzyme A:amino acid N-acyltransferase  (BAT) is responsible for the amidation of  bile acids  with the amino acids glycine and taurine", "triple_list": [["bile acids", "PRODUCT-OF", "Bile acid coenzyme A:amino acid N-acyltransferase"]]}, {"text": "Bile acid coenzyme A:amino acid N-acyltransferase ( BAT   is responsible for the amidation of  bile acids  with the amino acids glycine and taurine", "triple_list": [["bile acids", "PRODUCT-OF", "BAT"]]}, {"text": " Asparagine  secretion by MSCs was directly related to their  ASNS  expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed", "triple_list": [["Asparagine", "PRODUCT-OF", "ASNS"]]}, {"text": "Because of their low  asparagine  synthetase ( ASNS   expression and  asparagine  biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to  asparagine  depletion", "triple_list": [["asparagine", "PRODUCT-OF", "ASNS"]]}, {"text": "Because of their low  asparagine  synthetase (ASNS) expression and  asparagine  biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to  asparagine  depletion", "triple_list": [["asparagine", "PRODUCT-OF", "asparagine synthetase"]]}, {"text": " MK-801  ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive  NMDA receptor  antagonist, partially prevented the decrease in cell viability and the energy impairment", "triple_list": [["MK-801", "ANTAGONIST", "NMDA receptor"]]}, {"text": "MK-801 ( (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate  , a noncompetitive  NMDA receptor  antagonist, partially prevented the decrease in cell viability and the energy impairment", "triple_list": [["(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate", "ANTAGONIST", "NMDA receptor"]]}, {"text": "The parallel pattern of accumulation of 24:6n-3 and  DHA  in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for  D6D  may contribute to the limited accumulation of  DHA  in cell membranes.", "triple_list": [["DHA", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ( DHA ; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of  DHA  from ALA", "triple_list": [["DHA", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ( DHA ; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of  DHA  from ALA", "triple_list": [["DHA", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of alpha-linolenic acid ( ALA ; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from  ALA   We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of  ALA  in HepG2 cell phospholipids", "triple_list": [["ALA", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of alpha-linolenic acid ( ALA ; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from  ALA   We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of  ALA  in HepG2 cell phospholipids", "triple_list": [["ALA", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of  alpha-linolenic acid  (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA", "triple_list": [["alpha-linolenic acid", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of  alpha-linolenic acid  (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA", "triple_list": [["alpha-linolenic acid", "PRODUCT-OF", "D6D"]]}, {"text": "The accumulation of the post- D6D  products of 22:5n-3, 24:6n-3 and  DHA   in cell phospholipids was saturated at concentrations of >18 microM ALA", "triple_list": [["DHA", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of alpha-linolenic acid ( ALA   18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from  ALA ", "triple_list": [["ALA", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of alpha-linolenic acid ( ALA   18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from  ALA ", "triple_list": [["ALA", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to  docosahexaenoic acid  (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA", "triple_list": [["docosahexaenoic acid", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to  docosahexaenoic acid  (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA", "triple_list": [["docosahexaenoic acid", "PRODUCT-OF", "D6D"]]}, {"text": "The use of  Delta 6 desaturase  (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ( DHA   22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of  DHA  from ALA", "triple_list": [["DHA", "PRODUCT-OF", "Delta 6 desaturase"]]}, {"text": "The use of Delta 6 desaturase ( D6D   twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ( DHA   22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of  DHA  from ALA", "triple_list": [["DHA", "PRODUCT-OF", "D6D"]]}, {"text": "The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of  ALA  suggests that the competition between 24:5n-3 and  ALA  for  D6D  may contribute to the limited accumulation of DHA in cell membranes.", "triple_list": [["ALA", "PRODUCT-OF", "D6D"]]}, {"text": " Dopamine D1 receptor  agonist and D2 receptor antagonist effects of the natural product  (-)-stepholidine   molecular modeling and dynamics simulations", "triple_list": [["(-)-stepholidine", "AGONIST", "Dopamine D1 receptor"]]}, {"text": " (-)-Stepholidine  (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a  dopamine receptor D1  agonist and D2 antagonist", "triple_list": [["(-)-Stepholidine", "AGONIST", "dopamine receptor D1"]]}, {"text": "(-)-Stepholidine ( SPD  , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a  dopamine receptor D1  agonist and D2 antagonist", "triple_list": [["SPD", "AGONIST", "dopamine receptor D1"]]}, {"text": "Dopamine D1 receptor agonist and  D2 receptor  antagonist effects of the natural product  (-)-stepholidine   molecular modeling and dynamics simulations", "triple_list": [["(-)-stepholidine", "ANTAGONIST", "D2 receptor"]]}, {"text": " (-)-Stepholidine  (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and  D2  antagonist", "triple_list": [["(-)-Stepholidine", "ANTAGONIST", "D2"]]}, {"text": "(-)-Stepholidine ( SPD  , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and  D2  antagonist", "triple_list": [["SPD", "ANTAGONIST", "D2"]]}, {"text": "The Ki for  mycophenolic acid  inhibition of the  L263F  variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly", "triple_list": [["mycophenolic acid", "DOWNREGULATOR", "L263F"]]}, {"text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to  L-BOAA  toxicity as evidenced by activation of  AP1   loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection", "triple_list": [["L-BOAA", "ACTIVATOR", "AP1"]]}, {"text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to  L-BOAA  toxicity as evidenced by activation of AP1, loss of GSH and  complex I  activity indicating the important role of glutaredoxin in neuroprotection", "triple_list": [["L-BOAA", "ACTIVATOR", "complex I"]]}, {"text": " Estrogen  protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of  glutaredoxin  in the CNS", "triple_list": [["Estrogen", "ACTIVATOR", "glutaredoxin"]]}, {"text": " L-BOAA  causes loss of GSH and inhibition of  mitochondrial complex I  in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant", "triple_list": [["L-BOAA", "DOWNREGULATOR", "mitochondrial complex I"]]}, {"text": "Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to  L-BOAA  toxicity seen as  mitochondrial complex I  loss", "triple_list": [["L-BOAA", "DOWNREGULATOR", "mitochondrial complex I"]]}, {"text": "We have expressed  VIAAT  and the plasmalemmal transporters for glycine and  GABA  in a neuroendocrine cell line and measured the quantal release of glycine and  GABA  using a novel double-sniffer patch-clamp technique", "triple_list": [["GABA", "PRODUCT-OF", "VIAAT"]]}, {"text": "We have expressed VIAAT and the  plasmalemmal transporters  for glycine and  GABA  in a neuroendocrine cell line and measured the quantal release of glycine and  GABA  using a novel double-sniffer patch-clamp technique", "triple_list": [["GABA", "PRODUCT-OF", "plasmalemmal transporters"]]}, {"text": "We found that  glycine  is released from vesicles when  VIAAT  is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1", "triple_list": [["glycine", "PRODUCT-OF", "VIAAT"]]}, {"text": "However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic  glycine  concentration required for efficient vesicular loading by  VIAAT   The vesicular inhibitory phenotype was gradually altered from  glycine rgic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by  VIAAT ", "triple_list": [["glycine", "PRODUCT-OF", "VIAAT"]]}, {"text": "The vesicular inhibitory phenotype was gradually altered from glycinergic to  GABA ergic through mixed events when  GABA  is introduced into the secretory cell and competes for uptake by  VIAAT   Interestingly, the  VIAAT  ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes  GABA  transmission in the worm confers glycine specificity", "triple_list": [["GABA", "PRODUCT-OF", "VIAAT"]]}, {"text": "Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking  glycine  transmission, also supports  glycine  exocytosis in the presence of  GlyT2   and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers  glycine  specificity", "triple_list": [["glycine", "PRODUCT-OF", "GlyT2"]]}, {"text": "Together, these results suggest that an increased cytosolic availability of  glycine  in  VIAAT  containing terminals was crucial for the emergence of  glycine rgic transmission in vertebrates.", "triple_list": [["glycine", "PRODUCT-OF", "VIAAT"]]}, {"text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters,  glycine  and GABA, share the same  vesicular inhibitory amino acid transporter  (VIAAT) and are both present in neurons during postnatal development", "triple_list": [["glycine", "PRODUCT-OF", "vesicular inhibitory amino acid transporter"]]}, {"text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters,  glycine  and GABA, share the same vesicular inhibitory amino acid transporter ( VIAAT   and are both present in neurons during postnatal development", "triple_list": [["glycine", "PRODUCT-OF", "VIAAT"]]}, {"text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and  GABA   share the same  vesicular inhibitory amino acid transporter  (VIAAT) and are both present in neurons during postnatal development", "triple_list": [["GABA", "PRODUCT-OF", "vesicular inhibitory amino acid transporter"]]}, {"text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and  GABA   share the same vesicular inhibitory amino acid transporter ( VIAAT   and are both present in neurons during postnatal development", "triple_list": [["GABA", "PRODUCT-OF", "VIAAT"]]}, {"text": "We have expressed  VIAAT  and the plasmalemmal transporters for  glycine  and GABA in a neuroendocrine cell line and measured the quantal release of  glycine  and GABA using a novel double-sniffer patch-clamp technique", "triple_list": [["glycine", "PRODUCT-OF", "VIAAT"]]}, {"text": "We have expressed VIAAT and the  plasmalemmal transporters  for  glycine  and GABA in a neuroendocrine cell line and measured the quantal release of  glycine  and GABA using a novel double-sniffer patch-clamp technique", "triple_list": [["glycine", "PRODUCT-OF", "plasmalemmal transporters"]]}, {"text": " Na+  Cl- dipole couples agonist binding to  kainate receptor  activation", "triple_list": [["Na+", "ACTIVATOR", "kainate receptor"]]}, {"text": "Na+/ Cl-  dipole couples agonist binding to  kainate receptor  activation", "triple_list": [["Cl-", "ACTIVATOR", "kainate receptor"]]}, {"text": " Kainate-selective ionotropic glutamate receptors  (GluRs) require external Na+ and Cl- as well as the neurotransmitter  L-glutamate  for activation", "triple_list": [["L-glutamate", "ACTIVATOR", "Kainate-selective ionotropic glutamate receptors"]]}, {"text": "Kainate-selective ionotropic glutamate receptors ( GluRs   require external Na+ and Cl- as well as the neurotransmitter  L-glutamate  for activation", "triple_list": [["L-glutamate", "ACTIVATOR", "GluRs"]]}, {"text": " Kainate-selective ionotropic glutamate receptors  (GluRs) require external  Na+  and Cl- as well as the neurotransmitter L-glutamate for activation", "triple_list": [["Na+", "ACTIVATOR", "Kainate-selective ionotropic glutamate receptors"]]}, {"text": "Kainate-selective ionotropic glutamate receptors ( GluRs   require external  Na+  and Cl- as well as the neurotransmitter L-glutamate for activation", "triple_list": [["Na+", "ACTIVATOR", "GluRs"]]}, {"text": " Kainate-selective ionotropic glutamate receptors  (GluRs) require external Na+ and  Cl-  as well as the neurotransmitter L-glutamate for activation", "triple_list": [["Cl-", "ACTIVATOR", "Kainate-selective ionotropic glutamate receptors"]]}, {"text": "Kainate-selective ionotropic glutamate receptors ( GluRs   require external Na+ and  Cl-  as well as the neurotransmitter L-glutamate for activation", "triple_list": [["Cl-", "ACTIVATOR", "GluRs"]]}, {"text": "Additionally,  Na+  and Cl- ions coactivate  GluR6  receptors by establishing a dipole, accounting for their common effect on KARs", "triple_list": [["Na+", "ACTIVATOR", "GluR6"]]}, {"text": "Additionally, Na+ and  Cl-  ions coactivate  GluR6  receptors by establishing a dipole, accounting for their common effect on KARs", "triple_list": [["Cl-", "ACTIVATOR", "GluR6"]]}, {"text": " Phenserine  apparently reduces translational efficiency of  APP  mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element", "triple_list": [["Phenserine", "DOWNREGULATOR", "APP"]]}, {"text": "As a consequence,  phenserine  reduces  beta-amyloid  peptide (Abeta) formation in vitro and in vivo", "triple_list": [["phenserine", "DOWNREGULATOR", "beta-amyloid"]]}, {"text": "As a consequence,  phenserine  reduces beta-amyloid peptide ( Abeta   formation in vitro and in vivo", "triple_list": [["phenserine", "DOWNREGULATOR", "Abeta"]]}, {"text": " Phenserine   a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ( AChE   and was shown to improve cognition in various experimental paradigms in rodents and dogs", "triple_list": [["Phenserine", "DOWNREGULATOR", "AChE"]]}, {"text": " Phenserine   a derivative of physostigmine, was first described as an inhibitor of  acetylcholinesterase  (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs", "triple_list": [["Phenserine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "Phenserine is also unique because of differing actions of its enantiomers:  (-)-phenserine  is the active enantiomer for inhibition of  AChE   whereas (+)-phenserine ('posiphen') has weak activity as an  AChE  inhibitor and can be dosed much higher", "triple_list": [["(-)-phenserine", "DOWNREGULATOR", "AChE"]]}, {"text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of  AChE , whereas  (+)-phenserine  ('posiphen') has weak activity as an  AChE  inhibitor and can be dosed much higher", "triple_list": [["(+)-phenserine", "DOWNREGULATOR", "AChE"]]}, {"text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of  AChE , whereas (+)-phenserine (' posiphen  ) has weak activity as an  AChE  inhibitor and can be dosed much higher", "triple_list": [["posiphen", "DOWNREGULATOR", "AChE"]]}, {"text": "Phenserine, a derivative of  physostigmine   was first described as an inhibitor of acetylcholinesterase ( AChE   and was shown to improve cognition in various experimental paradigms in rodents and dogs", "triple_list": [["physostigmine", "DOWNREGULATOR", "AChE"]]}, {"text": "Phenserine, a derivative of  physostigmine   was first described as an inhibitor of  acetylcholinesterase  (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs", "triple_list": [["physostigmine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": " Phenserine  deserves attention for an additional quality of action: in addition to inhibiting  AChE   it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation", "triple_list": [["Phenserine", "DOWNREGULATOR", "AChE"]]}, {"text": " Phenserine  deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein ( APP ) in neuronal cell culture by reducing  APP  translation", "triple_list": [["Phenserine", "DOWNREGULATOR", "APP"]]}, {"text": "Additional pharmacological effects evoked by  AICAR  and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of  AMPK  in cell systems where Na+K+ATPase is an important component.", "triple_list": [["AICAR", "ACTIVATOR", "AMPK"]]}, {"text": "Additional pharmacological effects evoked by AICAR and  phenformin  on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of  AMPK  in cell systems where Na+K+ATPase is an important component.", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "Additional pharmacological effects evoked by AICAR and phenformin on I( ouabain  , with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of  AMPK  in cell systems where Na+K+ATPase is an important component.", "triple_list": [["ouabain", "ACTIVATOR", "AMPK"]]}, {"text": "BACKGROUND AND PURPOSE:  AMP-activated protein kinase  (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ( AICAR  ", "triple_list": [["AICAR", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ( AMPK   is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ( AICAR  ", "triple_list": [["AICAR", "ACTIVATOR", "AMPK"]]}, {"text": "BACKGROUND AND PURPOSE:  AMP-activated protein kinase  (AMPK) is activated by  metformin   phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)", "triple_list": [["metformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ( AMPK   is activated by  metformin   phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)", "triple_list": [["metformin", "ACTIVATOR", "AMPK"]]}, {"text": "BACKGROUND AND PURPOSE:  AMP-activated protein kinase  (AMPK) is activated by metformin,  phenformin   and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)", "triple_list": [["phenformin", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ( AMPK   is activated by metformin,  phenformin   and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "KEY RESULTS:  Phenformin   AICAR and metformin increased  AMPK (alpha1)  activity and decreased I(amiloride)", "triple_list": [["Phenformin", "ACTIVATOR", "AMPK (alpha1)"]]}, {"text": "KEY RESULTS: Phenformin,  AICAR  and metformin increased  AMPK (alpha1)  activity and decreased I(amiloride)", "triple_list": [["AICAR", "ACTIVATOR", "AMPK (alpha1)"]]}, {"text": "KEY RESULTS: Phenformin, AICAR and  metformin  increased  AMPK (alpha1)  activity and decreased I(amiloride)", "triple_list": [["metformin", "ACTIVATOR", "AMPK (alpha1)"]]}, {"text": "The  AMPK  inhibitor Compound C prevented the action of metformin and AICAR but not  phenformin   Phenformin and AICAR decreased I(ouabain) across H441 monolayers and decreased monolayer resistance", "triple_list": [["phenformin", "ACTIVATOR", "AMPK"]]}, {"text": "BACKGROUND AND PURPOSE:  AMP-activated protein kinase  (AMPK) is activated by metformin, phenformin, and the AMP mimetic,  5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside  (AICAR)", "triple_list": [["5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "ACTIVATOR", "AMP-activated protein kinase"]]}, {"text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ( AMPK   is activated by metformin, phenformin, and the AMP mimetic,  5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside  (AICAR)", "triple_list": [["5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "ACTIVATOR", "AMPK"]]}, {"text": "Compared with normal control group,  PTZ  kindled mice had significantly higher levels of malondialdehyde, nitrite,  myeloperoxidase  but had lower levels of reduced glutathione in the whole brain homogenate", "triple_list": [["PTZ", "ACTIVATOR", "myeloperoxidase"]]}, {"text": "Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or  rofecoxib  (selective  COX-2  inhibitor) against chemical kindling in mice", "triple_list": [["rofecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "With this background, the present study was designed to explore the possible effect of  nimesulide  (a preferential  COX-2  inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-2"]]}, {"text": "Neuroprotective effect of  nimesulide   a preferential  COX-2  inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-2"]]}, {"text": "These results suggested that  nimesulide   a preferential  COX-2  inhibitor offered neuroprotection against PTZ-induced kindling in mice.", "triple_list": [["nimesulide", "DOWNREGULATOR", "COX-2"]]}, {"text": "Previous studies have explored the protective effect of  naproxen  (non-selective  COX  inhibitor) or rofecoxib (selective  COX -2 inhibitor) against chemical kindling in mice", "triple_list": [["naproxen", "DOWNREGULATOR", "COX"]]}, {"text": "Brain cyclooxygenases ( COX  , the rate-limiting enzyme in  prostaglandin  synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons", "triple_list": [["prostaglandin", "PRODUCT-OF", "COX"]]}, {"text": "Brain  cyclooxygenases  (COX), the rate-limiting enzyme in  prostaglandin  synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons", "triple_list": [["prostaglandin", "PRODUCT-OF", "cyclooxygenases"]]}, {"text": "While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and  gallic acid  or n-propyl gallate efficiently inhibited the activity of all three  PHDs   demonstrating different functions of these antioxidants.", "triple_list": [["gallic acid", "DOWNREGULATOR", "PHDs"]]}, {"text": "While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or  n-propyl gallate  efficiently inhibited the activity of all three  PHDs   demonstrating different functions of these antioxidants.", "triple_list": [["n-propyl gallate", "DOWNREGULATOR", "PHDs"]]}, {"text": " LTC4  synthase ( LTC4 S), the pivotal enzyme for the biosynthesis of  LTC4  (ref", "triple_list": [["LTC4", "PRODUCT-OF", "LTC4 synthase"]]}, {"text": " LTC4  synthase ( LTC4 S , the pivotal enzyme for the biosynthesis of  LTC4  (ref", "triple_list": [["LTC4", "PRODUCT-OF", "LTC4S"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in  eicosanoid  and glutathione metabolism that includes 5-lipoxygenase-activating protein,  microsomal glutathione S-transferases  (MGSTs), and microsomal prostaglandin E synthase 1 (ref", "triple_list": [["eicosanoid", "PRODUCT-OF", "microsomal glutathione S-transferases"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in  eicosanoid  and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases ( MGSTs  , and microsomal prostaglandin E synthase 1 (ref", "triple_list": [["eicosanoid", "PRODUCT-OF", "MGSTs"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in  eicosanoid  and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and  microsomal prostaglandin E synthase 1  (ref", "triple_list": [["eicosanoid", "PRODUCT-OF", "microsomal prostaglandin E synthase 1"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and  glutathione  metabolism that includes 5-lipoxygenase-activating protein, microsomal  glutathione  S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref", "triple_list": [["glutathione", "PRODUCT-OF", "microsomal glutathione S-transferases"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and  glutathione  metabolism that includes 5-lipoxygenase-activating protein, microsomal  glutathione  S-transferases ( MGSTs  , and microsomal prostaglandin E synthase 1 (ref", "triple_list": [["glutathione", "PRODUCT-OF", "MGSTs"]]}, {"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and  glutathione  metabolism that includes 5-lipoxygenase-activating protein, microsomal  glutathione  S-transferases (MGSTs), and  microsomal prostaglandin E synthase 1  (ref", "triple_list": [["glutathione", "PRODUCT-OF", "microsomal prostaglandin E synthase 1"]]}, {"text": " Phenelzine  (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ( GABA-T  , markedly increasing brain GABA levels", "triple_list": [["Phenelzine", "DOWNREGULATOR", "GABA-T"]]}, {"text": " Phenelzine  (PLZ), a nonselective irreversible inhibitor of  monoamine oxidase  (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels", "triple_list": [["Phenelzine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": " Phenelzine  (PLZ), a nonselective irreversible inhibitor of monoamine oxidase ( MAO  , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels", "triple_list": [["Phenelzine", "DOWNREGULATOR", "MAO"]]}, {"text": " Phenelzine  (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits  GABA-transaminase  (GABA-T), markedly increasing brain GABA levels", "triple_list": [["Phenelzine", "DOWNREGULATOR", "GABA-transaminase"]]}, {"text": "To determine whether a metabolite formed by the action of  MAO  on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the  MAO  inhibitor  tranylcypromine  (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later", "triple_list": [["tranylcypromine", "DOWNREGULATOR", "MAO"]]}, {"text": "To determine whether a metabolite formed by the action of  MAO  on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the  MAO  inhibitor tranylcypromine ( TCP   before vehicle or PLZ (15 mg/kg), and brains collected 3 h later", "triple_list": [["TCP", "DOWNREGULATOR", "MAO"]]}, {"text": " Phenelzine  causes an increase in brain ornithine that is prevented by prior  monoamine oxidase  inhibition", "triple_list": [["Phenelzine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Phenelzine ( PLZ  , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ( GABA-T  , markedly increasing brain GABA levels", "triple_list": [["PLZ", "DOWNREGULATOR", "GABA-T"]]}, {"text": "Phenelzine ( PLZ  , a nonselective irreversible inhibitor of  monoamine oxidase  (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels", "triple_list": [["PLZ", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Phenelzine ( PLZ  , a nonselective irreversible inhibitor of monoamine oxidase ( MAO  , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels", "triple_list": [["PLZ", "DOWNREGULATOR", "MAO"]]}, {"text": "Phenelzine ( PLZ  , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits  GABA-transaminase  (GABA-T), markedly increasing brain GABA levels", "triple_list": [["PLZ", "DOWNREGULATOR", "GABA-transaminase"]]}, {"text": "Pretreatment with TCP completely abolished the  PLZ -induced increase in brain ORN, suggesting, as with GABA, that a metabolite of  PLZ  formed by the action of  MAO  is responsible for the elevation of brain ORN observed", "triple_list": [["PLZ", "PRODUCT-OF", "MAO"]]}, {"text": " PLZ  is also a substrate for  MAO   and studies suggest that a metabolite formed by the action of this enzyme on  PLZ  may be responsible for the increase in GABA observed", "triple_list": [["PLZ", "PRODUCT-OF", "MAO"]]}, {"text": "As further support,  alpha-methyl-DL-aspartate   an inhibitor of  argininosuccinate synthase  (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner", "triple_list": [["alpha-methyl-DL-aspartate", "DOWNREGULATOR", "argininosuccinate synthase"]]}, {"text": "As further support,  alpha-methyl-DL-aspartate   an inhibitor of argininosuccinate synthase ( AS  , a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner", "triple_list": [["alpha-methyl-DL-aspartate", "DOWNREGULATOR", "AS"]]}, {"text": "Nitric oxide ( NO   is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by  endothelial nitric oxide synthase  (e NO S)", "triple_list": [["NO", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Nitric oxide ( NO   is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (e NO S ", "triple_list": [["NO", "PRODUCT-OF", "eNOS"]]}, {"text": " Nitric oxide  (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by  endothelial nitric oxide synthase  (eNOS)", "triple_list": [["Nitric oxide", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": " Nitric oxide  (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase ( eNOS  ", "triple_list": [["Nitric oxide", "PRODUCT-OF", "eNOS"]]}, {"text": "Nitric oxide (NO) is an important vasorelaxant produced along with  L-citrulline  from L-arginine in a reaction catalyzed by  endothelial nitric oxide synthase  (eNOS)", "triple_list": [["L-citrulline", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Nitric oxide (NO) is an important vasorelaxant produced along with  L-citrulline  from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase ( eNOS  ", "triple_list": [["L-citrulline", "PRODUCT-OF", "eNOS"]]}, {"text": "Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from  L-arginine  in a reaction catalyzed by  endothelial nitric oxide synthase  (eNOS)", "triple_list": [["L-arginine", "PRODUCT-OF", "endothelial nitric oxide synthase"]]}, {"text": "Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from  L-arginine  in a reaction catalyzed by endothelial nitric oxide synthase ( eNOS  ", "triple_list": [["L-arginine", "PRODUCT-OF", "eNOS"]]}, {"text": "Caution is necessary only when it is coadministered with drugs metabolised by  CYP2D6   such as  metoprolol   or administered to the elderly or patients with severe hepatic or renal impairment", "triple_list": [["metoprolol", "PRODUCT-OF", "CYP2D6"]]}, {"text": " AZD6140  is a reversible oral  P2Y(12)  receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study)", "triple_list": [["AZD6140", "ANTAGONIST", "P2Y(12)"]]}, {"text": "AZD6140 is a reversible oral  P2Y(12)  receptor antagonist that has been studied in ACS patients in comparison with  clopidogrel  (DISPERSE-2 study)", "triple_list": [["clopidogrel", "ANTAGONIST", "P2Y(12)"]]}, {"text": "Inhibition of platelet aggregation by AZD6140, a reversible oral  P2Y12  receptor antagonist, compared with  clopidogrel  in patients with acute coronary syndromes", "triple_list": [["clopidogrel", "ANTAGONIST", "P2Y12"]]}, {"text": "Inhibition of platelet aggregation by  AZD6140   a reversible oral  P2Y12  receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes", "triple_list": [["AZD6140", "ANTAGONIST", "P2Y12"]]}, {"text": " Oxybutynin  (1) is a non-selective  muscarinic receptor  antagonist that is used clinically for the treatment of urinary incontinence", "triple_list": [["Oxybutynin", "ANTAGONIST", "muscarinic receptor"]]}, {"text": "Administration of  cevimeline hydrochloride   an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the  AQP5  protein level reduced by CTD and increased the AQP1 protein level above the control one", "triple_list": [["cevimeline hydrochloride", "ACTIVATOR", "AQP5"]]}, {"text": "Administration of  cevimeline hydrochloride   an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the  AQP1  protein level above the control one", "triple_list": [["cevimeline hydrochloride", "ACTIVATOR", "AQP1"]]}, {"text": "Administration of  chloroquine  (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the  AQP5  protein level reduced by CTD", "triple_list": [["chloroquine", "ACTIVATOR", "AQP5"]]}, {"text": "Degradation of submandibular gland  AQP5  by parasympathetic denervation of chorda tympani and its recovery by  cevimeline   an M3 muscarinic receptor agonist", "triple_list": [["cevimeline", "ACTIVATOR", "AQP5"]]}, {"text": "Administration of  cevimeline hydrochloride   an  M3 muscarinic receptor  agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one", "triple_list": [["cevimeline hydrochloride", "AGONIST", "M3 muscarinic receptor"]]}, {"text": "Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by  cevimeline   an  M3 muscarinic receptor  agonist", "triple_list": [["cevimeline", "AGONIST", "M3 muscarinic receptor"]]}, {"text": " threo-methylphenidate  inhibits the  dopamine transporter  and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release", "triple_list": [["threo-methylphenidate", "DOWNREGULATOR", "dopamine transporter"]]}, {"text": " threo-methylphenidate  inhibits the dopamine transporter and the  norepinephrine transporter   resulting in elevations of these monoamines after impulse release", "triple_list": [["threo-methylphenidate", "DOWNREGULATOR", "norepinephrine transporter"]]}, {"text": "threo-methylphenidate inhibits the  dopamine transporter  and the norepinephrine transporter, resulting in elevations of these  monoamines  after impulse release", "triple_list": [["monoamines", "PRODUCT-OF", "dopamine transporter"]]}, {"text": "threo-methylphenidate inhibits the dopamine transporter and the  norepinephrine transporter   resulting in elevations of these  monoamines  after impulse release", "triple_list": [["monoamines", "PRODUCT-OF", "norepinephrine transporter"]]}, {"text": "The direct inhibition of  stathmin  by  CCNU  is likely a contributing factor", "triple_list": [["CCNU", "DOWNREGULATOR", "stathmin"]]}, {"text": "CONCLUSIONS AND IMPLICATIONS:  Amiodarone  analogues with better  hERG  channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and  hERG  channel interaction are mechanistically distinct and separable properties of the compounds.", "triple_list": [["Amiodarone", "DOWNREGULATOR", "hERG"]]}, {"text": "The principal aim of the study was to find  amiodarone  analogues that retained  human ether-a-go-go-related protein (hERG) channel  inhibition but with reduced cytotoxicity", "triple_list": [["amiodarone", "DOWNREGULATOR", "human ether-a-go-go-related protein (hERG) channel"]]}, {"text": "In addition to  OT  and to a lesser extent AVP (pitressin), a number of  OT  and AVP analogues; such as  carbetocin  ( OT  agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile  OT  antagonist) are also in clinical use", "triple_list": [["carbetocin", "AGONIST", "OT"]]}, {"text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP ( desmopressin    V(2)  agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use", "triple_list": [["desmopressin", "AGONIST", "V(2)"]]}, {"text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist),  terlipressin  ( V(1a)  agonist), felypressin ( V(1a)  agonist) and atosiban (Tractocile OT antagonist) are also in clinical use", "triple_list": [["terlipressin", "AGONIST", "V(1a)"]]}, {"text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin ( V(1a)  agonist),  felypressin  ( V(1a)  agonist) and atosiban (Tractocile OT antagonist) are also in clinical use", "triple_list": [["felypressin", "AGONIST", "V(1a)"]]}, {"text": "In addition to  OT  and to a lesser extent AVP (pitressin), a number of  OT  and AVP analogues; such as carbetocin ( OT  agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and  atosiban  (Tractocile  OT  antagonist) are also in clinical use", "triple_list": [["atosiban", "ANTAGONIST", "OT"]]}, {"text": "In addition to  OT  and to a lesser extent AVP (pitressin), a number of  OT  and AVP analogues; such as carbetocin ( OT  agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban ( Tractocile   OT  antagonist) are also in clinical use", "triple_list": [["Tractocile", "ANTAGONIST", "OT"]]}, {"text": "While a number of orally active non-peptide  V(2)  antagonists (Vaptans); notably,  Tolvaptan   Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed  V(2) /V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Tolvaptan", "ANTAGONIST", "V(2)"]]}, {"text": "While a number of orally active non-peptide  V(2)  antagonists (Vaptans); notably, Tolvaptan,  Lixivaptan  and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed  V(2) /V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Lixivaptan", "ANTAGONIST", "V(2)"]]}, {"text": "While a number of orally active non-peptide  V(2)  antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and  Satavaptan   are currently in Phase III clinical trials; to date, only the mixed  V(2) /V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Satavaptan", "ANTAGONIST", "V(2)"]]}, {"text": "While a number of orally active non-peptide  V(2)  antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed  V(2)  V(1a), antagonist  Conivaptan  (Vaprisol), has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Conivaptan", "ANTAGONIST", "V(2)"]]}, {"text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/ V(1a)   antagonist  Conivaptan  (Vaprisol), has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Conivaptan", "ANTAGONIST", "V(1a)"]]}, {"text": "While a number of orally active non-peptide  V(2)  antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed  V(2)  V(1a), antagonist Conivaptan ( Vaprisol  , has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Vaprisol", "ANTAGONIST", "V(2)"]]}, {"text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/ V(1a)   antagonist Conivaptan ( Vaprisol  , has been approved by the US FDA for clinical use (by i.v", "triple_list": [["Vaprisol", "ANTAGONIST", "V(1a)"]]}, {"text": "Absorbable drugs ( fibric acids   nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce  plasma very-low-density lipoproteins  (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["fibric acids", "DOWNREGULATOR", "plasma very-low-density lipoproteins"]]}, {"text": "Absorbable drugs ( fibric acids   nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ( VLDL   and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["fibric acids", "DOWNREGULATOR", "VLDL"]]}, {"text": "Absorbable drugs ( fibric acids   nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very- low-density lipoproteins  (VLDL) and/or  low-density lipoproteins  (LDL) by a variety of mechanisms", "triple_list": [["fibric acids", "DOWNREGULATOR", "low-density lipoproteins"]]}, {"text": "Absorbable drugs ( fibric acids   nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V LDL ) and/or low-density lipoproteins ( LDL   by a variety of mechanisms", "triple_list": [["fibric acids", "DOWNREGULATOR", "LDL"]]}, {"text": "Absorbable drugs (fibric acids,  nicotinic acid   probucol, HMG-CoA reductase inhibitors) reduce  plasma very-low-density lipoproteins  (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["nicotinic acid", "DOWNREGULATOR", "plasma very-low-density lipoproteins"]]}, {"text": "Absorbable drugs (fibric acids,  nicotinic acid   probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ( VLDL   and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["nicotinic acid", "DOWNREGULATOR", "VLDL"]]}, {"text": "Absorbable drugs (fibric acids,  nicotinic acid   probucol, HMG-CoA reductase inhibitors) reduce plasma very- low-density lipoproteins  (VLDL) and/or  low-density lipoproteins  (LDL) by a variety of mechanisms", "triple_list": [["nicotinic acid", "DOWNREGULATOR", "low-density lipoproteins"]]}, {"text": "Absorbable drugs (fibric acids,  nicotinic acid   probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V LDL ) and/or low-density lipoproteins ( LDL   by a variety of mechanisms", "triple_list": [["nicotinic acid", "DOWNREGULATOR", "LDL"]]}, {"text": "Absorbable drugs (fibric acids, nicotinic acid,  probucol   HMG-CoA reductase inhibitors) reduce  plasma very-low-density lipoproteins  (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["probucol", "DOWNREGULATOR", "plasma very-low-density lipoproteins"]]}, {"text": "Absorbable drugs (fibric acids, nicotinic acid,  probucol   HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ( VLDL   and/or low-density lipoproteins (LDL) by a variety of mechanisms", "triple_list": [["probucol", "DOWNREGULATOR", "VLDL"]]}, {"text": "Absorbable drugs (fibric acids, nicotinic acid,  probucol   HMG-CoA reductase inhibitors) reduce plasma very- low-density lipoproteins  (VLDL) and/or  low-density lipoproteins  (LDL) by a variety of mechanisms", "triple_list": [["probucol", "DOWNREGULATOR", "low-density lipoproteins"]]}, {"text": "Absorbable drugs (fibric acids, nicotinic acid,  probucol   HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (V LDL ) and/or low-density lipoproteins ( LDL   by a variety of mechanisms", "triple_list": [["probucol", "DOWNREGULATOR", "LDL"]]}, {"text": " Fibric acids   in particular, act by stimulating the catabolism of  VLDL  and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake", "triple_list": [["Fibric acids", "DOWNREGULATOR", "VLDL"]]}, {"text": "accelerating reverse transport of  cholesteryl esters  from  high-density lipoproteins  to lower-density lipoproteins", "triple_list": [["cholesteryl esters", "PRODUCT-OF", "high-density lipoproteins"]]}, {"text": "accelerating reverse transport of  cholesteryl esters  from high-density lipoproteins to  lower-density lipoproteins   Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors", "triple_list": [["cholesteryl esters", "PRODUCT-OF", "lower-density lipoproteins"]]}, {"text": "CONCLUSIONS:  Lapatinib  is a dual inhibitor of the  EGFR  and HER2 tyrosine kinases", "triple_list": [["Lapatinib", "DOWNREGULATOR", "EGFR"]]}, {"text": "CONCLUSIONS:  Lapatinib  is a dual inhibitor of the EGFR and  HER2  tyrosine kinases", "triple_list": [["Lapatinib", "DOWNREGULATOR", "HER2"]]}, {"text": "CONCLUSIONS:  Lapatinib  is a dual inhibitor of the EGFR and HER2  tyrosine kinases   It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-positive MBC that has progressed with standard treatment", "triple_list": [["Lapatinib", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": " Lapatinib   a dual inhibitor of  human epidermal growth factor receptor  tyrosine kinases", "triple_list": [["Lapatinib", "DOWNREGULATOR", "human epidermal growth factor receptor"]]}, {"text": " Lapatinib   a dual inhibitor of human epidermal growth factor receptor  tyrosine kinases   BACKGROUND:  Lapatinib , the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)  tyrosine kinases , was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": "BACKGROUND:  Lapatinib   the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ( HER2   tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "HER2"]]}, {"text": "BACKGROUND:  Lapatinib   the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)  tyrosine kinases   was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "tyrosine kinases"]]}, {"text": "BACKGROUND:  Lapatinib   the first dual inhibitor of  epidermal growth factor receptor  (EGFR) and human  epidermal growth factor receptor  2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "epidermal growth factor receptor"]]}, {"text": "BACKGROUND:  Lapatinib   the first dual inhibitor of epidermal growth factor receptor ( EGFR   and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "EGFR"]]}, {"text": "BACKGROUND:  Lapatinib   the first dual inhibitor of epidermal growth factor receptor (EGFR) and  human epidermal growth factor receptor 2  (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007", "triple_list": [["Lapatinib", "DOWNREGULATOR", "human epidermal growth factor receptor 2"]]}, {"text": " Lapatinib  is metabolized primarily by the  cytochrome P450 3A4  isozyme, with 1 metabolite remaining active against EGFR but not HER2", "triple_list": [["Lapatinib", "PRODUCT-OF", "cytochrome P450 3A4"]]}, {"text": "Phenelzine is a more potent  monoamine oxidase  inhibitor than is  N2-acetylphenelzine   The most marked difference in the profile was that  N2-acetylphenelzine  had no effect on whole brain levels of the amino acid neurotransmitters alanine and gamma-aminobutyric acid, whereas phenelzine caused dramatic increases", "triple_list": [["N2-acetylphenelzine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Acetylation of  phenelzine  at the N2 position presumably interferes with the inhibition of the  transaminase  enzymes for gamma-aminobutyric acid and alanine.", "triple_list": [["phenelzine", "DOWNREGULATOR", "transaminase"]]}, {"text": "Acetylation of phenelzine at the  N2  position presumably interferes with the inhibition of the  transaminase  enzymes for gamma-aminobutyric acid and alanine.", "triple_list": [["N2", "DOWNREGULATOR", "transaminase"]]}, {"text": "Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the  transaminase  enzymes for  gamma-aminobutyric acid  and alanine.", "triple_list": [["gamma-aminobutyric acid", "DOWNREGULATOR", "transaminase"]]}, {"text": "Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the  transaminase  enzymes for gamma-aminobutyric acid and  alanine  ", "triple_list": [["alanine", "DOWNREGULATOR", "transaminase"]]}, {"text": " Phenelzine  is a more potent  monoamine oxidase  inhibitor than is N2-acetylphenelzine", "triple_list": [["Phenelzine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": " Quinpirole  and 7-OH-DPAT also increased the phosphorylation of  extracellular signal-regulated kinase  (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A", "triple_list": [["Quinpirole", "ACTIVATOR", "extracellular signal-regulated kinase"]]}, {"text": " Quinpirole  and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase ( ERK   within minutes, an effect blocked by pretreatment with SB-277011-A", "triple_list": [["Quinpirole", "ACTIVATOR", "ERK"]]}, {"text": "Quinpirole and  7-OH-DPAT  also increased the phosphorylation of  extracellular signal-regulated kinase  (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A", "triple_list": [["7-OH-DPAT", "ACTIVATOR", "extracellular signal-regulated kinase"]]}, {"text": "Quinpirole and  7-OH-DPAT  also increased the phosphorylation of extracellular signal-regulated kinase ( ERK   within minutes, an effect blocked by pretreatment with SB-277011-A", "triple_list": [["7-OH-DPAT", "ACTIVATOR", "ERK"]]}, {"text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of  extracellular signal-regulated kinase  (ERK) within minutes, an effect blocked by pretreatment with  SB-277011-A   Inhibition of the D2/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects", "triple_list": [["SB-277011-A", "DOWNREGULATOR", "extracellular signal-regulated kinase"]]}, {"text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase ( ERK   within minutes, an effect blocked by pretreatment with  SB-277011-A   Inhibition of the D2/D3 receptor signalling pathway to  ERK  was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects", "triple_list": [["SB-277011-A", "DOWNREGULATOR", "ERK"]]}, {"text": "All neurotrophic effects were blocked by the unselective D2/ D3 receptor  antagonist sulpiride (5 microm) and by the selective  D3 receptor  antagonist  SB-277011-A  at a low dose (50 nm)", "triple_list": [["SB-277011-A", "ANTAGONIST", "D3 receptor"]]}, {"text": "This study identified four clinically approved antihypertensive drugs ( efonidipine   felodipine, isradipine, and nitrendipine) as potent  T-channel  blockers (IC(50) < 3 microM)", "triple_list": [["efonidipine", "DOWNREGULATOR", "T-channel"]]}, {"text": "This study identified four clinically approved antihypertensive drugs (efonidipine,  felodipine   isradipine, and nitrendipine) as potent  T-channel  blockers (IC(50) < 3 microM)", "triple_list": [["felodipine", "DOWNREGULATOR", "T-channel"]]}, {"text": "This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine,  isradipine   and nitrendipine) as potent  T-channel  blockers (IC(50) < 3 microM)", "triple_list": [["isradipine", "DOWNREGULATOR", "T-channel"]]}, {"text": "This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and  nitrendipine   as potent  T-channel  blockers (IC(50) < 3 microM)", "triple_list": [["nitrendipine", "DOWNREGULATOR", "T-channel"]]}, {"text": "Triphosphate nucleotides (ATP, GTP, and  UTP   rapidly and reversibly inhibited  Panx1  currents via mechanism(s) independent of purine receptors", "triple_list": [["UTP", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency:  carbenoxolone  > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["carbenoxolone", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone >  disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate  (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate ( DIDS   approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["DIDS", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately  disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate  approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately  5-nitro-2-(3-phenylpropylamino)benzoic acid  > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["5-nitro-2-(3-phenylpropylamino)benzoic acid", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid >  indanyloxyacetic acid 94  >> probenecid >> flufenamic acid = niflumic acid", "triple_list": [["indanyloxyacetic acid 94", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >>  probenecid  >> flufenamic acid = niflumic acid", "triple_list": [["probenecid", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >>  flufenamic acid  = niflumic acid", "triple_list": [["flufenamic acid", "DOWNREGULATOR", "Panx1"]]}, {"text": "We found compounds that inhibited  Panx1  currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid =  niflumic acid   Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited  Panx1  currents via mechanism(s) independent of purine receptors", "triple_list": [["niflumic acid", "DOWNREGULATOR", "Panx1"]]}, {"text": " Triphosphate nucleotides  (ATP, GTP, and UTP) rapidly and reversibly inhibited  Panx1  currents via mechanism(s) independent of purine receptors", "triple_list": [["Triphosphate nucleotides", "DOWNREGULATOR", "Panx1"]]}, {"text": "Triphosphate nucleotides ( ATP   GTP, and UTP) rapidly and reversibly inhibited  Panx1  currents via mechanism(s) independent of purine receptors", "triple_list": [["ATP", "DOWNREGULATOR", "Panx1"]]}, {"text": "Triphosphate nucleotides (ATP,  GTP   and UTP) rapidly and reversibly inhibited  Panx1  currents via mechanism(s) independent of purine receptors", "triple_list": [["GTP", "DOWNREGULATOR", "Panx1"]]}, {"text": "When Panx1 was coexpressed with purinergic P2X(7) receptor ( P2X(7)R ),  DIDS  was found to act as a  P2X(7)R  antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited  P2X(7)R  currents", "triple_list": [["DIDS", "ANTAGONIST", "P2X(7)R"]]}, {"text": " MMP-2  and MMP-9 expressions and activities in right ventricles increased significantly in  monocrotaline  injected rats and captopril inhibited them", "triple_list": [["monocrotaline", "ACTIVATOR", "MMP-2"]]}, {"text": "MMP-2 and  MMP-9  expressions and activities in right ventricles increased significantly in  monocrotaline  injected rats and captopril inhibited them", "triple_list": [["monocrotaline", "ACTIVATOR", "MMP-9"]]}, {"text": "These findings indicate that captopril attenuates the development of  monocrotaline  induced right ventricular hypertrophy in association with inhibition of  MMP-2  and MMP-9 in rats.", "triple_list": [["monocrotaline", "ACTIVATOR", "MMP-2"]]}, {"text": "These findings indicate that captopril attenuates the development of  monocrotaline  induced right ventricular hypertrophy in association with inhibition of MMP-2 and  MMP-9  in rats.", "triple_list": [["monocrotaline", "ACTIVATOR", "MMP-9"]]}, {"text": " MMP-2  and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and  captopril  inhibited them", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-2"]]}, {"text": "MMP-2 and  MMP-9  expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and  captopril  inhibited them", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-9"]]}, {"text": "These findings indicate that  captopril  attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of  MMP-2  and MMP-9 in rats.", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-2"]]}, {"text": "These findings indicate that  captopril  attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and  MMP-9  in rats.", "triple_list": [["captopril", "DOWNREGULATOR", "MMP-9"]]}, {"text": "We investigated the effect of  captopril   an  ACE  inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy", "triple_list": [["captopril", "DOWNREGULATOR", "ACE"]]}, {"text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme  CA II , with  chlorthalidone   trichloromethiazide, and furosemide being efficient inhibitors against  CA II  (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["chlorthalidone", "DOWNREGULATOR", "CA II"]]}, {"text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme  CA II , with chlorthalidone,  trichloromethiazide   and furosemide being efficient inhibitors against  CA II  (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["trichloromethiazide", "DOWNREGULATOR", "CA II"]]}, {"text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme  CA II , with chlorthalidone, trichloromethiazide, and  furosemide  being efficient inhibitors against  CA II  (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["furosemide", "DOWNREGULATOR", "CA II"]]}, {"text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme  CA II , with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against  CA II  (K(I)s of 65-138 nM), whereas  indapamide  is a much weaker one (K(I) of 2520 nM)", "triple_list": [["indapamide", "DOWNREGULATOR", "CA II"]]}, {"text": " Thiazide  and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ( CA   EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide", "triple_list": [["Thiazide", "DOWNREGULATOR", "CA"]]}, {"text": " Thiazide  and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA,  EC 4.2.1.1   with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide", "triple_list": [["Thiazide", "DOWNREGULATOR", "EC 4.2.1.1"]]}, {"text": " Thiazide  and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of  carbonic anhydrase  (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide", "triple_list": [["Thiazide", "DOWNREGULATOR", "carbonic anhydrase"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ( CA   EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as  acetazolamide   methazolamide, and ethoxzolamide", "triple_list": [["acetazolamide", "DOWNREGULATOR", "CA"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA,  EC 4.2.1.1   with a very different profile as compared to classical inhibitors, such as  acetazolamide   methazolamide, and ethoxzolamide", "triple_list": [["acetazolamide", "DOWNREGULATOR", "EC 4.2.1.1"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of  carbonic anhydrase  (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as  acetazolamide   methazolamide, and ethoxzolamide", "triple_list": [["acetazolamide", "DOWNREGULATOR", "carbonic anhydrase"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ( CA   EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide,  methazolamide   and ethoxzolamide", "triple_list": [["methazolamide", "DOWNREGULATOR", "CA"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA,  EC 4.2.1.1   with a very different profile as compared to classical inhibitors, such as acetazolamide,  methazolamide   and ethoxzolamide", "triple_list": [["methazolamide", "DOWNREGULATOR", "EC 4.2.1.1"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of  carbonic anhydrase  (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide,  methazolamide   and ethoxzolamide", "triple_list": [["methazolamide", "DOWNREGULATOR", "carbonic anhydrase"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ( CA   EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and  ethoxzolamide   Some of these structurally related compounds have a very different behavior against the widespread isozyme  CA  II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against  CA  II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["ethoxzolamide", "DOWNREGULATOR", "CA"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA,  EC 4.2.1.1   with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and  ethoxzolamide   Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["ethoxzolamide", "DOWNREGULATOR", "EC 4.2.1.1"]]}, {"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of  carbonic anhydrase  (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and  ethoxzolamide   Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)", "triple_list": [["ethoxzolamide", "DOWNREGULATOR", "carbonic anhydrase"]]}, {"text": "We discovered  sergliflozin etabonate   a novel selective  SGLT2  inhibitor, and found that selective inhibition of  SGLT2  increased urinary glucose excretion and consequently decreased plasma glucose levels", "triple_list": [["sergliflozin etabonate", "DOWNREGULATOR", "SGLT2"]]}, {"text": "We discovered  sergliflozin etabonate   a novel selective  SGLT2  inhibitor, and found that selective inhibition of  SGLT2  increased urinary glucose excretion and consequently decreased plasma glucose levels", "triple_list": [["sergliflozin etabonate", "DOWNREGULATOR", "SGLT2"]]}, {"text": "In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an  alpha-glucosidase  inhibitor ( voglibose  ", "triple_list": [["voglibose", "DOWNREGULATOR", "alpha-glucosidase"]]}, {"text": " Sergliflozin etabonate   a selective  SGLT2  inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats", "triple_list": [["Sergliflozin etabonate", "DOWNREGULATOR", "SGLT2"]]}, {"text": "Chronic treatment with  sergliflozin etabonate  reduced the levels of  glycated hemoglobin  and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats", "triple_list": [["sergliflozin etabonate", "DOWNREGULATOR", "glycated hemoglobin"]]}, {"text": "The low-affinity sodium  glucose  cotransporter (SGLT2) is responsible for most of the  glucose  reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes", "triple_list": [["glucose", "PRODUCT-OF", "sodium glucose cotransporter"]]}, {"text": "The low-affinity sodium  glucose  cotransporter ( SGLT2   is responsible for most of the  glucose  reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes", "triple_list": [["glucose", "PRODUCT-OF", "SGLT2"]]}, {"text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with  fenoldopam   a D1-like receptor agonist, inhibited the stimulatory effect of  insulin   The inhibitory effect of  fenoldopam  on  insulin -mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist", "triple_list": [["fenoldopam", "DOWNREGULATOR", "insulin"]]}, {"text": "The inhibitory effect of  fenoldopam  on  insulin  mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist", "triple_list": [["fenoldopam", "DOWNREGULATOR", "insulin"]]}, {"text": " Fenoldopam  also inhibited  insulin receptor  mRNA and protein expression, which was time dependent and concentration dependent", "triple_list": [["Fenoldopam", "DOWNREGULATOR", "insulin receptor"]]}, {"text": "A PKC or MAP kinase inhibitor blocked the inhibitory effect of  fenoldopam  on  insulin receptor  expression, indicating that PKC and MAP kinase were involved in the signaling pathway", "triple_list": [["fenoldopam", "DOWNREGULATOR", "insulin receptor"]]}, {"text": "Although the  D1-like receptor , by itself, had no effect on VSMC proliferation, stimulation with  fenoldopam   a  D1-like receptor  agonist, inhibited the stimulatory effect of insulin", "triple_list": [["fenoldopam", "AGONIST", "D1-like receptor"]]}, {"text": "The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by  SCH23390   a  D1-like receptor  antagonist", "triple_list": [["SCH23390", "ANTAGONIST", "D1-like receptor"]]}, {"text": "The progress of the enzymatic reaction of the hydrolysis of  acetylthiocholine  at pH 8 in the presence of  AChE  and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh)", "triple_list": [["acetylthiocholine", "PRODUCT-OF", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime,  trimedoxime   obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["trimedoxime", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime,  obidoxime  and HI-6) and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["obidoxime", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and  HI-6   and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["HI-6", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and  diazepam  are used for the treatment of OP poisoning in humans", "triple_list": [["diazepam", "ACTIVATOR", "AChE"]]}, {"text": " atropine    AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["atropine", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended  pyridinium oximes  (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["pyridinium oximes", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes ( pralidoxime   trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans", "triple_list": [["pralidoxime", "ACTIVATOR", "AChE"]]}, {"text": "atropine,  AChE  reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of  OP  poisoning in humans", "triple_list": [["OP", "DOWNREGULATOR", "AChE"]]}, {"text": "The mechanism of  OP  poisoning involves inhibition of  acetylcholinesterase  (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission", "triple_list": [["OP", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "The mechanism of  OP  poisoning involves inhibition of acetylcholinesterase ( AChE   leading to inactivation of the enzyme which has an important role in neurotransmission", "triple_list": [["OP", "DOWNREGULATOR", "AChE"]]}, {"text": "They act by reactivation of  AChE  inhibited by  OP   However, they differ in their activity in poisoning with pesticides and warfare nerve agents and there is still no universal broad-spectrum oxime capable of protecting against all known  OP ", "triple_list": [["OP", "DOWNREGULATOR", "AChE"]]}, {"text": "Oral  palonosetron  is likely to be a useful addition to oral formulations of other  5-HT3 recepto   antagonists in preventing CINV in patients receiving MEC", "triple_list": [["palonosetron", "ANTAGONIST", "5-HT3 recepto"]]}, {"text": " Palonosetron  is a second-generation serotonin  5-HT3 receptor  antagonist, with a distinct pharmacological profile that differs from first-generation  5-HT3 receptor  antagonists", "triple_list": [["Palonosetron", "ANTAGONIST", "5-HT3 receptor"]]}, {"text": " Palonosetron  is a second-generation  serotonin 5-HT3 receptor  antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists", "triple_list": [["Palonosetron", "ANTAGONIST", "serotonin 5-HT3 receptor"]]}, {"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as  buserelin   goserelin, leuprorelin and triptorelin, stimulate the pituitary's  gonadotrophin-releasing hormone (GnRH) receptor   ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["buserelin", "ACTIVATOR", "gonadotrophin-releasing hormone (GnRH) receptor"]]}, {"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin,  goserelin   leuprorelin and triptorelin, stimulate the pituitary's  gonadotrophin-releasing hormone (GnRH) receptor   ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["goserelin", "ACTIVATOR", "gonadotrophin-releasing hormone (GnRH) receptor"]]}, {"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin,  leuprorelin  and triptorelin, stimulate the pituitary's  gonadotrophin-releasing hormone (GnRH) receptor   ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["leuprorelin", "ACTIVATOR", "gonadotrophin-releasing hormone (GnRH) receptor"]]}, {"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and  triptorelin   stimulate the pituitary's  gonadotrophin-releasing hormone (GnRH) receptor   ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["triptorelin", "ACTIVATOR", "gonadotrophin-releasing hormone (GnRH) receptor"]]}, {"text": "Luteinizing hormone-releasing hormone ( LH RH) agonists, such as  buserelin   goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of  LH  and testosterone levels", "triple_list": [["buserelin", "DOWNREGULATOR", "LH"]]}, {"text": "Luteinizing hormone-releasing hormone ( LH RH) agonists, such as buserelin,  goserelin   leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of  LH  and testosterone levels", "triple_list": [["goserelin", "DOWNREGULATOR", "LH"]]}, {"text": "Luteinizing hormone-releasing hormone ( LH RH) agonists, such as buserelin, goserelin,  leuprorelin  and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of  LH  and testosterone levels", "triple_list": [["leuprorelin", "DOWNREGULATOR", "LH"]]}, {"text": "Luteinizing hormone-releasing hormone ( LH RH) agonists, such as buserelin, goserelin, leuprorelin and  triptorelin   stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of  LH  and testosterone levels", "triple_list": [["triptorelin", "DOWNREGULATOR", "LH"]]}, {"text": " Luteinizing hormone-releasing hormone  (LHRH) agonists, such as  buserelin   goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["buserelin", "AGONIST", "Luteinizing hormone-releasing hormone"]]}, {"text": "Luteinizing hormone-releasing hormone ( LHRH   agonists, such as  buserelin   goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["buserelin", "AGONIST", "LHRH"]]}, {"text": " Luteinizing hormone-releasing hormone  (LHRH) agonists, such as buserelin,  goserelin   leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["goserelin", "AGONIST", "Luteinizing hormone-releasing hormone"]]}, {"text": "Luteinizing hormone-releasing hormone ( LHRH   agonists, such as buserelin,  goserelin   leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["goserelin", "AGONIST", "LHRH"]]}, {"text": " Luteinizing hormone-releasing hormone  (LHRH) agonists, such as buserelin, goserelin,  leuprorelin  and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["leuprorelin", "AGONIST", "Luteinizing hormone-releasing hormone"]]}, {"text": "Luteinizing hormone-releasing hormone ( LHRH   agonists, such as buserelin, goserelin,  leuprorelin  and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["leuprorelin", "AGONIST", "LHRH"]]}, {"text": " Luteinizing hormone-releasing hormone  (LHRH) agonists, such as buserelin, goserelin, leuprorelin and  triptorelin   stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["triptorelin", "AGONIST", "Luteinizing hormone-releasing hormone"]]}, {"text": "Luteinizing hormone-releasing hormone ( LHRH   agonists, such as buserelin, goserelin, leuprorelin and  triptorelin   stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels", "triple_list": [["triptorelin", "AGONIST", "LHRH"]]}, {"text": "Two pure  GnRH  antagonists have been developed,  abarelix  and degarelix, that are devoid of any agonist effect on the  GnRH  receptor and consequently do not result in testosterone flare", "triple_list": [["abarelix", "ANTAGONIST", "GnRH"]]}, {"text": "Two pure  GnRH  antagonists have been developed, abarelix and  degarelix   that are devoid of any agonist effect on the  GnRH  receptor and consequently do not result in testosterone flare", "triple_list": [["degarelix", "ANTAGONIST", "GnRH"]]}, {"text": " Abarelix  was the first  GnRH  antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary", "triple_list": [["Abarelix", "ANTAGONIST", "GnRH"]]}, {"text": " Fulvestrant   a pure  estrogen receptor  downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002", "triple_list": [["Fulvestrant", "DOWNREGULATOR", "estrogen receptor"]]}, {"text": "The concentration of  estramustine phosphate  required to inhibit the assembly or to induce the disassembly of  chick brain MAP2  tubulin microtubules is markedly dependent upon the microtubule protein concentration", "triple_list": [["estramustine phosphate", "ACTIVATOR", "chick brain MAP2"]]}, {"text": "The concentration of  estramustine phosphate  required to inhibit the assembly or to induce the disassembly of chick brain MAP2: tubulin  microtubules is markedly dependent upon the microtubule protein concentration", "triple_list": [["estramustine phosphate", "ACTIVATOR", "tubulin"]]}, {"text": "The concentration of  estramustine phosphate  required to inhibit the assembly or to induce the disassembly of  chick brain MAP2  tubulin microtubules is markedly dependent upon the microtubule protein concentration", "triple_list": [["estramustine phosphate", "DOWNREGULATOR", "chick brain MAP2"]]}, {"text": "The concentration of  estramustine phosphate  required to inhibit the assembly or to induce the disassembly of chick brain MAP2: tubulin  microtubules is markedly dependent upon the microtubule protein concentration", "triple_list": [["estramustine phosphate", "DOWNREGULATOR", "tubulin"]]}, {"text": "It is proposed that two molecules of  estramustine phosphate  interact with each of the three tubulin-binding sites of  MAP2  and inhibit the  MAP2  tubulin interaction by neutralising two highly conserved basic residues.", "triple_list": [["estramustine phosphate", "DOWNREGULATOR", "MAP2"]]}, {"text": "It is proposed that two molecules of  estramustine phosphate  interact with each of the three  tubulin -binding sites of MAP2 and inhibit the MAP2: tubulin  interaction by neutralising two highly conserved basic residues.", "triple_list": [["estramustine phosphate", "DOWNREGULATOR", "tubulin"]]}, {"text": "PURPOSE: XL184 ( cabozantinib   is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ( VEGFR2  , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["cabozantinib", "DOWNREGULATOR", "VEGFR2"]]}, {"text": "PURPOSE: XL184 ( cabozantinib   is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and  RET   with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["cabozantinib", "DOWNREGULATOR", "RET"]]}, {"text": "PURPOSE: XL184 ( cabozantinib   is a potent inhibitor of  MET   vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["cabozantinib", "DOWNREGULATOR", "MET"]]}, {"text": "PURPOSE: XL184 ( cabozantinib   is a potent inhibitor of MET,  vascular endothelial growth factor receptor 2  (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["cabozantinib", "DOWNREGULATOR", "vascular endothelial growth factor receptor 2"]]}, {"text": "PURPOSE:  XL184  (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ( VEGFR2  , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["XL184", "DOWNREGULATOR", "VEGFR2"]]}, {"text": "PURPOSE:  XL184  (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and  RET   with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["XL184", "DOWNREGULATOR", "RET"]]}, {"text": "PURPOSE:  XL184  (cabozantinib) is a potent inhibitor of  MET   vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["XL184", "DOWNREGULATOR", "MET"]]}, {"text": "PURPOSE:  XL184  (cabozantinib) is a potent inhibitor of MET,  vascular endothelial growth factor receptor 2  (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models", "triple_list": [["XL184", "DOWNREGULATOR", "vascular endothelial growth factor receptor 2"]]}, {"text": "Activity of  XL184  (Cabozantinib), an oral  tyrosine kinase  inhibitor, in patients with medullary thyroid cancer", "triple_list": [["XL184", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "Activity of XL184 ( Cabozantinib  , an oral  tyrosine kinase  inhibitor, in patients with medullary thyroid cancer", "triple_list": [["Cabozantinib", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "Further, we used this model to test the efficacy of  GDC-0941   a  PI3K  inhibitor, in clinical development, and showed that the tumors respond to  PI3K  inhibition.", "triple_list": [["GDC-0941", "DOWNREGULATOR", "PI3K"]]}, {"text": "Further, we used this model to test the efficacy of  GDC-0941   a  PI3K  inhibitor, in clinical development, and showed that the tumors respond to  PI3K  inhibition.", "triple_list": [["GDC-0941", "DOWNREGULATOR", "PI3K"]]}, {"text": " 4-MA   a well known  5 alpha-reductase  inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM", "triple_list": [["4-MA", "DOWNREGULATOR", "5 alpha-reductase"]]}, {"text": " 4-MA   a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of  3 beta-HSD  with a Ki value of 56 nM", "triple_list": [["4-MA", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": " Cyproterone acetate   a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit  3 beta-HSD  activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.", "triple_list": [["Cyproterone acetate", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Cyproterone acetate, a  progestin  used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit  3 beta-HSD  activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.", "triple_list": [["progestin", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as  norgestrel  and norethindrone that are widely used as oral contraceptives also inhibit  3 beta-HSD  activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.", "triple_list": [["norgestrel", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and  norethindrone  that are widely used as oral contraceptives also inhibit  3 beta-HSD  activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.", "triple_list": [["norethindrone", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Inhibitory effect of synthetic  progestins   4-MA and cyanoketone on  human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase  activity", "triple_list": [["progestins", "DOWNREGULATOR", "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase"]]}, {"text": "Inhibitory effect of synthetic progestins,  4-MA  and cyanoketone on  human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase  activity", "triple_list": [["4-MA", "DOWNREGULATOR", "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase"]]}, {"text": "Inhibitory effect of synthetic progestins, 4-MA and  cyanoketone  on  human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase  activity", "triple_list": [["cyanoketone", "DOWNREGULATOR", "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase"]]}, {"text": " Trilostane   epostane and cyanoketone are potent inhibitors of  3 beta-HSD  with Ki values of approximately 50 nM", "triple_list": [["Trilostane", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Trilostane,  epostane  and cyanoketone are potent inhibitors of  3 beta-HSD  with Ki values of approximately 50 nM", "triple_list": [["epostane", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": "Trilostane, epostane and  cyanoketone  are potent inhibitors of  3 beta-HSD  with Ki values of approximately 50 nM", "triple_list": [["cyanoketone", "DOWNREGULATOR", "3 beta-HSD"]]}, {"text": " Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase  (3 beta-HSD) purified from human placenta transforms C-21 ( pregnenolone  and 17 alpha-hydroxy  pregnenolone ) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["pregnenolone", "PRODUCT-OF", "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"]]}, {"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase ( 3 beta-HSD   purified from human placenta transforms C-21 ( pregnenolone  and 17 alpha-hydroxy  pregnenolone ) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["pregnenolone", "PRODUCT-OF", "3 beta-HSD"]]}, {"text": " Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase  (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and  17 alpha-hydroxy pregnenolone   as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["17 alpha-hydroxy pregnenolone", "PRODUCT-OF", "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"]]}, {"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase ( 3 beta-HSD   purified from human placenta transforms C-21 (pregnenolone and  17 alpha-hydroxy pregnenolone   as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["17 alpha-hydroxy pregnenolone", "PRODUCT-OF", "3 beta-HSD"]]}, {"text": " Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase  (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 ( dehydroepiandrosterone  and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["dehydroepiandrosterone", "PRODUCT-OF", "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"]]}, {"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase ( 3 beta-HSD   purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 ( dehydroepiandrosterone  and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["dehydroepiandrosterone", "PRODUCT-OF", "3 beta-HSD"]]}, {"text": " Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase  (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and  androst-5-ene-3 beta, 17 beta-diol   steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["androst-5-ene-3 beta, 17 beta-diol", "PRODUCT-OF", "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"]]}, {"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase ( 3 beta-HSD   purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and  androst-5-ene-3 beta, 17 beta-diol   steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["androst-5-ene-3 beta, 17 beta-diol", "PRODUCT-OF", "3 beta-HSD"]]}, {"text": " Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase  (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding  3-keto-4-ene-steroids  and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["3-keto-4-ene-steroids", "PRODUCT-OF", "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"]]}, {"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase ( 3 beta-HSD   purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding  3-keto-4-ene-steroids  and is thus involved in the biosynthesis of all classes of hormonal steroids", "triple_list": [["3-keto-4-ene-steroids", "PRODUCT-OF", "3 beta-HSD"]]}, {"text": "However, chronic treatment of cLH rats with  MPEP  did not reverse learned helplessness, indicating that the enhanced  mGlu5 receptor  function is not the only player in the behavioral phenotype of this genetic model of depression", "triple_list": [["MPEP", "ACTIVATOR", "mGlu5 receptor"]]}, {"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while  MS-275  or PEPA ( AMPA receptor  potentiator) failed to affect extinction acquisition in S1 mice", "triple_list": [["MS-275", "ACTIVATOR", "AMPA receptor"]]}, {"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or  PEPA  ( AMPA receptor  potentiator) failed to affect extinction acquisition in S1 mice", "triple_list": [["PEPA", "ACTIVATOR", "AMPA receptor"]]}, {"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of  valproic acid  (a GABAergic enhancer and  HDAC  inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice", "triple_list": [["valproic acid", "DOWNREGULATOR", "HDAC"]]}, {"text": "Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or  MS-275  ( histone deacetylase  (HDAC) inhibitor), applied after extinction training", "triple_list": [["MS-275", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or  MS-275  (histone deacetylase ( HDAC   inhibitor), applied after extinction training", "triple_list": [["MS-275", "DOWNREGULATOR", "HDAC"]]}, {"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or  AMN082  [ metabotropic glutamate receptor 7  (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice", "triple_list": [["AMN082", "AGONIST", "metabotropic glutamate receptor 7"]]}, {"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or  AMN082  [metabotropic glutamate receptor 7 ( mGlu7   agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice", "triple_list": [["AMN082", "AGONIST", "mGlu7"]]}, {"text": "These findings suggest that oral consumption of  nicotine  enhances the efficacy of  nicotinic acetylcholine receptors   Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning)", "triple_list": [["nicotine", "ACTIVATOR", "nicotinic acetylcholine receptors"]]}, {"text": "Electroencephalographic recordings during substance consumption showed reduced alpha activity and  P300  latencies in the  nicotine  group compared to the control group", "triple_list": [["nicotine", "DOWNREGULATOR", "P300"]]}, {"text": " GDC-0152  induces  NF-\u03baB  transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity", "triple_list": [["GDC-0152", "ACTIVATOR", "NF-\u03baB"]]}, {"text": " GDC-0152  is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing  IAPs    GDC-0152  induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity", "triple_list": [["GDC-0152", "ANTAGONIST", "IAPs"]]}, {"text": "Toxicity profile of small-molecule  IAP  antagonist  GDC-0152  is linked to TNF-\u03b1 pharmacology", "triple_list": [["GDC-0152", "ANTAGONIST", "IAP"]]}, {"text": "In TPC1, BCPAP, FRO, WRO cell lines  PJ34  induced a strong increase in  NIS  mRNA levels", "triple_list": [["PJ34", "ACTIVATOR", "NIS"]]}, {"text": "Accordingly, in transfection experiments performed in TPC1 cells, treatment with  PJ34  increased  NIS promoter  activity without affecting PARP-1 binding to the promoter sequence", "triple_list": [["PJ34", "ACTIVATOR", "NIS promoter"]]}, {"text": "We also investigated the epigenetic status of NIS promoter after  PJ34  treatment in TPC1 cell line: in addition to an increase of  histone modification activation marks  (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark", "triple_list": [["PJ34", "ACTIVATOR", "histone modification activation marks"]]}, {"text": "We also investigated the epigenetic status of NIS promoter after  PJ34  treatment in TPC1 cell line: in addition to an increase of histone modification activation marks ( H3K9K14ac   H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark", "triple_list": [["PJ34", "ACTIVATOR", "H3K9K14ac"]]}, {"text": "We also investigated the epigenetic status of NIS promoter after  PJ34  treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac,  H3K4me3  , surprisingly we observed also an increase of H3K27me3, a classical repressive mark", "triple_list": [["PJ34", "ACTIVATOR", "H3K4me3"]]}, {"text": "Since  PARP -1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the  PARP  inhibitor  PJ34  on several properties of thyroid cancer cell lines was investigated", "triple_list": [["PJ34", "DOWNREGULATOR", "PARP"]]}, {"text": "The  PARP  inhibitor  PJ34  modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines", "triple_list": [["PJ34", "DOWNREGULATOR", "PARP"]]}, {"text": "Both  apo-lycopenoic acids  also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in  NOX-4  and COX-2 expressions caused by CSE", "triple_list": [["apo-lycopenoic acids", "DOWNREGULATOR", "NOX-4"]]}, {"text": "Both  apo-lycopenoic acids  also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and  COX-2  expressions caused by CSE", "triple_list": [["apo-lycopenoic acids", "DOWNREGULATOR", "COX-2"]]}, {"text": "Here, in expressing  cocaine  hydrolyzing mutants of  BChE  in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered  BChE  proteins with desired properties.", "triple_list": [["cocaine", "PRODUCT-OF", "BChE"]]}, {"text": "Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme  butyrylcholinesterase  (BChE), which is capable of breaking down naturally occurring  (-)-cocaine  before the drug can influence the reward centers of the brain or affect other areas of the body", "triple_list": [["(-)-cocaine", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase ( BChE  , which is capable of breaking down naturally occurring  (-)-cocaine  before the drug can influence the reward centers of the brain or affect other areas of the body", "triple_list": [["(-)-cocaine", "PRODUCT-OF", "BChE"]]}, {"text": "This prompted the design of variants of  BChE  which exhibit significantly improved catalytic activity against  (-)-cocaine   Plants are a promising means to produce large amounts of these cocaine hydrolase variants of  BChE , cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources", "triple_list": [["(-)-cocaine", "PRODUCT-OF", "BChE"]]}, {"text": "Second, feeding increased both the expression of  COX  isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with  cimetidine   Third,  COX -1 was localized in goblet and Brunner's gland cells, Meissner's and Auerbach's plexus, smooth muscle cells, and arterioles; and  COX -2 was observed in capillaries, venules, and basal granulated cells", "triple_list": [["cimetidine", "DOWNREGULATOR", "COX"]]}, {"text": "We examined in cats the 1) ulcerogenic effects of selective  COX-1  ( SC-560   ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum", "triple_list": [["SC-560", "DOWNREGULATOR", "COX-1"]]}, {"text": "We examined in cats the 1) ulcerogenic effects of selective  COX-1  (SC-560,  ketorolac   and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum", "triple_list": [["ketorolac", "DOWNREGULATOR", "COX-1"]]}, {"text": "We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and  COX-2  ( celecoxib   meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum", "triple_list": [["celecoxib", "DOWNREGULATOR", "COX-2"]]}, {"text": "We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and  COX-2  (celecoxib,  meloxicam   inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum", "triple_list": [["meloxicam", "DOWNREGULATOR", "COX-2"]]}, {"text": "Reversal of inhibition by  D2  agonist quinpirole was produced by serotonin (50 \u00b5M) and by  neurotensin  (5-10 nM)", "triple_list": [["neurotensin", "ACTIVATOR", "D2"]]}, {"text": "Reversal of inhibition by  D2  agonist quinpirole was produced by  serotonin  (50 \u00b5M) and by neurotensin (5-10 nM)", "triple_list": [["serotonin", "ACTIVATOR", "D2"]]}, {"text": "Reversal of inhibition by  D2  agonist  quinpirole  was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)", "triple_list": [["quinpirole", "AGONIST", "D2"]]}, {"text": "Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or  cPKC  antagonist  5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile  (G\u00f66976)", "triple_list": [["5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile", "ANTAGONIST", "cPKC"]]}, {"text": "Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or  cPKC  antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile ( G\u00f66976  ", "triple_list": [["G\u00f66976", "ANTAGONIST", "cPKC"]]}, {"text": "However,  4'G-RSV   but not 3G-RSV, induced  SIRT1  dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV,  SIRT1  knockdown blunted these effects", "triple_list": [["4'G-RSV", "ACTIVATOR", "SIRT1"]]}, {"text": "However,  4'G-RSV   but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and  SOD2  expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects", "triple_list": [["4'G-RSV", "ACTIVATOR", "SOD2"]]}, {"text": " RSV  targets and activates the  NAD(+)-dependent protein deacetylase SIRT1   in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)", "triple_list": [["RSV", "ACTIVATOR", "NAD(+)-dependent protein deacetylase SIRT1"]]}, {"text": " RSV  targets and activates the NAD(+)-dependent protein deacetylase  SIRT1 ; in turn,  SIRT1  induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)", "triple_list": [["RSV", "ACTIVATOR", "SIRT1"]]}, {"text": " RSV  targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing  mitochondrial superoxide dismutase  (SOD2)", "triple_list": [["RSV", "ACTIVATOR", "mitochondrial superoxide dismutase"]]}, {"text": " RSV  targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase ( SOD2  ", "triple_list": [["RSV", "ACTIVATOR", "SOD2"]]}, {"text": "These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the  ABCA1  transporter during the  cholesterol  efflux process.", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "The bihelical  apolipoprotein mimetic peptide 5A  effluxes  cholesterol  from cells and reduces inflammation and atherosclerosis in animal models", "triple_list": [["cholesterol", "PRODUCT-OF", "apolipoprotein mimetic peptide 5A"]]}, {"text": "Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing  cholesterol  by the  ABCA1  transporter", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting  cholesterol  efflux by the  ABCA1  transporter", "triple_list": [["cholesterol", "PRODUCT-OF", "ABCA1"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the  GluK1  (GluR5)/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist  (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid  (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid", "ANTAGONIST", "GluK1"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 ( GluR5  /\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist  (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid  (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid", "ANTAGONIST", "GluR5"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/ \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor  antagonist  (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid  (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid", "ANTAGONIST", "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the  GluK1  (GluR5)/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ( LY293558   in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["LY293558", "ANTAGONIST", "GluK1"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 ( GluR5  /\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ( LY293558   in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["LY293558", "ANTAGONIST", "GluR5"]]}, {"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/ \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor  antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ( LY293558   in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman", "triple_list": [["LY293558", "ANTAGONIST", "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor"]]}, {"text": "Efficacy of the  GluK1  AMPA receptor antagonist  LY293558  against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration", "triple_list": [["LY293558", "ANTAGONIST", "GluK1"]]}, {"text": "Efficacy of the GluK1/ AMPA receptor  antagonist  LY293558  against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration", "triple_list": [["LY293558", "ANTAGONIST", "AMPA receptor"]]}, {"text": "Cellular release of  AChE  by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists  carbachol  or muscarine, with the effect of  carbachol  blocked by the mAChR antagonist atropine", "triple_list": [["carbachol", "ACTIVATOR", "AChE"]]}, {"text": "Cellular release of  AChE  by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or  muscarine   with the effect of carbachol blocked by the mAChR antagonist atropine", "triple_list": [["muscarine", "ACTIVATOR", "AChE"]]}, {"text": "Cellular release of  AChE  by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists  carbachol  or muscarine, with the effect of  carbachol  blocked by the mAChR antagonist atropine", "triple_list": [["carbachol", "ACTIVATOR", "AChE"]]}, {"text": "Cellular release of  AChE  by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist  atropine    AChE  has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD", "triple_list": [["atropine", "DOWNREGULATOR", "AChE"]]}, {"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the  muscarinic acetylcholine receptor  (mAChR) agonists  carbachol  or muscarine, with the effect of  carbachol  blocked by the mAChR antagonist atropine", "triple_list": [["carbachol", "AGONIST", "muscarinic acetylcholine receptor"]]}, {"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor ( mAChR   agonists  carbachol  or muscarine, with the effect of  carbachol  blocked by the  mAChR  antagonist atropine", "triple_list": [["carbachol", "AGONIST", "mAChR"]]}, {"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the  muscarinic acetylcholine receptor  (mAChR) agonists carbachol or  muscarine   with the effect of carbachol blocked by the mAChR antagonist atropine", "triple_list": [["muscarine", "AGONIST", "muscarinic acetylcholine receptor"]]}, {"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor ( mAChR   agonists carbachol or  muscarine   with the effect of carbachol blocked by the  mAChR  antagonist atropine", "triple_list": [["muscarine", "AGONIST", "mAChR"]]}, {"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor ( mAChR ) agonists carbachol or muscarine, with the effect of carbachol blocked by the  mAChR  antagonist  atropine   AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD", "triple_list": [["atropine", "ANTAGONIST", "mAChR"]]}, {"text": "Although  acetylcholine sterase ( AChE   is primarily a hydrolytic enzyme, metabolising the neurotransmitter  acetylcholine  in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised", "triple_list": [["acetylcholine", "PRODUCT-OF", "AChE"]]}, {"text": "Although  acetylcholine sterase (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter  acetylcholine  in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised", "triple_list": [["acetylcholine", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "Nevertheless, low  L-BMAA  concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination,  20S proteasomal  and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells", "triple_list": [["L-BMAA", "ACTIVATOR", "20S proteasomal"]]}, {"text": "Nevertheless, low  L-BMAA  concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and  caspase 12  activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells", "triple_list": [["L-BMAA", "ACTIVATOR", "caspase 12"]]}, {"text": "Nevertheless, low  L-BMAA  concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker  CHOP   and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells", "triple_list": [["L-BMAA", "ACTIVATOR", "CHOP"]]}, {"text": "Nevertheless, low  L-BMAA  concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of  elf2\u03b1  in SH-SY5Y cells", "triple_list": [["L-BMAA", "ACTIVATOR", "elf2\u03b1"]]}, {"text": " L-BMAA  induced ER stress and enhanced  caspase 12  cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations", "triple_list": [["L-BMAA", "ACTIVATOR", "caspase 12"]]}, {"text": "We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as  mycophenolic acid  and 6-mercaptopurine, up-regulated  F7  expression", "triple_list": [["mycophenolic acid", "ACTIVATOR", "F7"]]}, {"text": "We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and  6-mercaptopurine   up-regulated  F7  expression", "triple_list": [["6-mercaptopurine", "ACTIVATOR", "F7"]]}, {"text": " Ribavirin  unregulated  ELL  (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation", "triple_list": [["Ribavirin", "ACTIVATOR", "ELL"]]}, {"text": " Ribavirin  unregulated ELL ( eleven-nineteen lysine-rich leukaemia) 3  mRNA expression before F7 up-regulation", "triple_list": [["Ribavirin", "ACTIVATOR", "eleven-nineteen lysine-rich leukaemia) 3"]]}, {"text": " Ribavirin  unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before  F7  up-regulation", "triple_list": [["Ribavirin", "ACTIVATOR", "F7"]]}, {"text": "We observed that  ribavirin  enhanced  ELL3  recruitment to F7, whereas knockdown of  ELL3  diminished  ribavirin -induced FVII mRNA up-regulation", "triple_list": [["ribavirin", "ACTIVATOR", "ELL3"]]}, {"text": "We observed that  ribavirin  enhanced ELL3 recruitment to  F7   whereas knockdown of ELL3 diminished  ribavirin -induced FVII mRNA up-regulation", "triple_list": [["ribavirin", "ACTIVATOR", "F7"]]}, {"text": " Ribavirin  induced intracellular GTP depletion activates transcription elongation in  coagulation factor VII  gene expression", "triple_list": [["Ribavirin", "ACTIVATOR", "coagulation factor VII"]]}, {"text": "We observed that  ribavirin  enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished  ribavirin  induced  FVII  mRNA up-regulation", "triple_list": [["ribavirin", "ACTIVATOR", "FVII"]]}, {"text": " Ribavirin  also enhanced recruitment of  CDK9  (cyclin-dependent kinase 9) and AFF4 to F7", "triple_list": [["Ribavirin", "ACTIVATOR", "CDK9"]]}, {"text": " Ribavirin  also enhanced recruitment of CDK9 ( cyclin-dependent kinase 9   and AFF4 to F7", "triple_list": [["Ribavirin", "ACTIVATOR", "cyclin-dependent kinase 9"]]}, {"text": " Ribavirin  also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and  AFF4  to F7", "triple_list": [["Ribavirin", "ACTIVATOR", "AFF4"]]}, {"text": " Ribavirin  also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to  F7   These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to  F7 , and modulates FVII mRNA transcription elongation", "triple_list": [["Ribavirin", "ACTIVATOR", "F7"]]}, {"text": "These data suggest that  ribavirin  induced intracellular GTP depletion recruits a super elongation complex containing  P-TEFb   AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation", "triple_list": [["ribavirin", "ACTIVATOR", "P-TEFb"]]}, {"text": "These data suggest that  ribavirin  induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb,  AFF4  and ELL3, to F7, and modulates FVII mRNA transcription elongation", "triple_list": [["ribavirin", "ACTIVATOR", "AFF4"]]}, {"text": "These data suggest that  ribavirin  induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and  ELL3   to F7, and modulates FVII mRNA transcription elongation", "triple_list": [["ribavirin", "ACTIVATOR", "ELL3"]]}, {"text": "These data suggest that  ribavirin  induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to  F7   and modulates FVII mRNA transcription elongation", "triple_list": [["ribavirin", "ACTIVATOR", "F7"]]}, {"text": "Collectively, we have elucidated a basal mechanism for  ribavirin  induced  FVII  mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in\u00a0vivo.", "triple_list": [["ribavirin", "ACTIVATOR", "FVII"]]}, {"text": "It was reported previously that  FVII  gene (F7) expression was up-regulated by  ribavirin  treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown", "triple_list": [["ribavirin", "ACTIVATOR", "FVII"]]}, {"text": "It was reported previously that FVII gene ( F7   expression was up-regulated by  ribavirin  treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown", "triple_list": [["ribavirin", "ACTIVATOR", "F7"]]}, {"text": "In the present study, we investigated the molecular mechanism of  ribavirin  induced up-regulation of  F7  expression in HepG2 (human hepatoma cell line)", "triple_list": [["ribavirin", "ACTIVATOR", "F7"]]}, {"text": "Protein kinase C ( PKC ) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of  PKC  by  phorbol 12-myristate,13-acetate  potentiated GluK2/GluK5", "triple_list": [["phorbol 12-myristate,13-acetate", "ACTIVATOR", "PKC"]]}, {"text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of  GluK2 /GluK5, and conversely, direct activation of PKC by  phorbol 12-myristate,13-acetate  potentiated  GluK2  GluK5", "triple_list": [["phorbol 12-myristate,13-acetate", "ACTIVATOR", "GluK2"]]}, {"text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/ GluK5 , and conversely, direct activation of PKC by  phorbol 12-myristate,13-acetate  potentiated GluK2/ GluK5   Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the  GluK5  C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs", "triple_list": [["phorbol 12-myristate,13-acetate", "ACTIVATOR", "GluK5"]]}, {"text": "The potentiation of heteromeric  KARs  by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator  1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid  (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid", "DOWNREGULATOR", "KARs"]]}, {"text": "The potentiation of heteromeric KARs by  mGlu1  activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator  1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid  (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid", "DOWNREGULATOR", "mGlu1"]]}, {"text": "The potentiation of heteromeric  KARs  by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ( BAPTA  , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["BAPTA", "DOWNREGULATOR", "KARs"]]}, {"text": "The potentiation of heteromeric KARs by  mGlu1  activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ( BAPTA  , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["BAPTA", "DOWNREGULATOR", "mGlu1"]]}, {"text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the  phosphatase  inhibitor  okadaic acid   but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["okadaic acid", "DOWNREGULATOR", "phosphatase"]]}, {"text": "The potentiation of heteromeric  KARs  by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor  okadaic acid   but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["okadaic acid", "DOWNREGULATOR", "KARs"]]}, {"text": "The potentiation of heteromeric KARs by  mGlu1  activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor  okadaic acid   but unaffected by the tyrosine kinase inhibitor lavendustin A", "triple_list": [["okadaic acid", "DOWNREGULATOR", "mGlu1"]]}, {"text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the  tyrosine kinase  inhibitor  lavendustin A   Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5", "triple_list": [["lavendustin A", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "The potentiation of heteromeric  KARs  by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor  lavendustin A   Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5", "triple_list": [["lavendustin A", "DOWNREGULATOR", "KARs"]]}, {"text": "The potentiation of heteromeric KARs by  mGlu1  activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor  lavendustin A   Protein kinase C (PKC) inhibition reduced the potentiation by  mGlu1  of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5", "triple_list": [["lavendustin A", "DOWNREGULATOR", "mGlu1"]]}, {"text": " Fingolimod  (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different  sphingosine-1-phosphate receptor  (S1PR) subtypes", "triple_list": [["Fingolimod", "ACTIVATOR", "sphingosine-1-phosphate receptor"]]}, {"text": " Fingolimod  (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor ( S1PR   subtypes", "triple_list": [["Fingolimod", "ACTIVATOR", "S1PR"]]}, {"text": "Fingolimod ( FTY720  , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different  sphingosine-1-phosphate receptor  (S1PR) subtypes", "triple_list": [["FTY720", "ACTIVATOR", "sphingosine-1-phosphate receptor"]]}, {"text": "Fingolimod ( FTY720  , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor ( S1PR   subtypes", "triple_list": [["FTY720", "ACTIVATOR", "S1PR"]]}, {"text": "Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective  type-1 S1PR  (S1P1R) antagonist,  W146   and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways", "triple_list": [["W146", "ANTAGONIST", "type-1 S1PR"]]}, {"text": "Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR ( S1P1R   antagonist,  W146   and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways", "triple_list": [["W146", "ANTAGONIST", "S1P1R"]]}, {"text": "1.\u2002The disposition of  anagliptin   an orally active, highly selective  dipeptidyl peptidase-4  inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C] anagliptin  to six healthy men", "triple_list": [["anagliptin", "DOWNREGULATOR", "dipeptidyl peptidase-4"]]}, {"text": "Pharmacokinetics and metabolism of  [(14)C]anagliptin   a novel  dipeptidyl peptidase-4  inhibitor, in humans", "triple_list": [["[(14)C]anagliptin", "DOWNREGULATOR", "dipeptidyl peptidase-4"]]}, {"text": "Renal clearance of unbound  anagliptin  and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that  anagliptin  may be a substrate of  OAT1   OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.", "triple_list": [["anagliptin", "PRODUCT-OF", "OAT1"]]}, {"text": "Renal clearance of unbound  anagliptin  and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that  anagliptin  may be a substrate of OAT1,  OAT3   MDR1 and MRP2, and M1 a substrate of  OAT3 , BCRP, MRP2 and MRP4.", "triple_list": [["anagliptin", "PRODUCT-OF", "OAT3"]]}, {"text": "Renal clearance of unbound  anagliptin  and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that  anagliptin  may be a substrate of OAT1, OAT3,  MDR1  and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.", "triple_list": [["anagliptin", "PRODUCT-OF", "MDR1"]]}, {"text": "Renal clearance of unbound  anagliptin  and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that  anagliptin  may be a substrate of OAT1, OAT3, MDR1 and  MRP2   and M1 a substrate of OAT3, BCRP,  MRP2  and MRP4.", "triple_list": [["anagliptin", "PRODUCT-OF", "MRP2"]]}, {"text": "Antiretroviral  protease  inhibitors  lopinavir  (LPV) and ritonavir (RTV) are reported BSEP inhibitors", "triple_list": [["lopinavir", "DOWNREGULATOR", "protease"]]}, {"text": "Antiretroviral protease inhibitors  lopinavir  (LPV) and ritonavir (RTV) are reported  BSEP  inhibitors", "triple_list": [["lopinavir", "DOWNREGULATOR", "BSEP"]]}, {"text": "Antiretroviral  protease  inhibitors lopinavir ( LPV   and ritonavir (RTV) are reported BSEP inhibitors", "triple_list": [["LPV", "DOWNREGULATOR", "protease"]]}, {"text": "Antiretroviral protease inhibitors lopinavir ( LPV   and ritonavir (RTV) are reported  BSEP  inhibitors", "triple_list": [["LPV", "DOWNREGULATOR", "BSEP"]]}, {"text": "Antiretroviral  protease  inhibitors lopinavir (LPV) and  ritonavir  (RTV) are reported BSEP inhibitors", "triple_list": [["ritonavir", "DOWNREGULATOR", "protease"]]}, {"text": "Antiretroviral protease inhibitors lopinavir (LPV) and  ritonavir  (RTV) are reported  BSEP  inhibitors", "triple_list": [["ritonavir", "DOWNREGULATOR", "BSEP"]]}, {"text": "Antiretroviral  protease  inhibitors lopinavir (LPV) and ritonavir ( RTV   are reported BSEP inhibitors", "triple_list": [["RTV", "DOWNREGULATOR", "protease"]]}, {"text": "Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir ( RTV   are reported  BSEP  inhibitors", "triple_list": [["RTV", "DOWNREGULATOR", "BSEP"]]}, {"text": " GHRP-6  is a  growth hormone  secretagogue that also enhances tissue viability in different organs", "triple_list": [["GHRP-6", "ACTIVATOR", "growth hormone"]]}, {"text": "The altered activities of key enzymes such as  glucose-6-phosphatase  and fructose-1,6-bisphosphatase of  carbohydrate  metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)", "triple_list": [["carbohydrate", "PRODUCT-OF", "glucose-6-phosphatase"]]}, {"text": "The altered activities of key enzymes such as glucose-6-phosphatase and  fructose-1,6-bisphosphatase  of  carbohydrate  metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)", "triple_list": [["carbohydrate", "PRODUCT-OF", "fructose-1,6-bisphosphatase"]]}, {"text": " Ibandronate  increases the expression of the pro-apoptotic gene  FAS  by epigenetic mechanisms in tumor cells", "triple_list": [["Ibandronate", "ACTIVATOR", "FAS"]]}, {"text": "Data suggest that  bisphosphonates  via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of  FAS  expression", "triple_list": [["bisphosphonates", "ACTIVATOR", "FAS"]]}, {"text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of  DNMT1   which was rescued by re-isoprenylation by both  geranylgeranyl-pyrophosphate  and farnesylpyrophosphate", "triple_list": [["geranylgeranyl-pyrophosphate", "ACTIVATOR", "DNMT1"]]}, {"text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of  DNMT1   which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and  farnesylpyrophosphate   In contrast, ibandronate did not affect FAS and  DNMT1  expression in MC3T3-E1 non-neoplastic cells", "triple_list": [["farnesylpyrophosphate", "ACTIVATOR", "DNMT1"]]}, {"text": "The AhR target gene  CYP1A1  mRNA expression was induced by  TCDD   but was not affected by the AR CAG length", "triple_list": [["TCDD", "ACTIVATOR", "CYP1A1"]]}, {"text": " TCDD  had no effect on  AR  activity in PC-3 cells, whereas the shortest  AR  variant was induced by  TCDD  in PNT1A cells", "triple_list": [["TCDD", "ACTIVATOR", "AR"]]}, {"text": "Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several  cytokines  in mice and replacement of plasmid by  polyglutamate  reduced the elevation of all assayed  cytokines   In order to enhance siRNA lipoplexes efficiency, the addition of  polyglutamate  as anionic polymer should be preferred to plasmid DNA as far as in vitro as well as in vivo toxicity is concerned.", "triple_list": [["polyglutamate", "DOWNREGULATOR", "cytokines"]]}, {"text": "We found that  helenalin  markedly induced endoplasmic reticulum (ER) stress-related genes, such as  regulated in development and DNA damage responses (REDD) 1   activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP)", "triple_list": [["helenalin", "ACTIVATOR", "regulated in development and DNA damage responses (REDD) 1"]]}, {"text": "We found that  helenalin  markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1,  activating transcription factor-4  (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP)", "triple_list": [["helenalin", "ACTIVATOR", "activating transcription factor-4"]]}, {"text": "We found that  helenalin  markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 ( ATF4   and/or the CCAAT enhancer-binding protein-homologous protein (CHOP)", "triple_list": [["helenalin", "ACTIVATOR", "ATF4"]]}, {"text": "We found that  helenalin  markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the  CCAAT enhancer-binding protein-homologous protein  (CHOP)", "triple_list": [["helenalin", "ACTIVATOR", "CCAAT enhancer-binding protein-homologous protein"]]}, {"text": "We found that  helenalin  markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein ( CHOP  ", "triple_list": [["helenalin", "ACTIVATOR", "CHOP"]]}, {"text": "In conclusion,  rCtr1  can transport copper and  platinum  drugs, and sensitizes cells to their cytotoxicities", "triple_list": [["platinum", "PRODUCT-OF", "rCtr1"]]}, {"text": "DRG neurons display substantial capacity for accumulating  copper  via a transport process mediated by  rCtr1   but appear able to resist  copper  toxicity and use alternative mechanisms to take up oxaliplatin.", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "DRG neurons display substantial capacity for accumulating copper via a transport process mediated by  rCtr1   but appear able to resist copper toxicity and use alternative mechanisms to take up  oxaliplatin  ", "triple_list": [["oxaliplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of  copper   oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of  copper   oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper,  oxaliplatin   cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["oxaliplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper,  oxaliplatin   cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["oxaliplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper, oxaliplatin,  cisplatin  and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["cisplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper, oxaliplatin,  cisplatin  and carboplatin, in comparison to isogenic vector-transfected control cells", "triple_list": [["cisplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and  carboplatin   in comparison to isogenic vector-transfected control cells", "triple_list": [["carboplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Heterologous expression of  rCtr1  in HEK293 cells (HEK/ rCtr1  cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and  carboplatin   in comparison to isogenic vector-transfected control cells", "triple_list": [["carboplatin", "PRODUCT-OF", "rCtr1"]]}, {"text": "Cultured rat DRG neurons endogenously expressed  rCtr1  protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up  copper   but were resistant to  copper  toxicity", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "The uptake of  copper  by both cultured rat DRG neurons and HEK/ rCtr1  cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by  rCtr1 ", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "Contributions of  rat Ctr1  to the uptake and toxicity of  copper  and platinum anticancer drugs in dorsal root ganglion neurons", "triple_list": [["copper", "PRODUCT-OF", "rat Ctr1"]]}, {"text": "Contributions of  rat Ctr1  to the uptake and toxicity of copper and  platinum  anticancer drugs in dorsal root ganglion neurons", "triple_list": [["platinum", "PRODUCT-OF", "rat Ctr1"]]}, {"text": "In conclusion,  rCtr1  can transport  copper  and platinum drugs, and sensitizes cells to their cytotoxicities", "triple_list": [["copper", "PRODUCT-OF", "rCtr1"]]}, {"text": "In addition,  glucosamine  attenuated  p21  protein stability via the proteasomal proteolytic pathway, as well as inducing  p21  nuclear accumulation", "triple_list": [["glucosamine", "ACTIVATOR", "p21"]]}, {"text": "Altogether, our results suggest that a high dose of  glucosamine  may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of  p21 , p53 and HO-1 expression, and nuclear  p21  accumulation.", "triple_list": [["glucosamine", "ACTIVATOR", "p21"]]}, {"text": " Glucosamine  at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of  p53  and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression", "triple_list": [["Glucosamine", "ACTIVATOR", "p53"]]}, {"text": " Glucosamine  at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and  heme oxygenase-1  (HO-1), but also caused a reduction in p21 protein expression", "triple_list": [["Glucosamine", "ACTIVATOR", "heme oxygenase-1"]]}, {"text": "In addition,  glucosamine  attenuated  p21  protein stability via the proteasomal proteolytic pathway, as well as inducing  p21  nuclear accumulation", "triple_list": [["glucosamine", "DOWNREGULATOR", "p21"]]}, {"text": "Altogether, our results suggest that a high dose of  glucosamine  may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in  Rb  phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.", "triple_list": [["glucosamine", "DOWNREGULATOR", "Rb"]]}, {"text": "Examination of phosphorylation in  retinoblastoma (Rb) protein   we found an inhibitory effect by  glucosamine  at 20 and 50\u00a0mM", "triple_list": [["glucosamine", "DOWNREGULATOR", "retinoblastoma (Rb) protein"]]}, {"text": " Glucosamine  at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in  p21  protein expression", "triple_list": [["Glucosamine", "DOWNREGULATOR", "p21"]]}, {"text": "Characterization of substituted  phenylpropylamides  as highly selective agonists at the  melatonin MT2 receptor   Melatonin is a widely distributed hormone that regulates several major physiological processes, including the circadian rhythm and seasonal adaptation", "triple_list": [["phenylpropylamides", "AGONIST", "melatonin MT2 receptor"]]}, {"text": "We show that the expression of  PIM-1  is induced in response to  estradiol  in MCF-7 cells and that the induction is mediated by ER\u03b1-regulated enhancers located distally upstream from the gene", "triple_list": [["estradiol", "ACTIVATOR", "PIM-1"]]}, {"text": "We show that the expression of PIM-1 is induced in response to  estradiol  in MCF-7 cells and that the induction is mediated by  ER\u03b1  regulated enhancers located distally upstream from the gene", "triple_list": [["estradiol", "ACTIVATOR", "ER\u03b1"]]}, {"text": "In this work, the metabolism of four frequently prescribed inhaled GCs,  triamcinolone acetonide   flunisolide, budesonide, and fluticasone propionate, by the  CYP3A  family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites", "triple_list": [["triamcinolone acetonide", "PRODUCT-OF", "CYP3A"]]}, {"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide,  flunisolide   budesonide, and fluticasone propionate, by the  CYP3A  family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites", "triple_list": [["flunisolide", "PRODUCT-OF", "CYP3A"]]}, {"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide,  budesonide   and fluticasone propionate, by the  CYP3A  family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites", "triple_list": [["budesonide", "PRODUCT-OF", "CYP3A"]]}, {"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and  fluticasone propionate   by the  CYP3A  family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites", "triple_list": [["fluticasone propionate", "PRODUCT-OF", "CYP3A"]]}, {"text": " CYP3A5   which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize  triamcinolone acetonide   budesonide, and fluticasone propionate", "triple_list": [["triamcinolone acetonide", "PRODUCT-OF", "CYP3A5"]]}, {"text": " CYP3A5   which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide,  budesonide   and fluticasone propionate", "triple_list": [["budesonide", "PRODUCT-OF", "CYP3A5"]]}, {"text": " CYP3A5   which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and  fluticasone propionate   In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by  CYP3A5  or CYP3A7", "triple_list": [["fluticasone propionate", "PRODUCT-OF", "CYP3A5"]]}, {"text": "In contrast,  flunisolide  was only metabolized via  CYP3A4   with no significant turnover by CYP3A5 or CYP3A7", "triple_list": [["flunisolide", "PRODUCT-OF", "CYP3A4"]]}, {"text": "Distinct roles of  methamphetamine  in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of  ERK  and CREB activation in hippocampus and prefrontal cortex", "triple_list": [["methamphetamine", "ACTIVATOR", "ERK"]]}, {"text": "Distinct roles of  methamphetamine  in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and  CREB  activation in hippocampus and prefrontal cortex", "triple_list": [["methamphetamine", "ACTIVATOR", "CREB"]]}, {"text": "In contrast, activation of both  ERK  and CREB in the PFC was found following memory retrieval but not other processes in  METH  treated mouse groups", "triple_list": [["METH", "ACTIVATOR", "ERK"]]}, {"text": "In contrast, activation of both ERK and  CREB  in the PFC was found following memory retrieval but not other processes in  METH  treated mouse groups", "triple_list": [["METH", "ACTIVATOR", "CREB"]]}, {"text": "Moreover, activation of the  ERK  and CREB signaling pathway in the hippocampus might be involved in  METH  induced spatial memory changes.", "triple_list": [["METH", "ACTIVATOR", "ERK"]]}, {"text": "Moreover, activation of the ERK and  CREB  signaling pathway in the hippocampus might be involved in  METH  induced spatial memory changes.", "triple_list": [["METH", "ACTIVATOR", "CREB"]]}, {"text": "A reporter construct driven by 4 kb of the  chicken ras-dva  5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by  corticosterone   Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1", "triple_list": [["corticosterone", "ACTIVATOR", "chicken ras-dva"]]}, {"text": "A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative  pituitary-specific transcription factor-1 (Pit-1) binding sites  and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by  corticosterone   Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1", "triple_list": [["corticosterone", "ACTIVATOR", "pituitary-specific transcription factor-1 (Pit-1) binding sites"]]}, {"text": "A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential  glucocorticoid receptor (GR) binding sites   was highly activated in embryonic pituitary cells and up-regulated by  corticosterone   Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1", "triple_list": [["corticosterone", "ACTIVATOR", "glucocorticoid receptor (GR) binding sites"]]}, {"text": "However, mutating putative  GR binding sites  did not substantially reduce induction of ras-dva promoter activity by  corticosterone   suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation", "triple_list": [["corticosterone", "ACTIVATOR", "GR binding sites"]]}, {"text": "However, mutating putative GR binding sites did not substantially reduce induction of  ras-dva promoter  activity by  corticosterone   suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation", "triple_list": [["corticosterone", "ACTIVATOR", "ras-dva promoter"]]}, {"text": "To investigate the role of  mGluR8  in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of  mGluR8 , AZ12216052 (AZ) and the  mGluR8  specific orthosteric agonist  (S)-3,4-dicarboxyphenylglycine  (DCPG)", "triple_list": [["(S)-3,4-dicarboxyphenylglycine", "AGONIST", "mGluR8"]]}, {"text": "To investigate the role of  mGluR8  in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of  mGluR8 , AZ12216052 (AZ) and the  mGluR8  specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine ( DCPG  ", "triple_list": [["DCPG", "AGONIST", "mGluR8"]]}, {"text": "Here, we compared the effects of a dimeric  PSD-95  inhibitor,  UCCB01-125   and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain", "triple_list": [["UCCB01-125", "DOWNREGULATOR", "PSD-95"]]}, {"text": "Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the  NMDAR  antagonist,  MK-801   on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain", "triple_list": [["MK-801", "ANTAGONIST", "NMDAR"]]}, {"text": "UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the  NMDA receptor  antagonist  MK-801   Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95)", "triple_list": [["MK-801", "ANTAGONIST", "NMDA receptor"]]}, {"text": "The treatment also prevented the high  cholesterol  diet-induced increase in serum  creatine kinase   total and isoforms, markers of neurological, cardiac and muscular damage", "triple_list": [["cholesterol", "ACTIVATOR", "creatine kinase"]]}, {"text": "GIP potentiates  glucose  stimulated  insulin  secretion and induces energy accumulation into adipose tissue, resulting in obesity", "triple_list": [["glucose", "ACTIVATOR", "insulin"]]}, {"text": "We concluded that in overweight and obese women with PCOS  Orlistat  administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum  AMH  levels.", "triple_list": [["Orlistat", "ACTIVATOR", "AMH"]]}, {"text": "Diet, physical exercise and  Orlistat  administration increase serum  Anti-M\u00fcllerian Hormone  (AMH) levels in women with polycystic ovary syndrome (PCOS)", "triple_list": [["Orlistat", "ACTIVATOR", "Anti-M\u00fcllerian Hormone"]]}, {"text": "Diet, physical exercise and  Orlistat  administration increase serum Anti-M\u00fcllerian Hormone ( AMH   levels in women with polycystic ovary syndrome (PCOS)", "triple_list": [["Orlistat", "ACTIVATOR", "AMH"]]}, {"text": "Moreover,  1,25(OH)(2)D(3)  decreased expression of  Oat1  and Oat3 in rat kidney", "triple_list": [["1,25(OH)(2)D(3)", "DOWNREGULATOR", "Oat1"]]}, {"text": "Moreover,  1,25(OH)(2)D(3)  decreased expression of Oat1 and  Oat3  in rat kidney", "triple_list": [["1,25(OH)(2)D(3)", "DOWNREGULATOR", "Oat3"]]}, {"text": "The mechanism of interaction between JBP485 and  1,25(OH)(2)D(3)  could be explained at least in part by inhibitory effect of  1,25(OH)(2)D(3)  on expression of  Oats  in rat kidney.", "triple_list": [["1,25(OH)(2)D(3)", "DOWNREGULATOR", "Oats"]]}, {"text": "These results demonstrated for the first time that  ISO  induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating  JNK  and p38 kinases, and ROS stimulated by  ISO  is able to activate the MAPK singaling pathway as the upstream signaling molecules", "triple_list": [["ISO", "ACTIVATOR", "JNK"]]}, {"text": "These results demonstrated for the first time that  ISO  induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and  p38  kinases, and ROS stimulated by  ISO  is able to activate the MAPK singaling pathway as the upstream signaling molecules", "triple_list": [["ISO", "ACTIVATOR", "p38"]]}, {"text": "These results demonstrated for the first time that  ISO  induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38  kinases   and ROS stimulated by  ISO  is able to activate the MAPK singaling pathway as the upstream signaling molecules", "triple_list": [["ISO", "ACTIVATOR", "kinases"]]}, {"text": "These results demonstrated for the first time that  ISO  induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by  ISO  is able to activate the  MAPK  singaling pathway as the upstream signaling molecules", "triple_list": [["ISO", "ACTIVATOR", "MAPK"]]}, {"text": " ISO  significantly inhibited the levels of ERK1/2 kinase and increased the expression of  JNK  and p38 kinases", "triple_list": [["ISO", "ACTIVATOR", "JNK"]]}, {"text": " ISO  significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and  p38  kinases", "triple_list": [["ISO", "ACTIVATOR", "p38"]]}, {"text": " ISO  significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38  kinases   Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the  ISO -induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3", "triple_list": [["ISO", "ACTIVATOR", "kinases"]]}, {"text": "Furthermore,  U0126  (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the  Bax  Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3", "triple_list": [["U0126", "ACTIVATOR", "Bax"]]}, {"text": "Furthermore,  U0126  (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/ Bcl-2  ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3", "triple_list": [["U0126", "ACTIVATOR", "Bcl-2"]]}, {"text": "Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the  ISO  induced the  Bax  Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3", "triple_list": [["ISO", "ACTIVATOR", "Bax"]]}, {"text": "Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the  ISO  induced the Bax/ Bcl-2  ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3", "triple_list": [["ISO", "ACTIVATOR", "Bcl-2"]]}, {"text": "While SP600125 (a  JNK  inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by  ISO   Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of  ISO  on the ERK1/2 kinase", "triple_list": [["ISO", "ACTIVATOR", "JNK"]]}, {"text": "While SP600125 (a JNK inhibitor) and SB203580 (a  p38  inhibitor) markedly prevented the expression of these proteins induced by  ISO   Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of  ISO  on the ERK1/2 kinase", "triple_list": [["ISO", "ACTIVATOR", "p38"]]}, {"text": " ISO  is able to induce apoptosis through mitochondrial dysfunction and inhibition of  PI3K  Akt signaling pathway in HepG2 cells, however, the effects of  ISO  on MAPK signaling pathways remain unknown", "triple_list": [["ISO", "DOWNREGULATOR", "PI3K"]]}, {"text": " ISO  is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/ Akt  signaling pathway in HepG2 cells, however, the effects of  ISO  on MAPK signaling pathways remain unknown", "triple_list": [["ISO", "DOWNREGULATOR", "Akt"]]}, {"text": "While  SP600125  (a  JNK  inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO", "triple_list": [["SP600125", "DOWNREGULATOR", "JNK"]]}, {"text": "While SP600125 (a JNK inhibitor) and  SB203580  (a  p38  inhibitor) markedly prevented the expression of these proteins induced by ISO", "triple_list": [["SB203580", "DOWNREGULATOR", "p38"]]}, {"text": " NAC  also suppressed the p- JNK  and p-p38, but failed to reverse the effects of ISO", "triple_list": [["NAC", "DOWNREGULATOR", "JNK"]]}, {"text": " NAC  also suppressed the p-JNK and  p-p38   but failed to reverse the effects of ISO", "triple_list": [["NAC", "DOWNREGULATOR", "p-p38"]]}, {"text": "Treatment with  IMG  and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of  thrombin  and FXa, and  IMG  or hyperoside inhibited production of  thrombin  and FXa in HUVECs", "triple_list": [["IMG", "ACTIVATOR", "thrombin"]]}, {"text": "Treatment with  IMG  and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of  thrombin  and FXa, and  IMG  or hyperoside inhibited production of  thrombin  and FXa in HUVECs", "triple_list": [["IMG", "DOWNREGULATOR", "thrombin"]]}, {"text": "Treatment with  IMG  and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and  FXa   and  IMG  or hyperoside inhibited production of thrombin and  FXa  in HUVECs", "triple_list": [["IMG", "DOWNREGULATOR", "FXa"]]}, {"text": "Treatment with IMG and  hyperoside  resulted in significantly prolonged aPTT and PT and inhibition of the activities of  thrombin  and FXa, and IMG or  hyperoside  inhibited production of  thrombin  and FXa in HUVECs", "triple_list": [["hyperoside", "DOWNREGULATOR", "thrombin"]]}, {"text": "Treatment with IMG and  hyperoside  resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and  FXa   and IMG or  hyperoside  inhibited production of thrombin and  FXa  in HUVECs", "triple_list": [["hyperoside", "DOWNREGULATOR", "FXa"]]}, {"text": "Treatment with  IMG  and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and  FXa , and  IMG  or hyperoside inhibited production of thrombin and  FXa  in HUVECs", "triple_list": [["IMG", "DOWNREGULATOR", "FXa"]]}, {"text": "Treatment with IMG and  hyperoside  resulted in significantly prolonged aPTT and PT and inhibition of the activities of  thrombin  and FXa, and IMG or  hyperoside  inhibited production of  thrombin  and FXa in HUVECs", "triple_list": [["hyperoside", "DOWNREGULATOR", "thrombin"]]}, {"text": "Treatment with IMG and  hyperoside  resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and  FXa , and IMG or  hyperoside  inhibited production of thrombin and  FXa  in HUVECs", "triple_list": [["hyperoside", "DOWNREGULATOR", "FXa"]]}, {"text": "In addition, treatment with  IMG  and hyperoside resulted in inhibition of  TNF-\u03b1  induced production of PAI-1, and treatment with  IMG  resulted in significant reduction of the PAI-1 to t-PA ratio", "triple_list": [["IMG", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": "In addition, treatment with  IMG  and hyperoside resulted in inhibition of TNF-\u03b1-induced production of  PAI-1   and treatment with  IMG  resulted in significant reduction of the  PAI-1  to t-PA ratio", "triple_list": [["IMG", "DOWNREGULATOR", "PAI-1"]]}, {"text": "In addition, treatment with IMG and  hyperoside  resulted in inhibition of  TNF-\u03b1  induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio", "triple_list": [["hyperoside", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": "In addition, treatment with IMG and  hyperoside  resulted in inhibition of TNF-\u03b1-induced production of  PAI-1   and treatment with IMG resulted in significant reduction of the  PAI-1  to t-PA ratio", "triple_list": [["hyperoside", "DOWNREGULATOR", "PAI-1"]]}, {"text": "In addition, treatment with  IMG  and hyperoside resulted in inhibition of TNF-\u03b1-induced production of  PAI-1 , and treatment with  IMG  resulted in significant reduction of the  PAI-1  to t-PA ratio", "triple_list": [["IMG", "DOWNREGULATOR", "PAI-1"]]}, {"text": "In addition, treatment with  IMG  and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with  IMG  resulted in significant reduction of the PAI-1 to  t-PA  ratio", "triple_list": [["IMG", "DOWNREGULATOR", "t-PA"]]}, {"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ( JMC08-4   for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and  human leukotriene A(4) hydrolase  (LTA(4)H-h) was found", "triple_list": [["JMC08-4", "DOWNREGULATOR", "human leukotriene A(4) hydrolase"]]}, {"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ( JMC08-4   for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase ( LTA(4)H-h   was found", "triple_list": [["JMC08-4", "DOWNREGULATOR", "LTA(4)H-h"]]}, {"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ( JMC08-4   for  human nonpancreatic secretory phospholipase A(2)  (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found", "triple_list": [["JMC08-4", "DOWNREGULATOR", "human nonpancreatic secretory phospholipase A(2)"]]}, {"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ( JMC08-4   for human nonpancreatic secretory phospholipase A(2) ( hnps-PLA(2)   and human leukotriene A(4) hydrolase (LTA(4)H-h) was found", "triple_list": [["JMC08-4", "DOWNREGULATOR", "hnps-PLA(2)"]]}, {"text": "Optimization of  5-hydroxytryptamines  as dual function inhibitors targeting  phospholipase A2  and leukotriene A4 hydrolase", "triple_list": [["5-hydroxytryptamines", "DOWNREGULATOR", "phospholipase A2"]]}, {"text": "Optimization of  5-hydroxytryptamines  as dual function inhibitors targeting phospholipase A2 and  leukotriene A4 hydrolase   Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs", "triple_list": [["5-hydroxytryptamines", "DOWNREGULATOR", "leukotriene A4 hydrolase"]]}, {"text": "Dual function inhibitors targeting phospholipase A(2) ( PLA(2)   and leukotriene A(4) hydrolase (LTA(4)H) may balance the  arachidonic acid  (AA) metabolic network and be used as new anti-inflammatory drugs", "triple_list": [["arachidonic acid", "PRODUCT-OF", "PLA(2)"]]}, {"text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and  leukotriene A(4) hydrolase  (LTA(4)H) may balance the  arachidonic acid  (AA) metabolic network and be used as new anti-inflammatory drugs", "triple_list": [["arachidonic acid", "PRODUCT-OF", "leukotriene A(4) hydrolase"]]}, {"text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase ( LTA(4)H   may balance the  arachidonic acid  (AA) metabolic network and be used as new anti-inflammatory drugs", "triple_list": [["arachidonic acid", "PRODUCT-OF", "LTA(4)H"]]}, {"text": "Dual function inhibitors targeting  phospholipase A(2)  (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the  arachidonic acid  (AA) metabolic network and be used as new anti-inflammatory drugs", "triple_list": [["arachidonic acid", "PRODUCT-OF", "phospholipase A(2)"]]}, {"text": "In addition, we provide evidence that  apomorphine  also acts on endogenous  TRPA1  in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of  TRPA1   Our study shows that human  TRPA1  is a target for  apomorphine , suggesting that an activation of  TRPA1  might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with  apomorphine .", "triple_list": [["apomorphine", "ACTIVATOR", "TRPA1"]]}, {"text": "Our study shows that human  TRPA1  is a target for  apomorphine   suggesting that an activation of  TRPA1  might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with  apomorphine .", "triple_list": [["apomorphine", "ACTIVATOR", "TRPA1"]]}, {"text": "Our study shows that human  TRPA1  is a target for  apomorphine , suggesting that an activation of  TRPA1  might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with  apomorphine  ", "triple_list": [["apomorphine", "ACTIVATOR", "TRPA1"]]}, {"text": "Whereas the addition of  apomorphine  in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed  TRPA1  channels, resulting from a reduction of single-channel open times", "triple_list": [["apomorphine", "DOWNREGULATOR", "TRPA1"]]}, {"text": "Dietary  carbohydrates  increase  SCD-1  gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways", "triple_list": [["carbohydrates", "ACTIVATOR", "SCD-1"]]}, {"text": "Previous report demonstrated that  thyroid hormone  (TH) negatively regulates  mouse SCD-1 gene promoter  before SREBP-1c was revealed", "triple_list": [["thyroid hormone", "DOWNREGULATOR", "mouse SCD-1 gene promoter"]]}, {"text": " Human stearoyl-CoA desaturase 1  (SCD-1) gene expression is negatively regulated by  thyroid hormone  without direct binding of  thyroid hormone  receptor to the gene promoter", "triple_list": [["thyroid hormone", "DOWNREGULATOR", "Human stearoyl-CoA desaturase 1"]]}, {"text": "Human stearoyl-CoA desaturase 1 ( SCD-1   gene expression is negatively regulated by  thyroid hormone  without direct binding of  thyroid hormone  receptor to the gene promoter", "triple_list": [["thyroid hormone", "DOWNREGULATOR", "SCD-1"]]}, {"text": "Finally, chronic administration of  metformin  in diabetic mice restored cardiac autophagy by activating  JNK1  Bcl-2 pathways and dissociating Beclin1 and Bcl-2", "triple_list": [["metformin", "ACTIVATOR", "JNK1"]]}, {"text": "Finally, chronic administration of  metformin  in diabetic mice restored cardiac autophagy by activating JNK1- Bcl-2  pathways and dissociating Beclin1 and  Bcl-2 ", "triple_list": [["metformin", "ACTIVATOR", "Bcl-2"]]}, {"text": "Exposure of H9c2 cells to high  glucose  reduced  AMPK  activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2", "triple_list": [["glucose", "DOWNREGULATOR", "AMPK"]]}, {"text": "Exposure of H9c2 cells to high  glucose  reduced AMPK activity, inhibited  Jun NH2-terminal kinase 1  (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2", "triple_list": [["glucose", "DOWNREGULATOR", "Jun NH2-terminal kinase 1"]]}, {"text": "Exposure of H9c2 cells to high  glucose  reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 ( JNK1  -B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2", "triple_list": [["glucose", "DOWNREGULATOR", "JNK1"]]}, {"text": "Exposure of H9c2 cells to high  glucose  reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)- B-cell lymphoma 2  (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2", "triple_list": [["glucose", "DOWNREGULATOR", "B-cell lymphoma 2"]]}, {"text": "Exposure of H9c2 cells to high  glucose  reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 ( Bcl-2   signaling, and promoted Beclin1 binding to  Bcl-2 ", "triple_list": [["glucose", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "In this current study,  paclitaxel  was found to increase phosphorylation of  mitogen-activated protein kinase  (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells", "triple_list": [["paclitaxel", "ACTIVATOR", "mitogen-activated protein kinase"]]}, {"text": "In this current study,  paclitaxel  was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)- p38  MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells", "triple_list": [["paclitaxel", "ACTIVATOR", "p38"]]}, {"text": "In this current study,  paclitaxel  was found to increase phosphorylation of mitogen-activated protein kinase ( MAPK ) kinase 3/6 (MKK3/6)-p38  MAPK  as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells", "triple_list": [["paclitaxel", "ACTIVATOR", "MAPK"]]}, {"text": "In this current study,  paclitaxel  was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of  ERCC1  in H1650 and H1703 cells", "triple_list": [["paclitaxel", "ACTIVATOR", "ERCC1"]]}, {"text": "Moreover,  paclitaxel  induced  ERCC1  protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)", "triple_list": [["paclitaxel", "ACTIVATOR", "ERCC1"]]}, {"text": "Furthermore, metformin was able to not only decrease the  paclitaxel  induced  p38  MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by  paclitaxel ", "triple_list": [["paclitaxel", "ACTIVATOR", "p38"]]}, {"text": "Furthermore, metformin was able to not only decrease the  paclitaxel  induced p38  MAPK  mediated ERCC1 expression, but also augment the cytotoxic effect induced by  paclitaxel ", "triple_list": [["paclitaxel", "ACTIVATOR", "MAPK"]]}, {"text": "Furthermore, metformin was able to not only decrease the  paclitaxel  induced p38 MAPK-mediated  ERCC1  expression, but also augment the cytotoxic effect induced by  paclitaxel ", "triple_list": [["paclitaxel", "ACTIVATOR", "ERCC1"]]}, {"text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of  p38  activity by either a  p38  MAPK inhibitor  SB202190  or  p38  knockdown with specific small interfering RNA (siRNA)", "triple_list": [["SB202190", "DOWNREGULATOR", "p38"]]}, {"text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of  p38  activity by either a  p38  MAPK inhibitor  SB202190  or  p38  knockdown with specific small interfering RNA (siRNA)", "triple_list": [["SB202190", "DOWNREGULATOR", "p38"]]}, {"text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38  MAPK  inhibitor  SB202190  or p38 knockdown with specific small interfering RNA (siRNA)", "triple_list": [["SB202190", "DOWNREGULATOR", "MAPK"]]}, {"text": " Metformin  mediated downregulation of  p38  mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel", "triple_list": [["Metformin", "DOWNREGULATOR", "p38"]]}, {"text": " Metformin  mediated downregulation of p38  mitogen-activated protein kinase  dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel", "triple_list": [["Metformin", "DOWNREGULATOR", "mitogen-activated protein kinase"]]}, {"text": "Furthermore,  metformin  was able to not only decrease the paclitaxel-induced  p38  MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel", "triple_list": [["metformin", "DOWNREGULATOR", "p38"]]}, {"text": "Furthermore,  metformin  was able to not only decrease the paclitaxel-induced p38  MAPK  mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel", "triple_list": [["metformin", "DOWNREGULATOR", "MAPK"]]}, {"text": "Furthermore,  metformin  was able to not only decrease the paclitaxel-induced p38 MAPK-mediated  ERCC1  expression, but also augment the cytotoxic effect induced by paclitaxel", "triple_list": [["metformin", "DOWNREGULATOR", "ERCC1"]]}, {"text": "Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate  ERCC1  downregulation by  metformin  and paclitaxel as well as cell viability and DNA repair capacity", "triple_list": [["metformin", "DOWNREGULATOR", "ERCC1"]]}, {"text": "Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate  ERCC1  downregulation by metformin and  paclitaxel  as well as cell viability and DNA repair capacity", "triple_list": [["paclitaxel", "DOWNREGULATOR", "ERCC1"]]}, {"text": "Overall, our results suggest that inhibition of the  p38  MAPK signaling by  metformin  coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.", "triple_list": [["metformin", "DOWNREGULATOR", "p38"]]}, {"text": "Overall, our results suggest that inhibition of the p38  MAPK  signaling by  metformin  coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.", "triple_list": [["metformin", "DOWNREGULATOR", "MAPK"]]}, {"text": "Contrary to the hypothesis,  orlistat  at 1 nM inhibited  CES2  activity by 75% but no inhibition on CES1, placing  CES2  one of the most sensitive targets of  orlistat   The inhibition varied among some  CES2  polymorphic variants", "triple_list": [["orlistat", "DOWNREGULATOR", "CES2"]]}, {"text": "Contrary to the hypothesis,  orlistat  at 1 nM inhibited  CES2  activity by 75% but no inhibition on CES1, placing  CES2  one of the most sensitive targets of  orlistat   The inhibition varied among some  CES2  polymorphic variants", "triple_list": [["orlistat", "DOWNREGULATOR", "CES2"]]}, {"text": " Orlistat  has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal  lipases   These enzymes, like carboxylesterases (CESs), structurally belong to the \u03b1/\u03b2 hydrolase fold superfamily", "triple_list": [["Orlistat", "DOWNREGULATOR", "lipases"]]}, {"text": "Inhibition of this  carboxylesterase  probably presents a major source for altered therapeutic activity of these medicines if co-administered with  orlistat   In addition,  orlistat  has been linked to various types of organ toxicities, and this study provides an alternative target potentially involved in these toxicological responses.", "triple_list": [["orlistat", "DOWNREGULATOR", "carboxylesterase"]]}, {"text": "This study was designed to test the hypothesis that  orlistat  inhibits  CESs  with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity", "triple_list": [["orlistat", "DOWNREGULATOR", "CESs"]]}, {"text": "This study was designed to test the hypothesis that  orlistat  inhibits CESs with higher potency toward  CES1  than CES2, a carboxylesterase with little lipase activity", "triple_list": [["orlistat", "DOWNREGULATOR", "CES1"]]}, {"text": "This study was designed to test the hypothesis that  orlistat  inhibits CESs with higher potency toward CES1 than  CES2   a carboxylesterase with little lipase activity", "triple_list": [["orlistat", "DOWNREGULATOR", "CES2"]]}, {"text": "This study was designed to test the hypothesis that  orlistat  inhibits CESs with higher potency toward CES1 than CES2, a  carboxylesterase  with little lipase activity", "triple_list": [["orlistat", "DOWNREGULATOR", "carboxylesterase"]]}, {"text": "This study was designed to test the hypothesis that  orlistat  inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little  lipase  activity", "triple_list": [["orlistat", "DOWNREGULATOR", "lipase"]]}, {"text": "On stimulation by G(s), the activities of  ACs  can be further selectively modulated by other pathways to ensure precise control of intracellular  cAMP  responses to specific stimuli", "triple_list": [["cAMP", "PRODUCT-OF", "ACs"]]}, {"text": "Regulation of multiple  adenylyl cyclases  (AC) provides unique inputs to mediate the synthesis of  cAMP   a ubiquitous second messenger that controls many aspects of cellular function", "triple_list": [["cAMP", "PRODUCT-OF", "adenylyl cyclases"]]}, {"text": "Regulation of multiple adenylyl cyclases ( AC   provides unique inputs to mediate the synthesis of  cAMP   a ubiquitous second messenger that controls many aspects of cellular function", "triple_list": [["cAMP", "PRODUCT-OF", "AC"]]}, {"text": "We identified one compound,  E235  (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of  ATF4  in transformed cells", "triple_list": [["E235", "ACTIVATOR", "ATF4"]]}, {"text": "We identified one compound, E235  (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)   that activated the ISR and dose-dependently increased levels of  ATF4  in transformed cells", "triple_list": [["(N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)", "ACTIVATOR", "ATF4"]]}, {"text": " E235  also activated DNA damage response signaling, resulting in increased levels of Ser15- phosphorylated p53   \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although  E235  does not appear to cause physical DNA damage", "triple_list": [["E235", "ACTIVATOR", "phosphorylated p53"]]}, {"text": " E235  also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53,  \u03b3-H2AX   and phosphorylated checkpoint kinase 2 (Chk2), although  E235  does not appear to cause physical DNA damage", "triple_list": [["E235", "ACTIVATOR", "\u03b3-H2AX"]]}, {"text": " E235  also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and  phosphorylated checkpoint kinase 2  (Chk2), although  E235  does not appear to cause physical DNA damage", "triple_list": [["E235", "ACTIVATOR", "phosphorylated checkpoint kinase 2"]]}, {"text": " E235  also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 ( Chk2  , although  E235  does not appear to cause physical DNA damage", "triple_list": [["E235", "ACTIVATOR", "Chk2"]]}, {"text": "Cell culture studies demonstrated that  PKAA  is capable of delivering anti-TNF (tumor necrosis factor)-\u03b1 siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of  TNF-\u03b1   A mouse model of acetaminophen (APAP)-induced acute liver failure was used to evaluate in vivo siRNA delivery efficacy of  PKAA ", "triple_list": [["PKAA", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": " PKAA  anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the  ALT  (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice", "triple_list": [["PKAA", "DOWNREGULATOR", "ALT"]]}, {"text": " PKAA  anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT ( alanine transaminase   and the hepatic cellular damages in APAP-intoxicated mice", "triple_list": [["PKAA", "DOWNREGULATOR", "alanine transaminase"]]}, {"text": "Moreover, wogonin repressed  anisomycin  induced phosphorylation of  p38   cav-1 and vascular permeability", "triple_list": [["anisomycin", "ACTIVATOR", "p38"]]}, {"text": "Moreover, wogonin repressed  anisomycin  induced phosphorylation of p38,  cav-1  and vascular permeability", "triple_list": [["anisomycin", "ACTIVATOR", "cav-1"]]}, {"text": "These results suggested that wogonin could inhibit  H2O2  induced vascular permeability by downregulating the phosphorylation of  cav-1   and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.", "triple_list": [["H2O2", "ACTIVATOR", "cav-1"]]}, {"text": "Wogonin inhibits  H2O2  induced vascular permeability through suppressing the phosphorylation of  caveolin-1   Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity", "triple_list": [["H2O2", "ACTIVATOR", "caveolin-1"]]}, {"text": "We found that wogonin can suppress the  H2O2  stimulated  actin  remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231", "triple_list": [["H2O2", "ACTIVATOR", "actin"]]}, {"text": "We found that wogonin can suppress the  H2O2  stimulated actin remodeling and  albumin  uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231", "triple_list": [["H2O2", "ACTIVATOR", "albumin"]]}, {"text": "The mechanism revealed that wogonin inhibited  H2O2  induced phosphorylation of  caveolin-1  (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin", "triple_list": [["H2O2", "ACTIVATOR", "caveolin-1"]]}, {"text": "The mechanism revealed that wogonin inhibited  H2O2  induced phosphorylation of caveolin-1 ( cav-1   associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin", "triple_list": [["H2O2", "ACTIVATOR", "cav-1"]]}, {"text": "Moreover,  wogonin  repressed anisomycin-induced phosphorylation of  p38   cav-1 and vascular permeability", "triple_list": [["wogonin", "DOWNREGULATOR", "p38"]]}, {"text": "Moreover,  wogonin  repressed anisomycin-induced phosphorylation of p38,  cav-1  and vascular permeability", "triple_list": [["wogonin", "DOWNREGULATOR", "cav-1"]]}, {"text": "These results suggested that  wogonin  could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of  cav-1   and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.", "triple_list": [["wogonin", "DOWNREGULATOR", "cav-1"]]}, {"text": " Wogonin  inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of  caveolin-1    Wogonin , a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity", "triple_list": [["Wogonin", "DOWNREGULATOR", "caveolin-1"]]}, {"text": "We found that  wogonin  can suppress the H2O2-stimulated  actin  remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231", "triple_list": [["wogonin", "DOWNREGULATOR", "actin"]]}, {"text": "We found that  wogonin  can suppress the H2O2-stimulated actin remodeling and  albumin  uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231", "triple_list": [["wogonin", "DOWNREGULATOR", "albumin"]]}, {"text": "The mechanism revealed that  wogonin  inhibited H2O2-induced phosphorylation of  caveolin-1  (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin", "triple_list": [["wogonin", "DOWNREGULATOR", "caveolin-1"]]}, {"text": "The mechanism revealed that  wogonin  inhibited H2O2-induced phosphorylation of caveolin-1 ( cav-1   associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin", "triple_list": [["wogonin", "DOWNREGULATOR", "cav-1"]]}, {"text": "The mechanism revealed that  wogonin  inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of  VE-cadherin  and \u03b2-catenin", "triple_list": [["wogonin", "DOWNREGULATOR", "VE-cadherin"]]}, {"text": "The mechanism revealed that  wogonin  inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and  \u03b2-catenin   Moreover,  wogonin  repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability", "triple_list": [["wogonin", "DOWNREGULATOR", "\u03b2-catenin"]]}, {"text": "In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the  hERG  activity, conformational modifications of the core structure resulted in the identification of fused  oxadiazepines  such as 7i which had an improved  hERG  inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats", "triple_list": [["oxadiazepines", "DOWNREGULATOR", "hERG"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of  MAPK   Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "MAPK"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK,  Akt   and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "Akt"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and  p70S6K  and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "p70S6K"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors  survivin   Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "survivin"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin,  Bcl-2   and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and  X-linked inhibitor of apoptosis protein   These effects could be completely blocked by  BZA   Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)", "triple_list": [["BZA", "DOWNREGULATOR", "X-linked inhibitor of apoptosis protein"]]}, {"text": "The reduction of BiFC signal mediated by  nutlin-3  was correlated with an increase in  Puma  transactivation, PARP cleavage, and cell death", "triple_list": [["nutlin-3", "ACTIVATOR", "Puma"]]}, {"text": "The reduction of BiFC signal mediated by  nutlin-3  was correlated with an increase in Puma transactivation,  PARP  cleavage, and cell death", "triple_list": [["nutlin-3", "ACTIVATOR", "PARP"]]}, {"text": "We used  nutlin-3   a well-known disruptor of  p53  Mdm2 interaction, to validate the specificity of the assay", "triple_list": [["nutlin-3", "DOWNREGULATOR", "p53"]]}, {"text": "We used  nutlin-3   a well-known disruptor of p53- Mdm2  interaction, to validate the specificity of the assay", "triple_list": [["nutlin-3", "DOWNREGULATOR", "Mdm2"]]}, {"text": " Sal  toxicity coincided with reduced  pAkt  level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "pAkt"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors:  pCREB   pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "pCREB"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB,  pGSK-3\u03b2   Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "pGSK-3\u03b2"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2,  Bcl-2  and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "Bcl-2"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and  neurotrophins  GDNF, BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "neurotrophins"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins  GDNF   BDNF suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "GDNF"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF,  BDNF  suggesting repressed PI3K/Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "BDNF"]]}, {"text": " Sal  toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed  PI3K  Akt signaling", "triple_list": [["Sal", "DOWNREGULATOR", "PI3K"]]}, {"text": " Sal  toxicity coincided with reduced p Akt  level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/ Akt  signaling", "triple_list": [["Sal", "DOWNREGULATOR", "Akt"]]}, {"text": "This was confirmed on adding  LY294002  the  PI3K  inhibitor which abolished the protection", "triple_list": [["LY294002", "DOWNREGULATOR", "PI3K"]]}, {"text": " Isoproterenol  induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial  glutathione peroxidase   glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "glutathione peroxidase"]]}, {"text": " Isoproterenol  induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase,  glutathione reductase   reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "glutathione reductase"]]}, {"text": " Isoproterenol  induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and  NADH-dehydrogenases   cytochrome-C-oxidase and adenosine triphosphate", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "NADH-dehydrogenases"]]}, {"text": " Isoproterenol  induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases,  cytochrome-C-oxidase  and adenosine triphosphate", "triple_list": [["Isoproterenol", "DOWNREGULATOR", "cytochrome-C-oxidase"]]}, {"text": "Increased urinary excretion of  albumin   hemopexin, transferrin and VDBP correlates with chronic sensitization to  gentamicin  nephrotoxicity in rats", "triple_list": [["gentamicin", "ACTIVATOR", "albumin"]]}, {"text": "Increased urinary excretion of albumin,  hemopexin   transferrin and VDBP correlates with chronic sensitization to  gentamicin  nephrotoxicity in rats", "triple_list": [["gentamicin", "ACTIVATOR", "hemopexin"]]}, {"text": "Increased urinary excretion of albumin, hemopexin,  transferrin  and VDBP correlates with chronic sensitization to  gentamicin  nephrotoxicity in rats", "triple_list": [["gentamicin", "ACTIVATOR", "transferrin"]]}, {"text": "Increased urinary excretion of albumin, hemopexin, transferrin and  VDBP  correlates with chronic sensitization to  gentamicin  nephrotoxicity in rats", "triple_list": [["gentamicin", "ACTIVATOR", "VDBP"]]}, {"text": "Design and synthesis of novel  2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one  derivatives as  telomerase  inhibitors", "triple_list": [["2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one", "DOWNREGULATOR", "telomerase"]]}, {"text": " DPEP  inhibited LPS-induced phosphorylation of  ERK   JNK, and p38", "triple_list": [["DPEP", "DOWNREGULATOR", "ERK"]]}, {"text": " DPEP  inhibited LPS-induced phosphorylation of ERK,  JNK   and p38", "triple_list": [["DPEP", "DOWNREGULATOR", "JNK"]]}, {"text": " DPEP  inhibited LPS-induced phosphorylation of ERK, JNK, and  p38   Furthermore,  DPEP  inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50", "triple_list": [["DPEP", "DOWNREGULATOR", "p38"]]}, {"text": "Furthermore,  DPEP  inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB  p50   Taken together, the results of this study demonstrate that  DPEP  inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages.", "triple_list": [["DPEP", "DOWNREGULATOR", "p50"]]}, {"text": "Furthermore,  DPEP  inhibited the LPS-induced phosphorylation of  inhibitor \u03baB (I\u03baB)-\u03b1  and NF-\u03baB p50", "triple_list": [["DPEP", "DOWNREGULATOR", "inhibitor \u03baB (I\u03baB)-\u03b1"]]}, {"text": "Furthermore,  DPEP  inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and  NF-\u03baB  p50", "triple_list": [["DPEP", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "Taken together, the results of this study demonstrate that  DPEP  inhibits LPS-stimulated inflammation by blocking the  NF-\u03baB  and MAPK pathways in macrophages.", "triple_list": [["DPEP", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "Taken together, the results of this study demonstrate that  DPEP  inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and  MAPK  pathways in macrophages.", "triple_list": [["DPEP", "DOWNREGULATOR", "MAPK"]]}, {"text": " DPEP  induced dose-dependent reduction of the protein levels of  inducible nitric oxide synthase  (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))", "triple_list": [["DPEP", "DOWNREGULATOR", "inducible nitric oxide synthase"]]}, {"text": " DPEP  induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase ( iNOS   and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))", "triple_list": [["DPEP", "DOWNREGULATOR", "iNOS"]]}, {"text": " DPEP  induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and  cyclooxygenase-2  (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))", "triple_list": [["DPEP", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": " DPEP  induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 ( COX-2   and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))", "triple_list": [["DPEP", "DOWNREGULATOR", "COX-2"]]}, {"text": "Additionally,  DPEP  suppressed the production of inflammatory  cytokines   including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6", "triple_list": [["DPEP", "DOWNREGULATOR", "cytokines"]]}, {"text": "Additionally,  DPEP  suppressed the production of inflammatory cytokines, including  tumor necrosis factor-\u03b1  (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6", "triple_list": [["DPEP", "DOWNREGULATOR", "tumor necrosis factor-\u03b1"]]}, {"text": "Additionally,  DPEP  suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 ( TNF-\u03b1  , interleukin (IL)-1\u03b2, and IL-6", "triple_list": [["DPEP", "DOWNREGULATOR", "TNF-\u03b1"]]}, {"text": "Additionally,  DPEP  suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1),  interleukin (IL)-1\u03b2   and IL-6", "triple_list": [["DPEP", "DOWNREGULATOR", "interleukin (IL)-1\u03b2"]]}, {"text": "Additionally,  DPEP  suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and  IL-6   We investigated the mechanism by which  DPEP  inhibits NO and PGE(2) by examining the level of nuclear factor-\u03baB (NF-\u03baB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells", "triple_list": [["DPEP", "DOWNREGULATOR", "IL-6"]]}, {"text": "This leads to decreased expression of  glutamate  aspartate transporter  which in turn reduces  glutamate  transport", "triple_list": [["glutamate", "PRODUCT-OF", "glutamate aspartate transporter"]]}, {"text": " Tetrahydropyrroloquinolinone  type dual inhibitors of  aromatase  aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks", "triple_list": [["Tetrahydropyrroloquinolinone", "DOWNREGULATOR", "aromatase"]]}, {"text": " Tetrahydropyrroloquinolinone  type dual inhibitors of aromatase/ aldosterone synthase  as a novel strategy for breast cancer patients with elevated cardiovascular risks", "triple_list": [["Tetrahydropyrroloquinolinone", "DOWNREGULATOR", "aldosterone synthase"]]}, {"text": "Furthermore,  MDZ  caused mechanism-based inactivation of  cytochrome P450 3A  dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies", "triple_list": [["MDZ", "DOWNREGULATOR", "cytochrome P450 3A"]]}, {"text": "Furthermore, MDZ caused mechanism-based inactivation of  cytochrome P450 3A  dependent  TRZ  1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies", "triple_list": [["TRZ", "PRODUCT-OF", "cytochrome P450 3A"]]}, {"text": " Tamoxifen  represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating  c-Myc  in endometrial carcinoma cell lines", "triple_list": [["Tamoxifen", "ACTIVATOR", "c-Myc"]]}, {"text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as  Snail  and N-cadherin increased, whereas E-cadherin decreased in the  TAM  treated cells, contributing to  TAM -induced EMT in these endometrial cancer cells", "triple_list": [["TAM", "ACTIVATOR", "Snail"]]}, {"text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and  N-cadherin  increased, whereas E-cadherin decreased in the  TAM  treated cells, contributing to  TAM -induced EMT in these endometrial cancer cells", "triple_list": [["TAM", "ACTIVATOR", "N-cadherin"]]}, {"text": "Collectively, our data suggest that  TAM  can repress the miR-200 family and induce EMT via the up-regulation of  c-Myc  in endometrial cancer cells", "triple_list": [["TAM", "ACTIVATOR", "c-Myc"]]}, {"text": " miR-200   a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to  TAM  treatment", "triple_list": [["TAM", "DOWNREGULATOR", "miR-200"]]}, {"text": " Tamoxifen  represses  miR-200  microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines", "triple_list": [["Tamoxifen", "DOWNREGULATOR", "miR-200"]]}, {"text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas  E-cadherin  decreased in the  TAM  treated cells, contributing to  TAM -induced EMT in these endometrial cancer cells", "triple_list": [["TAM", "DOWNREGULATOR", "E-cadherin"]]}, {"text": "In addition, we showed that c-Myc directly binds to and represses the promoter of  miR-200  miRNAs, and its up-regulation in  TAM  treated endometrial cancer cells leads to the down-regulation of  miR-200  and eventually to EMT", "triple_list": [["TAM", "DOWNREGULATOR", "miR-200"]]}, {"text": "Collectively, our data suggest that  TAM  can repress the  miR-200  family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells", "triple_list": [["TAM", "DOWNREGULATOR", "miR-200"]]}, {"text": "Here, we show that oral administration of  resveratrol   which leads to activation of an  NAD(+)-dependent protein deacetylase SIRT1   suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice", "triple_list": [["resveratrol", "ACTIVATOR", "NAD(+)-dependent protein deacetylase SIRT1"]]}, {"text": "The pro-hypertrophic co-activator  p300  protein but not  p300  mRNA was up-regulated in the mdx heart, and  resveratrol  administration down-regulated the  p300  protein level", "triple_list": [["resveratrol", "DOWNREGULATOR", "p300"]]}, {"text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as  resveratrol   both of which down-regulated  p300  protein levels but not  p300  mRNA levels", "triple_list": [["resveratrol", "DOWNREGULATOR", "p300"]]}, {"text": "We previously reported that caffeoyl-amino acidyl-hydroxamic acid ( CA-Xaa-NHOH   acted as both a good antioxidant and  tyrosinase  inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine", "triple_list": [["CA-Xaa-NHOH", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "In addition, derivatives of  caffeic acid  and sinapic acid efficiently inhibited  tyrosinase  activity and reduced melanin content in melanocytes Mel-Ab cell.", "triple_list": [["caffeic acid", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "In addition, derivatives of caffeic acid and  sinapic acid  efficiently inhibited  tyrosinase  activity and reduced melanin content in melanocytes Mel-Ab cell.", "triple_list": [["sinapic acid", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "Synthesis and dual biological effects of  hydroxycinnamoyl phenylalanyl  prolyl hydroxamic acid derivatives as  tyrosinase  inhibitor and antioxidant", "triple_list": [["hydroxycinnamoyl phenylalanyl", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/ prolyl hydroxamic acid  derivatives as  tyrosinase  inhibitor and antioxidant", "triple_list": [["prolyl hydroxamic acid", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "We previously reported that  caffeoyl-amino acidyl-hydroxamic acid  (CA-Xaa-NHOH) acted as both a good antioxidant and  tyrosinase  inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine", "triple_list": [["caffeoyl-amino acidyl-hydroxamic acid", "DOWNREGULATOR", "tyrosinase"]]}, {"text": " Ruxolitinib  is a small-molecule inhibitor\u00a0of  JAK1  and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis", "triple_list": [["Ruxolitinib", "DOWNREGULATOR", "JAK1"]]}, {"text": " Ruxolitinib  is a small-molecule inhibitor\u00a0of JAK1 and  JAK2  and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis", "triple_list": [["Ruxolitinib", "DOWNREGULATOR", "JAK2"]]}, {"text": " Pb  and BaP treatments significantly increased active  caspase-3  levels in a time-dependent manner", "triple_list": [["Pb", "ACTIVATOR", "caspase-3"]]}, {"text": "Pb and  BaP  treatments significantly increased active  caspase-3  levels in a time-dependent manner", "triple_list": [["BaP", "ACTIVATOR", "caspase-3"]]}, {"text": " TAA  increased the number and area of  glutathione S-transferase placental form  (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections", "triple_list": [["TAA", "ACTIVATOR", "glutathione S-transferase placental form"]]}, {"text": " TAA  increased the number and area of glutathione S-transferase placental form ( GST-P  (+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections", "triple_list": [["TAA", "ACTIVATOR", "GST-P"]]}, {"text": " TAA  also increased the numbers of ED2(+),  cyclooxygenase-2  +), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes", "triple_list": [["TAA", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": " TAA  also increased the numbers of ED2(+), cyclooxygenase-2(+), and  heme oxygenase-1  +) liver cells, as well as the number of CD3(+) lymphocytes", "triple_list": [["TAA", "DOWNREGULATOR", "heme oxygenase-1"]]}, {"text": " TAA  also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of  CD3  +) lymphocytes", "triple_list": [["TAA", "DOWNREGULATOR", "CD3"]]}, {"text": "Although  ICA  greatly attenuates  ERG  inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence", "triple_list": [["ICA", "ACTIVATOR", "ERG"]]}, {"text": " ICA-105574  interacts with a common binding site to elicit opposite effects on inactivation gating of  EAG  and ERG potassium channels", "triple_list": [["ICA-105574", "ACTIVATOR", "EAG"]]}, {"text": " ICA-105574  interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and  ERG  potassium channels", "triple_list": [["ICA-105574", "ACTIVATOR", "ERG"]]}, {"text": " ICA-105574  interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG  potassium channels   Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) K(+) channels", "triple_list": [["ICA-105574", "ACTIVATOR", "potassium channels"]]}, {"text": "Although  ICA  greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of  EAG  inactivation without altering its voltage dependence", "triple_list": [["ICA", "DOWNREGULATOR", "EAG"]]}, {"text": " ICA  is a mixed agonist of mutant  EAG  and  EAG /ERG chimera channels that inactivate by a combination of slow and fast mechanisms", "triple_list": [["ICA", "AGONIST", "EAG"]]}, {"text": " ICA  is a mixed agonist of mutant  EAG  and  EAG  ERG chimera channels that inactivate by a combination of slow and fast mechanisms", "triple_list": [["ICA", "AGONIST", "EAG"]]}, {"text": " ICA  is a mixed agonist of mutant EAG and EAG/ ERG  chimera channels that inactivate by a combination of slow and fast mechanisms", "triple_list": [["ICA", "AGONIST", "ERG"]]}, {"text": "PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10\u00a0mg/kg) that was significantly reduced by the  serotonin 5-HT1a receptor  antagonist  WAY-100135   However the \u03b17 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987", "triple_list": [["WAY-100135", "ANTAGONIST", "serotonin 5-HT1a receptor"]]}, {"text": "However the  \u03b17 receptor  antagonist  methyllycaconitine  was unable to reverse these anxiety-like effects seen with PNU-282987", "triple_list": [["methyllycaconitine", "ANTAGONIST", "\u03b17 receptor"]]}, {"text": " Carnitine palmitoyltransferase 2  and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of  acylcarnitines  ", "triple_list": [["acylcarnitines", "PRODUCT-OF", "Carnitine palmitoyltransferase 2"]]}, {"text": "Carnitine palmitoyltransferase 2 and  carnitine/acylcarnitine translocase  are involved in the mitochondrial synthesis and export of  acylcarnitines  ", "triple_list": [["acylcarnitines", "PRODUCT-OF", "carnitine/acylcarnitine translocase"]]}, {"text": " Carnitine palmitoyltransferase 2  and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of  acylcarnitines   Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)", "triple_list": [["acylcarnitines", "PRODUCT-OF", "Carnitine palmitoyltransferase 2"]]}, {"text": "Carnitine palmitoyltransferase 2 and  carnitine/acylcarnitine translocase  are involved in the mitochondrial synthesis and export of  acylcarnitines   Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)", "triple_list": [["acylcarnitines", "PRODUCT-OF", "carnitine/acylcarnitine translocase"]]}, {"text": "This shows that  CPT2  and CACT are crucial for mitochondrial  acylcarnitine  formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R", "triple_list": [["acylcarnitine", "PRODUCT-OF", "CPT2"]]}, {"text": "This shows that CPT2 and  CACT  are crucial for mitochondrial  acylcarnitine  formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R", "triple_list": [["acylcarnitine", "PRODUCT-OF", "CACT"]]}, {"text": "As a result of this study,  microgrewiapine A  (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit  nicotinic receptor  antagonistic activity for both the h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes.", "triple_list": [["microgrewiapine A", "ANTAGONIST", "nicotinic receptor"]]}, {"text": "PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual  orexin receptor  antagonist  almorexant   METHODS: Pharmacokinetic interactions were investigated (n\u2009=\u200914 healthy male subjects in two treatment groups) between  almorexant  at steady-state when administered either concomitantly or 2\u00a0h after administration of single doses of simvastatin (40\u00a0mg) or atorvastatin (40\u00a0mg)", "triple_list": [["almorexant", "ANTAGONIST", "orexin receptor"]]}, {"text": "In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the  DOI -elicited-HTR also reduced the efficacy of  DOI  to activate  mouse 5-HT2C  receptor-mediated PLC signaling in HEK cells", "triple_list": [["DOI", "ACTIVATOR", "mouse 5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists ( CP 809101   Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["CP 809101", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101,  Ro 60-0175   WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["Ro 60-0175", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175,  WAY 161503   mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["WAY 161503", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175, WAY 161503,  mCPP   and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["mCPP", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and  1-methylpsilocin  , novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["1-methylpsilocin", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a0 4-phenyl-2-N,N-dimethyl-aminotetralin  (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["4-phenyl-2-N,N-dimethyl-aminotetralin", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin ( PAT  -type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["PAT", "AGONIST", "5-HT2C"]]}, {"text": "Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with  5-HT2A /2B antagonist activity), and antagonists selective for  5-HT2A  ( M100907  , 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["M100907", "ANTAGONIST", "5-HT2A"]]}, {"text": "Commercially-available  5-HT2C  agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type  5-HT2C  agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907),  5-HT2C  ( SB-242084  , and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR", "triple_list": [["SB-242084", "ANTAGONIST", "5-HT2C"]]}, {"text": "This investigation tested the hypothesis that  CYP2B6  is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based  CYP2B6  inhibitor  ticlopidine   given orally for 4 days", "triple_list": [["ticlopidine", "DOWNREGULATOR", "CYP2B6"]]}, {"text": " Methadone  N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and  CYP3A4 , but clinical disposition is often attributed to  CYP3A4   This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days", "triple_list": [["Methadone", "PRODUCT-OF", "CYP3A4"]]}, {"text": " Methadone  N-demethylation in vitro is catalyzed by hepatic  cytochrome P4502B6  (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4", "triple_list": [["Methadone", "PRODUCT-OF", "cytochrome P4502B6"]]}, {"text": " Methadone  N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 ( CYP2B6   and CYP3A4, but clinical disposition is often attributed to CYP3A4", "triple_list": [["Methadone", "PRODUCT-OF", "CYP2B6"]]}, {"text": " Methadone  N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and  CYP3A4   but clinical disposition is often attributed to  CYP3A4 ", "triple_list": [["Methadone", "PRODUCT-OF", "CYP3A4"]]}, {"text": "Methadone  N  demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and  CYP3A4 , but clinical disposition is often attributed to  CYP3A4   This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone  N -demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days", "triple_list": [["N", "PRODUCT-OF", "CYP3A4"]]}, {"text": "Methadone  N  demethylation in vitro is catalyzed by hepatic  cytochrome P4502B6  (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4", "triple_list": [["N", "PRODUCT-OF", "cytochrome P4502B6"]]}, {"text": "Methadone  N  demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 ( CYP2B6   and CYP3A4, but clinical disposition is often attributed to CYP3A4", "triple_list": [["N", "PRODUCT-OF", "CYP2B6"]]}, {"text": "Methadone  N  demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and  CYP3A4   but clinical disposition is often attributed to  CYP3A4 ", "triple_list": [["N", "PRODUCT-OF", "CYP3A4"]]}, {"text": " CYP2B6  inhibition reduces  methadone  N-demethylation and clearance, and alters  methadone  concentrations, demonstrating an important role for  CYP2B6  in clinical  methadone  disposition.", "triple_list": [["methadone", "PRODUCT-OF", "CYP2B6"]]}, {"text": "This investigation tested the hypothesis that  CYP2B6  is a prominent CYP isoform responsible for clinical  methadone  N-demethylation and clearance, using the in vivo mechanism-based  CYP2B6  inhibitor ticlopidine, given orally for 4 days", "triple_list": [["methadone", "PRODUCT-OF", "CYP2B6"]]}, {"text": "This investigation tested the hypothesis that  CYP 2B6 is a prominent  CYP  isoform responsible for clinical  methadone  N-demethylation and clearance, using the in vivo mechanism-based  CYP 2B6 inhibitor ticlopidine, given orally for 4 days", "triple_list": [["methadone", "PRODUCT-OF", "CYP"]]}, {"text": "This investigation tested the hypothesis that  CYP2B6  is a prominent CYP isoform responsible for clinical methadone  N  demethylation and clearance, using the in vivo mechanism-based  CYP2B6  inhibitor ticlopidine, given orally for 4 days", "triple_list": [["N", "PRODUCT-OF", "CYP2B6"]]}, {"text": "This investigation tested the hypothesis that  CYP 2B6 is a prominent  CYP  isoform responsible for clinical methadone  N  demethylation and clearance, using the in vivo mechanism-based  CYP 2B6 inhibitor ticlopidine, given orally for 4 days", "triple_list": [["N", "PRODUCT-OF", "CYP"]]}, {"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist,  quinpirole   triggered an increase in the expression of  GDNF  that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene", "triple_list": [["quinpirole", "ACTIVATOR", "GDNF"]]}, {"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist,  quinpirole   triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of  zinc-finger protein 268  (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene", "triple_list": [["quinpirole", "ACTIVATOR", "zinc-finger protein 268"]]}, {"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist,  quinpirole   triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 ( Zif268  , a DNA-binding transcription factor encoded by an immediate-early gene", "triple_list": [["quinpirole", "ACTIVATOR", "Zif268"]]}, {"text": "Moreover, the  D2R  inhibitor  raclopride  blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells", "triple_list": [["raclopride", "DOWNREGULATOR", "D2R"]]}, {"text": "Moreover, the D2R inhibitor  raclopride  blocked the increase of both  GDNF  and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells", "triple_list": [["raclopride", "DOWNREGULATOR", "GDNF"]]}, {"text": "Moreover, the D2R inhibitor  raclopride  blocked the increase of both GDNF and  Zif268  expression following potassium-evoked dopamine release in SH-SY5Y cells", "triple_list": [["raclopride", "DOWNREGULATOR", "Zif268"]]}, {"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the  dopamine D2 receptor  (D2R) agonist,  quinpirole   triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene", "triple_list": [["quinpirole", "AGONIST", "dopamine D2 receptor"]]}, {"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor ( D2R   agonist,  quinpirole   triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene", "triple_list": [["quinpirole", "AGONIST", "D2R"]]}, {"text": "In this paper a series of new  1,3,4-thiadiazole  derivatives has been designed, synthesized and evaluated as the  acetyl- and butyrylcholinesterase  inhibitors", "triple_list": [["1,3,4-thiadiazole", "DOWNREGULATOR", "acetyl- and butyrylcholinesterase"]]}, {"text": "Synthesis and biological evaluation of  1,3,4-thiadiazole  analogues as novel  AChE  and BuChE inhibitors", "triple_list": [["1,3,4-thiadiazole", "DOWNREGULATOR", "AChE"]]}, {"text": "Synthesis and biological evaluation of  1,3,4-thiadiazole  analogues as novel AChE and  BuChE  inhibitors", "triple_list": [["1,3,4-thiadiazole", "DOWNREGULATOR", "BuChE"]]}, {"text": " LY294002   a specific PI3K/AKT inhibitor, selectively activated the  p38  MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "ACTIVATOR", "p38"]]}, {"text": " LY294002   a specific PI3K/AKT inhibitor, selectively activated the p38  MAPK  kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "ACTIVATOR", "MAPK"]]}, {"text": " LY294002   a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK  kinase  pathway and enhanced c-Jun phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "ACTIVATOR", "kinase"]]}, {"text": " LY294002   a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced  c-Jun  phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "ACTIVATOR", "c-Jun"]]}, {"text": " LY294002   a specific  PI3K  AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "DOWNREGULATOR", "PI3K"]]}, {"text": " LY294002   a specific PI3K/ AKT  inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK", "triple_list": [["LY294002", "DOWNREGULATOR", "AKT"]]}, {"text": "The pharmacological inhibitors  SB203580  ( p38  inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis", "triple_list": [["SB203580", "DOWNREGULATOR", "p38"]]}, {"text": "The pharmacological inhibitors SB203580 (p38 inhibitor) and  SP600125  (a  JNK  inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis", "triple_list": [["SP600125", "DOWNREGULATOR", "JNK"]]}, {"text": "Today, we used  cobalt chloride   a hypoxia mimetic that inhibits proteasomal  HIF-1  degradation and generates reactive oxygen species (ROS)", "triple_list": [["cobalt chloride", "ACTIVATOR", "HIF-1"]]}, {"text": "An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the  p53  mut) presence decreased with  CoCl2  time exposure", "triple_list": [["CoCl2", "DOWNREGULATOR", "p53"]]}, {"text": "Cellular responses to DNA damage induced by  etoposide  or doxorubicin include down-regulation of endogenous supervillin coincident with increases in  p53   In DNA-damaged supervillin knockdown cells,  p53  knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation", "triple_list": [["etoposide", "ACTIVATOR", "p53"]]}, {"text": "Cellular responses to DNA damage induced by etoposide or  doxorubicin  include down-regulation of endogenous supervillin coincident with increases in  p53   In DNA-damaged supervillin knockdown cells,  p53  knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation", "triple_list": [["doxorubicin", "ACTIVATOR", "p53"]]}, {"text": "Cellular responses to DNA damage induced by  etoposide  or doxorubicin include down-regulation of endogenous  supervillin  coincident with increases in p53", "triple_list": [["etoposide", "DOWNREGULATOR", "supervillin"]]}, {"text": "Cellular responses to DNA damage induced by etoposide or  doxorubicin  include down-regulation of endogenous  supervillin  coincident with increases in p53", "triple_list": [["doxorubicin", "DOWNREGULATOR", "supervillin"]]}, {"text": "Novel  acylethanolamide  derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin ( POMC   and/or decreased neuropeptide Y (NPY)", "triple_list": [["acylethanolamide", "ACTIVATOR", "POMC"]]}, {"text": "Novel  acylethanolamide  derivatives that modulate body weight through enhancement of hypothalamic  pro-opiomelanocortin  (POMC) and/or decreased neuropeptide Y (NPY)", "triple_list": [["acylethanolamide", "ACTIVATOR", "pro-opiomelanocortin"]]}, {"text": "Novel  acylethanolamide  derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased  neuropeptide Y  (NPY)", "triple_list": [["acylethanolamide", "DOWNREGULATOR", "neuropeptide Y"]]}, {"text": "Novel  acylethanolamide  derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y ( NPY  ", "triple_list": [["acylethanolamide", "DOWNREGULATOR", "NPY"]]}, {"text": " Dexamethasone  suppressed  IL-11  gene transcription enhanced by PTH(1-34) without affecting \u0394FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with \u0394FosB", "triple_list": [["Dexamethasone", "DOWNREGULATOR", "IL-11"]]}, {"text": "Number and area of preneoplastic foci positive for  glutathione S-transferase placental form  (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with  HEP  or HCB alone", "triple_list": [["HEP", "ACTIVATOR", "glutathione S-transferase placental form"]]}, {"text": "Number and area of preneoplastic foci positive for glutathione S-transferase placental form ( GST-P   were consistently higher in these groups than the sum of individual values in the groups treated with  HEP  or HCB alone", "triple_list": [["HEP", "ACTIVATOR", "GST-P"]]}, {"text": "Number and area of preneoplastic foci positive for  glutathione S-transferase placental form  (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or  HCB  alone", "triple_list": [["HCB", "ACTIVATOR", "glutathione S-transferase placental form"]]}, {"text": "Number and area of preneoplastic foci positive for glutathione S-transferase placental form ( GST-P   were consistently higher in these groups than the sum of individual values in the groups treated with HEP or  HCB  alone", "triple_list": [["HCB", "ACTIVATOR", "GST-P"]]}, {"text": "On the basis of these findings, we conclude that  HEP  and HCB have additive and synergistic effects on the development of  GST-P  positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.", "triple_list": [["HEP", "ACTIVATOR", "GST-P"]]}, {"text": "On the basis of these findings, we conclude that HEP and  HCB  have additive and synergistic effects on the development of  GST-P  positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.", "triple_list": [["HCB", "ACTIVATOR", "GST-P"]]}, {"text": "Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to  DON  lead to similar intestinal lesions and activation of  MAPK   These effects could impair the homeostasis of intestinal tissue in the aspects of barrier function and immune protection", "triple_list": [["DON", "ACTIVATOR", "MAPK"]]}, {"text": "The food contaminant  deoxynivalenol  activates the  mitogen activated protein kinases  in the intestine: interest of ex vivo models as an alternative to in vivo experiments", "triple_list": [["deoxynivalenol", "ACTIVATOR", "mitogen activated protein kinases"]]}, {"text": "In particular, we showed that  Paeoniflorin  significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and  superoxide dismutase  (SOD) in EA.hy926 cells", "triple_list": [["Paeoniflorin", "ACTIVATOR", "superoxide dismutase"]]}, {"text": "In particular, we showed that  Paeoniflorin  significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase ( SOD   in EA.hy926 cells", "triple_list": [["Paeoniflorin", "ACTIVATOR", "SOD"]]}, {"text": "Treatment of these cells with  Paeoniflorin  significantly induced  HO-1  expression", "triple_list": [["Paeoniflorin", "ACTIVATOR", "HO-1"]]}, {"text": " Paeoniflorin  protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the  NF-E2-related factor 2  heme oxygenase-1 pathway", "triple_list": [["Paeoniflorin", "ACTIVATOR", "NF-E2-related factor 2"]]}, {"text": " Paeoniflorin  protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/ heme oxygenase-1  pathway", "triple_list": [["Paeoniflorin", "ACTIVATOR", "heme oxygenase-1"]]}, {"text": "The  Paeoniflorin  induced  HO-1  expression was abrogated by Nrf2 siRNA", "triple_list": [["Paeoniflorin", "ACTIVATOR", "HO-1"]]}, {"text": "Furthermore, inhibition of  HO-1  with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of  Paeoniflorin  against radiation-induced damage in EA.hy926 cells", "triple_list": [["Paeoniflorin", "ACTIVATOR", "HO-1"]]}, {"text": "Our findings confirmed that  Paeoniflorin  protected EA.hy926 cells against radiation-induced injury through the  Nrf2  HO-1 pathway.", "triple_list": [["Paeoniflorin", "ACTIVATOR", "Nrf2"]]}, {"text": "Our findings confirmed that  Paeoniflorin  protected EA.hy926 cells against radiation-induced injury through the Nrf2/ HO-1  pathway.", "triple_list": [["Paeoniflorin", "ACTIVATOR", "HO-1"]]}, {"text": "In particular, we showed that  Paeoniflorin  significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and  lactate dehydrogenase  (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells", "triple_list": [["Paeoniflorin", "DOWNREGULATOR", "lactate dehydrogenase"]]}, {"text": "In particular, we showed that  Paeoniflorin  significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase ( LDH   leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells", "triple_list": [["Paeoniflorin", "DOWNREGULATOR", "LDH"]]}, {"text": "Furthermore, inhibition of  HO-1  with  zinc protoporphyrin IX  (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells", "triple_list": [["zinc protoporphyrin IX", "DOWNREGULATOR", "HO-1"]]}, {"text": "Furthermore, inhibition of  HO-1  with zinc protoporphyrin IX ( ZNPP   significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells", "triple_list": [["ZNPP", "DOWNREGULATOR", "HO-1"]]}, {"text": " Palonosetron   a second-generation  5-HT3  receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation  5-HT3  receptor antagonists appears to be the most effective agent in its class", "triple_list": [["Palonosetron", "ANTAGONIST", "5-HT3"]]}, {"text": " Aprepitant   the first and only agent clinically available in the  NK1 receptor  antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV", "triple_list": [["Aprepitant", "ANTAGONIST", "NK1 receptor"]]}, {"text": " Rolapitant  and netupitant are other  NK1 receptor  antagonists that are currently in phase III clinical trials", "triple_list": [["Rolapitant", "ANTAGONIST", "NK1 receptor"]]}, {"text": "Rolapitant and  netupitant  are other  NK1 receptor  antagonists that are currently in phase III clinical trials", "triple_list": [["netupitant", "ANTAGONIST", "NK1 receptor"]]}, {"text": "Moderate inhibitory effect of  LDL  C oxidation by  phytosteryl phenolates  was observed", "triple_list": [["phytosteryl phenolates", "DOWNREGULATOR", "LDL"]]}, {"text": "Aqueous  ethanol  (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting  15-LOX  (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.", "triple_list": [["ethanol", "DOWNREGULATOR", "15-LOX"]]}, {"text": "Aqueous  ethanol  (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate  COX-1  (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.", "triple_list": [["ethanol", "DOWNREGULATOR", "COX-1"]]}, {"text": "Aqueous  ethanol  (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and  COX-2  (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.", "triple_list": [["ethanol", "DOWNREGULATOR", "COX-2"]]}, {"text": "Aqueous  ethanol  (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate  COX -1 (IC(50), 66 \u03bcg/ml) and  COX -2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the  COX  pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.", "triple_list": [["ethanol", "DOWNREGULATOR", "COX"]]}, {"text": "Aqueous  ethanol  (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15- LOX  (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild  LOX  inhibitory activity.", "triple_list": [["ethanol", "DOWNREGULATOR", "LOX"]]}, {"text": "We searched for inhibitors of  HDC  from the  ethyl acetate  extract of the petal of Filipendula ulmaria, also called meadowsweet", "triple_list": [["ethyl acetate", "DOWNREGULATOR", "HDC"]]}, {"text": " Histidine decarboxylase  (HDC) catalyses the formation of hist amine , a bioactive  amine   Agents that control HDC activity are beneficial for treating hist amine -mediated symptoms, such as allergies and stomach ulceration", "triple_list": [["amine", "PRODUCT-OF", "Histidine decarboxylase"]]}, {"text": "Histidine decarboxylase ( HDC   catalyses the formation of hist amine , a bioactive  amine   Agents that control  HDC  activity are beneficial for treating hist amine -mediated symptoms, such as allergies and stomach ulceration", "triple_list": [["amine", "PRODUCT-OF", "HDC"]]}, {"text": " Histidine decarboxylase  (HDC) catalyses the formation of  histamine   a bioactive amine", "triple_list": [["histamine", "PRODUCT-OF", "Histidine decarboxylase"]]}, {"text": "Histidine decarboxylase ( HDC   catalyses the formation of  histamine   a bioactive amine", "triple_list": [["histamine", "PRODUCT-OF", "HDC"]]}, {"text": "High throughput screening led to the identification of a novel series of  quinolone  \u03b17 nicotinic acetylcholine receptor ( nAChR   agonists", "triple_list": [["quinolone", "AGONIST", "nAChR"]]}, {"text": "High throughput screening led to the identification of a novel series of  quinolone   \u03b17 nicotinic acetylcholine receptor  (nAChR) agonists", "triple_list": [["quinolone", "AGONIST", "\u03b17 nicotinic acetylcholine receptor"]]}, {"text": "Discovery of a novel series of  quinolone   \u03b17 nicotinic acetylcholine receptor  agonists", "triple_list": [["quinolone", "AGONIST", "\u03b17 nicotinic acetylcholine receptor"]]}, {"text": "This is distinct from  Rock  inhibitors based on non- amino acid  derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of  Rock , nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.", "triple_list": [["amino acid", "DOWNREGULATOR", "Rock"]]}, {"text": "This is distinct from Rock inhibitors based on non- amino acid  derived quinazolinones, where high selectivity against  PKA  could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.", "triple_list": [["amino acid", "DOWNREGULATOR", "PKA"]]}, {"text": "This is distinct from  Rock  inhibitors based on non-amino acid derived  quinazolinones   where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of  Rock , nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.", "triple_list": [["quinazolinones", "DOWNREGULATOR", "Rock"]]}, {"text": "This is distinct from Rock inhibitors based on non-amino acid derived  quinazolinones   where high selectivity against  PKA  could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.", "triple_list": [["quinazolinones", "DOWNREGULATOR", "PKA"]]}, {"text": "SAR and lead optimization studies for  Rock  inhibitors based on  amino acid  derived quinazolines are described", "triple_list": [["amino acid", "DOWNREGULATOR", "Rock"]]}, {"text": "SAR and lead optimization studies for  Rock  inhibitors based on amino acid-derived  quinazolines  are described", "triple_list": [["quinazolines", "DOWNREGULATOR", "Rock"]]}, {"text": " Amino acid  derived quinazolines as  Rock  PKA inhibitors", "triple_list": [["Amino acid", "DOWNREGULATOR", "Rock"]]}, {"text": " Amino acid  derived quinazolines as Rock/ PKA  inhibitors", "triple_list": [["Amino acid", "DOWNREGULATOR", "PKA"]]}, {"text": "Amino acid derived  quinazolines  as  Rock  PKA inhibitors", "triple_list": [["quinazolines", "DOWNREGULATOR", "Rock"]]}, {"text": "Amino acid derived  quinazolines  as Rock/ PKA  inhibitors", "triple_list": [["quinazolines", "DOWNREGULATOR", "PKA"]]}, {"text": "The  cyclooxygenase-2  inhibitor,  diflunisal   is used in the clinic for its anti-inflammatory activity", "triple_list": [["diflunisal", "DOWNREGULATOR", "cyclooxygenase-2"]]}, {"text": "Although there was no change in the levels of insulin receptor (IR),  Akt  (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA,  BPA  significantly decreased the IR,  Akt  and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle", "triple_list": [["BPA", "DOWNREGULATOR", "Akt"]]}, {"text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 ( GLUT4 ) messenger RNA,  BPA  significantly decreased the IR, Akt and  GLUT4  protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle", "triple_list": [["BPA", "DOWNREGULATOR", "GLUT4"]]}, {"text": "Although there was no change in the levels of insulin receptor ( IR ), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA,  BPA  significantly decreased the  IR   Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle", "triple_list": [["BPA", "DOWNREGULATOR", "IR"]]}, {"text": "In conclusion,  BPA  has adverse effects on phosphorylation of  Akt   GLUT4 translocation and (14)C-glucose oxidation.", "triple_list": [["BPA", "DOWNREGULATOR", "Akt"]]}, {"text": "In conclusion,  BPA  has adverse effects on phosphorylation of Akt,  GLUT4  translocation and (14)C-glucose oxidation.", "triple_list": [["BPA", "DOWNREGULATOR", "GLUT4"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone,  lactate dehydrogenase   acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "lactate dehydrogenase"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase,  acid phosphatase   alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "acid phosphatase"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase,  alkaline phosphatase  and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "alkaline phosphatase"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and  testicular steroidogenic enzymes   3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "testicular steroidogenic enzymes"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes:  3\u03b2-hydroxysteroid dehydrogenase  (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "3\u03b2-hydroxysteroid dehydrogenase"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase ( HSD  , 17\u03b2- HSD  activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "HSD"]]}, {"text": "The obtained results showed that  Cd  increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD),  17\u03b2-HSD  activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values", "triple_list": [["Cd", "DOWNREGULATOR", "17\u03b2-HSD"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase ( GST  )", "triple_list": [["Cd", "DOWNREGULATOR", "GST"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system ( superoxide dismutase  (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "superoxide dismutase"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase ( SOD  , catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "SOD"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD),  catalase  (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "catalase"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase ( CAT  , glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "CAT"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT),  glutathione peroxidase  (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "glutathione peroxidase"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase ( GSH-Px  , glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "GSH-Px"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px),  glutathione reductase  (GR), glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "glutathione reductase"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase ( GR  , glutathione (GSH), and glutathione-S-transferase (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "GR"]]}, {"text": "Acute intoxication with  Cd  was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and  glutathione-S-transferase  (GST))", "triple_list": [["Cd", "DOWNREGULATOR", "glutathione-S-transferase"]]}, {"text": " MeHg  significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10\u00b5M), revealing that  MeHg  increases  tyrosine hydroxylase  activity", "triple_list": [["MeHg", "ACTIVATOR", "tyrosine hydroxylase"]]}, {"text": "The  tyrosine hydroxylase  inhibitor  \u03b1-methyltyrosine  (300\u00b5M, 24h) completely abolished MeHg-induced DA release", "triple_list": [["\u03b1-methyltyrosine", "DOWNREGULATOR", "tyrosine hydroxylase"]]}, {"text": "The solubility-driven structural modification of (pyridin-3-yl)  benzoxazinyl-oxazolidinone s is described, which resulted in the development of a new series of  benzoxazinyl-oxazolidinone  analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low  hERG  inhibition", "triple_list": [["benzoxazinyl-oxazolidinone", "DOWNREGULATOR", "hERG"]]}, {"text": "Secondary point mutations in the Fms-like tyrosine kinase 3 ( FLT3 ) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the  FLT3  inhibitors  AC220  (quizartinib) and sorafenib", "triple_list": [["AC220", "DOWNREGULATOR", "FLT3"]]}, {"text": "Secondary point mutations in the Fms-like tyrosine kinase 3 ( FLT3 ) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the  FLT3  inhibitors AC220 ( quizartinib   and sorafenib", "triple_list": [["quizartinib", "DOWNREGULATOR", "FLT3"]]}, {"text": "Secondary point mutations in the Fms-like tyrosine kinase 3 ( FLT3 ) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the  FLT3  inhibitors AC220 (quizartinib) and  sorafenib   Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation", "triple_list": [["sorafenib", "DOWNREGULATOR", "FLT3"]]}, {"text": " Ponatinib  (AP24534) is a  multikinase  inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation", "triple_list": [["Ponatinib", "DOWNREGULATOR", "multikinase"]]}, {"text": "Ponatinib ( AP24534   is a  multikinase  inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation", "triple_list": [["AP24534", "DOWNREGULATOR", "multikinase"]]}, {"text": "However, the involvement of the  caspase -dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan caspase  inhibitor  z-VAD-fmk   Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.", "triple_list": [["z-VAD-fmk", "DOWNREGULATOR", "caspase"]]}, {"text": "Moreover, since reduced levels of  p21CIP1  and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after  BSC  3g or 3n treatment our results suggest that  BSC  treated cells die from lethal mitosis.", "triple_list": [["BSC", "DOWNREGULATOR", "p21CIP1"]]}, {"text": "Moreover, since reduced levels of p21CIP1 and  Chk2  proteins but no change in p53 levels could be detected in MCF-7 cells after  BSC  3g or 3n treatment our results suggest that  BSC  treated cells die from lethal mitosis.", "triple_list": [["BSC", "DOWNREGULATOR", "Chk2"]]}, {"text": "These compounds were evaluated for their acetylcholinesterase ( AChE ) inhibitory activity and  5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile  was found to be the most potent against  AChE  with IC50 4.16 \u03bcmol/L.", "triple_list": [["5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile", "DOWNREGULATOR", "AChE"]]}, {"text": "A one-pot domino synthesis and discovery of highly functionalized  dihydrobenzo[b]thiophenes  as  AChE  inhibitors", "triple_list": [["dihydrobenzo[b]thiophenes", "DOWNREGULATOR", "AChE"]]}, {"text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including  paclitaxel   doxorubicin, actinomycin-D, and rapamycin, which are also  P-gp  substrates", "triple_list": [["paclitaxel", "PRODUCT-OF", "P-gp"]]}, {"text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel,  doxorubicin   actinomycin-D, and rapamycin, which are also  P-gp  substrates", "triple_list": [["doxorubicin", "PRODUCT-OF", "P-gp"]]}, {"text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin,  actinomycin-D   and rapamycin, which are also  P-gp  substrates", "triple_list": [["actinomycin-D", "PRODUCT-OF", "P-gp"]]}, {"text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and  rapamycin   which are also  P-gp  substrates", "triple_list": [["rapamycin", "PRODUCT-OF", "P-gp"]]}, {"text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM- MMC  rats showed higher  quinone reductase  and depleted xanthine oxidase activities", "triple_list": [["MMC", "ACTIVATOR", "quinone reductase"]]}, {"text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM- MMC  rats showed higher quinone reductase and depleted  xanthine oxidase  activities", "triple_list": [["MMC", "DOWNREGULATOR", "xanthine oxidase"]]}, {"text": "Conclusively, protein malnutrition alters CP, FU and  MMC  metabolism in rat stomach by enhancing  CCBL  pathway for CP activation, delaying FU elimination and activating two-electron reduction of  MMC , potentiating their gastrotoxicity.", "triple_list": [["MMC", "PRODUCT-OF", "CCBL"]]}, {"text": "N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase ( JNK   inhibitor ( SP600125   33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg/ml) and 3.3% FCS", "triple_list": [["SP600125", "DOWNREGULATOR", "JNK"]]}, {"text": "N-acetylcysteine (NAC, 33 mM) and the  c-jun N-terminal kinase  (JNK) inhibitor ( SP600125   33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg/ml) and 3.3% FCS", "triple_list": [["SP600125", "DOWNREGULATOR", "c-jun N-terminal kinase"]]}, {"text": " HENA  activated the  BK (cbv1 + \u03b21) channels  cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA", "triple_list": [["HENA", "ACTIVATOR", "BK (cbv1 + \u03b21) channels"]]}, {"text": "HENA activated the  BK (cbv1 + \u03b21) channels  cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of  LCA   This HENA action was replicated on native channels in rat cerebral artery myocytes", "triple_list": [["LCA", "ACTIVATOR", "BK (cbv1 + \u03b21) channels"]]}, {"text": " HENA  failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets  \u03b21-containing BK channels  via the BK \u03b21 steroid-sensing site", "triple_list": [["HENA", "ACTIVATOR", "\u03b21-containing BK channels"]]}, {"text": "RATIONALE:  Histamine H3 receptor  antagonists, such as  ABT-288   have been shown to possess cognitive-enhancing and wakefulness-promoting effects", "triple_list": [["ABT-288", "ANTAGONIST", "Histamine H3 receptor"]]}, {"text": "Assessment of the abuse liability of  ABT-288   a novel  histamine H3 receptor  antagonist", "triple_list": [["ABT-288", "ANTAGONIST", "histamine H3 receptor"]]}, {"text": "CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to  H3  antagonists, indicates that  ABT-288  is unlikely to possess a high potential for abuse in the human population and suggests that  H3  antagonists, as a class, are similar in this regard.", "triple_list": [["ABT-288", "ANTAGONIST", "H3"]]}, {"text": "This methodology was subsequently used to assess the relative contribution of  OATP1B1  uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%),  pitavastatin  (84%-98%) and lopinavir (64%-89%)", "triple_list": [["pitavastatin", "PRODUCT-OF", "OATP1B1"]]}, {"text": "This methodology was subsequently used to assess the relative contribution of  OATP1B1  uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and  lopinavir  (64%-89%)", "triple_list": [["lopinavir", "PRODUCT-OF", "OATP1B1"]]}, {"text": "Uptake of  estrone-3-sulfate  (5\u2009nM) by  OATP1B1  was reduced by 82%-95%", "triple_list": [["estrone-3-sulfate", "PRODUCT-OF", "OATP1B1"]]}, {"text": "This methodology was subsequently used to assess the relative contribution of  OATP1B1  uptake in human hepatocytes for  olmesartan  (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)", "triple_list": [["olmesartan", "PRODUCT-OF", "OATP1B1"]]}, {"text": "This methodology was subsequently used to assess the relative contribution of  OATP1B1  uptake in human hepatocytes for olmesartan (42%-62%),  valsartan  (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)", "triple_list": [["valsartan", "PRODUCT-OF", "OATP1B1"]]}, {"text": "This methodology was subsequently used to assess the relative contribution of  OATP1B1  uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%),  rosuvastatin  (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)", "triple_list": [["rosuvastatin", "PRODUCT-OF", "OATP1B1"]]}, {"text": " l-glutamine  decreased plasma glucose, increased plasma and pancreatic  insulin   increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.", "triple_list": [["l-glutamine", "ACTIVATOR", "insulin"]]}, {"text": " l-glutamine  decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active  GLP-1  (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.", "triple_list": [["l-glutamine", "ACTIVATOR", "GLP-1"]]}, {"text": "The objective of the present investigation was to evaluate  l-glutamine  increases  glucagon like peptide-1  (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats", "triple_list": [["l-glutamine", "ACTIVATOR", "glucagon like peptide-1"]]}, {"text": "The objective of the present investigation was to evaluate  l-glutamine  increases glucagon like peptide-1 ( GLP-1   (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats", "triple_list": [["l-glutamine", "ACTIVATOR", "GLP-1"]]}, {"text": "Oral  l-glutamine  increases active  GLP-1  (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats", "triple_list": [["l-glutamine", "ACTIVATOR", "GLP-1"]]}, {"text": "In the present study,  hinokitiol  (1 and 2\u03bcM) inhibited the  collagen  induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP", "triple_list": [["hinokitiol", "DOWNREGULATOR", "collagen"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of  phospholipase C (PLC)\u03b32   protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "phospholipase C (PLC)\u03b32"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32,  protein kinase C  (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "protein kinase C"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C ( PKC  , mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "PKC"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC),  mitogen-activated protein kinases  (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "mitogen-activated protein kinases"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases ( MAPKs  , and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "MAPKs"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and  Akt  in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "Akt"]]}, {"text": " Hinokitiol  inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in  collagen  activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "collagen"]]}, {"text": " Hinokitiol  also reduced the  PKC  activation and platelet aggregation stimulated by PDBu", "triple_list": [["Hinokitiol", "DOWNREGULATOR", "PKC"]]}, {"text": "In conclusion,  hinokitiol  may inhibit platelet activation by inhibiting the  PLC\u03b32  PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt", "triple_list": [["hinokitiol", "DOWNREGULATOR", "PLC\u03b32"]]}, {"text": "In conclusion,  hinokitiol  may inhibit platelet activation by inhibiting the PLC\u03b32- PKC  cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt", "triple_list": [["hinokitiol", "DOWNREGULATOR", "PKC"]]}, {"text": "In conclusion,  hinokitiol  may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of  MAPKs  and Akt", "triple_list": [["hinokitiol", "DOWNREGULATOR", "MAPKs"]]}, {"text": "In conclusion,  hinokitiol  may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and  Akt   Our study suggests that  hinokitiol  may represent a potential therapeutic agent for the prevention or treatment of thromboembolic disorders.", "triple_list": [["hinokitiol", "DOWNREGULATOR", "Akt"]]}, {"text": "Novel  5-(benzyloxy)pyridin-2(1H)-one  derivatives as potent  c-Met  inhibitors", "triple_list": [["5-(benzyloxy)pyridin-2(1H)-one", "DOWNREGULATOR", "c-Met"]]}, {"text": "Design, Synthesis, and Pharmacological Characterization of Novel  Endomorphin-1  Analogues as Extremely Potent  \u03bc-Opioid  Agonists", "triple_list": [["Endomorphin-1", "AGONIST", "\u03bc-Opioid"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and  TNF\u03b1  levels) was seen in LPS-stimulated human PBMCs, except with  JWH-210  and JWH-122 which caused a decrease of  TNF\u03b1  and IL-12/23p40", "triple_list": [["JWH-210", "DOWNREGULATOR", "TNF\u03b1"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6,  IL-12 /23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with  JWH-210  and JWH-122 which caused a decrease of TNF\u03b1 and  IL-12  23p40", "triple_list": [["JWH-210", "DOWNREGULATOR", "IL-12"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/ 23p40  and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with  JWH-210  and JWH-122 which caused a decrease of TNF\u03b1 and IL-12/ 23p40   All toxic effects were observed with concentrations higher than those expected in body fluids of users", "triple_list": [["JWH-210", "DOWNREGULATOR", "23p40"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and  TNF\u03b1  levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and  JWH-122  which caused a decrease of  TNF\u03b1  and IL-12/23p40", "triple_list": [["JWH-122", "DOWNREGULATOR", "TNF\u03b1"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6,  IL-12 /23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and  JWH-122  which caused a decrease of TNF\u03b1 and  IL-12  23p40", "triple_list": [["JWH-122", "DOWNREGULATOR", "IL-12"]]}, {"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/ 23p40  and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and  JWH-122  which caused a decrease of TNF\u03b1 and IL-12/ 23p40   All toxic effects were observed with concentrations higher than those expected in body fluids of users", "triple_list": [["JWH-122", "DOWNREGULATOR", "23p40"]]}, {"text": "GTLE pretreatment completely reversed the damaging effects of  AlCl3  on AA and  superoxide dismutase  activity, markedly corrected COX and AChE activities, and moderately improved TGC", "triple_list": [["AlCl3", "DOWNREGULATOR", "superoxide dismutase"]]}, {"text": "GTLE pretreatment completely reversed the damaging effects of  AlCl3  on AA and superoxide dismutase activity, markedly corrected  COX  and AChE activities, and moderately improved TGC", "triple_list": [["AlCl3", "DOWNREGULATOR", "COX"]]}, {"text": "GTLE pretreatment completely reversed the damaging effects of  AlCl3  on AA and superoxide dismutase activity, markedly corrected COX and  AChE  activities, and moderately improved TGC", "triple_list": [["AlCl3", "DOWNREGULATOR", "AChE"]]}, {"text": " AlCl3  markedly reduced AA performance and activities of  cytochrome c oxidase  (COX) and acetylcholinesterase (AChE) in all regions", "triple_list": [["AlCl3", "DOWNREGULATOR", "cytochrome c oxidase"]]}, {"text": " AlCl3  markedly reduced AA performance and activities of cytochrome c oxidase ( COX   and acetylcholinesterase (AChE) in all regions", "triple_list": [["AlCl3", "DOWNREGULATOR", "COX"]]}, {"text": " AlCl3  markedly reduced AA performance and activities of cytochrome c oxidase (COX) and  acetylcholinesterase  (AChE) in all regions", "triple_list": [["AlCl3", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": " AlCl3  markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase ( AChE   in all regions", "triple_list": [["AlCl3", "DOWNREGULATOR", "AChE"]]}, {"text": "Our study demonstrated that  curcumin  inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased  IL-10  level in bronchoalveolar lavage fluid", "triple_list": [["curcumin", "ACTIVATOR", "IL-10"]]}, {"text": "Histological studies demonstrated that  curcumin  substantially inhibited  OVA  induced eosinophilia in lung tissue", "triple_list": [["curcumin", "DOWNREGULATOR", "OVA"]]}, {"text": "The results in vivo show  ovalbumin  induced significantly broke Treg/Th17 balance;  curcumin  treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance", "triple_list": [["curcumin", "DOWNREGULATOR", "ovalbumin"]]}, {"text": "Our study demonstrated that  curcumin  inhibited  OVA  induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid", "triple_list": [["curcumin", "DOWNREGULATOR", "OVA"]]}, {"text": "Our study demonstrated that  curcumin  inhibited OVA-induced increases in eosinophil count;  interleukin (IL)-17A  level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid", "triple_list": [["curcumin", "DOWNREGULATOR", "interleukin (IL)-17A"]]}, {"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a  Gd  based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used  proton pump  inhibitor that binds to  proton pump s in the stomach and colon", "triple_list": [["Gd", "DOWNREGULATOR", "proton pump"]]}, {"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent ( DOTA  , with pantoprazole, which is a widely used  proton pump  inhibitor that binds to  proton pump s in the stomach and colon", "triple_list": [["DOTA", "DOWNREGULATOR", "proton pump"]]}, {"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with  pantoprazole   which is a widely used  proton pump  inhibitor that binds to  proton pump s in the stomach and colon", "triple_list": [["pantoprazole", "DOWNREGULATOR", "proton pump"]]}, {"text": "Synthesis of a  DOTA  (Gd(3+))-conjugate of  proton-pump  inhibitor pantoprazole for gastric wall imaging studies", "triple_list": [["DOTA", "DOWNREGULATOR", "proton-pump"]]}, {"text": "Synthesis of a DOTA ( Gd(3+)  -conjugate of  proton-pump  inhibitor pantoprazole for gastric wall imaging studies", "triple_list": [["Gd(3+)", "DOWNREGULATOR", "proton-pump"]]}, {"text": "Synthesis of a DOTA (Gd(3+))-conjugate of  proton-pump  inhibitor  pantoprazole  for gastric wall imaging studies", "triple_list": [["pantoprazole", "DOWNREGULATOR", "proton-pump"]]}, {"text": "Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible  AChE  inhibitor  donepezil  (100nM)", "triple_list": [["donepezil", "DOWNREGULATOR", "AChE"]]}, {"text": " CYP3A5  carrier status had no influence on midazolam oral clearance or its inhibition by  ketoconazole   This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013", "triple_list": [["ketoconazole", "DOWNREGULATOR", "CYP3A5"]]}, {"text": "We then evaluated the interactions with the  CYP3A  inhibitor  ketoconazole  (400\u2009mg q.d.) after nanogram and regular doses of midazolam", "triple_list": [["ketoconazole", "DOWNREGULATOR", "CYP3A"]]}, {"text": "A Nanogram Dose of the  CYP3A  Probe Substrate  Midazolam  to Evaluate Drug Interactions", "triple_list": [["Midazolam", "PRODUCT-OF", "CYP3A"]]}, {"text": " CYP3A5  carrier status had no influence on  midazolam  oral clearance or its inhibition by ketoconazole", "triple_list": [["midazolam", "PRODUCT-OF", "CYP3A5"]]}, {"text": "These studies show that  CYP3A4  and CYP3A5 metabolize  BDP  to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence  BDP  disposition in humans.", "triple_list": [["BDP", "PRODUCT-OF", "CYP3A4"]]}, {"text": "These studies show that CYP3A4 and  CYP3A5  metabolize  BDP  to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence  BDP  disposition in humans.", "triple_list": [["BDP", "PRODUCT-OF", "CYP3A5"]]}, {"text": "It is possible that variations in  cytochrome P450 3A  enzyme-mediated metabolism of  BDP  may contribute to this phenomenon", "triple_list": [["BDP", "PRODUCT-OF", "cytochrome P450 3A"]]}, {"text": "This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and  esterase  enzymes in the metabolism of  BDP  in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells", "triple_list": [["BDP", "PRODUCT-OF", "esterase"]]}, {"text": " CYP3A4  and CYP3A5 metabolized  BDP  via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize  BDP ", "triple_list": [["BDP", "PRODUCT-OF", "CYP3A4"]]}, {"text": "CYP3A4 and  CYP3A5  metabolized  BDP  via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize  BDP ", "triple_list": [["BDP", "PRODUCT-OF", "CYP3A5"]]}, {"text": "Metabolism of  Beclomethasone Dipropionate  by  Cytochrome P450 3A  Enzymes", "triple_list": [["Beclomethasone Dipropionate", "PRODUCT-OF", "Cytochrome P450 3A"]]}, {"text": "In macrophages, levels of  TNF-\u03b1   IFN-\u03b3, NO, IL-6 and IL-10 were increased by  CDM  used alone or in combination with HSV-2", "triple_list": [["CDM", "ACTIVATOR", "TNF-\u03b1"]]}, {"text": "In macrophages, levels of TNF-\u03b1,  IFN-\u03b3   NO, IL-6 and IL-10 were increased by  CDM  used alone or in combination with HSV-2", "triple_list": [["CDM", "ACTIVATOR", "IFN-\u03b3"]]}, {"text": "In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO,  IL-6  and IL-10 were increased by  CDM  used alone or in combination with HSV-2", "triple_list": [["CDM", "ACTIVATOR", "IL-6"]]}, {"text": "In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and  IL-10  were increased by  CDM  used alone or in combination with HSV-2", "triple_list": [["CDM", "ACTIVATOR", "IL-10"]]}, {"text": "Besides,  CDM  not only synergized  TNF-\u03b1  production combined with IFN-\u03b3, but also prolonged its expression in time", "triple_list": [["CDM", "ACTIVATOR", "TNF-\u03b1"]]}, {"text": "Besides,  CDM  not only synergized TNF-\u03b1 production combined with  IFN-\u03b3   but also prolonged its expression in time", "triple_list": [["CDM", "ACTIVATOR", "IFN-\u03b3"]]}, {"text": "Results indicate that  CDM  inhibits HSV-2 multiplication in epithelial cells and also increases  cytokine  production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina", "triple_list": [["CDM", "ACTIVATOR", "cytokine"]]}, {"text": "A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an  11\u03b2-HSD1  inhibitor,  AMG 221   These data were integrated with standard in vivo metabolism studies to elucidate the components contributing to the oral disposition of a novel drug candidate", "triple_list": [["AMG 221", "DOWNREGULATOR", "11\u03b2-HSD1"]]}, {"text": "Intestinal and hepatic first-pass extraction of the  11\u03b2-HSD1  inhibitor  AMG 221  in rats with chronic vascular catheters", "triple_list": [["AMG 221", "DOWNREGULATOR", "11\u03b2-HSD1"]]}, {"text": "In DU-PM cells with acquired resistance to  elisidepsin   ErbB3 expression was decreased, while  Bcl2  was increased", "triple_list": [["elisidepsin", "ACTIVATOR", "Bcl2"]]}, {"text": "In DU-PM cells with acquired resistance to  elisidepsin    ErbB3  expression was decreased, while Bcl2 was increased", "triple_list": [["elisidepsin", "DOWNREGULATOR", "ErbB3"]]}, {"text": "Administration of  bicuculline   a  GABAA  inhibitor, isolated a single response to \u03c9-agatoxin, which was characterized by a reduction in network activity", "triple_list": [["bicuculline", "DOWNREGULATOR", "GABAA"]]}, {"text": "Administration of  bicuculline   a GABAA inhibitor, isolated a single response to  \u03c9-agatoxin   which was characterized by a reduction in network activity", "triple_list": [["bicuculline", "DOWNREGULATOR", "\u03c9-agatoxin"]]}, {"text": "Compounds 8\u2009b and 10\u2009c selectively inhibited HDAC6 at the nanomolar level, whereas the other  hydroxamates  effected an increase in  acetyl-\u03b1-tubulin  levels in human acute myeloid leukemia U937 cells", "triple_list": [["hydroxamates", "ACTIVATOR", "acetyl-\u03b1-tubulin"]]}, {"text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the  tert-butylcarbamate  group at the CAP moiety as  histone deacetylase  (HDAC) inhibitors", "triple_list": [["tert-butylcarbamate", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the  tert-butylcarbamate  group at the CAP moiety as histone deacetylase ( HDAC   inhibitors", "triple_list": [["tert-butylcarbamate", "DOWNREGULATOR", "HDAC"]]}, {"text": "Herein we report novel  pyrrole   and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as  histone deacetylase  (HDAC) inhibitors", "triple_list": [["pyrrole", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Herein we report novel  pyrrole   and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ( HDAC   inhibitors", "triple_list": [["pyrrole", "DOWNREGULATOR", "HDAC"]]}, {"text": "Herein we report novel pyrrole- and  benzene  based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as  histone deacetylase  (HDAC) inhibitors", "triple_list": [["benzene", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Herein we report novel pyrrole- and  benzene  based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ( HDAC   inhibitors", "triple_list": [["benzene", "DOWNREGULATOR", "HDAC"]]}, {"text": "Herein we report novel pyrrole- and benzene-based  hydroxamates  (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as  histone deacetylase  (HDAC) inhibitors", "triple_list": [["hydroxamates", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Herein we report novel pyrrole- and benzene-based  hydroxamates  (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ( HDAC   inhibitors", "triple_list": [["hydroxamates", "DOWNREGULATOR", "HDAC"]]}, {"text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and  2'-aminoanilides  (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as  histone deacetylase  (HDAC) inhibitors", "triple_list": [["2'-aminoanilides", "DOWNREGULATOR", "histone deacetylase"]]}, {"text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and  2'-aminoanilides  (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ( HDAC   inhibitors", "triple_list": [["2'-aminoanilides", "DOWNREGULATOR", "HDAC"]]}, {"text": " tert-Butylcarbamate  Containing  Histone Deacetylase  Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells", "triple_list": [["tert-Butylcarbamate", "DOWNREGULATOR", "Histone Deacetylase"]]}, {"text": "As a potent synthetic  APN  inhibitor (IC50=850nM, versus  bestatin  of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than  bestatin ", "triple_list": [["bestatin", "DOWNREGULATOR", "APN"]]}, {"text": "As a potent synthetic  APN  inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM),  LB-4b  was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin", "triple_list": [["LB-4b", "DOWNREGULATOR", "APN"]]}, {"text": "As a potent synthetic  APN  inhibitor (IC50=850nM, versus  bestatin  of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than  bestatin   Besides, it is able to be easily synthesized with a high total yield, while the reported synthetic methods of  bestatin  are much more complex.", "triple_list": [["bestatin", "DOWNREGULATOR", "APN"]]}, {"text": " LB-4b  is the first synthetic  APN  inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects", "triple_list": [["LB-4b", "DOWNREGULATOR", "APN"]]}, {"text": "Discovery of a synthetic  Aminopeptidase N  inhibitor  LB-4b  as a potential anticancer agent", "triple_list": [["LB-4b", "DOWNREGULATOR", "Aminopeptidase N"]]}, {"text": "Both types of granules contain  catechol oxidase  that catalyzes oxidative cross-linking of  L-DOPA   Co-secretion of  catechol oxidase  guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets", "triple_list": [["L-DOPA", "PRODUCT-OF", "catechol oxidase"]]}, {"text": "Under  NaCl  and sorbitol stresses,  catalase  (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively", "triple_list": [["NaCl", "ACTIVATOR", "catalase"]]}, {"text": "Under  NaCl  and sorbitol stresses, catalase ( CAT   activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively", "triple_list": [["NaCl", "ACTIVATOR", "CAT"]]}, {"text": "Under NaCl and  sorbitol  stresses,  catalase  (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively", "triple_list": [["sorbitol", "ACTIVATOR", "catalase"]]}, {"text": "Under NaCl and  sorbitol  stresses, catalase ( CAT   activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively", "triple_list": [["sorbitol", "ACTIVATOR", "CAT"]]}, {"text": "Immunofluorescence staining and western blotting demonstrated that  cilostazol  treatment reduced GFAP and  VEGF  expression in the retinas of OLETF rats", "triple_list": [["cilostazol", "DOWNREGULATOR", "VEGF"]]}, {"text": "Immunofluorescence staining and western blotting demonstrated that  cilostazol  treatment reduced  GFAP  and VEGF expression in the retinas of OLETF rats", "triple_list": [["cilostazol", "DOWNREGULATOR", "GFAP"]]}, {"text": "Other dams received 1.8ng/kg/day of a mixture of  aryl hydrocarbon receptor  (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and  PC-dibenzofurans   without or with 0.5M (0.5MAhR)", "triple_list": [["PC-dibenzofurans", "AGONIST", "aryl hydrocarbon receptor"]]}, {"text": "Other dams received 1.8ng/kg/day of a mixture of  aryl hydrocarbon receptor  (AhR) agonists ( non-ortho PCB  , PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)", "triple_list": [["non-ortho PCB", "AGONIST", "aryl hydrocarbon receptor"]]}, {"text": "Other dams received 1.8ng/kg/day of a mixture of  aryl hydrocarbon receptor  (AhR) agonists (non-ortho PCBs,  PC-dibenzodioxins  and PC-dibenzofurans) without or with 0.5M (0.5MAhR)", "triple_list": [["PC-dibenzodioxins", "AGONIST", "aryl hydrocarbon receptor"]]}, {"text": "We report the discovery of a novel series of ATP-competitive  Janus kinase 3  (JAK3) inhibitors based on the  5H-pyrrolo[2,3-b]pyrazine  scaffold", "triple_list": [["5H-pyrrolo[2,3-b]pyrazine", "DOWNREGULATOR", "Janus kinase 3"]]}, {"text": "We report the discovery of a novel series of ATP-competitive Janus kinase 3 ( JAK3   inhibitors based on the  5H-pyrrolo[2,3-b]pyrazine  scaffold", "triple_list": [["5H-pyrrolo[2,3-b]pyrazine", "DOWNREGULATOR", "JAK3"]]}, {"text": "Discovery of a series of novel  5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers   as potent  JAK3  kinase inhibitors", "triple_list": [["5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers", "DOWNREGULATOR", "JAK3"]]}, {"text": "Discovery of a series of novel  5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers   as potent JAK3  kinase  inhibitors", "triple_list": [["5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers", "DOWNREGULATOR", "kinase"]]}, {"text": " ATO  inhibited the phosphorylation and activation of AKT and  STAT3  through Notch signaling blockade", "triple_list": [["ATO", "DOWNREGULATOR", "STAT3"]]}, {"text": " ATO  inhibited the phosphorylation and activation of AKT and STAT3 through  Notch  signaling blockade", "triple_list": [["ATO", "DOWNREGULATOR", "Notch"]]}, {"text": " ATO  inhibited the phosphorylation and activation of  AKT  and STAT3 through Notch signaling blockade", "triple_list": [["ATO", "DOWNREGULATOR", "AKT"]]}, {"text": "These data show that the  ATO  is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of  Notch  pathway.", "triple_list": [["ATO", "DOWNREGULATOR", "Notch"]]}, {"text": " Arsenic trioxide  depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of  Notch  pathway", "triple_list": [["Arsenic trioxide", "DOWNREGULATOR", "Notch"]]}, {"text": "Finally, epididymal mRNA abundance of  GLUT4  was significantly increased by  fisetin  supplementation, compared to levels in the control and HF groups", "triple_list": [["fisetin", "ACTIVATOR", "GLUT4"]]}, {"text": "Enhancement of  GLUT4  expression by  fisetin  was further confirmed in differentiated 3T3-L1 adipocytes", "triple_list": [["fisetin", "ACTIVATOR", "GLUT4"]]}, {"text": "The high fat diet significantly increased hepatic mRNA expressions of  PPAR\u03b3   SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with  fisetin   In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "PPAR\u03b3"]]}, {"text": "The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3,  SREBP1C  and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with  fisetin   In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "SREBP1C"]]}, {"text": "The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and  SCD-1  genes in comparison to the control diet, which was subsequently reversed by supplementation with  fisetin   In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "SCD-1"]]}, {"text": "In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of  FAS   ATPCL and G6Pase compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "FAS"]]}, {"text": "In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of FAS,  ATPCL  and G6Pase compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "ATPCL"]]}, {"text": "In addition,  fisetin  supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and  G6Pase  compared to the control group", "triple_list": [["fisetin", "DOWNREGULATOR", "G6Pase"]]}, {"text": "Western blot assay demonstrated that  DICO  decreased Bcl-2 level and induced  Bax  translocation to cause cytochrome c release", "triple_list": [["DICO", "ACTIVATOR", "Bax"]]}, {"text": "Western blot assay demonstrated that  DICO  decreased Bcl-2 level and induced Bax translocation to cause  cytochrome c  release", "triple_list": [["DICO", "ACTIVATOR", "cytochrome c"]]}, {"text": "Western blot assay demonstrated that  DICO  decreased  Bcl-2  level and induced Bax translocation to cause cytochrome c release", "triple_list": [["DICO", "DOWNREGULATOR", "Bcl-2"]]}, {"text": " Quercetin  and rutin also increased  alkaline phosphatase  activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)", "triple_list": [["Quercetin", "ACTIVATOR", "alkaline phosphatase"]]}, {"text": "Quercetin and  rutin  also increased  alkaline phosphatase  activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)", "triple_list": [["rutin", "ACTIVATOR", "alkaline phosphatase"]]}, {"text": "Further, both the  flavonoids  were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like  osteopontin   osterix, RunX2, osteoprotegerin and osteocalcin", "triple_list": [["flavonoids", "ACTIVATOR", "osteopontin"]]}, {"text": "Further, both the  flavonoids  were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin,  osterix   RunX2, osteoprotegerin and osteocalcin", "triple_list": [["flavonoids", "ACTIVATOR", "osterix"]]}, {"text": "Further, both the  flavonoids  were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix,  RunX2   osteoprotegerin and osteocalcin", "triple_list": [["flavonoids", "ACTIVATOR", "RunX2"]]}, {"text": "Further, both the  flavonoids  were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2,  osteoprotegerin  and osteocalcin", "triple_list": [["flavonoids", "ACTIVATOR", "osteoprotegerin"]]}, {"text": "Further, both the  flavonoids  were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and  osteocalcin   The current data suggests that certain classes of  flavonoids  like rutin and quercetin can be used in the cure and management of osteodegenerative disorders due to their osteoblast specific differentiation activities.", "triple_list": [["flavonoids", "ACTIVATOR", "osteocalcin"]]}, {"text": "LPO was increased while as GSH,  CAT  and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of  NAC  restored these liver markers to normal levels (p<0.001)", "triple_list": [["NAC", "ACTIVATOR", "CAT"]]}, {"text": "LPO was increased while as GSH, CAT and  GPx  decreased by the administration of CCl4 and TAA (p<0.001); co-administration of  NAC  restored these liver markers to normal levels (p<0.001)", "triple_list": [["NAC", "ACTIVATOR", "GPx"]]}, {"text": "Serum markers of liver damage ( AST   ALT, ALP and Bilirubin) were increased by  CCl4  and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["CCl4", "ACTIVATOR", "AST"]]}, {"text": "Serum markers of liver damage (AST,  ALT   ALP and Bilirubin) were increased by  CCl4  and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["CCl4", "ACTIVATOR", "ALT"]]}, {"text": "Serum markers of liver damage (AST, ALT,  ALP  and Bilirubin) were increased by  CCl4  and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["CCl4", "ACTIVATOR", "ALP"]]}, {"text": "Serum markers of liver damage ( AST   ALT, ALP and Bilirubin) were increased by CCl4 and  TAA  intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["TAA", "ACTIVATOR", "AST"]]}, {"text": "Serum markers of liver damage (AST,  ALT   ALP and Bilirubin) were increased by CCl4 and  TAA  intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["TAA", "ACTIVATOR", "ALT"]]}, {"text": "Serum markers of liver damage (AST, ALT,  ALP  and Bilirubin) were increased by CCl4 and  TAA  intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)", "triple_list": [["TAA", "ACTIVATOR", "ALP"]]}, {"text": "Serum markers of liver damage ( AST   ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with  NAC  reversed such changes (p<0.001)", "triple_list": [["NAC", "DOWNREGULATOR", "AST"]]}, {"text": "Serum markers of liver damage (AST,  ALT   ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with  NAC  reversed such changes (p<0.001)", "triple_list": [["NAC", "DOWNREGULATOR", "ALT"]]}, {"text": "Serum markers of liver damage (AST, ALT,  ALP  and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with  NAC  reversed such changes (p<0.001)", "triple_list": [["NAC", "DOWNREGULATOR", "ALP"]]}, {"text": " Cytochrome P450 2E1  (CYP 450 2E1), activity was determined as hydroxylation of  aniline  in liver microsomes", "triple_list": [["aniline", "PRODUCT-OF", "Cytochrome P450 2E1"]]}, {"text": "Cytochrome P450 2E1 ( CYP 450 2E1  , activity was determined as hydroxylation of  aniline  in liver microsomes", "triple_list": [["aniline", "PRODUCT-OF", "CYP 450 2E1"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory  interleukins   IL-6 and IL-8, caused by a mixture of  oxysterols  representative of a high cholesterol diet", "triple_list": [["oxysterols", "ACTIVATOR", "interleukins"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins,  IL-6  and IL-8, caused by a mixture of  oxysterols  representative of a high cholesterol diet", "triple_list": [["oxysterols", "ACTIVATOR", "IL-6"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and  IL-8   caused by a mixture of  oxysterols  representative of a high cholesterol diet", "triple_list": [["oxysterols", "ACTIVATOR", "IL-8"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory  interleukins   IL-6 and IL-8, caused by a mixture of oxysterols representative of a high  cholesterol  diet", "triple_list": [["cholesterol", "ACTIVATOR", "interleukins"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins,  IL-6  and IL-8, caused by a mixture of oxysterols representative of a high  cholesterol  diet", "triple_list": [["cholesterol", "ACTIVATOR", "IL-6"]]}, {"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and  IL-8   caused by a mixture of oxysterols representative of a high  cholesterol  diet", "triple_list": [["cholesterol", "ACTIVATOR", "IL-8"]]}, {"text": " Oxysterol  dependent  NOX1  activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids", "triple_list": [["Oxysterol", "ACTIVATOR", "NOX1"]]}, {"text": " Oxysterol  dependent NOX1 activation, as well as  interleukin  synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids", "triple_list": [["Oxysterol", "ACTIVATOR", "interleukin"]]}, {"text": "Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial  NOX1  down-regulation and was ineffective in interleukin synthesis induced by dietary  oxysterols   It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary  oxysterols  are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production", "triple_list": [["oxysterols", "ACTIVATOR", "NOX1"]]}, {"text": "Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in  interleukin  synthesis induced by dietary  oxysterols   It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary  oxysterols  are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production", "triple_list": [["oxysterols", "ACTIVATOR", "interleukin"]]}, {"text": "Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking  oxysterol  related  NOX1  induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary  oxysterol s.", "triple_list": [["oxysterol", "ACTIVATOR", "NOX1"]]}, {"text": "Oxysterol-dependent  NOX1  activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular  phenolic acids  and flavonoids", "triple_list": [["phenolic acids", "DOWNREGULATOR", "NOX1"]]}, {"text": "Oxysterol-dependent NOX1 activation, as well as  interleukin  synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular  phenolic acids  and flavonoids", "triple_list": [["phenolic acids", "DOWNREGULATOR", "interleukin"]]}, {"text": "Oxysterol-dependent  NOX1  activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and  flavonoids   Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial  NOX1  down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols", "triple_list": [["flavonoids", "DOWNREGULATOR", "NOX1"]]}, {"text": "Oxysterol-dependent NOX1 activation, as well as  interleukin  synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and  flavonoids   Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in  interleukin  synthesis induced by dietary oxysterols", "triple_list": [["flavonoids", "DOWNREGULATOR", "interleukin"]]}, {"text": "Besides this direct activity, an excess of  phenolic  compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related  NOX1  induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.", "triple_list": [["phenolic", "DOWNREGULATOR", "NOX1"]]}, {"text": " Arsenic  inhibits autophagic flux activating the  Nrf2  Keap1 pathway in a p62-dependent manner", "triple_list": [["Arsenic", "ACTIVATOR", "Nrf2"]]}, {"text": " Arsenic  inhibits autophagic flux activating the Nrf2- Keap1  pathway in a p62-dependent manner", "triple_list": [["Arsenic", "ACTIVATOR", "Keap1"]]}, {"text": "Collectively, these findings provide evidence that  arsenic  causes prolonged activation of  Nrf2  through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of  Nrf2  found in certain human cancers", "triple_list": [["arsenic", "ACTIVATOR", "Nrf2"]]}, {"text": "Collectively, these findings provide evidence that  arsenic  causes prolonged activation of  Nrf2  through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of  Nrf2  found in certain human cancers", "triple_list": [["arsenic", "ACTIVATOR", "Nrf2"]]}, {"text": "Thus,  arsenic  activates  Nrf2  through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of  Nrf2 ", "triple_list": [["arsenic", "ACTIVATOR", "Nrf2"]]}, {"text": "Thus,  arsenic  activates  Nrf2  through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of  Nrf2   In contrast, activation of  Nrf2  by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)", "triple_list": [["arsenic", "ACTIVATOR", "Nrf2"]]}, {"text": "In contrast, activation of  Nrf2  by  sulforaphane  and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)", "triple_list": [["sulforaphane", "ACTIVATOR", "Nrf2"]]}, {"text": "In contrast, activation of  Nrf2  by sulforaphane and  tert-butylhydroquinone  depend upon Keap1-C151 and not p62 (the canonical mechanism)", "triple_list": [["tert-butylhydroquinone", "ACTIVATOR", "Nrf2"]]}, {"text": " Arsenic  deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of  p62   Keap1, and LC3", "triple_list": [["Arsenic", "DOWNREGULATOR", "p62"]]}, {"text": " Arsenic  deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62,  Keap1   and LC3", "triple_list": [["Arsenic", "DOWNREGULATOR", "Keap1"]]}, {"text": " Arsenic  deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and  LC3   Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2", "triple_list": [["Arsenic", "DOWNREGULATOR", "LC3"]]}, {"text": " MT1R  was increased in ovaries and uteri of  melatonin  treated rats", "triple_list": [["melatonin", "ACTIVATOR", "MT1R"]]}, {"text": "Ovarian  AR  was not influenced by either treatment, and oviduct  AR  was reduced after  ethanol  melatonin combination", "triple_list": [["ethanol", "DOWNREGULATOR", "AR"]]}, {"text": "Ovarian  AR  was not influenced by either treatment, and oviduct  AR  was reduced after ethanol- melatonin  combination", "triple_list": [["melatonin", "DOWNREGULATOR", "AR"]]}, {"text": "Oviduct  ER-\u03b1   ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either  ethanol  or melatonin", "triple_list": [["ethanol", "DOWNREGULATOR", "ER-\u03b1"]]}, {"text": "Oviduct ER-\u03b1,  ER-\u03b2  and uterine  ER-\u03b2  were down-regulated by either  ethanol  or melatonin", "triple_list": [["ethanol", "DOWNREGULATOR", "ER-\u03b2"]]}, {"text": "Oviduct ER-\u03b1,  ER-\u03b2  and uterine  ER-\u03b2  were down-regulated by either  ethanol  or melatonin", "triple_list": [["ethanol", "DOWNREGULATOR", "ER-\u03b2"]]}, {"text": "Oviduct  ER-\u03b1   ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or  melatonin   Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol- melatonin  combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption", "triple_list": [["melatonin", "DOWNREGULATOR", "ER-\u03b1"]]}, {"text": "Oviduct ER-\u03b1,  ER-\u03b2  and uterine  ER-\u03b2  were down-regulated by either ethanol or  melatonin   Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol- melatonin  combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption", "triple_list": [["melatonin", "DOWNREGULATOR", "ER-\u03b2"]]}, {"text": "Oviduct ER-\u03b1,  ER-\u03b2  and uterine  ER-\u03b2  were down-regulated by either ethanol or  melatonin   Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol- melatonin  combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption", "triple_list": [["melatonin", "DOWNREGULATOR", "ER-\u03b2"]]}, {"text": "Conversely, ovarian  PRA  and PRB were positively regulated by  ethanol  and  ethanol -melatonin combination, whereas  PRA  was down-regulated in the uterus and oviduct after  ethanol  consumption", "triple_list": [["ethanol", "DOWNREGULATOR", "PRA"]]}, {"text": "Intraplantar or intrathecal administered Ph\u03b11\u03b2 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with  SB366791   a specific  TRPV1  antagonist", "triple_list": [["SB366791", "ANTAGONIST", "TRPV1"]]}, {"text": "We found that, before apoptosis,  cisplatin  induces  c-Abl  and TAp73 expression in the oocyte", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "We found that, before apoptosis,  cisplatin  induces c-Abl and  TAp73  expression in the oocyte", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "While imatinib was unable to block  cisplatin  induced DNA damage and damage response, such as the upregulation of  p53   imatinib inhibited the  cisplatin -induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["cisplatin", "ACTIVATOR", "p53"]]}, {"text": "While  imatinib  was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53,  imatinib  inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of  TAp63  and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["imatinib", "ACTIVATOR", "TAp63"]]}, {"text": "While imatinib was unable to block  cisplatin -induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the  cisplatin  induced nuclear accumulation of  c-Abl  TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "While imatinib was unable to block  cisplatin -induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the  cisplatin  induced nuclear accumulation of c-Abl/ TAp73  and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "While imatinib was unable to block  cisplatin -induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the  cisplatin  induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of  Bax   thereby abrogating oocyte cell death", "triple_list": [["cisplatin", "ACTIVATOR", "Bax"]]}, {"text": "Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of  c-Abl  and TAp73 caused by  cisplatin   These data suggest that TAp63 is the master regulator of  cisplatin -induced oocyte death", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and  TAp73  caused by  cisplatin   These data suggest that TAp63 is the master regulator of  cisplatin -induced oocyte death", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "The expression kinetics of  TAp63 , c-Abl and TAp73 suggest that  cisplatin  activates  TAp63  dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression", "triple_list": [["cisplatin", "ACTIVATOR", "TAp63"]]}, {"text": "The expression kinetics of TAp63,  c-Abl  and TAp73 suggest that  cisplatin  activates TAp63-dependent expression of  c-Abl  and TAp73 and, in turn, the activation of TAp73 by  c-Abl -induced BAX expression", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "The expression kinetics of TAp63, c-Abl and  TAp73  suggest that  cisplatin  activates TAp63-dependent expression of c-Abl and  TAp73  and, in turn, the activation of  TAp73  by c-Abl-induced BAX expression", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "The expression kinetics of TAp63, c-Abl and  TAp73  suggest that  cisplatin  activates TAp63-dependent expression of c-Abl and  TAp73  and, in turn, the activation of  TAp73  by c-Abl-induced BAX expression", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "The expression kinetics of TAp63,  c-Abl  and TAp73 suggest that  cisplatin  activates TAp63-dependent expression of  c-Abl  and TAp73 and, in turn, the activation of TAp73 by  c-Abl  induced BAX expression", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that  cisplatin  activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced  BAX  expression", "triple_list": [["cisplatin", "ACTIVATOR", "BAX"]]}, {"text": "Our findings indicate that  imatinib  protects oocytes from cisplatin-induced cell death by inhibiting c-Abl  kinase   which would otherwise activate TAp73-BAX-mediated apoptosis", "triple_list": [["imatinib", "ACTIVATOR", "kinase"]]}, {"text": "Our findings indicate that imatinib protects oocytes from  cisplatin  induced cell death by inhibiting  c-Abl  kinase, which would otherwise activate TAp73-BAX-mediated apoptosis", "triple_list": [["cisplatin", "ACTIVATOR", "c-Abl"]]}, {"text": "Our findings indicate that imatinib protects oocytes from  cisplatin  induced cell death by inhibiting c-Abl  kinase   which would otherwise activate TAp73-BAX-mediated apoptosis", "triple_list": [["cisplatin", "ACTIVATOR", "kinase"]]}, {"text": "Our findings indicate that imatinib protects oocytes from  cisplatin  induced cell death by inhibiting c-Abl kinase, which would otherwise activate  TAp73  BAX-mediated apoptosis", "triple_list": [["cisplatin", "ACTIVATOR", "TAp73"]]}, {"text": "Our findings indicate that imatinib protects oocytes from  cisplatin  induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73- BAX  mediated apoptosis", "triple_list": [["cisplatin", "ACTIVATOR", "BAX"]]}, {"text": "Recently, the  c-Abl  kinase inhibitor  imatinib mesylate  (imatinib) has become the focus of research as a fertoprotective drug against cisplatin", "triple_list": [["imatinib mesylate", "DOWNREGULATOR", "c-Abl"]]}, {"text": "Recently, the c-Abl  kinase  inhibitor  imatinib mesylate  (imatinib) has become the focus of research as a fertoprotective drug against cisplatin", "triple_list": [["imatinib mesylate", "DOWNREGULATOR", "kinase"]]}, {"text": "Recently, the  c-Abl  kinase inhibitor  imatinib  mesylate ( imatinib   has become the focus of research as a fertoprotective drug against cisplatin", "triple_list": [["imatinib", "DOWNREGULATOR", "c-Abl"]]}, {"text": "Recently, the c-Abl  kinase  inhibitor  imatinib  mesylate ( imatinib   has become the focus of research as a fertoprotective drug against cisplatin", "triple_list": [["imatinib", "DOWNREGULATOR", "kinase"]]}, {"text": "While  imatinib  was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53,  imatinib  inhibited the cisplatin-induced nuclear accumulation of  c-Abl  TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["imatinib", "DOWNREGULATOR", "c-Abl"]]}, {"text": "While  imatinib  was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53,  imatinib  inhibited the cisplatin-induced nuclear accumulation of c-Abl/ TAp73  and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["imatinib", "DOWNREGULATOR", "TAp73"]]}, {"text": "While  imatinib  was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53,  imatinib  inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of  Bax   thereby abrogating oocyte cell death", "triple_list": [["imatinib", "DOWNREGULATOR", "Bax"]]}, {"text": "While imatinib was unable to block  cisplatin -induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the  cisplatin  induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of  TAp63  and upregulation of Bax, thereby abrogating oocyte cell death", "triple_list": [["cisplatin", "DOWNREGULATOR", "TAp63"]]}, {"text": "Our findings indicate that  imatinib  protects oocytes from cisplatin-induced cell death by inhibiting  c-Abl  kinase, which would otherwise activate TAp73-BAX-mediated apoptosis", "triple_list": [["imatinib", "DOWNREGULATOR", "c-Abl"]]}, {"text": "Our findings indicate that  imatinib  protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate  TAp73  BAX-mediated apoptosis", "triple_list": [["imatinib", "DOWNREGULATOR", "TAp73"]]}, {"text": "Our findings indicate that  imatinib  protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73- BAX  mediated apoptosis", "triple_list": [["imatinib", "DOWNREGULATOR", "BAX"]]}, {"text": "Thus,  imatinib  and other  c-Abl  kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.", "triple_list": [["imatinib", "DOWNREGULATOR", "c-Abl"]]}, {"text": "Thus,  imatinib  and other c-Abl  kinase  inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.", "triple_list": [["imatinib", "DOWNREGULATOR", "kinase"]]}, {"text": "These results suggest that  ZIP8  plays a pivotal role in the transport and toxicity of  Cd(2+)  and Mn(2+) in RBL-2H3 cells.", "triple_list": [["Cd(2+)", "PRODUCT-OF", "ZIP8"]]}, {"text": "Among the possible transporters involved in the uptake of  Cd(2+)  and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by  Slc39a8   showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Cd(2+)", "PRODUCT-OF", "Slc39a8"]]}, {"text": "Among the possible transporters involved in the uptake of  Cd(2+)  and Mn(2+), the expression of  ZIP8  (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Cd(2+)", "PRODUCT-OF", "ZIP8"]]}, {"text": "Among the possible transporters involved in the uptake of  Cd(2+)  and Mn(2+), the expression of ZIP8 ( Zrt-, Irt-related protein 8  , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Cd(2+)", "PRODUCT-OF", "Zrt-, Irt-related protein 8"]]}, {"text": "Among the possible transporters involved in the uptake of Cd(2+) and  Mn(2+)   the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by  Slc39a8   showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Mn(2+)", "PRODUCT-OF", "Slc39a8"]]}, {"text": "Among the possible transporters involved in the uptake of Cd(2+) and  Mn(2+)   the expression of  ZIP8  (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Mn(2+)", "PRODUCT-OF", "ZIP8"]]}, {"text": "Among the possible transporters involved in the uptake of Cd(2+) and  Mn(2+)   the expression of ZIP8 ( Zrt-, Irt-related protein 8  , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells", "triple_list": [["Mn(2+)", "PRODUCT-OF", "Zrt-, Irt-related protein 8"]]}, {"text": "These results suggest that  ZIP8  plays a pivotal role in the transport and toxicity of Cd(2+) and  Mn(2+)  in RBL-2H3 cells.", "triple_list": [["Mn(2+)", "PRODUCT-OF", "ZIP8"]]}, {"text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of  1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione  inhibitors of  HIV capsid  (CA) assembly are described", "triple_list": [["1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione", "DOWNREGULATOR", "HIV capsid"]]}, {"text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of  1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione  inhibitors of HIV capsid ( CA   assembly are described", "triple_list": [["1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione", "DOWNREGULATOR", "CA"]]}, {"text": "Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of  HIV capsid  assembly inhibitors 2: Structure-activity relationships (SAR) of the C3- phenyl  moiety", "triple_list": [["phenyl", "DOWNREGULATOR", "HIV capsid"]]}, {"text": "Optimization of a  1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione  series of  HIV capsid  assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety", "triple_list": [["1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione", "DOWNREGULATOR", "HIV capsid"]]}, {"text": " Arsenic  upregulates the expression of  angiotensin II Type I receptor  in mouse aortic endothelial cells", "triple_list": [["Arsenic", "ACTIVATOR", "angiotensin II Type I receptor"]]}, {"text": "Taken together, our results indicate that  arsenic  indeed upregulates the  AT1R  expression, thus highlighting a role of  arsenic -induced aberrant  AT1R  signaling in the pathogenesis of hypertension.", "triple_list": [["arsenic", "ACTIVATOR", "AT1R"]]}, {"text": "Taken together, our results indicate that  arsenic  indeed upregulates the  AT1R  expression, thus highlighting a role of  arsenic  induced aberrant  AT1R  signaling in the pathogenesis of hypertension.", "triple_list": [["arsenic", "ACTIVATOR", "AT1R"]]}, {"text": "Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2  AT1R  subtypes, AT1AR and AT1BR following  sodium arsenite  (SA) treatment", "triple_list": [["sodium arsenite", "ACTIVATOR", "AT1R"]]}, {"text": "Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes,  AT1AR  and AT1BR following  sodium arsenite  (SA) treatment", "triple_list": [["sodium arsenite", "ACTIVATOR", "AT1AR"]]}, {"text": "Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and  AT1BR  following  sodium arsenite  (SA) treatment", "triple_list": [["sodium arsenite", "ACTIVATOR", "AT1BR"]]}, {"text": "Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific  JNK  inhibitor,  SP6001325   strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the  JNK  signaling pathway", "triple_list": [["SP6001325", "DOWNREGULATOR", "JNK"]]}, {"text": "Finally, SA-induced  AT1R  expression was found to be prevented both by NAC and specific JNK inhibitor,  SP6001325   strongly indicating that  AT1R  upregulation is a result of the ROS-mediated activation of the JNK signaling pathway", "triple_list": [["SP6001325", "DOWNREGULATOR", "AT1R"]]}, {"text": "The expressions of  HSP70  and HO-1 were significantly (P<0.05) increased in the  NaAsO2  group and reduced in the combined treatment group", "triple_list": [["NaAsO2", "ACTIVATOR", "HSP70"]]}, {"text": "The expressions of HSP70 and  HO-1  were significantly (P<0.05) increased in the  NaAsO2  group and reduced in the combined treatment group", "triple_list": [["NaAsO2", "ACTIVATOR", "HO-1"]]}, {"text": "The mRNA levels of  SOD1   CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined  Na2SeO3  NaAsO2 treatment group", "triple_list": [["Na2SeO3", "ACTIVATOR", "SOD1"]]}, {"text": "The mRNA levels of SOD1,  CAT   GPx and Txnrd1 were increased significantly (P<0.05) in the combined  Na2SeO3  NaAsO2 treatment group", "triple_list": [["Na2SeO3", "ACTIVATOR", "CAT"]]}, {"text": "The mRNA levels of SOD1, CAT,  GPx  and Txnrd1 were increased significantly (P<0.05) in the combined  Na2SeO3  NaAsO2 treatment group", "triple_list": [["Na2SeO3", "ACTIVATOR", "GPx"]]}, {"text": "The mRNA levels of  SOD1   CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+ NaAsO2  treatment group", "triple_list": [["NaAsO2", "DOWNREGULATOR", "SOD1"]]}, {"text": "The mRNA levels of SOD1,  CAT   GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+ NaAsO2  treatment group", "triple_list": [["NaAsO2", "DOWNREGULATOR", "CAT"]]}, {"text": "The mRNA levels of SOD1, CAT,  GPx  and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+ NaAsO2  treatment group", "triple_list": [["NaAsO2", "DOWNREGULATOR", "GPx"]]}, {"text": "The mRNA levels of SOD1, CAT, GPx and  Txnrd1  were increased significantly (P<0.05) in the combined Na2SeO3+ NaAsO2  treatment group", "triple_list": [["NaAsO2", "DOWNREGULATOR", "Txnrd1"]]}, {"text": "The mRNA levels of SOD1, CAT, GPx and  Txnrd1  were increased significantly (P<0.05) in the combined  Na2SeO3  NaAsO2 treatment group", "triple_list": [["Na2SeO3", "DOWNREGULATOR", "Txnrd1"]]}, {"text": "In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate,  methyl-3,5-di-O-caffeoylquinate  showed competitive inhibition of  rhAR   Furthermore,  methyl-3,5-di-O-caffeoylquinate  inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications.", "triple_list": [["methyl-3,5-di-O-caffeoylquinate", "DOWNREGULATOR", "rhAR"]]}, {"text": "From the 10 isolated compounds,  methyl-3,5-di-O-caffeoylquinate  showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for  rAR  and rhAR, respectively", "triple_list": [["methyl-3,5-di-O-caffeoylquinate", "DOWNREGULATOR", "rAR"]]}, {"text": "From the 10 isolated compounds,  methyl-3,5-di-O-caffeoylquinate  showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and  rhAR   respectively", "triple_list": [["methyl-3,5-di-O-caffeoylquinate", "DOWNREGULATOR", "rhAR"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of  amitriptyline   imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam", "triple_list": [["amitriptyline", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline,  imipramine   ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam", "triple_list": [["imipramine", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine,  ketotifen   pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam", "triple_list": [["ketotifen", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen,  pizotifen   olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam", "triple_list": [["pizotifen", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen,  olanzapine   diphenhydramine, tamoxifen, ketoconazole and midazolam", "triple_list": [["olanzapine", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine,  diphenhydramine   tamoxifen, ketoconazole and midazolam", "triple_list": [["diphenhydramine", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine,  tamoxifen   ketoconazole and midazolam", "triple_list": [["tamoxifen", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen,  ketoconazole  and midazolam", "triple_list": [["ketoconazole", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Using recombinant  UGT2B10   we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and  midazolam   These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group", "triple_list": [["midazolam", "PRODUCT-OF", "UGT2B10"]]}, {"text": "This group of drugs contains secondary or primary amines, and these results suggest that  UGT2B10  preferably conjugates  tertiary amines   This preference is partial because  UGT2B10  did not conjugate the tertiary cyclic amine in trifluoperazine", "triple_list": [["tertiary amines", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Recent observations revealed that  human UDP-glucuronosyltransferase (UGT) 2B10  catalyzes N-glucuronidation of  amine  containing compounds", "triple_list": [["amine", "PRODUCT-OF", "human UDP-glucuronosyltransferase (UGT) 2B10"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of  UGT2B10  for  amitriptyline   imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher", "triple_list": [["amitriptyline", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for  amitriptyline   imipramine, and diphenhydramine are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["amitriptyline", "PRODUCT-OF", "UGT1A4"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for  amitriptyline   imipramine, and diphenhydramine are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["amitriptyline", "PRODUCT-OF", "UGT1A4"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of  UGT2B10  for amitriptyline,  imipramine   and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher", "triple_list": [["imipramine", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline,  imipramine   and diphenhydramine are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["imipramine", "PRODUCT-OF", "UGT1A4"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline,  imipramine   and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and  UGT1A3   although the Vmax values of UGT1A4 toward these drugs are considerably higher", "triple_list": [["imipramine", "PRODUCT-OF", "UGT1A3"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline,  imipramine   and diphenhydramine are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["imipramine", "PRODUCT-OF", "UGT1A4"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of  UGT2B10  for amitriptyline, imipramine, and  diphenhydramine  are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher", "triple_list": [["diphenhydramine", "PRODUCT-OF", "UGT2B10"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and  diphenhydramine  are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["diphenhydramine", "PRODUCT-OF", "UGT1A4"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and  diphenhydramine  are significantly higher than the corresponding values of UGT1A4 and  UGT1A3   although the Vmax values of UGT1A4 toward these drugs are considerably higher", "triple_list": [["diphenhydramine", "PRODUCT-OF", "UGT1A3"]]}, {"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and  diphenhydramine  are significantly higher than the corresponding values of  UGT1A4  and UGT1A3, although the Vmax values of  UGT1A4  toward these drugs are considerably higher", "triple_list": [["diphenhydramine", "PRODUCT-OF", "UGT1A4"]]}, {"text": "In conclusion, this study expands the understanding of the substrate specificity of  UGT2B10   highlighting its preference for  tertiary amines  with higher affinities and clearance values than those of UGT1A4 and UGT1A3.", "triple_list": [["tertiary amines", "PRODUCT-OF", "UGT2B10"]]}, {"text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for  tertiary amines  with higher affinities and clearance values than those of  UGT1A4  and UGT1A3.", "triple_list": [["tertiary amines", "PRODUCT-OF", "UGT1A4"]]}, {"text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for  tertiary amines  with higher affinities and clearance values than those of UGT1A4 and  UGT1A3  ", "triple_list": [["tertiary amines", "PRODUCT-OF", "UGT1A3"]]}, {"text": " SB225002  (SB) is an  IL-8  receptor B ( IL-8 RB) antagonist that has previously been shown to inhibit  IL-8  based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects", "triple_list": [["SB225002", "DOWNREGULATOR", "IL-8"]]}, {"text": " SB225002  (SB) is an  IL-8 receptor B  (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects", "triple_list": [["SB225002", "ANTAGONIST", "IL-8 receptor B"]]}, {"text": " SB225002  (SB) is an IL-8 receptor B ( IL-8RB   antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects", "triple_list": [["SB225002", "ANTAGONIST", "IL-8RB"]]}, {"text": "Of note,  SB265610  which is a close structural analogue of SB225002 with a potent  IL-8RB  antagonistic activity did not exhibit a similar antimitotic activity", "triple_list": [["SB265610", "ANTAGONIST", "IL-8RB"]]}, {"text": "Of note, SB265610 which is a close structural analogue of  SB225002  with a potent  IL-8RB  antagonistic activity did not exhibit a similar antimitotic activity", "triple_list": [["SB225002", "ANTAGONIST", "IL-8RB"]]}, {"text": "In support of this observation, elongation can be reversed by the  tyrosine kinase  inhibitor  SU5402   mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino", "triple_list": [["SU5402", "DOWNREGULATOR", "tyrosine kinase"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor  p27Kip   Overexpression of Akt1 or Akt2 in TW2.6 cells rescued growth inhibition caused by  CAPE  treatment", "triple_list": [["CAPE", "ACTIVATOR", "p27Kip"]]}, {"text": " Caffeic Acid Phenethyl Ester  Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of  Akt  Signaling", "triple_list": [["Caffeic Acid Phenethyl Ester", "DOWNREGULATOR", "Akt"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of  Akt    Akt 1,  Akt 2,  Akt 3, phospho- Akt  Ser473, phospho- Akt  Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Akt"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt,  Akt1   Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Akt1"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1,  Akt2   Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Akt2"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2,  Akt3   phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Akt3"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3,  phospho-Akt  Ser473,  phospho-Akt  Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-Akt"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3,  phospho-Akt  Ser473,  phospho-Akt  Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-Akt"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308,  GSK3\u03b2   FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "GSK3\u03b2"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2,  FOXO1   FOXO3a, phospho- FOXO1  Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "FOXO1"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1,  FOXO3a   phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "FOXO3a"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a,  phospho-FOXO1  Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-FOXO1"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24,  phospho-FoxO3a  Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-FoxO3a"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32,  NF-\u03baB   phospho- NF-\u03baB  Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "NF-\u03baB"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB,  phospho-NF-\u03baB  Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-NF-\u03baB"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536,  Rb   phospho- Rb  Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Rb"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb,  phospho-Rb  Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "phospho-Rb"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811,  Skp2   and cyclin D1, but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "Skp2"]]}, {"text": "Treatment with  CAPE  decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and  cyclin D1   but increased cell cycle inhibitor p27Kip", "triple_list": [["CAPE", "DOWNREGULATOR", "cyclin D1"]]}, {"text": "Here we show that  fisetin  rapidly increases the levels of both  Nrf2  and ATF4 as well as  Nrf2 - and ATF4-dependent gene transcription via distinct mechanisms", "triple_list": [["fisetin", "ACTIVATOR", "Nrf2"]]}, {"text": "Here we show that  fisetin  rapidly increases the levels of both Nrf2 and  ATF4  as well as Nrf2- and  ATF4 -dependent gene transcription via distinct mechanisms", "triple_list": [["fisetin", "ACTIVATOR", "ATF4"]]}, {"text": "Here we show that  fisetin  rapidly increases the levels of both  Nrf2  and ATF4 as well as  Nrf2   and ATF4-dependent gene transcription via distinct mechanisms", "triple_list": [["fisetin", "ACTIVATOR", "Nrf2"]]}, {"text": "Here we show that  fisetin  rapidly increases the levels of both Nrf2 and  ATF4  as well as Nrf2- and  ATF4  dependent gene transcription via distinct mechanisms", "triple_list": [["fisetin", "ACTIVATOR", "ATF4"]]}, {"text": "Although  fisetin  greatly increases the stability of both  Nrf2  and ATF4, only the effect on ATF4 is dependent on protein kinase activity", "triple_list": [["fisetin", "ACTIVATOR", "Nrf2"]]}, {"text": "Although  fisetin  greatly increases the stability of both Nrf2 and  ATF4   only the effect on  ATF4  is dependent on protein kinase activity", "triple_list": [["fisetin", "ACTIVATOR", "ATF4"]]}, {"text": " Cynomolgus FMO1   FMO2, FMO3, and FMO5 metabolized  benzydamine   and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively", "triple_list": [["benzydamine", "PRODUCT-OF", "Cynomolgus FMO1"]]}, {"text": "Cynomolgus FMO1,  FMO2   FMO3, and FMO5 metabolized  benzydamine   and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO2"]]}, {"text": "Cynomolgus FMO1, FMO2,  FMO3   and FMO5 metabolized  benzydamine   and FMO1/ FMO3  and  FMO3  also metabolized methimazole and trimethylamine, respectively", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Cynomolgus FMO1, FMO2, FMO3, and  FMO5  metabolized  benzydamine   and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO5"]]}, {"text": "Cynomolgus  FMO1 , FMO2, FMO3, and FMO5 metabolized benzydamine, and  FMO1  FMO3 and FMO3 also metabolized  methimazole  and trimethylamine, respectively", "triple_list": [["methimazole", "PRODUCT-OF", "FMO1"]]}, {"text": "Cynomolgus FMO1, FMO2,  FMO3 , and FMO5 metabolized benzydamine, and FMO1/ FMO3  and  FMO3  also metabolized  methimazole  and trimethylamine, respectively", "triple_list": [["methimazole", "PRODUCT-OF", "FMO3"]]}, {"text": "Cynomolgus FMO1, FMO2,  FMO3 , and FMO5 metabolized benzydamine, and FMO1/ FMO3  and  FMO3  also metabolized  methimazole  and trimethylamine, respectively", "triple_list": [["methimazole", "PRODUCT-OF", "FMO3"]]}, {"text": "Cynomolgus  FMO1 , FMO2, FMO3, and FMO5 metabolized benzydamine, and  FMO1  FMO3 and FMO3 also metabolized methimazole and  trimethylamine   respectively", "triple_list": [["trimethylamine", "PRODUCT-OF", "FMO1"]]}, {"text": "Cynomolgus FMO1, FMO2,  FMO3 , and FMO5 metabolized benzydamine, and FMO1/ FMO3  and  FMO3  also metabolized methimazole and  trimethylamine   respectively", "triple_list": [["trimethylamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Cynomolgus FMO1, FMO2,  FMO3 , and FMO5 metabolized benzydamine, and FMO1/ FMO3  and  FMO3  also metabolized methimazole and  trimethylamine   respectively", "triple_list": [["trimethylamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Rates of  benzydamine  N-oxygenation (catalyzed by  FMO3   varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with  FMO3  protein expression, indicating that the inter-animal variations in  benzydamine  N-oxygenation might be partly accounted for by the variable  FMO3  expression", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Rates of benzydamine  N  oxygenation (catalyzed by  FMO3   varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with  FMO3  protein expression, indicating that the inter-animal variations in benzydamine  N -oxygenation might be partly accounted for by the variable  FMO3  expression", "triple_list": [["N", "PRODUCT-OF", "FMO3"]]}, {"text": "Rates of  benzydamine  N-oxygenation (catalyzed by  FMO3 ) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with  FMO3  protein expression, indicating that the inter-animal variations in  benzydamine  N-oxygenation might be partly accounted for by the variable  FMO3  expression", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Rates of benzydamine  N -oxygenation (catalyzed by  FMO3 ) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with  FMO3  protein expression, indicating that the inter-animal variations in benzydamine  N  oxygenation might be partly accounted for by the variable  FMO3  expression", "triple_list": [["N", "PRODUCT-OF", "FMO3"]]}, {"text": " Cynomolgus FMO6  metabolized  benzydamine  only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional", "triple_list": [["benzydamine", "PRODUCT-OF", "Cynomolgus FMO6"]]}, {"text": "Cynomolgus FMO6 metabolized  benzydamine  only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus  FMO1   FMO2, FMO3, and FMO5 which were all functional", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO1"]]}, {"text": "Cynomolgus FMO6 metabolized  benzydamine  only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1,  FMO2   FMO3, and FMO5 which were all functional", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO2"]]}, {"text": "Cynomolgus FMO6 metabolized  benzydamine  only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2,  FMO3   and FMO5 which were all functional", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO3"]]}, {"text": "Cynomolgus FMO6 metabolized  benzydamine  only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and  FMO5  which were all functional", "triple_list": [["benzydamine", "PRODUCT-OF", "FMO5"]]}, {"text": "Activation of  AMPK  using  AICAR  resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry", "triple_list": [["AICAR", "ACTIVATOR", "AMPK"]]}, {"text": "Activation of AMPK using  AICAR  resulted in  STIM1  phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry", "triple_list": [["AICAR", "ACTIVATOR", "STIM1"]]}, {"text": "Activation of AMPK using  AICAR  resulted in STIM1 phosphorylation on serine residues and prevented  PAR-1  induced Ca2+ entry", "triple_list": [["AICAR", "DOWNREGULATOR", "PAR-1"]]}, {"text": "Further,  AICAR  pretreatment blocked  PAR-1  induced increase in permeability of mouse-lung microvessels", "triple_list": [["AICAR", "DOWNREGULATOR", "PAR-1"]]}, {"text": "Interestingly,  SB203580   a selective inhibitor of  p38  MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry", "triple_list": [["SB203580", "DOWNREGULATOR", "p38"]]}, {"text": "Interestingly,  SB203580   a selective inhibitor of p38  MAPK   blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry", "triple_list": [["SB203580", "DOWNREGULATOR", "MAPK"]]}, {"text": "Interestingly,  SB203580   a selective inhibitor of p38 MAPK, blocked  STIM1  phosphorylation and led to sustained  STIM1 -puncta formation and Ca2+ entry", "triple_list": [["SB203580", "DOWNREGULATOR", "STIM1"]]}, {"text": "The precise fashion in which these proteins interact and move  cholesterol  from the OMM to  P450scc   and the means by which  cholesterol  is loaded into the OMM, remain unclear", "triple_list": [["cholesterol", "PRODUCT-OF", "P450scc"]]}, {"text": "Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the  cholesterol  side-chain cleavage enzyme,  P450scc   and its two electron-transfer partners, ferredoxin reductase and ferredoxin", "triple_list": [["cholesterol", "PRODUCT-OF", "P450scc"]]}, {"text": "New series of  pyrrolidine mercaptosulfide   2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine  matrix metalloproteinase  inhibitors (MMPIs) were designed, synthesized, and evaluated", "triple_list": [["pyrrolidine mercaptosulfide", "DOWNREGULATOR", "matrix metalloproteinase"]]}, {"text": "Exhibiting unique properties over other MMPIs (e.g.,  hydroxamates  , these newly reported compounds are capable of modulating activities of several  MMPs  in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)", "triple_list": [["hydroxamates", "DOWNREGULATOR", "MMPs"]]}, {"text": "Exhibiting unique properties over other MMPIs (e.g.,  hydroxamates  , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including  MMP-2  (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)", "triple_list": [["hydroxamates", "DOWNREGULATOR", "MMP-2"]]}, {"text": "Exhibiting unique properties over other MMPIs (e.g.,  hydroxamates  , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM),  MMP-13  (~2 to 50 nM), and MMP-14 (~4 to 60 nM)", "triple_list": [["hydroxamates", "DOWNREGULATOR", "MMP-13"]]}, {"text": "Exhibiting unique properties over other MMPIs (e.g.,  hydroxamates  , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and  MMP-14  (~4 to 60 nM)", "triple_list": [["hydroxamates", "DOWNREGULATOR", "MMP-14"]]}, {"text": "New series of pyrrolidine mercaptosulfide,  2-mercaptocyclopentane arylsulfonamide   and 3-mercapto-4-arylsulfonamido pyrrolidine  matrix metalloproteinase  inhibitors (MMPIs) were designed, synthesized, and evaluated", "triple_list": [["2-mercaptocyclopentane arylsulfonamide", "DOWNREGULATOR", "matrix metalloproteinase"]]}, {"text": "New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and  3-mercapto-4-arylsulfonamido pyrrolidine   matrix metalloproteinase  inhibitors (MMPIs) were designed, synthesized, and evaluated", "triple_list": [["3-mercapto-4-arylsulfonamido pyrrolidine", "DOWNREGULATOR", "matrix metalloproteinase"]]}, {"text": " Matrix Metalloproteinase  Inhibitors Based on the  3-Mercaptopyrrolidine  Core", "triple_list": [["3-Mercaptopyrrolidine", "DOWNREGULATOR", "Matrix Metalloproteinase"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as  interleukin-1\u03b2  (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "interleukin-1\u03b2"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 ( IL-1\u03b2  , and apoptosis (Bax and caspase 3 expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "IL-1\u03b2"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis ( Bax  and caspase 3 expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "Bax"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and  caspase 3  expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "caspase 3"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased  nuclear factor (NF)-kB  translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "nuclear factor (NF)-kB"]]}, {"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive  RS -GRA  significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory  cytokine  production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)", "triple_list": [["RS -GRA", "DOWNREGULATOR", "cytokine"]]}, {"text": "Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in  glucosinolates   which upon  myrosinase  hydrolysis release the corresponding isothiocyanates", "triple_list": [["glucosinolates", "PRODUCT-OF", "myrosinase"]]}, {"text": "Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon  myrosinase  hydrolysis release the corresponding  isothiocyanates   This study examines the potential neuroprotective and immunomodulatory effects of (RS )-glucoraphanin from Tuscan black kale (Brassica oleracea L", "triple_list": [["isothiocyanates", "PRODUCT-OF", "myrosinase"]]}, {"text": "There was also an increase in  \u03b3-GCS  and HO-1 levels in  calycopterin  pretreated cells", "triple_list": [["calycopterin", "ACTIVATOR", "\u03b3-GCS"]]}, {"text": "There was also an increase in \u03b3-GCS and  HO-1  levels in  calycopterin  pretreated cells", "triple_list": [["calycopterin", "ACTIVATOR", "HO-1"]]}, {"text": "In the presence of H2O2,  calycopterin  inhibited decrease in GSH level and  SOD  activity", "triple_list": [["calycopterin", "ACTIVATOR", "SOD"]]}, {"text": "Moreover,  calycopterin   in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors,  CREB  and Nrf2, which play an important role in antioxidant capacity of the cell", "triple_list": [["calycopterin", "ACTIVATOR", "CREB"]]}, {"text": "Moreover,  calycopterin   in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and  Nrf2   which play an important role in antioxidant capacity of the cell", "triple_list": [["calycopterin", "ACTIVATOR", "Nrf2"]]}, {"text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on  H2O2  induced disruption of  phase II detoxifying enzyme  system and cAMP response element binding protein (CREB) phosphorylation", "triple_list": [["H2O2", "DOWNREGULATOR", "phase II detoxifying enzyme"]]}, {"text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on  H2O2  induced disruption of phase II detoxifying enzyme system and  cAMP response element binding protein  (CREB) phosphorylation", "triple_list": [["H2O2", "DOWNREGULATOR", "cAMP response element binding protein"]]}, {"text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on  H2O2  induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein ( CREB   phosphorylation", "triple_list": [["H2O2", "DOWNREGULATOR", "CREB"]]}, {"text": "In H2O2-treated cells,  calycopterin  also suppressed  cytochrome C  release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells", "triple_list": [["calycopterin", "DOWNREGULATOR", "cytochrome C"]]}, {"text": "Activation of  STAT3   which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and  TCDD   Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and  TCDD , and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and  STAT3 , raising a possibility that stimulatory activities of I3S and  TCDD  on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates  STAT3  activation", "triple_list": [["TCDD", "ACTIVATOR", "STAT3"]]}, {"text": "Activation of STAT3, which is phosphorylated by the  IL-6  signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and  TCDD   Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and  TCDD , and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and  TCDD  on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation", "triple_list": [["TCDD", "ACTIVATOR", "IL-6"]]}, {"text": "Phosphorylation of  c-Src   which was shown to be activated by AhR ligands, was also increased by  I3S  and TCDD, and blocking of  c-Src  activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of  I3S  and TCDD on Th17 differentiation could be exerted via increased phosphorylation of  c-Src , which in turn stimulates STAT3 activation", "triple_list": [["I3S", "ACTIVATOR", "c-Src"]]}, {"text": "Phosphorylation of  c-Src   which was shown to be activated by AhR ligands, was also increased by I3S and  TCDD   and blocking of  c-Src  activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of I3S and  TCDD  on Th17 differentiation could be exerted via increased phosphorylation of  c-Src , which in turn stimulates STAT3 activation", "triple_list": [["TCDD", "ACTIVATOR", "c-Src"]]}, {"text": " Indoxyl 3-sulfate  stimulates Th17 differentiation enhancing phosphorylation of  c-Src  and STAT3 to worsen experimental autoimmune encephalomyelitis", "triple_list": [["Indoxyl 3-sulfate", "ACTIVATOR", "c-Src"]]}, {"text": " Indoxyl 3-sulfate  stimulates Th17 differentiation enhancing phosphorylation of c-Src and  STAT3  to worsen experimental autoimmune encephalomyelitis", "triple_list": [["Indoxyl 3-sulfate", "ACTIVATOR", "STAT3"]]}, {"text": "Phosphorylation of  c-Src , which was shown to be activated by AhR ligands, was also increased by  I3S  and TCDD, and blocking of  c-Src  activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of  I3S  and TCDD on Th17 differentiation could be exerted via increased phosphorylation of  c-Src   which in turn stimulates STAT3 activation", "triple_list": [["I3S", "ACTIVATOR", "c-Src"]]}, {"text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by  I3S  and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and  STAT3 , raising a possibility that stimulatory activities of  I3S  and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates  STAT3  activation", "triple_list": [["I3S", "ACTIVATOR", "STAT3"]]}, {"text": "Phosphorylation of  c-Src , which was shown to be activated by AhR ligands, was also increased by I3S and  TCDD , and blocking of  c-Src  activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of I3S and  TCDD  on Th17 differentiation could be exerted via increased phosphorylation of  c-Src   which in turn stimulates STAT3 activation", "triple_list": [["TCDD", "ACTIVATOR", "c-Src"]]}, {"text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and  TCDD , and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and  STAT3 , raising a possibility that stimulatory activities of I3S and  TCDD  on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates  STAT3  activation", "triple_list": [["TCDD", "ACTIVATOR", "STAT3"]]}, {"text": "Finally, we found that  I3S  worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of  IL-17  producing cells in draining lymph nodes.", "triple_list": [["I3S", "ACTIVATOR", "IL-17"]]}, {"text": "In the present study, using in vitro Th17 differentiation model, we examined effects of  AhR  activation by  indoxyl 3-sulfate  (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms", "triple_list": [["indoxyl 3-sulfate", "ACTIVATOR", "AhR"]]}, {"text": "In the present study, using in vitro Th17 differentiation model, we examined effects of  AhR  activation by indoxyl 3-sulfate ( I3S  , a uremic toxin, on Th17 differentiation and investigated underlying mechanisms", "triple_list": [["I3S", "ACTIVATOR", "AhR"]]}, {"text": " I3S  increased expression of  ROR\u03b3t   the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand", "triple_list": [["I3S", "ACTIVATOR", "ROR\u03b3t"]]}, {"text": "Activation of  STAT3   which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by  I3S  and TCDD", "triple_list": [["I3S", "ACTIVATOR", "STAT3"]]}, {"text": "Activation of STAT3, which is phosphorylated by the  IL-6  signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by  I3S  and TCDD", "triple_list": [["I3S", "ACTIVATOR", "IL-6"]]}, {"text": "Phosphorylation of  c-Src , which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of  c-Src  activity by  4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine  (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of  c-Src , which in turn stimulates STAT3 activation", "triple_list": [["4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "DOWNREGULATOR", "c-Src"]]}, {"text": "Phosphorylation of  c-Src , which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of  c-Src  activity by  4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine  (PP2) inhibited phosphorylation of both  c-Src  and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of  c-Src , which in turn stimulates STAT3 activation", "triple_list": [["4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "DOWNREGULATOR", "c-Src"]]}, {"text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by  4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine  (PP2) inhibited phosphorylation of both c-Src and  STAT3   raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates  STAT3  activation", "triple_list": [["4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "DOWNREGULATOR", "STAT3"]]}, {"text": "This inhibition was mediated by a  TCDD  induced secreted factor which was identified as  insulin-like growth factor binding protein 4  (IGFBP-4)", "triple_list": [["TCDD", "ACTIVATOR", "insulin-like growth factor binding protein 4"]]}, {"text": "This inhibition was mediated by a  TCDD  induced secreted factor which was identified as insulin-like growth factor binding protein 4 ( IGFBP-4  ", "triple_list": [["TCDD", "ACTIVATOR", "IGFBP-4"]]}, {"text": " TCDD  induces the expression of  insulin-like growth factor binding protein 4  in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity", "triple_list": [["TCDD", "ACTIVATOR", "insulin-like growth factor binding protein 4"]]}, {"text": "The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of  IGFBP-4  by  TCDD   These findings emphasise a particular caution when interpreting and extrapolating results on the action mechanisms of  TCDD  obtained in studies using 5L cells as a model system.", "triple_list": [["TCDD", "ACTIVATOR", "IGFBP-4"]]}, {"text": "By \"working upwards\" from mTOR, we observed that  TCDD  inhibited endogenous and  IGF-I  induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1", "triple_list": [["TCDD", "DOWNREGULATOR", "IGF-I"]]}, {"text": "By \"working upwards\" from mTOR, we observed that  TCDD  inhibited endogenous and IGF-I-induced  AKT  and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1", "triple_list": [["TCDD", "DOWNREGULATOR", "AKT"]]}, {"text": "By \"working upwards\" from mTOR, we observed that  TCDD  inhibited endogenous and IGF-I-induced AKT and  ERK  activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1", "triple_list": [["TCDD", "DOWNREGULATOR", "ERK"]]}, {"text": "The induction of  IGFBP-4  protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of  IGFBP-4  mRNA indicating that  IGFBP-4  is a previously unknown transcriptional target of  TCDD  in 5L cells", "triple_list": [["TCDD", "DOWNREGULATOR", "IGFBP-4"]]}, {"text": "Inhibition of MCF-7 cell growth by the selective  calmodulin  antagonists W-13 and W-12 is consistent with a role for  calmodulin  antagonism in the broad growth-inhibitory properties of  pimozide   We conclude that  pimozide  and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and ER-negative human breast tumors.", "triple_list": [["pimozide", "DOWNREGULATOR", "calmodulin"]]}, {"text": "Inhibition of MCF-7 cell growth by the selective  calmodulin  antagonists  W-13  and W-12 is consistent with a role for  calmodulin  antagonism in the broad growth-inhibitory properties of pimozide", "triple_list": [["W-13", "ANTAGONIST", "calmodulin"]]}, {"text": "Inhibition of MCF-7 cell growth by the selective  calmodulin  antagonists W-13 and  W-12  is consistent with a role for  calmodulin  antagonism in the broad growth-inhibitory properties of pimozide", "triple_list": [["W-12", "ANTAGONIST", "calmodulin"]]}, {"text": "Although numerous mechanisms of action of  pimozide  and thioridazine have been identified, both drugs are  calmodulin  antagonists at drug concentrations that inhibit breast cancer cell growth in vitro", "triple_list": [["pimozide", "ANTAGONIST", "calmodulin"]]}, {"text": "Although numerous mechanisms of action of pimozide and  thioridazine  have been identified, both drugs are  calmodulin  antagonists at drug concentrations that inhibit breast cancer cell growth in vitro", "triple_list": [["thioridazine", "ANTAGONIST", "calmodulin"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.),  MAO-B  by  (-)deprenyl  (1 mg/kg i.p.), both MAO-A and  MAO-B  by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)", "triple_list": [["(-)deprenyl", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A ( MAO-A ) by clorgyline (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both  MAO-A  and MAO-B by  nialamide  (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)", "triple_list": [["nialamide", "DOWNREGULATOR", "MAO-A"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.),  MAO-B  by (-)deprenyl (1 mg/kg i.p.), both MAO-A and  MAO-B  by  nialamide  (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)", "triple_list": [["nialamide", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A ( MAO -A) by clorgyline (4 mg/kg i.p.),  MAO -B by (-)deprenyl (1 mg/kg i.p.), both  MAO -A and  MAO -B by nialamide (75 mg/kg i.p.) or peripheral neuronal  MAO  by  debrisoquin  (40 mg/kg i.p.)", "triple_list": [["debrisoquin", "DOWNREGULATOR", "MAO"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of  monoamine oxidase type A  (MAO-A) by  clorgyline  (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)", "triple_list": [["clorgyline", "DOWNREGULATOR", "monoamine oxidase type A"]]}, {"text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A ( MAO-A   by  clorgyline  (4 mg/kg i.p.), MAO-B by (-)deprenyl (1 mg/kg i.p.), both  MAO-A  and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.)", "triple_list": [["clorgyline", "DOWNREGULATOR", "MAO-A"]]}, {"text": "The results suggest that most of the HVA in plasma is derived from deamination of  DA  by  MAO-A  in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.", "triple_list": [["DA", "PRODUCT-OF", "MAO-A"]]}, {"text": "The results suggest that most of the  HVA  in plasma is derived from deamination of DA by  MAO-A  in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of  HVA  after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.", "triple_list": [["HVA", "PRODUCT-OF", "MAO-A"]]}, {"text": "After  loperamide  administration  ACTH  levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an  ACTH  increase; the pattern of  ACTH  response to CRH was slightly delayed", "triple_list": [["loperamide", "ACTIVATOR", "ACTH"]]}, {"text": "After  loperamide  administration  ACTH  levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an  ACTH  increase; the pattern of  ACTH  response to CRH was slightly delayed", "triple_list": [["loperamide", "DOWNREGULATOR", "ACTH"]]}, {"text": "Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the  acetylcholinesterase  inhibitor  neostigmine   These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of  acetylcholinesterase  and concomitant antagonism by blockade of muscarinic receptors", "triple_list": [["neostigmine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "These data suggested that  ambenonium  had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of  acetylcholinesterase  and concomitant antagonism by blockade of muscarinic receptors", "triple_list": [["ambenonium", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "These data suggested that  ambenonium  had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of  muscarinic receptors   The Schild regressions obtained for  ambenonium  antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)", "triple_list": [["ambenonium", "DOWNREGULATOR", "muscarinic receptors"]]}, {"text": " Ambenonium  is known to be an inhibitor of  acetylcholinesterase   and recent data have shown this drug to antagonize muscarinic receptors as well", "triple_list": [["Ambenonium", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "These data suggested that ambenonium had a dual effect on tissue responses to  acetylcholine  producing potentiation by blockade of  acetylcholine sterase and concomitant antagonism by blockade of muscarinic receptors", "triple_list": [["acetylcholine", "AGONIST", "acetylcholinesterase"]]}, {"text": "These data suggested that  ambenonium  had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of  muscarinic receptors   The Schild regressions obtained for  ambenonium  antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)", "triple_list": [["ambenonium", "ANTAGONIST", "muscarinic receptors"]]}, {"text": " Ambenonium  is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize  muscarinic receptors  as well", "triple_list": [["Ambenonium", "ANTAGONIST", "muscarinic receptors"]]}, {"text": "However,  betaxolol  produces less systemic beta 2- and possibly  beta 1-adrenergic receptor  blockade than either timolol or levobunolol", "triple_list": [["betaxolol", "DOWNREGULATOR", "beta 1-adrenergic receptor"]]}, {"text": "However, betaxolol produces less systemic beta 2- and possibly  beta 1-adrenergic receptor  blockade than either  timolol  or levobunolol", "triple_list": [["timolol", "DOWNREGULATOR", "beta 1-adrenergic receptor"]]}, {"text": "However, betaxolol produces less systemic beta 2- and possibly  beta 1-adrenergic receptor  blockade than either timolol or  levobunolol   Betaxolol may be relatively safer to use in patients with reactive airway disease than either timolol or  levobunolol ", "triple_list": [["levobunolol", "DOWNREGULATOR", "beta 1-adrenergic receptor"]]}, {"text": " Phenol oxidase  inhibitors such as  phenylthiourea   potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis", "triple_list": [["phenylthiourea", "DOWNREGULATOR", "Phenol oxidase"]]}, {"text": " Phenol oxidase  inhibitors such as phenylthiourea,  potassium cyanide   and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis", "triple_list": [["potassium cyanide", "DOWNREGULATOR", "Phenol oxidase"]]}, {"text": " Phenol oxidase  inhibitors such as phenylthiourea, potassium cyanide, and  sodium azide  inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis", "triple_list": [["sodium azide", "DOWNREGULATOR", "Phenol oxidase"]]}, {"text": " Mimosine   a well-known competitive inhibitor of  tyrosinase   competitively inhibited the new reaction also", "triple_list": [["Mimosine", "DOWNREGULATOR", "tyrosinase"]]}, {"text": "Present studies demonstrate that  mushroom tyrosinase  will also catalyze quinone methide production with the same active site copper if a suitable substrate such as  3,4-dihydroxymandelic acid  is provided.", "triple_list": [["3,4-dihydroxymandelic acid", "PRODUCT-OF", "mushroom tyrosinase"]]}, {"text": " Tyrosinase  usually catalyzes the conversion of  monophenols  to o-diphenols and oxidation of diphenols to the corresponding quinones", "triple_list": [["monophenols", "PRODUCT-OF", "Tyrosinase"]]}, {"text": " Tyrosinase  usually catalyzes the conversion of monophenols to o- diphenols  and oxidation of  diphenols  to the corresponding quinones", "triple_list": [["diphenols", "PRODUCT-OF", "Tyrosinase"]]}, {"text": " Tyrosinase  catalyzes an unusual oxidative decarboxylation of  3,4-dihydroxymandelate    Tyrosinase  usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones", "triple_list": [["3,4-dihydroxymandelate", "PRODUCT-OF", "Tyrosinase"]]}, {"text": "Present studies demonstrate that  mushroom tyrosinase  will also catalyze  quinone methide  production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.", "triple_list": [["quinone methide", "PRODUCT-OF", "mushroom tyrosinase"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ( t-PA   is inhibited by Cl-, at physiological concentrations, and stimulated by  epsilon-aminocaproic acid  (EACA), as well as fibrin(ogen)", "triple_list": [["epsilon-aminocaproic acid", "ACTIVATOR", "t-PA"]]}, {"text": "The activation of  human [Glu1]plasminogen  [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by  epsilon-aminocaproic acid  (EACA), as well as fibrin(ogen)", "triple_list": [["epsilon-aminocaproic acid", "ACTIVATOR", "human [Glu1]plasminogen"]]}, {"text": "The activation of human [Glu1]plasminogen [ ( Glu1]Pg   by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by  epsilon-aminocaproic acid  (EACA), as well as fibrin(ogen)", "triple_list": [["epsilon-aminocaproic acid", "ACTIVATOR", "( Glu1]Pg"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain  tissue plasminogen activator  (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by  epsilon-aminocaproic acid  (EACA), as well as fibrin(ogen)", "triple_list": [["epsilon-aminocaproic acid", "ACTIVATOR", "tissue plasminogen activator"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ( t-PA   is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ( EACA  , as well as fibrin(ogen)", "triple_list": [["EACA", "ACTIVATOR", "t-PA"]]}, {"text": "The activation of  human [Glu1]plasminogen  [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ( EACA  , as well as fibrin(ogen)", "triple_list": [["EACA", "ACTIVATOR", "human [Glu1]plasminogen"]]}, {"text": "The activation of human [Glu1]plasminogen [ ( Glu1]Pg   by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ( EACA  , as well as fibrin(ogen)", "triple_list": [["EACA", "ACTIVATOR", "( Glu1]Pg"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain  tissue plasminogen activator  (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ( EACA  , as well as fibrin(ogen)", "triple_list": [["EACA", "ACTIVATOR", "tissue plasminogen activator"]]}, {"text": "The presence of  Cl-  inhibits the stimulation of  [Glu1]Pg  activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.", "triple_list": [["Cl-", "DOWNREGULATOR", "[Glu1]Pg"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ( t-PA   is inhibited by  Cl-   at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)", "triple_list": [["Cl-", "DOWNREGULATOR", "t-PA"]]}, {"text": "The activation of  human [Glu1]plasminogen  [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by  Cl-   at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)", "triple_list": [["Cl-", "DOWNREGULATOR", "human [Glu1]plasminogen"]]}, {"text": "The activation of human [Glu1]plasminogen [ ( Glu1]Pg   by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by  Cl-   at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)", "triple_list": [["Cl-", "DOWNREGULATOR", "( Glu1]Pg"]]}, {"text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain  tissue plasminogen activator  (t-PA) is inhibited by  Cl-   at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)", "triple_list": [["Cl-", "DOWNREGULATOR", "tissue plasminogen activator"]]}, {"text": "Whole-cell voltage-clamp of h NE T 293 cells reveals  NE  induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells", "triple_list": [["NE", "ACTIVATOR", "hNET"]]}, {"text": "Sodium-dependent  norepinephrine  induced currents in  norepinephrine -transporter transfected HEK-293 cells blocked by cocaine and antidepressants", "triple_list": [["norepinephrine", "ACTIVATOR", "norepinephrine-transporter"]]}, {"text": "Whole-cell voltage-clamp of  hNET  293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and  cocaine  that are absent in parental cells", "triple_list": [["cocaine", "DOWNREGULATOR", "hNET"]]}, {"text": "Sodium-dependent norepinephrine-induced currents in  norepinephrine-transporter  transfected HEK-293 cells blocked by  cocaine  and antidepressants", "triple_list": [["cocaine", "DOWNREGULATOR", "norepinephrine-transporter"]]}, {"text": "To explain our observations, we propose that h NE Ts function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to  NE  transport", "triple_list": [["NE", "PRODUCT-OF", "hNETs"]]}, {"text": "BACKGROUND: The active metabolite of the anti-inflammatory drug  nabumetone  has been characterized as a selective inhibitor of the inducible  prostaglandin H synthase  (PGHS)", "triple_list": [["nabumetone", "DOWNREGULATOR", "prostaglandin H synthase"]]}, {"text": "BACKGROUND: The active metabolite of the anti-inflammatory drug  nabumetone  has been characterized as a selective inhibitor of the inducible prostaglandin H synthase ( PGHS  ", "triple_list": [["nabumetone", "DOWNREGULATOR", "PGHS"]]}, {"text": "The daily administration of low-dose  aspirin  (40 mg), a selective inhibitor of platelet  PGHS-1   caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover", "triple_list": [["aspirin", "DOWNREGULATOR", "PGHS-1"]]}, {"text": "CONCLUSIONS:  Nabumetone  does dose-dependently inhibit the  cyclooxygenase  activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo", "triple_list": [["Nabumetone", "DOWNREGULATOR", "cyclooxygenase"]]}, {"text": "CONCLUSIONS:  Nabumetone  does dose-dependently inhibit the cyclooxygenase activity of platelet  PGHS-1  of healthy subjects both in vivo and ex vivo", "triple_list": [["Nabumetone", "DOWNREGULATOR", "PGHS-1"]]}, {"text": "Moreover, the production of  TXB2  during whole blood clotting was assessed as an index of the  cyclooxygenase  activity of platelet PGHS-1 ex vivo", "triple_list": [["TXB2", "PRODUCT-OF", "cyclooxygenase"]]}, {"text": "Moreover, the production of  TXB2  during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet  PGHS-1  ex vivo", "triple_list": [["TXB2", "PRODUCT-OF", "PGHS-1"]]}, {"text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet  PGHS-1   caused a cumulative inhibition of urinary  11-dehydro-TXB2  and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover", "triple_list": [["11-dehydro-TXB2", "PRODUCT-OF", "PGHS-1"]]}, {"text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet  PGHS-1   caused a cumulative inhibition of urinary 11-dehydro- TXB2  and whole blood  TXB2  production that recovered with a timecourse consistent with platelet turnover", "triple_list": [["TXB2", "PRODUCT-OF", "PGHS-1"]]}, {"text": "Preclinical efficacy of  emedastine   a potent, selective  histamine H1  antagonist for topical ocular use", "triple_list": [["emedastine", "ANTAGONIST", "histamine H1"]]}, {"text": "(2) Exposure histories vary in secondary 11q23 leukemia, as the only  topoisomerase II  inhibitor was  dactinomycin  in one case, and, in another case, no  topoisomerase II  inhibitor was administered", "triple_list": [["dactinomycin", "DOWNREGULATOR", "topoisomerase II"]]}, {"text": " Indomethacin   piroxicam, and sulindac sulfide were found to preferentially inhibit  PGHS-1   Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies", "triple_list": [["Indomethacin", "DOWNREGULATOR", "PGHS-1"]]}, {"text": "Indomethacin,  piroxicam   and sulindac sulfide were found to preferentially inhibit  PGHS-1   Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies", "triple_list": [["piroxicam", "DOWNREGULATOR", "PGHS-1"]]}, {"text": "Indomethacin, piroxicam, and  sulindac sulfide  were found to preferentially inhibit  PGHS-1   Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies", "triple_list": [["sulindac sulfide", "DOWNREGULATOR", "PGHS-1"]]}, {"text": " 6-Methoxy-2-naphthylacetic acid   the active metabolite of Relafen, inhibits murine  PGHS-2  preferentially", "triple_list": [["6-Methoxy-2-naphthylacetic acid", "DOWNREGULATOR", "PGHS-2"]]}, {"text": "6-Methoxy-2-naphthylacetic acid, the active metabolite of  Relafen   inhibits murine  PGHS-2  preferentially", "triple_list": [["Relafen", "DOWNREGULATOR", "PGHS-2"]]}, {"text": " Aspirin  irreversibly inhibits  PGHS-1   preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2", "triple_list": [["Aspirin", "DOWNREGULATOR", "PGHS-1"]]}, {"text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of  PGHS-2  causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ( 15-HETE   instead of PGH2", "triple_list": [["15-HETE", "PRODUCT-OF", "PGHS-2"]]}, {"text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of  PGHS-2  causes this enzyme to form  15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid  (15-HETE) instead of PGH2", "triple_list": [["15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid", "PRODUCT-OF", "PGHS-2"]]}, {"text": "Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and  phenylpropanolamine  seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of  phenylpropanolamine   to stimulate directly  alpha 1-adrenoceptors   It has been suggested that beta- and  alpha 1-adrenoceptors  and D1 dopamine receptors are involved in their effect on food intake", "triple_list": [["phenylpropanolamine", "ACTIVATOR", "alpha 1-adrenoceptors"]]}, {"text": "Under these conditions, blockade of  monoamine oxidase  with  pargyline  (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine", "triple_list": [["pargyline", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "In addition several ligands known to act as agonists at either  5-HT2A  or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP),  Ru 24969   MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["Ru 24969", "AGONIST", "5-HT2A"]]}, {"text": "In addition several ligands known to act as agonists at either 5-HT2A or  5-HT2C  receptors including 1-m-chlorophenylpiperazine (m-CPP),  Ru 24969   MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["Ru 24969", "AGONIST", "5-HT2C"]]}, {"text": "In addition several ligands known to act as agonists at either  5-HT2A  or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969,  MK 212  and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["MK 212", "AGONIST", "5-HT2A"]]}, {"text": "In addition several ligands known to act as agonists at either 5-HT2A or  5-HT2C  receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969,  MK 212  and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["MK 212", "AGONIST", "5-HT2C"]]}, {"text": "In addition several ligands known to act as agonists at either  5-HT2A  or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and  SCH 23390  were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["SCH 23390", "AGONIST", "5-HT2A"]]}, {"text": "In addition several ligands known to act as agonists at either 5-HT2A or  5-HT2C  receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and  SCH 23390  were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["SCH 23390", "AGONIST", "5-HT2C"]]}, {"text": "In addition several ligands known to act as agonists at either  5-HT2A  or 5-HT2C receptors including  1-m-chlorophenylpiperazine  (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["1-m-chlorophenylpiperazine", "AGONIST", "5-HT2A"]]}, {"text": "In addition several ligands known to act as agonists at either 5-HT2A or  5-HT2C  receptors including  1-m-chlorophenylpiperazine  (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["1-m-chlorophenylpiperazine", "AGONIST", "5-HT2C"]]}, {"text": "In addition several ligands known to act as agonists at either  5-HT2A  or 5-HT2C receptors including 1-m-chlorophenylpiperazine ( m-CPP  , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["m-CPP", "AGONIST", "5-HT2A"]]}, {"text": "In addition several ligands known to act as agonists at either 5-HT2A or  5-HT2C  receptors including 1-m-chlorophenylpiperazine ( m-CPP  , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive", "triple_list": [["m-CPP", "AGONIST", "5-HT2C"]]}, {"text": "Neither ryanodine nor  EGTA  inhibited down-regulation of  alpha-AR  mRNA by NE", "triple_list": [["EGTA", "ACTIVATOR", "alpha-AR"]]}, {"text": "Neither  ryanodine  nor EGTA inhibited down-regulation of  alpha-AR  mRNA by NE", "triple_list": [["ryanodine", "ACTIVATOR", "alpha-AR"]]}, {"text": "Neither ryanodine nor EGTA inhibited down-regulation of  alpha-AR  mRNA by  NE   Actinomycin D caused  alpha-AR  mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal  alpha-AR  mRNA level", "triple_list": [["NE", "DOWNREGULATOR", "alpha-AR"]]}, {"text": " Actinomycin D  caused  alpha-AR  mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal  alpha-AR  mRNA level", "triple_list": [["Actinomycin D", "DOWNREGULATOR", "alpha-AR"]]}, {"text": " Actinomycin D  caused  alpha-AR  mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal  alpha-AR  mRNA level", "triple_list": [["Actinomycin D", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "Both  NE  and phorbol esters increased the rate of  alpha-AR  mRNA degradation", "triple_list": [["NE", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "Both NE and  phorbol esters  increased the rate of  alpha-AR  mRNA degradation", "triple_list": [["phorbol esters", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "In  NE  desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of  alpha-AR  mRNA", "triple_list": [["NE", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "In NE-desensitized cells,  phorbol esters  and bradykinin each caused the expected down-regulation of  alpha-AR  mRNA", "triple_list": [["phorbol esters", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "The  protein phosphatase  inhibitor  okadaic acid  prolonged the normally transient effect of NE for at least 24 h", "triple_list": [["okadaic acid", "DOWNREGULATOR", "protein phosphatase"]]}, {"text": " NE   phorbol esters, and bradykinin each decreased  alpha-AR  mRNA levels by 70-80%", "triple_list": [["NE", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "Phorbol esters and  norepinephrine  destabilize  alpha 1B-adrenergic receptor  mRNA in vascular smooth muscle cells", "triple_list": [["norepinephrine", "DOWNREGULATOR", "alpha 1B-adrenergic receptor"]]}, {"text": "NE,  phorbol esters   and bradykinin each decreased  alpha-AR  mRNA levels by 70-80%", "triple_list": [["phorbol esters", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "The mechanism by which  norepinephrine  (NE) down-regulates  alpha 1B-adrenergic receptor  (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells", "triple_list": [["norepinephrine", "DOWNREGULATOR", "alpha 1B-adrenergic receptor"]]}, {"text": "The mechanism by which  norepinephrine  (NE) down-regulates alpha 1B-adrenergic receptor ( alpha-AR   mRNA was studied in rabbit aortic smooth muscle cells", "triple_list": [["norepinephrine", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "The  protein kinase C  inhibitor  (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride  (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%", "triple_list": [["(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride", "DOWNREGULATOR", "protein kinase C"]]}, {"text": "The  protein kinase C  inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride ( H-7   abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%", "triple_list": [["H-7", "DOWNREGULATOR", "protein kinase C"]]}, {"text": "The mechanism by which norepinephrine ( NE   down-regulates  alpha 1B-adrenergic receptor  (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells", "triple_list": [["NE", "DOWNREGULATOR", "alpha 1B-adrenergic receptor"]]}, {"text": "The mechanism by which norepinephrine ( NE   down-regulates alpha 1B-adrenergic receptor ( alpha-AR   mRNA was studied in rabbit aortic smooth muscle cells", "triple_list": [["NE", "DOWNREGULATOR", "alpha-AR"]]}, {"text": "HeLa cells transfected with the MR77 gene exhibited inhibition of  adenylate cyclase  in response to  serotonin   MR77 is expressed at low levels throughout the brain, with the greatest expression in the cortex, hippocampus, and striatum", "triple_list": [["serotonin", "DOWNREGULATOR", "adenylate cyclase"]]}, {"text": "The specific binding is displaced by the selective  5-HT1D  agonist  sumatriptan  but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine", "triple_list": [["sumatriptan", "AGONIST", "5-HT1D"]]}, {"text": "The antiarrhythmic effects of exogenous  adenosine  and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous  adenosine  may modulate VT through alterations in autonomic tone by activation of arterial  chemoreceptors   and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch", "triple_list": [["adenosine", "ACTIVATOR", "chemoreceptors"]]}, {"text": " Edrophonium  (10 mg i.v.), a  cholinesterase  inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine", "triple_list": [["Edrophonium", "DOWNREGULATOR", "cholinesterase"]]}, {"text": "Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the  muscarinic cholinergic receptor   terminated VT in four of four patients, an effect that was reversed by  atropine   Group 2 (n = 6): In patients with reentrant VT, dipyridamole and edrophonium had no effect on VT cycle length or duration", "triple_list": [["atropine", "DOWNREGULATOR", "muscarinic cholinergic receptor"]]}, {"text": "VT recurred with the addition of  aminophylline   a competitive  adenosine A1-receptor  antagonist", "triple_list": [["aminophylline", "ANTAGONIST", "adenosine A1-receptor"]]}, {"text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked  amantadine  induction of  Fos  in the striatum", "triple_list": [["amantadine", "ACTIVATOR", "Fos"]]}, {"text": "However,  amantadine  induction of  Fos  in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride", "triple_list": [["amantadine", "ACTIVATOR", "Fos"]]}, {"text": "These results suggest that  amantadine  induction of  Fos  in the rat striatum is related to dopamine D1 and NMDA receptors.", "triple_list": [["amantadine", "ACTIVATOR", "Fos"]]}, {"text": " Amantadine  induces  c-fos  in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists", "triple_list": [["Amantadine", "ACTIVATOR", "c-fos"]]}, {"text": " Amantadine  (1-aminoadamantane) induced  Fos  expression in the central, dorsal-medial and ventral-medial part of the striatum", "triple_list": [["Amantadine", "ACTIVATOR", "Fos"]]}, {"text": "Amantadine ( 1-aminoadamantane   induced  Fos  expression in the central, dorsal-medial and ventral-medial part of the striatum", "triple_list": [["1-aminoadamantane", "ACTIVATOR", "Fos"]]}, {"text": "The distribution pattern of  Fos  induced by  amantadine  was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists", "triple_list": [["amantadine", "ACTIVATOR", "Fos"]]}, {"text": "Pretreatment with the dopamine D1 receptor antagonist,  SCH23390   and the NMDA receptor antagonist, MK-801, blocked amantadine induction of  Fos  in the striatum", "triple_list": [["SCH23390", "DOWNREGULATOR", "Fos"]]}, {"text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist,  MK-801   blocked amantadine induction of  Fos  in the striatum", "triple_list": [["MK-801", "DOWNREGULATOR", "Fos"]]}, {"text": "However, amantadine induction of Fos in the striatum was unaffected by the  dopamine D2 receptor  antagonist,  sulpiride   These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.", "triple_list": [["sulpiride", "ANTAGONIST", "dopamine D2 receptor"]]}, {"text": "Pretreatment with the  dopamine D1 receptor  antagonist,  SCH23390   and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum", "triple_list": [["SCH23390", "ANTAGONIST", "dopamine D1 receptor"]]}, {"text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the  NMDA receptor  antagonist,  MK-801   blocked amantadine induction of Fos in the striatum", "triple_list": [["MK-801", "ANTAGONIST", "NMDA receptor"]]}, {"text": "bolus); finally, 8 rabbits received  aurintrycarboxilic acid  (ATA), an inhibitor of platelet  glycoprotein Ib  von Willebrand factor interaction (10 mg/kg i.v", "triple_list": [["aurintrycarboxilic acid", "DOWNREGULATOR", "glycoprotein Ib"]]}, {"text": "bolus); finally, 8 rabbits received  aurintrycarboxilic acid  (ATA), an inhibitor of platelet glycoprotein Ib/ von Willebrand factor  interaction (10 mg/kg i.v", "triple_list": [["aurintrycarboxilic acid", "DOWNREGULATOR", "von Willebrand factor"]]}, {"text": "bolus); finally, 8 rabbits received aurintrycarboxilic acid ( ATA  , an inhibitor of platelet  glycoprotein Ib  von Willebrand factor interaction (10 mg/kg i.v", "triple_list": [["ATA", "DOWNREGULATOR", "glycoprotein Ib"]]}, {"text": "bolus); finally, 8 rabbits received aurintrycarboxilic acid ( ATA  , an inhibitor of platelet glycoprotein Ib/ von Willebrand factor  interaction (10 mg/kg i.v", "triple_list": [["ATA", "DOWNREGULATOR", "von Willebrand factor"]]}, {"text": "These events are stimulated by NE and by guanethidine, an  hNET  substrate, and they are blocked by  cocaine  and the antidepressant desipramine", "triple_list": [["cocaine", "DOWNREGULATOR", "hNET"]]}, {"text": "These events are stimulated by NE and by guanethidine, an  hNET  substrate, and they are blocked by cocaine and the antidepressant  desipramine   Voltage-clamp data combined with NE uptake data from these same cells indicate that  hNET s have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)", "triple_list": [["desipramine", "DOWNREGULATOR", "hNET"]]}, {"text": "Voltage-clamp data combined with  NE  uptake data from these same cells indicate that h NE Ts have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)", "triple_list": [["NE", "PRODUCT-OF", "hNETs"]]}, {"text": "These events are stimulated by  NE  and by guanethidine, an h NE T substrate, and they are blocked by cocaine and the antidepressant desipramine", "triple_list": [["NE", "PRODUCT-OF", "hNET"]]}, {"text": "These events are stimulated by NE and by  guanethidine   an  hNET  substrate, and they are blocked by cocaine and the antidepressant desipramine", "triple_list": [["guanethidine", "PRODUCT-OF", "hNET"]]}, {"text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the  mineralocorticoid receptor  (MR) antagonist  RU28318   (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting", "triple_list": [["RU28318", "ANTAGONIST", "mineralocorticoid receptor"]]}, {"text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor ( MR   antagonist  RU28318   (v) is via classical  MR , in that it is blocked by concurrent administration of the  MR  antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting", "triple_list": [["RU28318", "ANTAGONIST", "MR"]]}, {"text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor ( MR ) antagonist RU28318; (v) is via classical  MR   in that it is blocked by concurrent administration of the  MR  antagonist  potassium canrenoate   and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting", "triple_list": [["potassium canrenoate", "ANTAGONIST", "MR"]]}, {"text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor ( MR ) antagonist RU28318; (v) is via classical  MR , in that it is blocked by concurrent administration of the  MR  antagonist  potassium canrenoate   and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting", "triple_list": [["potassium canrenoate", "ANTAGONIST", "MR"]]}, {"text": "The results when considered with previous reports in the literature show that  amezinium  is about 1000 times more potent and debrisoquine is about 20 times more potent for  MAO  inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1", "triple_list": [["amezinium", "DOWNREGULATOR", "MAO"]]}, {"text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and  debrisoquine  is about 20 times more potent for  MAO  inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1", "triple_list": [["debrisoquine", "DOWNREGULATOR", "MAO"]]}, {"text": " Amezinium  is much less potent as a  MAO  inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart", "triple_list": [["Amezinium", "DOWNREGULATOR", "MAO"]]}, {"text": "The results also confirmed previous reports that  amezinium  is highly selective for  MAO-A  ", "triple_list": [["amezinium", "DOWNREGULATOR", "MAO-A"]]}, {"text": "Previous studies have resulted in the classification of  amezinium  as a selective inhibitor of neuronal  monoamine oxidase  (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates", "triple_list": [["amezinium", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Previous studies have resulted in the classification of  amezinium  as a selective inhibitor of neuronal monoamine oxidase ( MAO  , because it is a much more potent  MAO  inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates", "triple_list": [["amezinium", "DOWNREGULATOR", "MAO"]]}, {"text": "Previous studies have resulted in the classification of  amezinium  as a selective inhibitor of neuronal monoamine oxidase ( MAO ), because it is a much more potent  MAO  inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates", "triple_list": [["amezinium", "DOWNREGULATOR", "MAO"]]}, {"text": "In addition, another drug that is both a substrate of uptake1 and a  MAO  inhibitor,  debrisoquine   was investigated in the study", "triple_list": [["debrisoquine", "DOWNREGULATOR", "MAO"]]}, {"text": " Amezinium  and debrisoquine are substrates of uptake1 and potent inhibitors of  monoamine oxidase  in perfused lungs of rats", "triple_list": [["Amezinium", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "Amezinium and  debrisoquine  are substrates of uptake1 and potent inhibitors of  monoamine oxidase  in perfused lungs of rats", "triple_list": [["debrisoquine", "DOWNREGULATOR", "monoamine oxidase"]]}, {"text": "When MAO-B was also inhibited, 10 nmol/l  amezinium  caused 84% inhibition of the deamination of noradrenaline by  MAO-A  in the lungs", "triple_list": [["amezinium", "DOWNREGULATOR", "MAO-A"]]}, {"text": "The results when considered with previous reports in the literature show that  amezinium  is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by  uptake1   Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart", "triple_list": [["amezinium", "PRODUCT-OF", "uptake1"]]}, {"text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and  debrisoquine  is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by  uptake1   Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart", "triple_list": [["debrisoquine", "PRODUCT-OF", "uptake1"]]}, {"text": " Amezinium  is much less potent as a MAO inhibitor in cells with the  uptake2 transporter   such as the myocardial cells of the heart", "triple_list": [["Amezinium", "PRODUCT-OF", "uptake2 transporter"]]}, {"text": "In addition, another drug that is both a substrate of  uptake1  and a MAO inhibitor,  debrisoquine   was investigated in the study", "triple_list": [["debrisoquine", "PRODUCT-OF", "uptake1"]]}, {"text": " Amezinium  and debrisoquine are substrates of  uptake1  and potent inhibitors of monoamine oxidase in perfused lungs of rats", "triple_list": [["Amezinium", "PRODUCT-OF", "uptake1"]]}, {"text": "Amezinium and  debrisoquine  are substrates of  uptake1  and potent inhibitors of monoamine oxidase in perfused lungs of rats", "triple_list": [["debrisoquine", "PRODUCT-OF", "uptake1"]]}, {"text": "We have investigated the effects of  CP-99,994  [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a  tachykinin NK1 receptor  antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["CP-99,994", "ANTAGONIST", "tachykinin NK1 receptor"]]}, {"text": "We have investigated the effects of CP-99,994  [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]   a  tachykinin NK1 receptor  antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]", "ANTAGONIST", "tachykinin NK1 receptor"]]}, {"text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist,  HOE 140  (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a  bradykinin B2 receptor  antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["HOE 140", "ANTAGONIST", "bradykinin B2 receptor"]]}, {"text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140  (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)   a  bradykinin B2 receptor  antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)", "ANTAGONIST", "bradykinin B2 receptor"]]}, {"text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and  ketotifen  (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a  histamine H1 receptor  antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["ketotifen", "ANTAGONIST", "histamine H1 receptor"]]}, {"text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen  (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)   a  histamine H1 receptor  antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde", "triple_list": [["(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)", "ANTAGONIST", "histamine H1 receptor"]]}, {"text": " HERG  IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide,  E4031   and MK-499, at submicromolar concentrations", "triple_list": [["E4031", "DOWNREGULATOR", "HERG"]]}, {"text": "HERG/ IKr  channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide,  E4031   and MK-499, at submicromolar concentrations", "triple_list": [["E4031", "DOWNREGULATOR", "IKr"]]}, {"text": " HERG  IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and  MK-499   at submicromolar concentrations", "triple_list": [["MK-499", "DOWNREGULATOR", "HERG"]]}, {"text": "HERG/ IKr  channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and  MK-499   at submicromolar concentrations", "triple_list": [["MK-499", "DOWNREGULATOR", "IKr"]]}, {"text": "Molecular determinants of  dofetilide  block of  HERG  K+ channels", "triple_list": [["dofetilide", "DOWNREGULATOR", "HERG"]]}, {"text": "Molecular determinants of  dofetilide  block of HERG  K+ channels   The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr)", "triple_list": [["dofetilide", "DOWNREGULATOR", "K+ channels"]]}, {"text": " HERG  IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic  methanesulfonanilide  drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations", "triple_list": [["methanesulfonanilide", "DOWNREGULATOR", "HERG"]]}, {"text": "HERG/ IKr  channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic  methanesulfonanilide  drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations", "triple_list": [["methanesulfonanilide", "DOWNREGULATOR", "IKr"]]}, {"text": " HERG  IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as  dofetilide   E4031, and MK-499, at submicromolar concentrations", "triple_list": [["dofetilide", "DOWNREGULATOR", "HERG"]]}, {"text": "HERG/ IKr  channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as  dofetilide   E4031, and MK-499, at submicromolar concentrations", "triple_list": [["dofetilide", "DOWNREGULATOR", "IKr"]]}, {"text": "Treatment using a combination of testosterone and the  aromatase  inhibitor  testolactone  may have significantly better effects on sexual function and also seizure frequency than testosterone alone.", "triple_list": [["testolactone", "DOWNREGULATOR", "aromatase"]]}, {"text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with  DNA-topoisomerase II  inhibitors,  etoposide  and mitoxantrone, and an alkylating agent, cyclophosphamide", "triple_list": [["etoposide", "DOWNREGULATOR", "DNA-topoisomerase II"]]}, {"text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with  DNA-topoisomerase II  inhibitors, etoposide and  mitoxantrone   and an alkylating agent, cyclophosphamide", "triple_list": [["mitoxantrone", "DOWNREGULATOR", "DNA-topoisomerase II"]]}, {"text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with  DNA-topoisomerase II  inhibitors,  etoposide  and mitoxantrone, and the alkylating agent, cyclophosphamide", "triple_list": [["etoposide", "DOWNREGULATOR", "DNA-topoisomerase II"]]}, {"text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with  DNA-topoisomerase II  inhibitors, etoposide and  mitoxantrone   and the alkylating agent, cyclophosphamide", "triple_list": [["mitoxantrone", "DOWNREGULATOR", "DNA-topoisomerase II"]]}, {"text": "A low tyramine diet is recommended if  selegiline  is used together with nonselective  MAO  inhibitors or the selective, reversible  MAO -A inhibitor, moclobemide", "triple_list": [["selegiline", "DOWNREGULATOR", "MAO"]]}, {"text": "A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible  MAO-A  inhibitor,  moclobemide   Several adverse effects have been reported when fluoxetine and selegiline have been used together", "triple_list": [["moclobemide", "DOWNREGULATOR", "MAO-A"]]}, {"text": " Selegiline  (deprenyl), a selective, irreversible inhibitor of  monoamine oxidase type B  (MAO-B) is widely used in the treatment of Parkinson's disease", "triple_list": [["Selegiline", "DOWNREGULATOR", "monoamine oxidase type B"]]}, {"text": " Selegiline  (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B ( MAO-B   is widely used in the treatment of Parkinson's disease", "triple_list": [["Selegiline", "DOWNREGULATOR", "MAO-B"]]}, {"text": "Unlike the nonselective  MAO  inhibitors,  selegiline  does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease", "triple_list": [["selegiline", "DOWNREGULATOR", "MAO"]]}, {"text": "Selegiline ( deprenyl  , a selective, irreversible inhibitor of  monoamine oxidase type B  (MAO-B) is widely used in the treatment of Parkinson's disease", "triple_list": [["deprenyl", "DOWNREGULATOR", "monoamine oxidase type B"]]}, {"text": "Selegiline ( deprenyl  , a selective, irreversible inhibitor of monoamine oxidase type B ( MAO-B   is widely used in the treatment of Parkinson's disease", "triple_list": [["deprenyl", "DOWNREGULATOR", "MAO-B"]]}, {"text": " Ibuprofen  inhibits  cystic fibrosis transmembrane conductance regulator  mediated Cl- secretion", "triple_list": [["Ibuprofen", "DOWNREGULATOR", "cystic fibrosis transmembrane conductance regulator"]]}, {"text": " Ibuprofen  (300 microM) reduced  CFTR  Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3)", "triple_list": [["Ibuprofen", "DOWNREGULATOR", "CFTR"]]}, {"text": "Similarly,  salicylic acid  (3 mM) reduced  CFTR  Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4)", "triple_list": [["salicylic acid", "DOWNREGULATOR", "CFTR"]]}, {"text": "Based on these results, we conclude that the NSAIDs  ibuprofen  and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of  CFTR  Cl- channels as well as basolateral membrane K+ channels", "triple_list": [["ibuprofen", "DOWNREGULATOR", "CFTR"]]}, {"text": "Based on these results, we conclude that the NSAIDs  ibuprofen  and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR  Cl- channels  as well as basolateral membrane K+ channels", "triple_list": [["ibuprofen", "DOWNREGULATOR", "Cl- channels"]]}, {"text": "Based on these results, we conclude that the NSAIDs  ibuprofen  and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane  K+ channels   This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and/or function in secretory epithelia.", "triple_list": [["ibuprofen", "DOWNREGULATOR", "K+ channels"]]}, {"text": "Based on these results, we conclude that the NSAIDs ibuprofen and  salicylic acid  inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of  CFTR  Cl- channels as well as basolateral membrane K+ channels", "triple_list": [["salicylic acid", "DOWNREGULATOR", "CFTR"]]}, {"text": "Based on these results, we conclude that the NSAIDs ibuprofen and  salicylic acid  inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR  Cl- channels  as well as basolateral membrane K+ channels", "triple_list": [["salicylic acid", "DOWNREGULATOR", "Cl- channels"]]}, {"text": "Based on these results, we conclude that the NSAIDs ibuprofen and  salicylic acid  inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane  K+ channels   This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and/or function in secretory epithelia.", "triple_list": [["salicylic acid", "DOWNREGULATOR", "K+ channels"]]}, {"text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective  5-HT2A  5-HT2C antagonist  ritanserin  ", "triple_list": [["ritanserin", "ANTAGONIST", "5-HT2A"]]}, {"text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/ 5-HT2C  antagonist  ritanserin  ", "triple_list": [["ritanserin", "ANTAGONIST", "5-HT2C"]]}, {"text": "These data indicate that mixed  5-HT1  5-HT2 receptor antagonists such as  pizotifen  and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "triple_list": [["pizotifen", "ANTAGONIST", "5-HT1"]]}, {"text": "These data indicate that mixed 5-HT1/ 5-HT2  receptor antagonists such as  pizotifen  and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective  5-HT2 A/ 5-HT2 C antagonist ritanserin.", "triple_list": [["pizotifen", "ANTAGONIST", "5-HT2"]]}, {"text": "These data indicate that mixed  5-HT1  5-HT2 receptor antagonists such as pizotifen and  methysergide   and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "triple_list": [["methysergide", "ANTAGONIST", "5-HT1"]]}, {"text": "These data indicate that mixed 5-HT1/ 5-HT2  receptor antagonists such as pizotifen and  methysergide   and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective  5-HT2 A/ 5-HT2 C antagonist ritanserin.", "triple_list": [["methysergide", "ANTAGONIST", "5-HT2"]]}, {"text": "The cardiovascular effects of three different  acetylcholinesterase  inhibitors:  physostigmine   tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats", "triple_list": [["physostigmine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "The cardiovascular effects of three different  acetylcholinesterase  inhibitors: physostigmine,  tacrine  and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats", "triple_list": [["tacrine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "The cardiovascular effects of three different  acetylcholinesterase  inhibitors: physostigmine, tacrine and  rivastigmine  injected by intravenous (i.v.) route were compared in freely moving Wistar rats", "triple_list": [["rivastigmine", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "The  alpha1-adrenoceptor  antagonist  prazosin  or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly", "triple_list": [["prazosin", "ANTAGONIST", "alpha1-adrenoceptor"]]}, {"text": "The alpha1-adrenoceptor antagonist prazosin or the  vasopressin V1 receptor  antagonist,  [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin  partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly", "triple_list": [["[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin", "ANTAGONIST", "vasopressin V1 receptor"]]}, {"text": "administration of the non-selective  muscarinic receptor  antagonist  atropine  (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)", "triple_list": [["atropine", "ANTAGONIST", "muscarinic receptor"]]}, {"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the  muscarinic M1 receptor  antagonist  pirenzepine  (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)", "triple_list": [["pirenzepine", "ANTAGONIST", "muscarinic M1 receptor"]]}, {"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the  muscarinic M2 receptor  antagonist  methoctramine  (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)", "triple_list": [["methoctramine", "ANTAGONIST", "muscarinic M2 receptor"]]}, {"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the  muscarinic M3 receptor  antagonist  para-fluoro-hexahydro-sila-difenidol  (ID50 = 31.19 microg)", "triple_list": [["para-fluoro-hexahydro-sila-difenidol", "ANTAGONIST", "muscarinic M3 receptor"]]}, {"text": " Cocaine  block of  human cardiac (hH1)  and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells", "triple_list": [["Cocaine", "DOWNREGULATOR", "human cardiac (hH1)"]]}, {"text": " Cocaine  block of human cardiac (hH1) and  rat skeletal (mu1) muscle sodium channels  was examined under whole-cell voltage clamp in transiently transfected HEK293t cells", "triple_list": [["Cocaine", "DOWNREGULATOR", "rat skeletal (mu1) muscle sodium channels"]]}, {"text": " Cocaine  block of  hH1 channels  was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of  hH1 channels  in this voltage range makes them more susceptible to cocaine block", "triple_list": [["Cocaine", "DOWNREGULATOR", "hH1 channels"]]}, {"text": " Cocaine  block of hH1 channels was greater than block of  mu1 channels  at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block", "triple_list": [["Cocaine", "DOWNREGULATOR", "mu1 channels"]]}, {"text": " Cocaine  block of  hH1 channels  was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of  hH1 channels  in this voltage range makes them more susceptible to cocaine block", "triple_list": [["Cocaine", "DOWNREGULATOR", "hH1 channels"]]}, {"text": "Cocaine block of  hH1 channels  was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of  hH1 channels  in this voltage range makes them more susceptible to  cocaine  block", "triple_list": [["cocaine", "DOWNREGULATOR", "hH1 channels"]]}, {"text": "State-dependent  cocaine  block of  sodium channel  isoforms, chimeras, and channels coexpressed with the beta1 subunit", "triple_list": [["cocaine", "DOWNREGULATOR", "sodium channel"]]}]